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Semliki Forest virus (SFV) has been much used to study the cell biology and
molecular pathogenesis of RNA viruses, particularly virus encephalitis. The genome
encodes nine functional proteins in two open-reading frames (ORFs). The 5' ORF
carries information for synthesis of four non-structural replicase proteins (nsPl -
nsP4). The 3' third of the genome encodes the structural proteins. The aim of this
study was to develop novel reporter systems to study the pathogenesis of SFV in vivo.
Two different types of recombinant viruses each carrying one of two foreign genes,
enhanced green fluorescent protein (eGFP) or Cre recombinase, were constructed
based on the SFV4 backbone. In the first type of construct the transgene was inserted
in the non-structural ORF, between the coding sequences for nsP3 and nsP4, flanked
by processing sites recognised by the nsP2 proteinase. In the second type of
constructs the 2A sequence from foot-and-mouth disease virus was added to the C-
terminus of the foreign gene and this was placed between the capsid and the p62
protein of SFV4 (structural ORF). The in vitro and in vivo phenotypes of the
resulting viruses were assessed and compared to SFV4.
All recombinant viruses constructed were viable and able to replicate in vitro. eGFP
expressing viruses reached titres similar to those of wild-type virus whereas Cre
expressing viruses were slightly attenuated. For viruses with the marker gene
inserted in the non-structural ORF, western blotting showed that the processing
pattern of the non-structural polyprotein was similar to that of SFV4 and verified the
expression of both foreign genes. In vivo, following intracerebral inoculation, all
viruses caused encephalitis. Viruses expressing the foreign gene as a cleavable
component of the structural ORF induced disease slower than SFV4 or viruses
carrying the transgene in the replicase ORF. eGFP fluorescence was stronger and
occurred later in infection when expressed in the structural ORF than in the replicase
ORF.
eGFP expression from the replicase ORF marked only recently infected cells; a
property useful in pathogenesis studies. eGFP expressing viruses demonstrated the
same cell tropism as SFV4 with infection principally of neurons and
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oligodendrocytes. None of the mice infected intraperitoneal^ with SFV4 or the
recombinant viruses succumbed to infection demonstrating poor neuroinvasiveness.
The powerful suppression of alphavirus replication by the interferon system was
demonstrated in IFN a/p receptor knockout mice. The true tropism and the potential
of SFV4 was revealed in the absence of a functional IFN system.
These studies demonstrated that foreign genes can be inserted into the non-structural
or the structural ORF of SFV4 without destroying virus infectivity or major changes
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Chapter 1 Introduction
Alphaviruses: Morphology, classification, geographical distribution and
disease associations
Togaviridae is a large family of enveloped, positive-strand RNA viruses. The family,
which takes its name from the morphology of the virus particles (toga stands for
cloak in Latin), consists of two genera, Alphavirus, which has 28 members, and
Rubivirus, which has a single member, rubella virus (Strauss & Strauss, 1994).
Alphaviruses are transmitted by arthropod vectors (mainly mosquitoes) with small
mammals and birds serving as natural reservoirs. Occasionally, infection of dead-end
hosts, including large mammals and humans, results in outbreaks of significant size.
Examples include outbreaks of encephalitis in the Americas (associated with Eastern
and Venezuelan equine encephalitis viruses) and of severe arthralgia in Australia and
in the islands of the Indian Ocean, associated with Ross River and Chikungunya
virus, respectively (Vodkin et al., 1993; Lindsay et al., 1996; Camara et al., 2003;
Schuffenecker et al., 2006). The natural enzootic and epizootic (or epidemic) cycles
of alphaviruses can be seen in Figure 1.1. An example of these cycles is given below
using Eastern equine encephalitis virus (EEEV). Naturally, the virus is maintained in
an enzootic cycle between the ornithophilic species of mosquito Culiseta melanura
and migratory passerine songbirds (Dalrymple et al, 1972). Mosquitoes of the Aedes
species, which feed on both birds and susceptible mammals act as a bridge vector
between the virus reservoir and dead-end hosts (Scott & Weaver, 1989; Mitchell et
al., 1992).
Alphaviruses are classified into 7 distinct antigenic complexes (based on structural
polyprotein sequences) and have a worldwide and geographically distinct distribution.
Members of the genus can be found in all continents except Antarctica (Powers et al.,
2001). Examples of alphaviruses inhabiting different continents include EEEV and
Venezuelan equine encephalitis virus (VEEV) in the Americas, Sindbis virus (SV) in
Europe, Semliki Forest virus (SFV) in Africa and Ross River virus in Australia.
Alphaviruses have the ability to infect a wide range of hosts including insects, fish,
birds, rodents, amphibians, reptiles, primates, horses and humans. In humans,
alphaviruses are associated with a range of symptomatic diseases varying from a
2
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mild febrile illness through to rash, arthritis and fatal encephalitis (Mathiot et al.,





Figure 1.1. Natural enzootic cycle of alphaviruses. In nature alphaviruses circulate
between mosquitoes and their natural hosts, small mammals and birds. Occasionally,
and through a mosquito vector that feeds in both the natural hosts and dead-end hosts









Alphaviruses, also known for their use as research tools, are amongst the simplest
enveloped animal viruses (Atkins et al., 1999). An icosahedral capsid (T=4
symmetry) composed of 240 copies of a single capsid protein surrounds a single-
stranded positive sense RNA genome with a size of approximately 11 - 13 kb. The
capsid is enveloped in a lipid envelope derived from the plasma membrane of the
host cell. Eighty spikes, composed of El and E2 glycoprotein heterotrimers cover the
virion in a T=4 lattice. Alphavirus virions have a size of approximately 70 nm,
depicted in Figure 1.2, (Paredes et al., 1993; Strauss & Strauss, 1994; Cheng et al.,
1995). Alphaviruses infect their host cells via receptor-mediated endocytosis. Virus
particles attach to the receptor on the cell surface through the receptor-binding
domains of E2 glycoprotein (Strauss & Strauss, 1994; Smith et al., 1995; Kuhn,
2007). However, the identity of the receptor which mediates viral attachment and
entry remains unclear. The list of putative receptors include the class 1 major
histocompatibility complex, laminin, heparin sulphate and C-type lectins (Helenius et
al., 1978; Wang et al., 1992; Klimstra et al., 1998; Klimstra et al., 2003).
Alphaviruses, especially SV and SFV have widely been used to study the viral and
immunological events of viral encephalitis, the mechanisms of viral apoptosis and
the effects of interferon during viral infection. Moreover, they have been used as a
model to understand the pathogenesis of both alphavirus and non-alphavirus
encephalitides and provide a useful model for other central nervous system (CNS)
diseases such as multiple sclerosis (Atkins et al., 1999; Ryman et al., 2000;
Fazakerley & Allsopp, 2001; Fazakerley, 2002).
5
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Figure 1.2. Three-dimensional structure of Sindbis virus particles. The yellow
area represents the envelope with the spikes. The red area represents the




Genome structure, life cycle and replication of alphaviruses
The genome of alphaviruses is short (11.7 kb for SV and 11.5 kb for SFV) and
encodes nine functional proteins from two open reading frames. The 5' end of the
genome is capped and the 3' end of the genome is polyadenylated (Kaariainen &
Soderlund, 1978; Hill et al., 1997). Like most RNA viruses, alphaviruses express
their proteins in the form of large polyproteins which are co- and post-translationally
processed to form the mature viral proteins (Figure 1.3). The 5' two-thirds of the
genome correspond to four non-structural proteins (nsPl - 4) whereas the 3' third of
the genome encodes five structural proteins (C, El, E2, E3 & 6K) under the control
of an internal subgenomic (26S) promoter (Ding & Schlesinger, 1989; Hardy &
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Figure 1.3. Schematic representation of SFV genome. SFV genome is 11,445
nucleotides long. The 5' two-thirds of the genome (light blue) correspond to the non¬
structural ORF of the virus whereas the 3' third (light yellow) encodes the structural
proteins of the virus. The proteolytic processing of the viral polyproteins is shown.
The black arrows highlight the position of the nsP2 protease recognition sites in the
non-structural ORF. The capsid protein self-cleaves itself from the rest of the
structural polyprotein (blue arrow). The proteolytic processing of the remaining
proteins is mediated by the cellular enzyme signalase; positions of cleavage sites are
highlighted by red arrows.
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Following attachment to the cell membrane viral particles are endocytosed through a
clathrin-dependent pathway (DeTulleo & Kirchhausen, 1998). The acidic
environment of the endosomes alters the three-dimensional structure of the spike
protein and the El spike protein facilitates the fusion between the virus envelope and
the endosome membrane (White & Helenius, 1980; Wahlberg et al., 1992; Wahlberg
& Garoff, 1992; Glomb-Reinmund & Kielian, 1998). Numerous studies have shown
that the presence of cholesterol is obligatory for fusion to occur (Phalen & Kielian,
1991; Lu et al., 1999).
After fusion, the nucleocapsid is released into the cytoplasm. It has been suggested
that the acidic conditions of the endosomes also modify the conformation of the
capsid protein revealing ribosomal binding sites. Ribosomes bind to these sites, the
nucleocapsid is then disassembled and the viral RNA is uncoated in the cell
cytoplasm (Singh & Helenius, 1992; Wengler et al., 1996). In the cytoplasm viral
RNA functions as mRNA.
Upon entry and uncoating, ribosomes bind to the 5' end of the genome and the four
non-structural proteins are translated either as two overlapping polyproteins (PI23 &
PI234) in SV or as a single polyprotein (PI234) in the case of SFV. This difference
is due to the presence of an opal termination codon at the end of the nsP3 sequence
of SV. Ocassionally, read-through translation (with an efficiency of 10-20%) occurs
to produce full length P1234 (Strauss et al., 1983; Takkinen, 1986; de Groot et al.,
1990; Shirako & Strauss, 1994). The polyprotein(s) is then processed into its
individual components through the proteinase activity of the C-terminus of nsP2,
which is a papain-like protease domain (Ding & Schlesinger, 1989; Hardy & Strauss,
1989; Merits et al., 2001; Vasiljeva et al., 2001).
Processing of the non-structural polyprotein is highly regulated and in turn regulates
the viral replication process (Lemm & Rice, 1993b; Lemm et al., 1994; Shirako &
Strauss, 1994). Initially, the non-structural polyprotein is cleaved between nsP3 and
nsP4 in trans (in cis for SV). The protein complex formed (PI23 and nsP4) is the
early replication complex responsible for the synthesis of the negative strand RNA
intermediate (Lemm & Rice, 1993b; Lemm et al., 1994; Shirako & Strauss, 1994;
Vasiljeva et al., 2003). Following cleavage between nsP3 and nsP4 the site between
nsPl and nsP2 is cleaved in cis and then the site between nsP2 and nsP3 in trans
9
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leading to the formation of four individual proteins which remain together as a
protein complex. This complex is the viral replication complex responsible for the
synthesis of the positive-strand RNA. The mature replication complex is targeted to
membranous structures of endosomic and lysosomic origin known as cytoplasmic
vacuoles (CPVs). On the external surface of CPVs numerous invaginations called
spherules can be found. Synthesis of viral RNA occurs on these spherules. During
the late stages of infection this processing pattern is altered to inhibit the formation
of new replication complexes and synthesis of minus-strand RNA (Grimley et al.,
1968; Froshauer et al., 1988; Lemm et al., 1994; Kujala et al., 2001; Vasiljeva et al.,
2003; Salonen et al., 2003; Kim et al., 2004). The nsP2 processing site between nsP3
and nsP4 has been well characterised for SFV (Merits et al., 2001; Vasiljeva et al.,
2003; Lulla et al., 2006).
The viral structural proteins are translated as a single ORF. The capsid protein is
autocatalytically released from the rest of the polyprotein. On translation of the p62
signal sequence, translation is translocated to the endoplasmic reticulum. The
subsequent polyprotein is cleaved to its individual components by the cellular
enzyme signalase and the glycoproteins are transported to the golgi apparatus for
post-translational modifications and maturation before migrating to the cell
membrane. The genomic RNA has packaging signals (in nsPl for SV and in nsP2 for
SFV) that facilitate binding and encapsidation of the RNA (Frolova et al., 1997).
Only the genomic RNA is packaged in alphavirus particles, the sole exception is
AURA virus, which packages both the genomic and the subgenomic RNAs. The
nucleocapsid then interacts with E2 through helical transmembrane segments of the
cytoplasmic tail of the latter and new virus particles are released from the cell by
budding. The 6K structural protein has an important role in the budding process and
experiments with a 6K-deficient SFV show that the structure of the spikes was
altered and the membrane fusion capacity of the virus was reduced (Melancon &
Garoff, 1986; Garoff et al., 1990; Strauss & Strauss, 1994; Loewy et al., 1995;
Mclnerney et al., 2004; Kuhn, 2007).
Alphaviruses express a limited number of proteins many of which are
multifunctional. The functions of the non-structural proteins will be discussed briefly.
10
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nsPl catalyses the capping of both genomic and subgenomic messages through its
methyl and guanylyl transferase activities (Mi & Stollar, 1991; Laakkonen et al.,
1994; Ahola & Kaariainen, 1995). In addition, together with a conserved area at the
3' end of the viral genome it is involved in the initiation of the negative-strand RNA
synthesis and the docking of the mature replicase complexes onto the surface of
membranes (Hahn et al., 1989; Peranen & Kaariainen, 1991; Ahola et al., 1997).
Palmitoylation of nsPl appears to be important for membrane binding. Mutant
viruses that have lost their ability to palmitoylate nsPl are still viable but have
attenuated neurovirulence (Laakkonen et al., 1996; Ahola et al., 2000; Zusinaite et
al., 2007).
nsP2 is a very interesting protein, the N-terminal domain has ATPase, GTPase as
well as RNA helicase activities. Its RNA triphosphatase activity is involved in
capping of viral RNA (Rikkonen et al., 1994a; Gomez et al., 1999; Vasiljeva et al.,
2000). The C-terminal domain is a papain-like protease which is exclusively
responsible for the processing of the replicase polyprotein (Hardy & Strauss, 1989;
Merits et al., 2001). nsP2 is also involved in the regulation of subgenomic RNA
synthesis and the shut-off of minus-strand RNA synthesis (Hahn et al., 1989; Wang
et al., 1994; Suopanki et al., 1998; Sawicki et al., 2006). Another interesting feature
of nsP2 is a nuclear localisation signal which facilitates translocation of
approximately 50% of the protein to the nucleus of infected cells (Rikkonen et al.,
1992; Rikkonen et al., 1994b). The reason for that is not entirely clear but it has been
suggested that nsP2 functions as a type-I IFN suppressor (Breakwell et al., 2007). In
addition, nsP2 is implicated in pathogenesis and virulence both in vitro and in vivo;
viruses with mutations in nsP2 are less cytopathic and have attenuated
neurovirulence (Rikkonen et al., 1994b; Perri et al., 2000; Fazakerley et al., 2002;
Frolova et al., 2002).
nsP3's function is not known yet. This phosphoprotein is essential for replication and
studies suggest that it is involved in minus-strand and subgenomic RNA production;
viruses with mutations or deletions in nsP3 produce lower amounts of RNA.
Numerous studies suggest that nsP3 contains important determinants of alphavirus
neurovirulence in mice (Lastarza et al., 1994; LaStarza et al., 1994; Wang et al.,
1994; Tuittilaet al., 2000; Vihinen et al., 2001; Galbraith et al., 2006).
11
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nsP4 has catalytic activity and is the viral RNA polymerase. Interestingly, nsP4 is
synthesised to considerably lower amounts compared to nsP3 and in most
alphaviruses expression of nsP4 occurs only when the ribosomes read-through the
opal-termination codon at the end of nsP3. Various studies have shown that nsP4 is
degraded via proteasome-mediated degradation according to the N-end rule.
However, the exact sequence that directs nsP4 to the proteasome compartment is not
found yet (de Groot et al., 1991; Merits et al., 2001).
12
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Pathogenesis of Semliki Forest virus
SFV is an arbovirus circulating in sub-Saharan Africa and it was first isolated in
Uganda in 1942 from mosquitoes of the Aedes abnormalis species (Smithburn &
Haddow, 1944). SFV is predominantly transmitted by two species of mosquitoes;
Aedes africanus and Aedes aegypti. Infections of monkeys, humans and horses have
been reported. In humans the virus is associated with a mild febrile illness. The
symptoms of this illness include fever, myalgia (pain of muscles), arthralgia (pain of
joints) and persistent headaches. SFV has proven to be the causative agent of human
disease in two instances one of which was fatal. In 1987 SFV was isolated from
blood samples of 22 French soldiers with symptoms of a mild febrile illness. The
virus has also been associated with the death of a laboratory worker in Germany
(Willems et al., 1979; Mathiot et al., 1990; Fazakerley, 2002).
There are numerous viral strains infecting various experimental animals including
mice, rats, rabbits and guinea pigs (Bradish et al., 1971; Atkins et al., 1990). Two
different cell lines permissive for infection are usually used for in vitro studies.
Chicken embryo fibroblasts (CEF) and baby hamster kidney (BHK) cells but the
virus has the ability to infect many other cell lines; examples include Vero cells
originating from African green monkey and human lung carcinoma A549 cell line
(Atkins et al., 1999; Deuber & Pavlovic, 2007; Griffin, 2007). Infection of laboratory
mice with SFV is a very useful model for the study of virus pathogenesis and in
particular virus encephalitis (Fazakerley, 2004).
Four strains of SFV have been studied most extensively. L10 and prototype which
are virulent in adult mice and A7 and A7(74) which are avirulent in adult mice. All
strains of SFV (virulent and avirulent) are neuroinvasive and virulent in neonatal
mice (Seamer et al., 1967; Bradish et al., 1971;Pusztai et al., 1971).
A unique characteristic of the avirulent SFV strains is their age-related virulence.
Neonatal or young suckling mice (up to 11 days old) inoculated intraperitoneally
with SFV A7(74) exhibit symptoms of fulminant encephalitis and succumb to
infection 48 to 96 hours post-inoculation due to widespread apoptotic neuronal cell
death; from 12 days onwards the infection is avirulent (Gates et al., 1984; Oliver et
al., 1997; Oliver & Fazakerley, 1997; Allsopp et al., 1998). Studies utilising adult
13
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athymic nu/nu mice and adult mice with severe combined immunodeficiency showed
that the spread of SFV A7(74) in the CNS remained limited and concentrated to
perivascular foci in the brain and the spinal cord suggesting that the age-related
virulence is not dependent upon specific immune responses (Fazakerley et al., 1993;
Amor etal, 1996).
All evidence to date suggests that the age-related virulence of the avirulent SFV
strains is closely related to the maturation of the nervous system. During the first two
weeks after birth, the mouse CNS undergoes a series of major maturational processes
including synaptogenesis, gliogenesis, axonogenesis and myelination (Oliver et al.,
1997; Oliver & Fazakerley, 1997; Fazakerley, 2001). Upon completion of the CNS
maturation, virus replication becomes restricted, especially in neurons (Fazakerley et
al., 1993). As mentioned earlier, replication of SFV is associated with membranes;
during the early developmental stages of the murine CNS large amounts of smooth
membrane vesicles are produced. The virus uses these membranes to productively
replicate and spread in the immature brain and when their production is halted
replication of the virus is restricted to small foci of infection (Froshauer et al., 1988;
Fazakerley, 2001). Furthermore, when gold compounds (aurothiolates), which
stimulate the production of smooth membranes in neurons, were used to treat adult
Balb/c mice, the SFV A7(74) avirulent strain spread in the mature brain to the same
extent as the virulent SFV L10 strain. Notably, following treatment with
aurothiolates neurons did not become susceptible to apoptosis. This finding outlines
the crucial role that smooth membranes have in SFV replication in the CNS (Mehta
et al., 1990; Scallan & Fazakerley, 1999).
Differential susceptibility to apoptotic cell death could also explain the age-related
virulence of SFV. As neurons mature, they become less susceptible to apoptosis
probably as a defence mechanism to avoid destruction of vital, non-replaceable cell
populations. Infection of neurons in the brain of neonatal mice by the avirulent SFV
A7(74) strain results in apoptotic cell death. In contrast, infection of the mature brain
with the same virus results in persistent infection, even after direct intracerebral
inoculation (Fazakerley et al., 1993; Allsopp & Fazakerley, 2000; Fazakerley &
Allsopp, 2001). The connection between the developmental status of neuronal cells
and the susceptibility to apoptotic cell death was also studied using a rat model.
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Adult rats were infected with the SFV4 virulent strain. In the brains of these animals,
apoptosis was observed only in the rostral migratory stream, an area of the brain
along which neuronal precursors constantly renew and differentiate (Sammin et al.,
1999). Upregulation of anti-apoptotic genes like bcl-2 in the mature brain might also
contribute to reduced susceptibility to apoptosis. Expression of bcl-2 has been
previously shown to have a protective effect against alphaviral infection both in vitro
and in vivo (Levine et al., 1996; Scallan et al., 1997).
Age-related virulence has been also shown for numerous other viruses including the
very similar alphavirus; Sindbis virus. Studies using avirulent strains of SV in
neonatal mice suggest that death in these animals is the result of a systemic
inflammatory response characterised by high levels of expression of a, P and y
interferon, tumour necrosis factor a and other cytokines (Sherman & Griffin, 1990;
Klimstra et al., 1999; Trgovcich etal., 1999).
Following intraperitoneal inoculation SFV has been documented to replicate in
muscle tissue (skeletal, smooth and cardiac) and in lymph nodes establishing a high
titre plasma viraemia (Grimley & Friedman, 1970; Amor et al., 1996; Fazakerley,
2002). Subsequently, the virus infects cerebrovascular endothelial cells and enters
the brain where it replicates and initiates small perivascular foci of infection. In the
brain, the virus infects neurons and oligodendrocytes but not astrocytes (Pathak &
Webb, 1978; Soilu-Flanninen et al., 1994; Amor et al., 1996; Fazakerley, 2002).
Interestingly, both virulent and avirulent strains of SFV exhibit similar tropism in the
CNS (Balluz et al., 1993; Fazakerley et al., 2006). Although astrocyte infection has
not been reported in vivo, various alphaviruses including SFV, SV and VEEV have
the ability to infect these cells in vitro (Brodie et al., 1997; Schoneboom et al., 1999;
McKimmie & Fazakerley, 2005).
The progress and the outcome of the infection is mainly based on two factors; the
strain of the virus and the age of the inoculated animal. In neonatal mice where the
CNS is still immature, widespread neuronal death due to apoptosis is observed
following infection with virulent or avirulent strains (Gates et al., 1984; Oliver et al.,
1997; Oliver & Fazakerley, 1997; Allsopp et al., 1998). In adult mice infection with
a virulent strain, like SFV L10 or SFV4, leads to rapid death (72 - 96 hours after
inoculation). Post-mortem examination of infected brains shows extensive neuronal
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cell death due to necrosis (Fazakerley et al., 1993). It is believed that virulent strains
induce death because in contrast to the avirulent strains they have the ability to
replicate productively and destroy a large number of mature neurons before
intervention of immune responses (Atkins & Sheahan, 1982; Smyth et al., 1990;
Fazakerley et al., 1993).
Infection of adult mice with avirulent strains is limited to small foci of infection
around blood vessels. Infectious virus is cleared from the brain 7 to 10 days post-
inoculation and lesions of demyelination scattered throughout the brain are apparent
at approximately 14 days post-inoculation (Amor et al., 1996; Donnelly et al., 1997;
Fazakerley, 2002). Responsible for this demyelination are activated CD8+ T
lymphocytes which destroy virally infected oligodendrocytes. Further studies using
nu/nu and SCID mice outline the importance of cellular immune responses in
induction of lesions of demyelination (Subak-Sharpe et al., 1993; Amor et al., 1996).
The ability of SFV to induce demyelination has made SFV infection of the laboratory
mouse a valuable model for multiple sclerosis a human demyelinating disease
(Mokhtarian et al., 1994; Atkins et al., 1999).
Another interesting pathogenic complication of infection with avirulent strains of
SFV is that these viruses can cross the placenta in pregnant mice and can either
induce abortions or have a teratogenetic effect on the foetuses (Atkins et al., 1982;
Mabruk et al., 1989).
Immune responses to Semliki Forest virus
Both humoural and cellular immune responses are required to control SFV infection
of the CNS. In the absence of specific immune responses the avirulent strains of the
virus have the ability to persist in the CNS for long periods of time without any
obvious cytotoxic effect (Fazakerley et al., 1993; Amor et al., 1996; Fazakerley,
2002).
Following intraperitoneal inoculation with SFV A7(74) a high level plasma viraemia
which peaks at 24 hours post-inoculation is established. Infectious virus is cleared
from the periphery and from the brain by day 3 and day 8 post-inoculation
respectively (Fazakerley et al., 1993). In athymic nu/nu mice, which produce IgM
antibodies but cannot class switch to produce IgG, viraemia is cleared in an identical
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manner to wild-type Balb/c mice but infectious virus in the brain persists for long
periods of time. This suggests that IgM antibody alone can clear the viraemia but it is
unable to control virus in the brain (Suckling et al., 1982; Amor et al., 1996). In
SCID mice, which do not produce antibodies or T-cells, persistent viraemia and
persistent infection of the CNS is established. Transfer of serum from infected nu/nu
mice to infected SCID mice resulted in clearance of the viraemia but not of the brain
virus. When serum from infected Balb/c was used to perform the same experiment
the infectious virus was cleared from both the blood and the brain. However, the
effect of the serum transfer was transient suggesting that T-cell responses are
required for sterilising immunity (Amor et al., 1996; Dixon, 2007 PhD Thesis). The
role of antibody in clearance of infectious virus was further highlighted using pMT
mice, which lack antibodies but have an intact T-cell response. These animals were
not able to clear infectious virus from their blood or their brain and SFV RNA was
detectable in their brain for up to 12 weeks post-infection (Rennos Fragkoudis,
manuscript in preparation). Similar studies with Sindbis virus have shown the
important role that antibody plays in infectious virus clearance and prevention of
reactivation (Byrnes et al., 2000; Burdeinick-Kerr et al., 2007).
Although infectious virus is cleared from the brain, viral RNA persists for long
periods of time (Levine & Griffin, 1992; Donnelly et al., 1997). Cells that contain
viral RNA possibly are cleared by cytotoxic T-cell responses. However, CD8+ T-
cells have been shown to be responsible for brain histopathology (mononuclear
infiltrates are mostly CD8+) and the appearance of lesions of demyelination
following inoculation with avirulent strains of SFV (Subak-Sharpe et al., 1993;
Mokhtarian et al., 2003).
Even though antibody and T-cell responses are important for clearance of infectious
virus and prevention of reactivation the mice would not survive long enough to
benefit from these specific immune responses without type-I interferons (interferon
a/p). Mice with impaired type-I IFN responses succumb to infection after the
administration of low doses of virulent or avirulent strains of SFV. In early studies
on the protective effect of interferon it had been shown that administration of IFN
derived from mice infected with West Nile virus had a protective effect against
virulent strains of SFV (Finter, 1966). In this and subsequent studies, the extent of
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protection was clearly dependent upon the virus strain, dose and time of
administration (Smillie et al., 1973; Bradish & Titmuss, 1981). When a-IFN
antibodies were administered, SFV avirulent infection became highly virulent
(Fauconnier, 1971). Levels of type-I IFN directly correlate to the levels of infectious
virus in the blood (Bradish et al., 1975). Muller et al. (1994) have shown that
genetically modified mice which lack a functional type-I interferon system succumb
much more rapidly to SFV infection (with either a virulent or an avirulent strain)
compared to immunocompetent mice. Administration of an avirulent strain of SFV
prior to challenge with a virulent strain like SFV L10 or SFV VI3 has also been
shown to have a protective effect (Smillie et al., 1973). The type-I interferon system
has also been demonstrated to be crucial for the protection of mice from nominally
avirulent strains of other alphaviruses including Venezuelan equine encephalitis and
Sindbis viruses (Grieder & Vogel, 1999; Ryman et al., 2000). Interestingly, the
action of type-I interferon determines the tropism of the virus by strongly curtailing
virus spread in many cell types in many tissues, for example meningeal cells in the
brain but it is not responsible for the restricted replication of SFV A7(74) in mature
neuronal cells (Ryman et al., 2000; Fragkoudis et al. manuscript submitted).
Alphaviral vectors
The idea of using a viral vector for therapeutic purposes (gene therapy) or as a
vaccine has been around for quite a long time. Both RNA and DNA viruses have
been used as expression systems for the expression and the delivery of foreign genes.
A successful vector suitable for applications in humans should include the following
features:
• High level of biological safety.
• High level transient heterologous protein expression.
• Ability to carry large inserts.
• Lack of pre-existing immunity.
• Broad host range and tissue/cell tropism
• Ability to induce adequate levels of humoural and cellular immunity.
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Expression vectors based on alphavirus are highly successful because they
encompass all the above mentioned characteristics (Frolov et al., 1996; Lundstrom et
al., 2001). Construction of alphavirus-based expression vectors required the
development of infectious cDNA (icDNA) clones. Such clones have been developed
for several alphaviruses; the viruses used most extensively for the construction of
expression vectors include SFV, SV and VEEV (Rice et al., 1987; Davis et al., 1989;
Liljestrom & Garoff, 1991). To express non-viral genes using an alphavirus, two
different types of vectors have been constructed, replication competent and
replication deficient vectors.
Replication-deficient vectors
For vaccination and gene therapy applications the replication deficient system is
preferred because it offers a very high level of biosafety. As already mentioned the
genome of alphaviruses has two ORFs, one encoding for the non-structural proteins
and one encoding for the structural proteins. In this approach, the part of the genome
corresponding to the structural proteins is replaced by the gene of interest, which is
placed under the control of the subgenomic promoter. The subgenomic promoter,
which is very powerful due to the presence of a translational enhancer found in the
capsid protein, can be duplicated and consequently two proteins can be expressed
concurrently (Sjoberg et al., 1994; Frolov & Schlesinger, 1994b; Frolov et al., 1996;
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Figure 1.4. Alphavirus replicon system, (a) Alphavirus genome; light blue area
corresponds to the non-structural genes. The light yellow area corresponds to the
structural genes, (b) In the replicon system the structural protein coding region is
replaced by a foreign gene (dark blue), (c) The subgenomic promoter can be
duplicated and two foreign genes can be inserted and expressed. In some vectors, the




To mobilise alphaviral vectors three different strategies have been applied to date.
The first approach, and possibly the most efficient utilises suicidal viral particles
known as virus-like particles (VLPs) capable of only one round of replication. To
generate VLPs, the structural genes are provided in trans either as separate RNA
messages lacking packaging signals, (called helper) or in packaging cell lines (Polo
et al., 1999; Karlsson & Liljestrom, 2003). In the early studies the structural genes
were provided as a single RNA message. This was proven problematic because
recombination between the replicon and the helper RNA leading to the production of
infectious virus was often observed (Berglund et al., 1993; Pushko et al., 1997). To
circumvent that problem, systems where the structural genes are provided as two
separate RNA messages were developed. In these systems, known as two-helper or
split-helper system, the capsid and glycoprotein genes are separated and expressed
by two individual RNAs. To further increase biosafety, mutations were incorporated
in the structural genes (Pushko et al., 1997; Smerdou & Liljestrom, 1999; Fayzulin et
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Figure 1.5. The split-helper system of SFV replicons. Three plasmids coding for
the replicon with the foreign gene of interest, the glycoprotein genes and the capsid
gene are linearised using Spe I and following in vitro transcription the RNAs are
used to co-transfect BHK-21 cells. Recombinant VLPs are made and released and
following titration they can be used to infect cells into which high-level transient
expression of the foreign gene occurs.
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In a different system, naked DNA encoding for the replicase genes and one or more
foreign genes (under the control of the 26S subgenomic promoter) are placed under
the control of a eukaryotic promoter like the CMV - IE promoter (cytomegalovirus
immediate-early) and the constructs are transfected into cells. This vector system is
known as layered DNA/RNA vector. The system provides strong transient
expression of the gene of interest. Additionally, the production is easier and more
cost effective compared to VLP production because in vitro transcription is not
required (Dubensky, Jr. et al., 1996; Berglund et al., 1998). Finally, in vitro
transcribed RNA encoding the replicon (replicase genes and gene of interest) can be
directly transfected into cells (Karlsson & Liljestrom, 2003).
All three strategies described above have been proven efficient to carry, deliver and
express proteins (genes up to 5 kb can be inserted) at high levels over extended
periods of time (Xiong et al., 1989; Morris-Downes et al., 2001; Graham et al.,
2006). Vaccines based on alphavirus vectors are very appealing because replication
occurs in the cytoplasm and thus there is no risk of integration of genes into the host
cell genome. In addition, alphavirus replicons induce apoptosis in the host cell. Other
advantageous characteristics of alphaviral systems include lack of pre-existing
immunity and a broad range of susceptible cells (Morris-Downes et al., 2001;
Karlsson & Liljestrom, 2003). Various studies have shown that alphaviruses induce
adequate immune responses and have the potential to be used as vaccines for
bacterial, parasitic and viral diseases. Examples include HIV, influenza, and malaria
(Tsuji et al., 1998; Nordstrom et al., 2005).
Since alphaviruses have a tropism for the CNS, especially for neurons, they appear to
be good candidates for gene therapy in the brain (Frolov et al., 1996; Ehrengruber,
2002). Also a study using SFV replicons showed that SFV induces p53-independent
apoptosis in tumour cells suggesting a potential use in tumour therapy (Glasgow et
al., 1998).
Even though alphaviral vectors have excellent properties their use in humans is
hampered due to their cytotoxicity in vitro and in vivo. More specifically, after
infection by an alphavirus, the host cell transcriptional and translational machinery is
shut down and eventually the cell dies (Frolov & Schlesinger, 1994a; Lundstrom et
al., 2003; Graham et al., 2006). nsP2 appears to play a critical role in alphavirus-
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mediated cytotoxicity. During infection 50% of the synthesised nsP2 migrates to the
nucleus (Peranen et al., 1990). Mutation of a single amino acid in the nuclear
localisation signal of nsP2 results in the production of a virus with reduced virulence
(Fazakerley et al., 2002). Much work has been conducted in order to produce
alphaviral vectors with reduced cytotoxicity. Through these studies vectors with
reduced cytotoxicity which are able to persistently infect the host cell have been
produced. Most of the less cytotoxic vectors carry mutations in their nsP2 protein;
such vectors have been described for SFV, SV and VEEV (Dryga et al., 1997;
Lundstrom et al., 2003; Kim et al., 2004; Petrakova et al., 2005). Interestingly,
although mutations in nsP2 usually result in decreased viral RNA synthesis the
expression levels of the foreign gene are increased. This possibly happens because
host cell protein synthesis is not affected to such extent in cells infected with mutant
replicons compared to cells infected with wild-type replicons (Lundstrom et al.,
2003; Kim et al., 2004; Petrakova et al., 2005). During studies for less cytotoxic
replicons, temperature-sensitive mutations in the non-structural genes have been
identified. These mutations offer a means to control expression of foreign genes by
shifting the temperature, from the non-permissive temperature to the permissive and
vice versa (Boorsma et al., 2000; Lundstrom et al., 2003). Cells persistently infected
with alphavirus replicons could be used for the screening of antiviral compounds or
for expression of recombinant proteins.
In vivo, in the CNS of rodents (mice and rats) non-replicating alphavirus vectors
have the ability to express foreign genes at high levels and for prolonged periods of
time. Most studies to assess the efficiency of gene transfer in neuronal cells have
been performed using replicons expressing enhanced green fluorescent protein
(eGFP). Both SV and SFV packaged vectors have the ability to infect neurons and
readily produce fluorescence (Gwag et al., 1998; Ehrengruber et al., 2001; D'Apuzzo
et al., 2001; Jeromin et al., 2003). In most studies mentioned above eGFP-positive
cells were detectable for 5 - 9 days after intracerebral inoculation. Graham et. al.
(2006) showed that stereotaxic inoculation of eGFP-expressing SFV VLPs into the
substantia nigra, an area of the brain damaged in patients with Parkinson's disease,
resulted in eGFP expression in dopaminergic neurons for up to 12 weeks. However,
dopaminergic neurons of the substantia nigra showed signs of apoptosis and
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axonopathy indicative of the cytopathic effect that SFV VLPs have. In contrast to SV,
SFV has the ability to infect oligodendrocytes. To study the interactions between this
particular cell type eGFP-expressing VLPs were used (Fazakerley et al., 2006).
The examples mentioned above highlight the potential applications of SFV in
therapeutic and experimental procedures. However, the use of replication deficient
vectors in in vivo pathogenesis studies is limited because they can only undergo a
single round of replication and therefore cannot spread far from the point of
inoculation. For that purpose, propagating vectors are required.
Replication-competent vectors
Replication-competent vectors have been constructed from many members of the
alphaviruses including SV, SFV, VEEV and Chickungunya virus (CHICK).
Traditionally, to construct a replication-competent vector the foreign gene of interest
is inserted under the control of a duplicated subgenomic promoter. The duplicated
subgenomic promoter can be inserted either into the 3' non-translated region of the
genome or into the short non-translated region between the replicase and the
structural ORF (Raju & Huang, 1991; Hahn et al., 1992; Caley et al., 1999; Vaha-
Koskela et al., 2003; Vanlandingham et al., 2005). The possible ways to insert a




Figure 1.6. Alphavirus replication-competent vectors, (a) Schematic
representation of alphaviral genome; light blue area corresponds to the replicase ORF
and light yellow area to the structural ORF. (b) Insertion of the second 26S promoter
at the 3' end of the structural polyprotein. (c) Insertion of the second 26S promoter at
the 5' end of the structural polyprotein.
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The position of insertion (upstream, 5', or downstream, 3', the structural ORF), the
length and the nature of the inserted sequence appear to be crucial for the levels of
transgene expression and the genetic stability of these vectors (Pugachev et al., 1995;
Higgs et al., 1999; Vanlandingham et al., 2005). Most studies to date suggest that
expression is stronger if the foreign gene is inserted downstream from the structural
ORF. This has been shown in numerous studies; examples include SV duplicated
subgenomic vectors expressing eGFP and Japanese encephalitis sequences, VEEV
vectors expressing the MA/CA domain of F1IV gag protein and CHICK vectors
expressing eGFP (Pugachev et al., 1995; Caley et al., 1999; Pierro et al., 2003;
Vanlandingham et al., 2005). However, according to the study by Pugachev et al.
(1995) levels of expression are not different when long sequences are inserted in
either the 5' or the 3' position.
In terms of genetic stability, constructs having the second subgenomic promoter and
the foreign gene of interest inserted at the 5' of the structural ORF are in general
more stable compared to those carrying insert at the 3' of the same region of the
genome (Pugachev et al., 1995; Caley et al., 1999; Pierro et al., 2003;
Vanlandingham et al., 2005). The length and the nature of the transgene are
important determinants of genetic stability; viruses expressing long sequences (3-4
kb) are less stable than constructs carrying shorter genes (1 - 2kb) and have the
ability to reach titres similar to those of the parental virus strain (Hahn et al., 1992;
Chen et al., 1995; Caley et al., 1999). Constructs with duplicated subgenomic
promoter have been used to express many genes; examples include influenza
haemagglutinin, bcl-2, eGFP, luciferase, antisense RNAs (Hahn et al., 1992; Levine
et al., 1996; Johnson et al., 1999; Cook & Griffin, 2003; Vaha-Koskela et al., 2003).
These constructs have been extensively used in mammalian and insect systems for in
vitro and in vivo applications. However, these viruses exhibit high levels of genetic
instability probably because the inserted sequences are incorporated as separate
transcription units that do not provide any selective advantage to the virus. This
instability has been attributed to a slower replication rate; viruses that eliminate the
inserted sequences replicate faster. Recombination between the duplicated
subgenomic promoters is another possibility (Pugachev et al., 1995; Pugachev et al.,
2000; Thomas et al., 2003; Vaha-Koskela et al., 2003; Gehrke et al., 2005).
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Alternative strategies to construct genetically stable replication-competent vectors
To construct replication-competent vectors with increased genetic stability several
alternative approaches have been employed. Pugachev et al, (2000) constructed a
recombinant rubella virus expressing foreign genes under the control of an IRES
(internal ribosomal entry sequence) from encephalomyocarditis virus (EMCV;
picornavirus). This virus was capable of stable expression of the transgene following
several passages in tissue culture.
More recently, recombinant viruses expressing foreign genes as components of the
natural expression units, the replicase or the structural ORF, of the virus have been
constructed. Using this method recombinant SV expressing eGFP, and firefly
luciferase in fusion with nsP2 or nsP3 non-structural proteins have been produced
(Bick et al., 2003; Zhimin Liang and Guangpu Li, 2005; Frolova et al., 2006;
Atasheva et al., 2007). Additionally, a similar virus expressing eGFP and cherry red
in fusion with nsP2 and nsP3 proteins respectively has been constructed. This virus,
although it replicated to lower levels compared to its parental strain was viable and
capable of expressing both proteins. An interesting finding of this study was that
insertions in the N-terminal domain of nsP2 had a negative effect on the cleavage of
the nsP2/nsP3 site. This supports the hypothesis that the N-terminal region of nsP2
has a possible function as a protease co-factor (Vasiljeva et al., 2003; Atasheva et al.,
2007).
A different strategy was employed by Thomas et al. (2003). In their vector, foreign
proteins are cloned into the structural ORF as a cleavable component. The transgene
is released by the autocatalytic activity of the capsid protein at its 5' - end and by the
autoprotease activity of the 2A peptide from foot-and-mouth disease virus (FMDV)
at its 3' - end (Donnelly et al., 2001a; Thomas et al., 2003). This virus has increased
genetic stability compared to duplicated subgenomic promoter constructs and
additionally it offers high levels of transgene expression since the foreign gene is
under the control of the powerful 26S promoter. It is important to mention that as
with other studies, this study showed that genetic stability is dependent on the size
and nature of the inserted sequences.
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All the replication-competent vectors mentioned above have their advantages and
disadvantages as discussed. However, they all share a common disadvantage; the
icDNA plasmids appear to be toxic for E. coli cells and this makes purification of
these plasmids a difficult procedure. It is believed that in SFV, this is due to the
presence of cryptic E. coli promoters in nsP2, which drive the expression of the viral
structural proteins and these proteins are toxic for the bacterial cells (personal
communication with Professor Andres Merits). A possible solution for this problem
would be the use of low-copy number plasmids as described for VEEV and EEEV
recombinant viruses (Petrakova et al, 2005).
Marker genes in virology
Marker genes are very valuable tools for various studies in virology. Applications of
marker genes will be discussed below.
Viruses tagged with marker genes have been widely used to study virus life cycle,
replication, protein localisation and cell-to-cell spread as well as virus interactions
with cellular components. The most widely used marker protein is eGFP because it is
easy to detect and most standard fluorescent microscopes have a filter suitable for its
visualisation.
In recent studies investigating replication complex formation of alphaviruses, nsP2
and nsP3 non-structural proteins of SV have been tagged with eGFP or cherry red.
This facilitated visualisation and isolation of replication complexes at early and late
time-points post-infection. In addition using a-eGFP antibodies it was possible to
isolate the complexes of cellular proteins associated with the nsP3-eGFP fusion
protein and study their role in the formation of alphaviral replication complexes
(Frolova et al., 2006; Atasheva et al., 2007). Visualisation of replication complexes
by tagging non-structural proteins with eGFP has been demonstrated for a number of
other viruses including hepatitis C virus (HCV) and equine arteritis virus (EAV). In
these studies eGFP was fused to the 5A and upstream of nsPl or nsP2 non-structural
proteins respectively (Moradpour et al., 2004; van den Born et al., 2007).
eGFP has also been used to study the localisation and the function of numerous
proteins. It is known that during alphaviral replication approximately 50% of nsP2
protein is translocated to the nucleus. Using nsP2-eGFP fusion protein it was feasible
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to observe that distribution without the need of an immunostaining (Atasheva et al.,
2007; Breakwell et al., 2007). In another study eGFP was used to study the
localisation and the function of the L protein (RNA-dependent RNA polymerase) of
measles virus (Duprex et al., 2002). To examine the role of the NS2B-NS3 protease
precursor of dengue virus in induction of apoptosis, NS2B-NS3 was fused to eGFP
(Shafee & AbuBakar, 2003).
Virus entry into permissive cells and spread of viruses from one cell to another, both
in vivo and in vitro, is another field in which eGFP-tagged viruses have been used
successfully. Examples include herpes simplex virus, measles virus and rabies virus
(Foster et al., 1998; Duprex et al., 1999; Finke et al., 2004).
During development of viral vectors for protein expression, vaccine production or
gene therapy the use of marker genes is a very valuable tool in order to assess the
levels of expression that the candidate vector provides, its genetic stability and its
cytotoxicity. eGFP and luciferase are usually the markers of choice due to the ease in
their detection. Most studies for alphavirus vector development, both replication-
deficient and replication-competent, utilise eGFP to assess the length and the
strength of expression (Lundstrom et al., 2003; Jeromin et al., 2003; Frolova et al.,
2006). Luciferase and eGFP have also been used to assess the suitability of mouse
hepatitis virus and of poliovirus respectively as expression vectors (Mueller &
Wimmer, 1998; de Haan et al., 2005). Viral vectors expressing eGFP have also been
used for the screening of antiviral compounds like morpholino oligomers and for
their potential in gene therapy against various diseases like Parkinson's disease and
in tumour therapy in melanoma (van den Born et al., 2005; Vaha-Koskela et al.,
2006; Graham et al., 2006).
Probably, the most important contribution of marker viruses is their use for in vivo
pathogenesis studies. The examples of neurotropic marker viruses used for such
studies are multiple. SV expressing luciferase under the control of a duplicated
subgenomic promoter has been used to study the progress of infection following
peripheral infection in living animals (Cook & Griffin, 2003). Various strains of SFV
and SFV replicons expressing eGFP have also been used to examine the spread of
the virus in the brain as well as its cell tropism and its ability to establish persistent
infections (Vaha-Koskela et al., 2003; Fazakerley et al., 2006). Similar studies on
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virus spread and persistence have been performed for measles virus, SARS
coronavirus and mouse hepatitis virus (Duprex et al., 2000; Sims et al., 2005;
Schubert et al., 2006).
Viruses carrying marker genes have also been constructed for several plant viruses
like tobacco etch potyvirus, and other members of the potyvirus genus to investigate
their replication and the distribution in susceptible species of plants. For the labelling
of these viruses eGFP and DSRed proteins have been used (Dolja et al., 1993;
Dietrich & Maiss, 2003).
Marker viruses have a tremendous impact on virology studies. The ease of detection
and the high sensitivity compared to traditional immunohistochemistry methods
make them a very powerful tool for various studies on the field.
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Aims of the project
The aims of this project were:
• To construct SFV-based recombinant viruses expressing marker genes.
• To characterise these viruses.
• To assess their suitability for in vivo pathogenesis studies.
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Viruses and Virus-Like Particles (VLPs)
Materials & Methods
Viruses and Virus Propagation
Various strains of Semliki Forest virus (SFV), existing and newly made were utilised
in this project (Table 2.1).
Virus Strain Backbone Modification
SFV4 n/a Virus derived from SFV4 cDNA clone
(prototype strain of virus).
A7(74) n/a None, naturally occurring strain of SFV
SFV L10 n/a None, naturally occurring strain of SFV
SFV4(3H)-eGFP virus is
annotated SFV(3H)-eGFP
in Tamberg et. al. (2007)
SFV4 Insertion of enhanced green fluorescent
protein (eGFP) gene between nsP3 and
nsP4, designed for fast processing of
foreign gene from the non-structural
polyprotein.
SFV4(3L)-eGFP SFV4 Insertion of eGFP gene between nsP3 and
nsP4, designed for slower processing of
foreign gene from the non-structural
polyprotein.
SFV4(3H)-euCre SFV4 Insertion of ere recombinase gene between
nsP3 and nsP4, designed for fast
processing of foreign gene from non¬
structural polyprotein.
SFV4(3L)-euCre SFV4 Insertion of ere recombinase gene between
nsP3 and nsP4, designed for slower
processing of foreign gene from the non¬
structural polyprotein.
SFV4-steGFP SFV4 Insertion of eGFP gene between the capsid
gene and the pE2/3 gene (structural area of
the genome).
SFV4-steuCre SFV4 Insertion of ere recombinase gene between
the capsid gene and the pE2/3 gene
(structural area of the genome).
SFV4-RDR-steGFP SFV4-
RDR
Same as SFV4-steGFP but backbone has a
mutation at the nuclear localisation signal
of nsP2 that makes the virus less virulent.
SFV4-RDR-steuCre SFV4-
RDR
Same as SFV4-steuCre but backbone has a
mutation at the nuclear localisation signal
of nsP2 that makes the virus less virulent.
Table 2.1 List of all viruses used in this project.
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All recombinant viruses were constructed in the Estonian Biocentre, University of
Tartu, Tartu, Estonia by Professor Andres Merits. Viruses were safely transported
back to Edinburgh in the form of infectious plasmid cDNA (icDNA). icDNA was
used to transform XL-10 Gold Escherichia coli (E. colt) Ultracompetent cells
according to the protocol described in this chapter. Following growth of bacteria
icDNA plasmid was extracted and quantified. Two pg of icDNA were then linearised
using SpeI restriction endonucleases and transcribed in vitro. The in vitro transcript
was electroporated into baby hamster kidney (BHK-21) cells; the contents of an
2 •
approximately 80% confluent 175 cm" tissue culture flask was electroporated.
Electroporated cells were put in a fresh 175 cm2 tissue culture flask together with 20
ml of 10% GMEM culture medium and incubated at 37°C in a humid environment
enriched with 5% CCE. Supernatant containing virus was collected 24 hrs after
electroporation, centrifuged at 450 x g for 5 minutes to remove any cell debris and
aliquoted into 1 ml aliquots in cryovials and stored at - 80°C.
To further propagate recombinant or natural occurring viruses, approximately 80%
confluent 175 cm2 tissue culture flasks of BHK-21 cells were infected with the virus
to be propagated at a multiplicity of infection (M.O.I) of 0.1 for 1 hour at room
temperature. Twenty ml of 2% GMEM culture medium were added and cells were
incubated for 24 hours at 37°C, 5% CO2. Virus containing supernatant was collected
and stored at - 80°C. All viruses were titrated using standard plaque assay.
Virus-Like Particles (VLPs)
The split-helper system developed by Smerdou and Liljestrom (Smerdou &
Liljestrom, 1999) was used for the production of VLPs carrying the gene for ere
recombinase. Briefly, pSFVl-euCre and pSFV-helper (containing the genes coding
for the structural proteins of the virus) plasmids were linearised using Spe 1
restriction endonuclease and after purification were in vitro transcribed to produce
RNA. The RNAs were mixed and electroporated into 1 x 107 BHK-21 cells. The
cells were then placed into a 175 cm2 tissue culture flask with 35 ml of pre-warmed
medium. The flask was incubated at 33°C, 5% CO2. When cytopathic effect was
observed (approximately 48 hours after electroporation), the supernatant was
collected and clarified by centrifugation, three times for 30 minutes each at 27000 x
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g. Fifteen ml of 20% (w/v) sucrose in sterile TNE buffer (pH 7.4) was added to each
ultracentrifugation tube and 17.5 ml of clarified supernatant was layered on top of
the sucrose cushion using a 20 ml sterile syringe. Tubes were placed in the holder
and balanced. The holders were then attached to the rotor and ultracentrifuged at
84,600 x g for 90 minutes. Supernatants were decanted and the VLP containing
pellets resuspended in 100 pi TNE buffer for 2 hours. Pellets were collected and the
tubes were rinsed with an additional 50 pi TNE buffer. Aliquots of 50 pi were
prepared, snap frozen in liquid nitrogen and stored at - 80°C. VLPs expressing eGFP,
SFVl-eGFP, were used in one experiment. These VLPs were kindly donated by Mr
Gerald Barry.
In vitro Transcription
Approximately 1.66 pg of plasmid DNA or icDNA was linearised using Spe I
restriction endonuclease and was in vitro transcribed to synthesise capped transcripts.
The reagents shown in Table 2.2 were added to an eppendorf tube at room
temperature (except SP6 polymerase) in the order listed.
Reagent Quantity
Spe / cut plasmid 1.66 pg
10X SP6 buffer 5.0 pi
10 mM M7 G (5')ppp (5') G (cap analog) 5.0 pi
50 mM DL Dithiothretiol (DTT) 5.0 pi
rNTP mix (10 mM ATP, CTP and UTP, 5 mM GTP 5.0 pi
Recombinant RNasin Ribonuclease Inhibitor (60 U) 1.5 pi
SP6 RNA Polymerase (75 U) 1.5 pi
Nuclease-free HiO to 50 pi
Table 2.2 Reagents used for in vitro transcription
The reaction was incubated for an hour at 37°C to produce capped transcripts.
Synthesis of RNA was verified using a 1% agarose gel. In vitro transcripts were






Various strains of mice were used (Table 2.3). Mice were maintained in the Centre
for Infectious Diseases animal unit at the University of Edinburgh under pathogen-
free conditions, with environmental enrichment, a 12 h light/dark cycle and food and
water supplied at libitum. Most mice used were between 3 and 6 weeks of age. A
small number of neonatal mice (8 days old) were used. All experiments were
approved by the University of Edinburgh ethical review process and were carried out
under the authority of a UK Home Office license.
Strain Description Background Source
Balb/c Harlan
wtl29 On site
A129 IFN a/p receptor knockout wtl29 B&K
ROSA26 eGFP inserted at the ROSA26
locus
C57B1/6 On site
ROSA26-EYFP EYFP inserted into the ROSA26
locus
C57B1/6 On site
sGFP7 Random insertion of eGFP
expressing cassette
C57B1/6 On site
sGFP97 Random insertion of eGFP
expressing cassette
C57B1/6 On site
Table 2.3 List of mouse strains used.
Infection ofMice
Two different routes of infection were used.
I. Intra-cerebral infection (i.e.): Mice were anaesthetised using halothane
mixed with O2 and 20 pi of 5 x 104 PFU/ml of virus in 0.75% PBSA
(phosphate buffered saline containing 0.75% of bovine serum albumin (BSA))
were inoculated directly into the brain using a 28 G needle.
II. Intra-peritonial infection (i.p.): Mice were immobilised and 100 pi of virus
in 0.75% PBSA were given i.p to each mouse using a 20 G needle. Two
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different doses of virus were used. The intraperitoneal route was also used for
administration of hyperimmune serum (Hi-serum).
All virus inoculation stocks were titrated prior to their use to make sure the doses of
virus given were correct.
Tissue Sampling
Mice were euthanised by CO2 overdose according the Home Office legislation. To
collect blood and internal organs the abdominal region of the animal was opened
using surgical scissors and using a pasteur pipette two drops of heparin were added
to the thoracic cavity. The right auricle of the heart was cut and blood was collected
into eppendorf tubes and centrifuged at 500 x g in a standard bench top centrifuge for
5 minutes to separate the cellular fraction of blood from serum. Serum samples were
stored at - 80°C. After collection of blood, the internal organs of the animal were
collected and placed into bijoux tubes containing 4% neutral buffered formaldehyde.
Heart, lung, liver, kidney, spleen and pancreas were collected and processed for
histology. Subsequently, the skull of the mouse was carefully opened, the spinal cord
was cut and the brain was bisected sagitally down the midline. Half of the brain was
placed into 4% neutral buffered formaldehyde and processed for histology. The other
half of the brain was either snap frozen using dry ice to be used for virus titration or
was submerged immediately in 2 ml RNA/afer RNA a reagent, which inhibits
RNases (RNA-degrading enzymes) and preserves RNA in tissue samples to be used
for RNA extraction. RNA/tf?er stabilised samples were stored at 4°C.
Histology
Processing ofTissues and Cryosectioning
After sampling, tissues intended to be used for histology studies were kept for at least
24 hours (maximum 48 hours) into 4% neutral buffered formaldehyde. Then the
tissues were processed through graded sucrose solutions to 25% sucrose (5% (w/v)
for 1 hour, 10% (w/v) for 1 hour and 25% (w/v) overnight), embedded into OCT
cryoprotection medium and frozen using isopentane. Tissue containing OCT blocks
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were then stored at - 80°C. Using a cryomicrotome tissues were sectioned into 12 -
14 pm thick sections and placed on polysine coated slides to ensure optimal adhesion.
Slides were stored at - 80°C.
Immunostaining
Cryosections of brain tissue were immunostained using antibodies targeting various
viral and cellular epitopes. Initially, slides were removed from - 80°C, placed in
front of a fan and allowed to dry for approximately 30 minutes at room temperature.
Two different methods were used in order to increase permeability of cell
membranes in the sections; sections were either treated with 0.3% Triton-XlOO for
15 minutes at room temperature or with proteinase K (20 pg/ml) for 15 minutes at
37°C followed by a 5 minute inactivation step using EDTA/Glycine/PBS. Following
membrane permeabilisation the slides were placed on a staining rack and washed in
PBS 3 times for 10 minutes constant shaking. Excess PBS was removed and tissue
sections were treated with CAS block for 30 minutes at room temperature inside a
humid chamber. Blocking solution was removed and the primary antibody was
diluted to the desired concentration in CAS block and added to the sections. Sections
were covered using parafdm, placed into a humid chamber and incubated overnight
with primary antibody. The following day parafilm was removed carefully, excess
primary antibody solution was drained from the slides and the slides were washed 3
times, for 15 minutes each, with PBS. The secondary antibody was diluted using
CAS block and added to the sections which were then incubated for a further 3 hours
at room temperature. All secondary antibodies were biotinylated. After incubation
with secondary antibody sections were washed 3 times, for 15 minutes each, with
PBS. Streptavidin (SA) conjugated Alexa Fluor 594 (excitation 590 and emission
617 nm) was diluted 1:1400 in H2O and added to the sections for 45 minutes at room
temperature. The slides were washed 3 times, for 15 minutes each, with PBS and
then mounted. The mounting media contained DAPI (4'-6-Diamidino-2-
phenylindole) to allow visualisation of nuclei. In some cases sections were incubated
with TO-PRO 3 nuclear marker solution before mounting with fluorescence
mounting medium (without DAPI). Coverslips were then permanently sealed around
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the perimeter using nail varnish and stored in a dark box at 4°C. Sections of non-
infected brain or sections of infected brain where no primary or no secondary
antibody was added were used as controls. Systematic optimisation was performed
and optimum conditions for all antibodies used were established. In Table 2.4 the
antibodies used are shown together with their optimal dilutions.
Name Type Host Isotype Source Optimum
Dilution
anti-nsP3 Primary Rabbit Polyclonal Tero Ahola 1:800
anti-SFV Primary Rabbit Polyclonal In house 1:500
anti-GFAP Primary Rabbit IgG Sigma 1:750
anti-NeuN Primary Mouse IgG 1 Chemicon 1:400
anti-CNPase Primary Rabbit Polyclonal Wistar Institute 1:400
anti-F4/80 Primary Rat IgG2b Abeam *
anti-Cre Primary Mouse IgGl Abeam *
anti-Rabbit IgG
biotinylated
Secondary Goat IgG Vector Labs 1:500
anti-Mouse IgG
biotinylated
Secondary Sheep IgG Diagnostics 1:500
anti-Rat Ig
biotinylated
Secondary Rabbit Polyclonal Abeam *
SA-Alexa Fluor
594
Tertiary - - Invitrogen 1:1400
Table 2.4 List of antibodies used for immunostainings.
Microscopy ofAnimal Tissues
Sections of various tissues on polysine coated slides were submerged in PBS, excess
liquid was drained and slides were mounted as described above (some slides were
mounted using mounting medium containing propidium iodide (PI) as a nuclear
marker). Standard histology stains such as eosin and haematoxylin were not used
because they mask the fluorescence signal. Sections were screened for fluorescence
using a standard Zeiss Axioskop2 microscope with filters suitable for visualisation of
eGFP (green), Alexa Fluor 594 (red) and DAPI (UV) or a Zeiss Axioskop confocal
microscope using 3 different lasers; an argon laser (488 nm) suitable for visualisation
of eGFP, a Helium/Neon laser (Fle/Ne 1, 543 nm), suitable for visualisation of Alexa
Fluor 594 and PI and a Helium/Neon laser (He/Ne 2, 633 nm), suitable for






BHK-21 (clone 13) cells were used to propagate and titrate viruses and to determine
• ••• • . . . 2the infectious virus titre of various samples. Cells were maintained in 175 cm" tissue
culture flasks using Glasgow's minimum essential medium (GMEM) containing 10%
new born calf serum (NBCS), 10% tryptose phosphate broth, antibiotics
(penicillin/streptomycin - lOOU/ml and 100 pg/ml, respectively) and L-glutamine (2
mM) at 37°C and in a humidified environment containing 5% CO2. When cells were
confluent, culture medium was removed and the cell monolayer rinsed with 0.02%
versene. After versene was removed 5 ml of 0.25% trypsin/EDTA was added and
the cells were incubated at room temperature until dislodged from the plastic.
Following that, 10 ml of 10% GMEM was added to neutralise the trypsin and the cell
suspension was centrifuged for 5 minutes at 450 x g. The supernatant was discarded
and the cells were resuspended in 10 ml medium. Ten pi of the cell suspension was
diluted into 90 pi of trypan blue and using a glass haemocytometer the number of
• • 2
cells was calculated. Three to five million cells were seeded into 175 cm tissue
culture flasks with 25 - 30 ml of 10% GMEM and kept at 37°C with 5% CO2. Cells
were passaged about 30 times after that their growth was very slow.
ROSA26 Mouse Embryonic Fibroblasts (MEFs)
To produce MEFs from ROSA26 Cre reporter mice a 13.5 days pregnant mouse was
sacrificed by cervical dislocation. The animal was swabbed with absolute ethanol
and the abdomen was dissected. The uterine horns were removed and placed into a
petri dish with sterile phosphate buffered saline (sPBS) to remove blood. The
amniotic sac was then removed and placed in another petri dish with sPBS. Embryos
were released from the amniotic sac and placed in a petri dish with sPBS. Neuronal
tissue was removed by decapitation. Following that the liver was removed and the
embryos were grinded using a blade into 1 ml trypsin/EDTA. Ground tissue was
incubated at 37°C for 10 minutes. A further 2 ml of trypsin/EDTA were then added
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and the tissue was incubated for a further 10 minutes. Digested tissue was transferred
to a universal tube and allowed to settle. The supernatant containing cells was placed
into a fresh universal tube and following the addition of fresh Dulbecco's modified
eagle's medium (D-MEM), containing 10% of foetal calf serum (FCS), antibiotics
(100 U/ml penicillin and 100 pg/ml streptomycin) and L-glutamine, the cells were
centrifuged for 5 minutes at 450 x g. The pellet was resuspended in 10 ml of medium
and centrifuged again. The medium was decanted and cells were resuspended in
■y t
fresh medium and added into a 80 cm' tissue culture flask along with 15 ml of fresh
medium. Cells were incubated for approximately 2 days at 37°C in humidified
environment containing 5% CCf. After 2 days dead cell debris was removed, fresh
medium was added and cells were incubated until 90% confluent. Then the cells
were passaged into 175 cm2 flasks and maintained as described above for BHK-21
cells. Before passage 2 vials of cells were frozen and stored in liquid nitrogen.
C6/36 Mosquito Cells
C6/36 cells are mosquito larvae cells derived from Aedes albopictus. Cells were
purchased from European Collection of Cell Cultures. C6/36 cells were maintained
using L-15 medium (Leibovitz) containing 10% FCS, 10% tryptose phosphate
broth, and L-glutamine (2mM) in 175 cm2 tissue culture flasks. Tissue culture
flasks containing cells were kept at 28°C without additional CO?. To passage the
cells, old medium was removed from the tissue culture flask and the cell
monolayer was rinsed with 5 ml of fresh L-15 medium. To dislodge the cells,
medium was removed, and a cell scraper was used. Following that 10 ml of L-15
medium was added and the suspension containing the cells was transferred into a
universal tube. The suspension was centrifuged at 450 x g for 5 minutes. The
supernatant was discarded and the cells were resuspended in 10 ml of medium.
Cells were counted using a haemocytometer as previously described and 175 cm2
flasks were seeded with 5 x 106 cells.
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K562 and K562-DSRed[EGFP] cell lines
K562 and K562-DSRed[EGFP] cells were kindly provided by Dr Peter Ponsaerts,
University of Antwerp. Briefly, K.562 cells were cultured in Iscove's modified
Dulbecco's medium (IMDM) containing 10% foetal calf serum (FCS), 2 mM L-
glutamine, 100 U/ml penicillin and 100 pg/ml streptomycin. To maintain K562-
DSRed[EGFP] cells the culture medium described above was used but G418
(geneticin sulphate) was supplemented at a concentration of 0.5 mg/ml to avoid
elimination of the DSRed[EGFP] insert. Cells were cultured in suspension and
maintained at 37°C in a humidified environment with 5% CO2. In order to maintain
cells in logarithmic phase growth, when the desired confluency was reached cells
were passaged into fresh culture media in a 1:3 or 1:5 ratio.
Rat Hippocampal Neurons
Rat hippocampal neurons were kindly provided by Colin Rickman, Centre for
Integrative Physiology, University of Edinburgh. Cells were isolated from rat pup
brain and plated in 6 well plates onto poly-D-lysine coated coverslips (optimal
• 9 ...
plating density -150 cells/mm"). Cells were maintained using neurobasal-A/B-27
growth medium containing 10% horse serum, L-glutamine (0.5 mM), B-27
supplement (1 ml of 50X per 50ml), penicillin and streptomycin (125 U/ml). Plates
were maintained in a humidified environment with 5% CO2. The cells were given
enough time to transform to mature neurons (approximately 3 weeks) and were then
infected with virus.
Infection ofCultured Cells
All adherent cell lines (BHK-21, ROSA26 MEFs, C6/36 mosquito cells and rat
hippocampal neurons) were infected as described in the plaque assay protocol. For
the infection of K562 and K562-DSRed[EGFP] cells, the cell suspension was
centrifuged for 5 minutes at 450 x g and resuspended in 10 ml of fresh culture
medium. Cells were counted and diluted to the desired density using serum-free
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culture medium. Virus was added (at the appropriate M.O.I) and cells were incubated
for 1 hour at room temperature with constant shaking. Following infection cells were
centrifuged at 450 x g for 5 minutes and the virus containing supernatant was
decanted, cells were washed for one more time using serum-free culture medium and
transferred to tissue culture flasks containing complete media. The same protocols
were used for infection using virus like particles (VLPs).
Transfection ofCultured Cells by Electroporation
Nucleic acids were transfected into BHK-21 cells, ROSA26 MEFs and K.562/K562-
DSRed[EGFP] cells using a BioRad Gene Pulser Xcell electroporator. On the day of
the experiment cells were collected, counted and resuspended in ice-cold phosphate
buffered saline (PBS) at a concentration of 6.25 x 106 cells per ml. Plasmid DNA or
in vitro transcribed RNA were mixed with 800 pi of cell suspension. Four hundred pi
of cells/nucleic acid mixture were added to a 0.4 cm electroporation cuvette and cells
were pulsed twice using a square wave of 140 volts for 25 mseconds. Electroporated
# 2
cells were transferred to suitable containers (6 well plates or 175 cm" tissue culture
flasks) and appropriate tissue culture media added. Plates or flasks were incubated at
33 or 37°C (depending on the application) with 5% CO2.
Microscopy ofInfected and Transfected Cells
Infected cells were examined for cytopathic effect and/or presence of eGFP
fluorescence using a Nikon inverted microscope. Given that multiple layers of plastic,
distort the UV light it was not always possible to obtain good images using this
microscope. For this reason cells were cultured on chamber slides, infected, fixed,
mounted and examined using either a standard Zeiss Axioskop2 microscope or a
Zeiss Axioskop confocal microscope.
Freezing and Thawing Cell lines
To ensure adequate amounts of cells were always available frozen stocks of all cell
lines mentioned above (sole exception being the rat hippocampal neurons) were
45
Chapter 2 Materials & Methods
prepared. Briefly, 5 x 106 cells were resuspended in 1 ml of FCS containing 10%
dimethylsulfoxide (DMSO) and cells were put into vials suitable for deep freezing
(cryovials). Cryovials were put into a cell freezer containing isopropanol and the cell
freezer was placed in - 80°C overnight. The next morning the cells were transferred
to liquid nitrogen. To grow the cells from frozen stocks, cryovials were removed
from liquid nitrogen and kept in dry ice. Then the cells were thawed rapidly using a
37°C water bath and slowly mixed with 10 ml of pre-warmed culture medium. Cell
suspension was centrifuged at 450 x g and the supernatant was decanted. Ten ml of
fresh medium were added and cells were transferred into a 25 cm2 tissue culture flask
and incubated in a humidified environment at 37°C with 5% CCE.
It is important to note that all the tissue culture procedures described above were
carried out in a class II hood under aseptic conditions to avoid microbiological
contamination.
Plaque Assay
Plaque assay was used to detect and titrate infectious virus in the brains of infected
mice and in infected cell supernatants. Six well plates were seeded with 2 ml 10%
GMEM containing 3 x lO3 BHK-21 cells and incubated at 37°C and in a humidified
environment containing 5% CO2. During incubation GMEM containing 2% NBCS
was prepared and half brain samples were thawed and homogenised immediately in
1.35 ml of sPBS. It is estimated that the mass of a half brain is -0.15 g,
homogenisation in 1.35 ml therefore gives a final volume of 1.5 ml and a 1 in 10
weight to volume homogenate. Ten-fold serial dilutions of brain homogenates/cell
supernatants/animal blood were prepared using 0.75% PBSA. When the monolayers
were approximately 80% confluent, growth medium was removed, monolayers were
washed with sPBS and 400 p.1 of each dilution were added to duplicate wells starting
with the most dilute sample. The plates were incubated for 1 hour at room
temperature inside a humid box. GMEM containing 2% NBCS was mixed with 4%
agar (10:3 ratio) and 2 ml of the mixture was used to overlay each well. The plates
were then incubated for 48-72 hours (depending on the phenotype of the viral strain)
at 37°C in 5% CCE. After incubation, the plates were fixed with 3 ml of 4% neutral
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buffered formaldehyde for 1 hour at room temperature. The fixative and the agar
plug were then removed and the monolayers stained with 0.1% toluidine blue for 30
minutes. Finally, the plates were washed and the plaques counted. To calculate the
pfu per ml content of each sample the following formula was used: (average number
of plaques/amount of inoculum) x dilution factor.
Plaque Assay-Limit of Detection
The limit of detection of the plaque assay was determined for each one of the animal
tissues and the cell supernatants. Limit of detection is the threshold below which the
assay was unable to detect any infectious virus. The formula shown above was used
to calculate the titre if the most concentrated dilution used in each assay produced a
single plaque. When brain homogenate was used the 10"' dilution was the highest
dilution used. Because the brain homogenate was already a 1 in 10 dilution of the
original material the 10"' dilution used in the plaque assay was actually a 10"2.
Applying the formula mentioned above it works out that if this dilution was used if
would give a titre 250 PFU/ml. The logarithm of that is 2.397(~2.4) Logio PFU/ml.
In an identical manner, the limit of detection of the plaque assay using animal blood
or cell supernatants was calculated to be 1.397(~1.4) Logio PFU/ml.
Plaque Purification of Viruses
To purify viruses from plaques the virus containing cell supernatant/brain
homogenate was first titrated according to the protocol described above. Following
that, fresh 6 well plates were seeded with BHK-21 cells and the virus containing cell
supernatant/brain homogenate was diluted in 0.75% PBSA so as approximately 20
PFU were contained in 400 pi and the suspension was used to infect 80% confluent
monolayers of BHK-21 cells. The plates were covered with agar as described above
and incubated for 48-72 hours at 37°C in 5% CO2. After this, an extra ml of GMEM
containing 2% NBCS mixed with 4% agar (10:3 ratio) and 0.02% neutral red was
added to each well in order to facilitate visualisation of plaques. The plates were
incubated for another 24 hours. In the meantime, 24 well plates were seeded with 2
ml of 10% GMEM containing 1 x 105 BHK-21 cells and incubated at 37°C and in an
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environment containing 5% CO2. The following day, sterile pipette tips were used to
pick individual plaques and each plaque was then added to a separate well of a 24
well plate. The plates were incubated further at 37°C in 5% CO2 until cytopathic
effect was observed.
One-Step Growth Curves
To obtain One-Step growth curves BHK-21 cells monolayers were infected at an
M.O.I of 10 in triplicate. Briefly, 6 well plates were seeded with BHK-21 cells and
incubated at 37°C with 5% CO2. When the monolayers reached the desired
confluency the growth medium (GMEM with 10% NBCS) was removed and the
cells were washed with sPBS and infected with the required amount of virus diluted
in 400 pi of 0.75% PBSA. Infection was 1 hour long and took place in a humid
chamber at room temperature with constant gentle shaking. After 1 hour the
monolayers were washed three times using 0.75% PBSA to remove any unbound
virus. Two ml of pre-warmed 10% GMEM were added. That was time-point zero.
Two hundred pi of supernatant were collected every 2 hours for the next 12 hours in
sterile eppendorf tubes and the samples were stored at - 80°C. All samples were
titrated according to the protocol described above and one-step growth curves were
constructed.
Western Blotting
BHK-21 cells were grown in 6 well plates until approximately 80% confluent. Cells
were infected as previously described. Following that, and at various time-points
depending on the strain of virus used, culture medium was removed and cells were
lysed using 300 pi Laemmli sample buffer. Lysates were transferred to an eppendorf
tube and heated at 100°C for 5 minutes. BioRad's Mini-Protean II apparatus was
used for protein electrophoresis. Briefly, the gel casting apparatus was assembled and
filled with resolving gel containing 10% acrylamide to a level just below the bottom
of the comb. A layer of isobutanol was added and the gel allowed to set for
approximately 20 minutes. Isopropanol was removed with filter paper and stacking
gel containing 4% acrylamide was added, the combs were inserted and the gel
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allowed to set for approximately 20 minutes. The combs were removed, the gel was
assembled in the electrophoresis tank of the Mini-Protean II apparatus and the
chambers of the apparatus were filled with running buffer (BioRaD lOx
Tris/Glycine/SDS Buffer). Ten pi of each sample was added to the wells and the gel
electrophoresis was performed by applying 170 V for 1 hour (electrophoresis was
stopped when blue dye band reached the bottom of the resolving gel).
Nitrocellulose membrane was soaked in distilled H2O for 3 minutes and then in
transfer buffer (Tris base 5.8 g, glycine 2.9 g, SDS 0.37 g, ethanol 200 ml and H2O to
a final volume of 1 L) for 10 minutes. The gel was also soaked in transfer buffer for
5 minutes. A sandwich consisting of 3 MM Whatman paper (x3) cut in the size of the
gel and soaked into transfer buffer, nitrocellulose membrane, SDS gel and another 3
pieces of 3 MM Whatman paper. The proteins were transferred to the membrane by
applying a current of 25 V for 30 minutes. Nitrocellulose membrane was blocked
overnight at 4°C using blocking solution containing 5% non-fat milk in PBS
containing 0.1% Tween 20. Primary antibody was diluted in blocking solution and
added to the membrane for approximately 1 hour at room temperature. The
membrane was washed 3 times for 15 minutes each using wash buffer (50 ml 1M
Tris pH 7.5, 30 ml 5M NaCl, 1 ml Tween 20 and H2O to a final volume of 1 It).
Secondary antibody was diluted in blocking solution and added to the membrane for
45 minutes at room temperature. The membrane was washed 3 more times for 10
minutes each. The reagents of the ECL detection kit were mixed (1:1) and added to
the membrane for 1 minute. Nitrocellulose membrane was wrapped using cling film,
put into exposure cassette and taped in place. X-ray film was exposed to the
membrane, time varied between 1 minute and 1 hour, developed and dried. Optimal
concentrations of all antibodies used for western blotting can be seen in Table 2.5.
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Name Type Host Isotype Source Optimum
Dilution
anti-nsPl Primary Rabbit Polyclonal Tero Ahola 1 10000
anti-nsP2 Primary Mouse Monoclonal Tero Ahola 1 6000
anti-nsP3 Primary Rabbit Polyclonal Tero Ahola 1 10000
anti-nsP4 Primary Rabbit Polyclonal Tero Ahola 1 4000
anti-capsid Primary Rabbit Polyclonal Andres Merits 1 10000
anti-eGFP Primary Rabbit IgGl Molecular
Probes
1 1000
anti-Cre Primary Mouse IgGl Abeam 1:500
anti-Rabbit IgG
peroxidase
Secondary Goat IgG Sigma 1:10000
anti-Mouse IgG
peroxidase
Secondary Goat IgG Sigma 1:10000
Table 2.5 List of antibodies used for western blotting.
RNA Extraction
From Cultured Cells
Total RNA was extracted from virally infected cells using the Qiagen RNeasy Mini
kit according to the manufacturer's instructions. Briefly, 1 x 106 infected cells were
lysed using 350 pi of RLT buffer containing 1% (3-mercaptoethanol. Cell lysate was
transferred to a 1.75 ml sterile RNase-free eppendorf tube and passed at least 10
times through a 21 gauge needle to ensure complete lysis. Three hundred and fifty pi
of 70% molecular grade ethanol was added to the lysate and the mixture mixed by
pippeting. Seven hundred pi of suspension were added in an RNeasy mini column
and the column centrifuged for 15 seconds at 8,000 x g in a table top centrifuge. The
column was then washed by adding 350 pi of RW1 buffer and centrifuging at 8,000
x g for 15 seconds. Eighty pi of RNase-free DNase was then added directly onto the
membrane of the column and the column was incubated for 15 minutes at room
temperature. Another 350 pi of RW1 buffer were added and the column was
centrifuged. The column was then transferred to a new collection tube and 500 pi of
buffer RPE was added to the column in order to precipitate the RNA. After
centrifugation at 8,000 x g for 15 seconds another 500 pi of buffer RPE was added
and the column was centrifuged for 3 minutes at maximum speed to ensure all
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residual ethanol was removed. Thirty pi
through the column to elute the RNA.
From Brain Samples
Materials & Methods
of RNase-free water was passed twice
All brain samples were stored in KNAlater stabilisation reagent, which inhibits
RNAses and preserves RNA in tissue samples. Total RNA was extracted using the
RNeasy Lipid kit according to the manufacturer's instructions. Briefly, 100 mg of
brain tissue was homogenised with 1 ml of QIAzol lysis reagent using a disposable
RNase-free plastic homogeniser. The homogenate was passed through a 20 gauge
needle at least 20 times and was then incubated for 5 minutes at room temperature to
promote dissociation of nucleoprotein complexes. Then 200 pi of chloroform was
added and the homogenate was shaken vigorously. After a 3 minute incubation at
room temperature the sample was centrifuged at 12000 x g for 15 minutes at. 4°C.
Following centrifugation three separate layers were formed; the upper aqueous phase
was transferred to a new RNase-free eppendorf tube and 70% ethanol was added (1:1
ratio). The subsequent steps of the protocol are identical to the ones described above.
Nucleic Acid Quantification and Qualification
All RNA samples were quantified using a NanoDrop ND-1000 spectrophotometer
and the quality of the RNA was assessed using the Agilent Bioanalyser. Briefly, 1 pi
of each RNA sample was placed in the NanoDrop ND-1000 spectrophotometer and
the RNA concentration was measured (range 2 ng/pl-3 pg/pl). After this 1 pi of each
sample was diluted using RNase-free water to obtain samples within a range of 50-
250 ng/pl. All samples were heat-denatured (70°C for 2 minutes) and placed
immediately on ice. Finally, samples were loaded to the Agilent RNA 6000 Nano
assay chip (12 samples per chip) following the manufacturer's instructions and the
chip was analysed using the Agilent 2100 Bioanalyser. At the end of the assay the
analysis software provides information about the integrity of the RNA. This data can
then be used to assess if the RNA samples are suitable for downstream procedures.
All DNA samples were quantified using the NanoDrop ND-1000 spectrophotometer
in a similar manner to the RNA samples.
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First-Strand cDNA Synthesis by Reverse Transcription
Reverse transcription was performed into 0.2 ml thin-walled PCR tubes. The reaction
mixture had a volume of 20 pi and contained the following: 1 pi of Oligo (dt)i5
primer, 2 pg total RNA, 1 pi of 10 mM dNTPs and DNase/RNase-free water to a
volume of 12 pi. The mixture was heated for 5 minutes at 65 °C and then chilled on
ice for a minute. The tubes were kept on ice and 4 pi of 5X First-Strand buffer, 2 pi
of 0.1 M DTT and 1 pi of RNasin recombinant ribonuclease inhibitor were added.
The tubes were then incubated at 42°C for two minutes. Following that, 1 pi of
Superscript II RNase FF reverse transcriptase enzyme (from Moloney Murine
leukaemia virus) was added and the reaction was incubated for an hour at 42°C. A
final incubation of 15 minutes at 70°C was performed and the cDNA was stored at -
20°C.
Polymerase Chain Reaction (PCR)
Polymerase chain reaction (PCR) was utilised for the amplification of nucleic acids.
Two different thermostable polymerases were used depending on the downstream
application for which the amplified fragment would be used. If the amplified
fragment was intended to be used for blunt-end cloning and subsequent sub-cloning
into SFV replicons and/or full length SFV icDNA Platinum Pfx DNA polymerase,
which also provides high fidelity amplification, was used. The reaction mixture had a
volume of 50 pi and contained the following: 5 pi I OX Pfx amplification buffer, 1.5
pi of 10 mM dNTPs, 1 pi of 50 mM MgSC>4, 1 pi of each primer (50 pM), 2 pi of
template DNA, 1 U of Platinum Pfx DNA polymerase and DNase/RNase-free water
to a final volume of 50 pi. The reactions were incubated in a thermal cycler using the
following protocol: an initial denaturation step of 3 minutes at 94°C followed by 30
cycles of three steps; denaturation at 94°C for 15 seconds, annealing at 55°C for 30
seconds and extension at 68°C for 1 minute 30 seconds. Then a final extension step
was performed at 72°C for 15 minutes. A non-template (FhO) control was used in
every PCR run to test possible contamination of the reagents. The PCR products
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were analysed using gel electrophoresis (1% agarose gel) and stored at - 20°C for
further experiments.
For diagnostic PCR and to use the amplified fragments for sequencing standard Taq
DNA polymerase was used. The reaction mixture had a volume of 20 pi and
contained the following: 2 pi of 10X PCR buffer containing 15 mM MgC^, 0.4 pi of
10 mM dNTPs, 0.5 pi of each primer (50 pM), 0.3 pi of Taq DNA polymerase and
DNase/RNase-free water to a final volume of 20 pi. The reactions were incubated in
a thermal cycler using the following protocol: an initial denaturation step of 5
minutes at 95°C followed by 27 cycles of three steps; denaturation at 94°C for 30
seconds, annealing at 55°C for 30 seconds and extension at 72°C (time varied
depending on the size of the amplified fragment. Then a final extension step was
performed at 72°C for 15 minutes. A non-template (H2O) control was used in every
PCR run to test for possible contamination of the reagents. Suitable positive controls
were also included when diagnostic PCR was performed The PCR products were
analysed using gel electrophoresis (1% agarose gel) and stored at - 20°C for further
experiments. A list of all primers used is shown in Table 2.6.











Table 2.6 List of primers used for PCR amplification.
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Agarose Gel Electrophoresis
DNA and RNA were analysed by agarose gel electrophoresis. Briefly, 0.7 - 2%
agarose gels were prepared using 0.5 M Tris borate (TBE) buffer with 0.5 pg/ml
ethidium bromide to enable visualisation of DNA or RNA under UV light. Samples
were mixed with 6X loading buffer and loaded in the wells of the agarose gel.
Electric current was then applied to the gel (100 - 130 volts depending on the
percentage of the gel) for approximately 1 hour in order to separate different
fragments of nucleic acid. As a size marker, two different DNA ladders were used; 1
Kb and 100 bp DNA ladder. Using a UV transilluminator nucleic acid fragments
were visualised.
DNA Extraction from Agarose Gel
DNA fragments were extracted from agarose gel using the QIAquick Gel Extraction
Kit according to the manufacturer's instructions. Briefly, DNA fragments were
separated by electrophoresis and long wavelength UV light was used to visualise the
fragments. Using a sterile blade the fragment was excised from the agarose gel and
weighed. Three volumes of Buffer QG were added and the sample was incubated at
50°C until completely dissolved. One volume of isopropanol was then added and the
sample mixed. The sample was applied to a QIAquick column and centrifuged for 1
minute at 17900 x g to bind the DNA onto the silica membrane. Flow-through was
decanted and 500 pi of QG Buffer was added to remove any traces of agarose. The
column was spun again and 750 pi of PE Buffer was applied, the column was
allowed to stand for 5 minutes and centrifuged for 1 minute at 17900 x g. To ensure
complete removal of residual ethanol, the QIAquick column was centrifuged for an
additional minute. To obtain increased yield of DNA 30 pi of DNase-free H2O were
added to the column and the column was allowed to stand for 1 minute. Finally, the







Zero Blunt® TOPO® PCR cloning was used for cloning of blunt-ended PCR
fragments. The cloning reaction contained; 2 pi fresh PCR product, 1 pi salt solution,
2 pi molecular grade H2O and 1 pi of pCR®-Blunt Il-TOPO® vector. The reaction
was incubated at room temperature for 15 minutes. Then 2 pi of the ligation reaction
were used to transform One Shot® DH5a-Tl chemically competent E. coli cells.
pGEM-T Easy Cloning
PCR fragments were cloned into the pGEM®-T Easy vector according to the
manufacturer's instructions. Briefly, 5 pi of 2X Rapid Ligation buffer, 1 pi (50 ng)
of pGEM -T-Easy Vector, 1 - 3 pi PCR product (depending on the size of the
fragment), 3 Weiss units of T4 DNA ligase (1 pi) and molecular grade H2O to a final
volume of 10 pi. The reaction was incubated for approximately 16 hours at 4°C to
maximise number of transformants. Following incubation 3 pi of the ligation
reaction were used to transform subcloning efficiency DH5a chemically competent
E. coli cells.
pSFVl Vector Cloning
pSFVl vector was kindly provided by Professor Peter Liljestrom, Karolinska
Institute, Sweeden. The vector has a multiple cloning site, which facilitates the
insertion of foreign genes. For the insertion of a foreign gene the vector was digested
using BamH\ and Sma\ restriction endonucleases; because these two enzymes exhibit
their maximum activity in different buffers sequential digestions were performed.
One hour before the end of the second digestion calf-intestinal alkaline phosphatase
(CIAP, lU/pg of plasmid DNA) was added to the reaction in order to
dephosphorylate the vector and avoid religation. The digested dephosphorylated
vector was then purified using a Jetquick kit according to the protocol described
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below. The insert was sequentially digested using BglU and Smal restriction
endonucleases and it was purified using a QIAquick PCR purification kit according
to the protocol described below. Both the linearised vector and the insert were run on
a 0.7% agarose gel to verify their size. Subsequently, ligation reactions using a 1:1,
1:3 and 3:1 molar ratio of vector:insert DNA were prepared. Each ligation reaction
had a final volume of 10 pi and contained 1 pi ligase 10X buffer, 1 pi of T4 DNA
ligase, and LEO to make up the final volume. The amount of vector and insert varied
according to the vectoninsert ratio. To calculate the amounts of insert and vector
required for each reaction the following formula was used: ((ng of vector x kb size of
insert)/kb size of vector) x insert:vector molar ratio) = ng of insert. The reactions
were incubated overnight at 4°C. Five pi of the ligation reaction were then used to
transform subcloning efficiency DH5a chemically competent E. coli cells.
Bacterial Techniques
Bacterial Culture
Various laboratory strains of E. coli were used. These were grown in Luria-Bertani
(LB) medium or on LB plates with 1.5% agar. Media was sterilised and agar melted
by autoclaving. Media was supplemented with appropriate antibiotics (100 pg/ml
ampicillin or 50 pg/ml kanamycin) prior to use. LB agar was poured into 10 cm
diameter Petri dishes. Bacteria were plated on the surface of LB agar by spreading
with a glass spreader and plates were incubated, inverted, at 37°C for approximately
16 hours. Single colonies from agar plates were used to inoculate liquid medium.
Liquid cultures were incubated for approximately 16 hours with constant shaking at
225 rpm in an orbital shaker at 37°C. All bacterial procedures were performed under
aseptic conditions.
Transformation ofOne Shot® DH5a- T1 and DEI5a Chemically Competent cells
One Shot" DH5a - T1 chemically competent cells were transformed with the
products of the TOPO cloning reaction. In brief, a vial of competent cells was
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thawed on ice. Two pi of the cloning reaction were added to the cells and mixed
gently. The vial was then incubated on ice for 30 minutes. Cells were then heat-
shocked for 30 seconds at 42°C and 250 pi of pre-warmed SOC medium was added.
The vials were incubated for 1 hour at 37°C with constant shaking at 225 rpm in an
orbital shaker. Fifty or 100 pi of the transformation reaction was then plated on LB
agar plates supplemented with 50 pg/ml kanamycin and the plates were incubated,
inverted, for approximately 16 hours at 37°C.
To transform subcloning efficiency DH5a chemically competent cells, a vial of cells
was thawed on ice and cells were aliquoted into 50 pi aliquots in 1.5 ml sterile
eppendorf tubes. Three pi of the pGEM-T easy ligation reaction or 5 pi of the pSFVl
ligation reaction were added to the cells and the mixture was incubated for 30
minutes on ice. Cells were then heat-shocked for 20 seconds at 37°C and 950 pi of
pre-warmed SOC medium was added. The vials were incubated for 1 hour at 37°C
with constant shaking at 225 rpm in an orbital shaker. Fifty and 150 pi of the
transformed cells was plated on LB agar plates supplemented with 100 pg/ml
ampicillin and the plates were incubated, inverted, for approximately 16 hrs at 37°C.
pGEM-T Easy vector allows blue/white colony screening to facilitate the selection of
colonies carrying recombinant plasmids (insertion of a PCR fragment disrupts the
coding sequence of P-galactosidase and colonies appear white on indicator plates) .
Indicator plates were made by spreading 100 pi of 100 mM IPTG (isopropyl-beta-D-
thiogalactopyranoside) and 20 pi pf 50 mg/ml X-Gal on the surface on LB agar
plates supplemented with ampicillin. Plates were allowed to absorb IPTG/X-Gal for
30 minutes at 37°C. To allow development of colour these plates were incubated,
inverted, for at least 17 hours at 37°C.
Transformation ofXL 10-Gold Ultracompetent cells
Efficiency of transformation of DH5a cells by large constructs, like icDNA of the
recombinant viruses, is low. For this reason XL 10-Gold ultracompetent cells, which
are suitable for the transformation of large DNA molecules with high efficiency were
used. Ultracompetent cells were chilled on ice and 100 pi were aliquoted into 15 ml
pre-chilled Falcon tubes. Four pi of P-mercaptoethanol were added to the cells and
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the cells were incubated for 10 minutes on ice; mixed gently every 2 minutes.
Approximately 200 ng of plasmid DNA was added to the cells and the tubes were
incubated for 30 minutes on ice. Cells were then heat-shocked for 30 seconds at 42°C
and placed on ice for 2 more minutes. Pre-warmed SOC medium was added to a final
volume of 1 ml and the tubes were incubated for 1 hour at 37°C with constant
shaking at 225 rpm in an orbital shaker. Two hundred pi of the transformation mix
was plated on LB agar plates supplemented with 50 pg/ml ampicillin and the plates
were incubated, inverted, at 37°C for 24 hours.
Plasmid DNA extraction for Diagnostic Purposes (Miniprep)
The QIAprep Spin Miniprep Kit was used, according to the instructions given by the
manufacturer, to isolate small amounts of plasmid DNA for diagnostic purposes
(sequencing and restriction digestions). A single fresh colony was isolated from an
LB agar plate and placed into 5 ml of LB broth supplemented with either 100 pg/ml
ampicillin (50 pg/ml for XL 10-Gold ultracompetent cells) of 50 pg/ml kanamycin in
universal tubes. Tubes were incubated overnight at 37°C at 225 rpm in an orbital
shaker. After overnight incubation tubes were centrifuged at 1,500 x g for 6 minutes.
Pelleted bacterial cells were resuspended in 250 pi Buffer PI and transferred to a
microcentrifuge tube. Lysis Buffer P2 was added (250 pi) and the tube was mixed by
gentle inversion. Lysis was allowed to proceed for 5 minutes and 350 pi of buffer N3
was added and the tube was mixed gently and centrifuged at 17,900 x g for 10
minutes. The supernatant was transferred to a QIAprep Spin column and the column
was centrifuged for 1 minute at 17,900 x g to bind the DNA to the silica-gel
membrane. The column was washed by adding 500 pi of Buffer PB and centrifuged
at 17,900 x g for 1 minute. An additional wash wish 750 pi of Buffer PE was
performed followed by another centrifugation step. Column was centrifuged for an
additional minute to remove residual wash buffer. To elute DNA 50 pi of DNase-free
HiO was added directly onto the silica-gel membrane, the column was allowed to
stand for 1 minute and centrifuged for one minute at 17,900 x g. DNA samples were




Large Scale Plasmid DNA Extraction (Maxiprep)
Materials & Methods
For the extraction of large amounts of high quality plasmid DNA the Qiagen
EndoFree Plasmid Maxi Kit was used. A single colony was isolated from an LB agar
plate and used to inoculate a starter culture of 2 ml LB medium containing the
appropriate antibiotic, 100 pg/ml ampicillin (50 pg/ml for XL 10-Gold
Ultracompetent cells) or 50 pg/ml kanamycin. The starter culture was incubated for
6-8 hours at 37°C in an orbital shaker (225 rpm). Five hundred pi of the starter
colony was inoculated in 250 ml of LB medium supplemented with the appropriate
antibiotic. The culture was grown for 14-16 hours at 37°C with constant shaking.
Bacterial cells were harvested by centrifugation at 6,000 x g for 15 minutes at 4°C.
Ten ml of Buffer PI was used to resuspend the bacterial pellet and following the
addition of 10 ml of Buffer P2 the mixture was gently mixed and lysis was allowed
to proceed for no more than 5 minutes. Chilled Buffer P3 (10 ml) was added to the
lysate and the lysate was poured into the barrel of the QIAfilter Cartridge and
incubated for 10 minutes at room temperature. Cell lysate was then filtered into a 50
ml tube and 2.5 ml of Buffer ER was added; the tube was inverted 10 times to mix
the contents and incubated on ice for 30 minutes. A QIAGEN-tip 500 was
equilibrated by applying 10 ml Buffer QBT; Buffer was allowed to flow through by
gravity flow. The filtered lysate was added to the equilibrated QIAGEN-tip and
allowed to enter the resin. QIAGEN-tip was washed twice with 30 ml of Buffer QC,
which was allowed to move through the tip by gravity flow. Fifteen ml of Buffer QN
was used to elute the DNA. DNA was precipitated by the addition of 0.7 volumes of
room temperature isopropanol and the mixture was centrifuged at 15,000 x g for 30
minutes at 4°C. The pellet containing the DNA was washed with 5 ml of 70%
ethanol and centrifuged at 15,000 x g for 10 minutes. The supernatant was removed;
the pellet air-dried for approximately 10 minutes and resuspended with 300 pi of
DNase-free FLO. Samples were stored at - 80°C.
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Preparation ofFrozen Stocks ofTransformed Bacteria
A single colony was isolated from an LB agar plate and used to inoculate 5 ml of LB
medium containing the appropriate antibiotic. The culture was grown for
approximately 16 hours at 37°C in an orbital shaker (225 rpm). Bacteria were
pelleted by centrifugation (6 minutes at 1,500 x g) and the pellet was resuspended
using 1 ml of 50% glycerol in H2O. The sample was transferred to sterile eppendorf
tubes and snap frozen using dry ice. Tubes were stored at - 80°C.
Plasmid DNA Restriction Digestion
Restriction endonucleases were used to digest plasmid DNA. Various restriction
endonucleases were used for the purposes of this project. In general, digestion
reactions had a final volume of 20 pi and the reaction mixture contained: 2 pi of
digestion buffer, 2 pi of 10X BSA, 1 pi of restriction endonucleases, plasmid DNA
(volume varied according to the required amount of plasmid DNA) and DNase-free
H2O to the final volume. The reactions were then incubated for 2 - 4 hours at the
optimum temperature for each restriction endonuclease and the products were
purified as described below and analysed using agarose gel electrophoresis.
Purification of Restriction Digestion Products
To purify DNA fragments from restriction digestion reactions two different kits were
used. For fragments up to 10 kb the QIAquick PCR purification Kit was used. In
brief, 5 volumes of buffer PB were added to 1 volume of the digestion reaction and
mixed by pippeting. To bind the DNA the sample was applied to the QIAquick
column and the column was centrifuged for 1 minute at 17900 x g. Flow-through was
discarded and 750 pi of Buffer PE were added followed by a 1 minute centrifugation.
An additional centrifugation of one minute was performed to remove any residual
ethanol. DNA was eluted using 30 pi of DNase-free H2O as previously described and
samples were stored at - 20°C. For fragments larger than 10 kb the Jetquick
(Genomed) kit was used. The volume of the digestion restriction reaction was
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adjusted to 100 pi with DNase-free H2O and 400 pi of solution HI were added. The
mixture was loaded onto the provided column and centrifuged for 1 minute at 12000
x g. The flow-through was discarded and 500 pi of solution H2 were added and the
centrifugation step was removed twice to ensure complete removal of ethanol.
DNase-free H2O was heated at 65-70°C and 30 pi were added directly onto the silica
matrix. The column was allowed to stand for 1 minute and then centrifuged for 1
more minute. Eluted nucleic acid was stored at - 20°C.
Sequencing of Plasmid DNA and Sequence Analysis
In order to verify that the gene of interest was amplified and cloned successfully into
the pCR®-Blunt 1I-TOPO® vector, approximately 5 pg of multiple plasmid DNA
samples were sent to the departmental sequencing facility and were sequenced using
M13 forward and reverse primers. For sequencing of PCR fragments cloned into the
pGEM®-T-Easy Vector, 2 pg of multiple plasmid DNA samples were sent to MWG-
Biotech and were sequenced using Ml3 forward and reverse primers. Sequences
were analysed using BLAST (http://www.ncbi.nlm.nih.gov/BLAST) and the BioEdit
software package.
Details about the manufacturers of kits used in this project and recipes of common
solutions can be found in Appendix E
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Introduction
Fleterologous gene expression from RNA viruses or viral vectors has potential
applications in biotechnology (recombinant protein production, vaccines and
therapeutics) as well as in basic research (examples include virus replication studies
and in vivo pathogenesis studies). The development of infectious cDNA (icDNA)
clones for many RNA viruses, both positive and negative strand, has simplified the
process of manipulating the genomes of these viruses and allowed researchers to
introduce various genes.
Alphavirus-based vectors are currently amongst the most widely used expression
vector systems. icDNA clones and expression vectors have been developed for most
alphaviruses including Semliki Forest virus (SFV), Sindbis virus (SV) and
Chikungunya virus (Rice et al., 1987; Liljestrom & Garoff, 1991; Vanlandingham et
al., 2005). In order to express non-viral genes using these systems two different types
of vectors have been constructed. Replication-deficient vectors, also known as
replicons, and replication competent vectors.
Replication-deficient vectors are ideal for in vitro studies on virus replication and are
potential candidates for vaccines and therapeutics applications. They have an ability
to carry large inserts and have good biosafety (Smerdou & Liljestrom, 1999).
Flowever, these vectors have a major disadvantage which does not allow their use for
in vivo pathogenesis studies; they lack the structural ORF of the virus and therefore
can only undergo a single cycle of infection (Frolov et al., 1996).
To create replication-competent vectors a duplicated subgenomic 26S promoter was
inserted into either the 3' non-translated region of the genomic 42S RNA or the short
non-translated region between the non-structural and the structural ORF (Raju &
Huang, 1991; Hahn et al., 1992; Vanlandingham et al., 2005). An alternative strategy
employed by Pugachev et al. (2000) expressed the foreign gene using an internal
ribosomal entry site element (IRES) from a picornavirus in the genome of rubella
virus (also a member of the Togaviridae family). Double-subgenomic promoter
replicating vectors carrying a variety of foreign genes including marker genes (for
example eGFP and luciferase) have been constructed and used in animal studies
(Cook & Griffin, 2003; Vaha-Koskela et al., 2003). Although very useful, double-
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subgenomic promoter viruses have generally proved to be genetically unstable. That
is somehow expected since inserted genes are incorporated as separate transcription
units that do not provide any selective advantage to the virus (Pugachev et al., 1995;
Caley et al., 1999; Pugachev et al., 2000).
Alphavirus vectors with increased genetic stability have been constructed by
applying an alternative approach. The foreign gene of interest was inserted into the
non-structural (replicase) ORF. Using this method SV with marker genes (eGFP and
firefly luciferase) inserted in the replicase ORF (in fusion with nsP2 or nsP3
proteins) have been constructed (Bick et al., 2003; Frolova et al., 2006; Atasheva et
al., 2007).
In the present study, replication-competent SFV vectors carrying eGFP were
generated and characterised. The eGFP gene was inserted in the non-structural ORF
of SFV4 between nsP3 and nsP4. The novelty of these newly made marker viruses
was based on their ability to express eGFP as a cleavable component of the replicase
polyprotein. The complete in vitro and in vivo characterisation of these two newly
made replicating vectors is described in this chapter.
Objectives
The objectives of this study were:
• To investigate if insertion of eGFP in the replicase ORF alters the replicase
polyprotein processing or the replication efficiency of the virus.
• To test if levels of eGFP expression are adequate for detection using a
standard fluorescent microscope.
• To examine the effect of the eGFP insertion on the in vitro and in vivo
virulence of SFV4.
• To assess the phenotypic and genotypic stability of recombinant viruses in
vitro and in vivo.
• To evaluate the suitability of the recombinant viruses for in vivo pathogenesis
studies.
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Construction of recombinant viruses
Recombinant viruses used for this project were constructed by Professor Andres
Merits at the Estonian Biocentre. Initially, a vector annotated pSFV4(3F) designed to
express foreign proteins fused to the C-terminus of nsP3 was constructed. To
facilitate the insertion of foreign genes in this vector, a short polylinker incorporating
Apa\ and BamHI restriction sites was inserted (Tamberg et al., 2007). Enhanced
green fluorescent protein (eGFP) was amplified from pEGFP-Nl plasmid (Clontech)
with primers incorporating Apa\ and BamH\ adapter sites (shown in materials and
methods chapter) and cloned in-frame into the C-terminus of nsP3 (amino acid 452).
The resulting construct (pSFV4(3F)-eGFP) was used to produce infectious virus
(SFV4(3F)-eGFP) as described by Liljestrom et al. (1991) (Fig 3.1a).
Characterisation of SFV4(3F)-eGFP showed that although the virus was viable, able
to infect cells and express an nsP3-eGFP fusion protein, it was genetically highly
unstable. SFV4(3F)-eGFP has potential use as a tool to investigate the expression of
SFV replicase genes and the formation of SFV replicase complexes in vitro but is not
suitable for in vivo pathogenesis studies due to its genetic instability (Tamberg et al.,
2007).
To construct a replicating vector able to express eGFP as a separate protein (not
fused to nsPs) pSFV4(3F) was engineered further. The native C-terminus of nsP3
was restored by duplication of its last 30 amino acids (aa 453-482) and one of two
optimised artificial nsP2 protease recognition sites was inserted between the C-
terminus of nsP3 and eGFP. The two artificial protease recognition sites were
designated L and H, standing for low and high respectively, indicating the efficiency
by which these sites are cleaved by nsP2 protease. In both L and H the first amino
acid residue (PI') after the cleavage was mutated from a tyrosine'(Y) to a glycine (G)
for two reasons: glycine is a stabilising amino acid according to the N-end rule
(Varshavsky, 1996) and nsP2 protease cleaves more efficiently with glycine in that
position (Lulla et al., 2006). In the case of the H recognition site, amino acid residues
2-7 from the N-terminus of nsP4 were inserted after glycine to enhance the cleavage
efficiency. The additional proline inserted at the end of the H and L nsP2 recognition
sites originates from the Apal restriction site. The resulting vectors were annotated
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pSFV4(3L) and pSFV4(3H). eGFP was amplified and cloned into these vectors as
described above and infectious viruses designated SFV4(3L)-eGFP and SFV4(3H)-
eGFP were obtained from their icDNA clones (Fig 3.1b). The recombinant viruses
described in this thesis and the Tamberg et. al. (2007) publication are identical. The
differences in the clone names are due to different annotation systems used in
Edinburgh and Tartu, respectively. SFV4(3F)-eGFP is annotated SFV(3F)4-eGFP
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Figure 3.1. Schematic representation of eGFP expressing replicating vectors, (a).
SFV4(3F)-eGFP, construction and predicted processing of the non-structural
polyprotein. The amino acid sequence, the position of the native nsP2 protease
recognition site between nsP3 and nsP4 and the 30 amino acids (453-482) from the
C-terminus of nsP3 which were fused at the C-terminus of eGFP are shown.
Tyrosine residue at position PI' is shown in red. (b). SFV4(3L)-eGFP and
SFV4(3H)-eGFP, construction and predicted processing of the non-structural
polyprotein. The amino acid sequence, the position of both the artificial and the
native nsP2 protease recognition sites and the 30 amino acids (453-482) from the C-
terminus of nsP3 which were fused at the C-terminus of eGFP are shown. Tyrosine
residue in the native cleavage site and glycine residue in the artificial sites are shown
in red. In the predicted processing of SFV4(3H)-eGFP, (6) corresponds to the
IFSSDT sequence. The proline (P) residue at the end of both L and H constructs is
the result of the insertion ofApa\ restriction site.
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Assessment of the expression levels of a marker gene (eGFP) as part of
the replicase ORF and the effect of this insertion on virus viability and
replication.
Experimental design
To assess the effect of eGFP insertion on virus viability and replication efficiency,
BHK-21 cells were infected with SFV4, SFV4(3H)-eGFP and SFV4(3L)-eGFP at a
multiplicity of infection (M.O.I) of 10 in triplicate and virus replication was
compared in a one-step growth curve. Two hundred p.1 of virus containing
supernatant were collected and replaced with an equal amount of fresh medium every
2 hours for 12 hours. All samples were then titrated using standard plaque assay. In
addition, to determine whether or not eGFP was expressed to adequate levels to be
detected using a standard fluorescent microscope and to determine the kinetics of
eGFP expression, cultures of BHK-21 cells were infected with SFV4(3H)-eGFP and
SFV4(3L)-eGFP at an M.O.I of 10 and were monitored for expression of eGFP every
hour for the first 12 hours post-infection and every 4-6 hours thereafter. The ability
of these viruses to induce a cytopathic effect (CPE) was determined by infection of
parallel cultures of BHK-21 cells.
One-step growth curves
One-step growth curves (Figure 3.2a) demonstrated that insertion of eGFP into the
replicase polyprotein did not have a major effect on the viability and replication
efficiency of SFV. Both SFV4(3H)-eGFP and SFV4(3L)-eGFP were able to infect
BHK-21 cells and replicated to similar levels to SFV4. However, there were minor
differences, at 4 hours post-infection SFV4(3H)-eGFP and SFV4(3L)-eGFP had
significantly lower titres than SFV4 (P<0.05). At 6 hours post-infection SFV4(3H)-
eGFP had similar titres to SFV4 (no significant difference, P>0.05), whereas
SFV4(3L)-eGFP still had significantly lower titres (P<0.05). From 8 hours post¬
infection until the end of the experiment (12 hours post-infection) all viruses had
similar titres (no significant differences, P>0.05). Titres at each time-point were
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compared using a paired t-test. Titration of the supernatant samples showed that on
BHK-21 cells, SFV4(3H)-eGFP and SFV4(3L)-eGFP produced plaques with size
similar to SFV4 (data not shown).
eGFP expression and development ofCPE in BHK-21 cells
Following infection of BHK-21 cells with SFV4, SFV4(3H)-eGFP and SFV4(3L)-
eGFP cells were monitored at regular intervals for eGFP fluorescence and CPE. For
the cultures infected with the eGFP marker viruses, fluorescent signal was detected
as early as 2 hours post-infection, a representative example of eGFP fluorescence
early during infection can be seen in Figure 3.2b. The intensity of the fluorescence
signal increased until about 6 hours post-infection and then rapidly decreased. Late in
infection cells had a dull green fluorescent signal. Prior to approximately 16-20 hours
post-infection with all three viruses, cells had the typical elongated morphology of
BHK-21 cells and no sign of CPE was observed (Figure 3.2b). Between 16-20 hours
post-infection CPE was first apparent (Figure 3.2c). Cells rounded up and their
nuclei condensed suggesting that cells were dieing. At 36 hours post-infection almost
all the cells were detached. Infection progressed in an identical manner with all three
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Figure 3.2. Growth curves and expression of eGFP in BHK-21 cells, (a)
Monolayers of BHK-21 cells were infected in triplicate with SFV4 (dark blue
circles), SFV4(3H)-eGFP (light blue circles) or SFV4(3L)-eGFP (inverted dark blue
triangles) at an M.O.I of 10. Supernatant samples were collected every 2 hours for 12
hours and titrated for infectious virus. Each point represents the mean of 3 samples.
The bar represents the standard deviation (SD). (b) and (c). All growth curves shown
in this thesis were performed in parallel. The data for SFV4 presented in this figure is
identical to that in Figures 4.2a and 5.3a allowing comparison of the growth of all
recombinant viruses. Images of BHK-21 cells infected with SFV4(3H)-eGFP virus at
an M.O.I of 10 taken 4 and 20 hours post-infection, respectively. Panel (b) shows the
typical morphology of BHK-21 cells observed early in infection whereas panel (c)
shows the characteristic morphology of cells dying at the late stages of infection. No
difference on eGFP expression or development of CPE was observed when
SFV4(3L)-eGFP was used to infect BHK-21 cells. Pictures acquired with Zeiss
Axioskop microscope.
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Expression and stability of the replicase complex and eGFP proteins in
eGFP expressing viruses
Experimental design
To investigate if insertion of eGFP between nsP3 and nsP4 altered the pattern of
expression of the four non-structural proteins and to study the stability of the viral
non-structural proteins and of eGFP, two experiments were performed.
Experiment I) BF1K-21 cells were infected with SFV4(3H)-eGFP or SFV4(3L)-
eGFP at an M.O.I of 20. PBSA was used as a negative control to mock-infect cells.
After 6 hours, cells were lysed and samples corresponding to 100,000 cells were
separated on an SDS-PAGE gel and proteins were transferred to a nitrocellulose
membrane. Antibodies recognising specific epitopes on nsPl, nsP2, nsP3, nsP4 and
eGFP were used (see methods) to detect SFV non-structural proteins and eGFP.
Experiment II) To investigate the stability of eGFP, BHK-21 cells were infected at
an M.O.I of 100 with SFV4, SFV4(3H)-eGFP or SFV4(3L)-eGFP for 3 hours. Using
[°S]methionine and [j3S]cysteine, cells were metabolically labelled and chased for 1,
3, 8 or 24 hours. nsPl, nsP3 and eGFP antibodies were used to immunoprecipitate
the respective labelled proteins in cell lysates. This experiment was performed by my
colleague Mrs Nele Tamberg at Estonian Biocentre according to the method
described in Tamberg et al. (2007).
Expression ofeGFP & of the replicase proteins ofSFV4(3H)-eGFP and SFV4(3L)-
eGFP in BHK-21 cells
As it can be seen in Figure 3.3a, all non-structural proteins and eGFP were expressed
from both recombinant viruses. All proteins had correct molecular weights (migrated
to the expected position) on the SDS-PAGE gel. The artificial cleavage sites inserted
between nsP3 and eGFP appeared to be cleaved very efficiently; no band
corresponding to an nsP3-eGFP fusion protein was visible. In contrast, an eGFP-
nsP4 fusion protein was detected when anti-nsP4 and anti-eGFP antibodies were
used. Comparison of the density of the bands corresponding to eGFP-nsP4, nsP4 and
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eGFP proteins for both recombinant viruses shows that the amounts of eGFP-nsP4
fusion protein were considerably lower than the amounts of individual nsP4 and
eGFP proteins. The results of this experiment indicate that insertion of eGFP as a
cleavable protein between nsP3 and nsP4 does not interfere with the expression of
the non-structural proteins of SFV. The western blotting analysis (Figure 3.3a)
suggested that both SFV4(3H)-eGFP and SFV4(3L)-eGFP produced similar amounts
of non-structural proteins and eGFP at 6 hours post-infection; however the one-step
growth curves (Figure 3.2a) at this same time-point showed that more SFV4(3H)-
eGFP infectious virus was produced than SFV4(3L)-eGFP. This inconsistency could,
for example, be related to differences in the release of infectious virus particles
between SFV4(3H)-eGFP and SFV4(3L)-eGFP, perhaps as a result of slower
replication of the virus resulting from slower processing of the replicase polyprotein.
Another possibility is that SFV4(3L)-eGFP produced more DI particles than
SFV4(3H)-eGFP.
Stability of eGFP & of the non-structural proteins of SFV4(3H)-eGFP and
SFV4(3L)-eGFP in BHK-21 cells
The intensity of the eGFP fluorescence signal in BHK-21 cells dramatically
decreased late in infection (from 6 hours onwards). The eGFP used in these
constructs normally has a half-life of approximately 24 hours in BHK-21 cells
(personal communication with Clontech technical support). One explanation would
be an increased instability of eGFP. Following shut-off of the replicase gene
translation, which starts a few hours after infection, fluorescence intensity can be
taken as a measure of eGFP stability. Rapid loss of fluorescence after 6 hours
indicates high instability of eGFP. The results of the pulse-chase experiment (Figure
3.3b) showed that nsPl and nsP3 were stable throughout the 24 hours of the
experiment, only a minor decrease in nsP3 was observed. It is important to note that
this result was very similar for both the recombinant viruses and SFV4. In contrast,
eGFP was detectable only for up to 8 hours and was thereafter below the limit of
detection. This finding is in accordance with the findings obtained from microscopic
examination of infected BHK-21 cells and again suggests that rapid degradation of
eGFP is responsible for the low intensity and short duration of the fluorescent signal.
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Figure 3.3. Expression and stability of the repliease complex and eGFP proteins
in eGFP expressing viruses, (a) Western blotting of cell lysates of BHK-21 cells
inoculated with SFV4(3H)-eGFP (3H), SFV4(3L)-eGFP (3L) (M.O.I 20) or PBSA
(mock-infection M). Specific bands of the appropriate molecular weight for nsPl,
nsP2, nsP3, nsP4 non-structural proteins and for eGFP are shown with a black
arrowhead. The blue arrowheads on the panels corresponding to nsP4 and eGFP
indicate an eGFP-nsP4 fusion protein, (b) BHK-21 cells were infected with SFV4,
SFV4(3L)-eGFP, SFV4(3H)-eGFP (M.O.I 100) or PBSA (M). Synthesised protein
was labelled with [33S]methionine and [35S]cysteine at 3 hours post-infection and
chased for 1, 3, 8 or 24 hours. Cell lysates were immunoprecipitated with nsPl, nsP3
and eGFP specific antibodies. Picture for 3.3(b) was kindly provided by Mrs Nele
Tamberg.
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Distribution of eGFP and nsP3 non-structural protein in BHK-21 cells
infected with SFV4(3H)-eGFP and SFV4(3L)-eGFP
Experimental design
SFV RNA replication complexes consisting of the 4 fully processed non-structural
proteins are known to associate with cellular membranes, especially the cytoplasmic
surface of endosomes and lysosomes (Froshauer et al., 1988; Salonen et al., 2005). It
has been also shown that free eGFP is distributed throughout the cell cytoplasm and
the nucleus. Recent studies using replicating Sindbis virus vectors expressing eGFP
in fusion with nsP3 show that eGFP and nsP3 co-localise in the cytoplasm of
infected cells (Frolova et al., 2006). In order to examine if eGFP was released free
from the replicase complex in SFV4(3H)-eGFP and SFV4(3L)-eGFP infected cells,
cultures of BHK-21 cells on glass slides were infected at an M.O.I of 10 and at 6
hours, fixed and stained with anti-nsP3 antibody.
Distribution ofeGFP and nsP3 in BHK-21 cells
In BHK-21 cells infected with SFV4(3H)-eGFP (Figure 3.4a) or SFV4(3L)-eGFP
(Figure 3.4d) distribution of eGFP was very similar; fluorescence was observed
throughout the cytoplasm and the nucleus of the infected cells. SFV replication and
eGFP protein synthesis occur in the cytoplasm of the cell. Due to its small size, eGFP,
can also diffuse through the nuclear pores and localise in the nucleus (passive
transfer). Interestingly, eGFP fluorescence was more intense in the nuclei of infected
cells than in the cytoplasm. On the other hand, nsP3 was detected only in the
cytoplasm of infected cells with both viruses (Figure 3.4b and Figure 3.4e). During
infection, after the replicase polyprotein is processed by the viral protease (nsP2),
individual proteins assemble to form replication complexes (Lemm & Rice, 1993a;
Kujala et al., 2001; Salonen et al., 2003). The punctate, predominantly perinuclear,
cytoplasmic staining for nsP3 most probably corresponds to the location of these
replication complexes. The absence of co-localisation between eGFP and nsP3
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suggest, as also observed by western blotting (Figure 3.3a), that eGFP was cleaved
efficiently from the replicase polyprotein.
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Figure 3.4. Distribution of eGFP and nsP3 in BHK-21 cells. Confocal microscopy
images of BHK-21 cultures infected with SFV4(3H)-eGFP [(a), (b) and (c)] or
SFV4(3L)-eGFP [(d), (e) and (f)] at an M.O.I of 10. Mock- infected (PBSA) control
culture can be seen on panels (g), (h) and (i). Cells marked with an asterisk show the
characteristic distribution of eGFP in BHK-21 cells, where eGFP stains the
cytoplasm of the cell and also diffuses to the nucleus. Arrows point to cells
exhibiting punctate nsP3 staining; the staining is consistent with the distribution of
virus replication complexes formed by fully processed non-structural proteins on the
surface of cytoplasmic membranes.
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In vitro phenotypic and genotypic stability of SFV4(3H)-eGFP and
SFV4(3L)-eGFP in BHK-21 cells
Experimental design
To examine whether the recombinant viruses maintained their ability to express
eGFP or if the inserted gene was eliminated after several passages in vitro,
SFV4(3H)-eGFP and SFV4(3L)-eGFP were passaged 5 times in BHK.-21 cells at an
M.O.I of 0.01 (low M.O.I increases the possibility to detect changes). Figure 3.5
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Figure 3.5. Experimental design to investigate in vitro phenotypic and genotypic
stability. In triplicate, monolayers of BHK.-21 cells were infected with recombinant
viruses. Supernatant was collected at 24 h and total RNA was extracted from the
cells and analysed by RT-PCR for virus RNA. Each supernatant was passaged four
more times through BHK-21 cells. Supernatants after each passage were then titrated
and used to infect (20 PFU) fresh BHK-21 cells. These monolayers were overlayed
with agar and 96 plaques were purified; individual plaques were transferred to 24-
well plates and each well was analysed for eGFP expression.
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Phenotypic stability ofSFV4(3H)-eGFP & SFV4(3L)-eGFP
Viruses from 96 plaques purified from each of 5 in vitro passages were used to infect
BHK-21 cells and eGFP expression was determined by fluorescent microscopy. For
the first two passages, 100% of plaque purified viruses for both recombinant viruses
were eGFP positive. After 3 passages 98.9% of SFV4(3H)-eGFP and 94.5% of
SFV4(3L)-eGFP plaque purified viruses maintained their ability to express the
marker gene. These percentages went down to 95.2% and 68.75% respectively after
the 4th passage. At the 5th passage 93.6% of SFV4(3H)-eGFP and 50% of SFV4(3L)-
eGFP plaque purified viruses were expressing eGFP (Figure 3.6a).
Genotypic stability ofSFV4(3H)-eGFP <& SFV4(3L)-eGFP
After removal of the supernatants from the BHK-21 cells for the assessment of
phenotypic stability, RNA was extracted from these cells. The RNA was quantified,
its quality was tested using an Agilent Bioanalyzer and 2 p,g were reverse-transcribed
to cDNA. Primers flanking the area of the eGFP insertion were used for
amplification. If the intact insert was present a product with a size of approximately
1,500 bp would be produced. If the insert was eliminated the expected product would
have a size of approximately 670 bp. The results obtained (Figure 3.6b) indicate that
the amount of product (and consequently of eGFP negative viruses) of -670 bp
gradually increased between the 2nd and 5th passage for both recombinant viruses.
The increase was considerably greater for SFV4(3L)-eGFP and at the 4th and 5th
passage the amount exceeded that of the product corresponding to the eGFP positive
virus. In contrast, the levels of product corresponding to eGFP negative virus did not
increase much when SFV4(3H)-eGFP was passaged and did not exceeded the eGFP
positive virus.
As can be seen on the panel of Figure 3.6b corresponding to the 5th passage;
numerous bands appear between the band corresponding to the product
containing the eGFP insert and the band of the product where the insert was
eliminated (especially for SFV4(3H)-eGFP; lanes 1-3). These bands together with
the -1,500 bp and the -670 bp bands were extracted from the gel and sub-cloned into
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the pGEM-T Easy vector which was amplified and sent off for commercial
sequencing. Sequencing was carried out from both ends of the cloned insert and the
consensus sequences are shown in Appendix II. The obtained sequences were
aligned to SFV4 and to SFV4(3H)-eGFP or SFV4(3L)-eGFP using the BioEdit
software. The -1,500 bp product contained the complete inserted sequence. The
-670 bp product had a complete elimination of the inserted sequence. The
intermediate sized bands contained in-frame deletions varying in size from 75
nucleotides to 843 nucleotides (Appendix II). Interestingly, in most of these
recombinants deletion started at the inserted nsP2 protease recognition site upstream
of eGFP. This site is located directly after the C-terminus of nsP3, the 30 amino acids
of which are repeated downstream from eGFP. This suggests that recombination may
have occured between the duplicated nsP3 C-terminal sequences. The genotypic
stability analysis is consistent with the phenotypic stability; SFV4(3L)-eGFP











& // *+ #
*






4th 1 2 3 4 5 6 1 5"' 1 2 3 4 5
W W W ^ v..v W
Figure 3.6. In vitro phenotypic and genotypic stability of SFV4(3H)-eGFP and
SFV4(3L)-eGFP. (a) percentage of eGFP positive plaque purified viruses after serial
passaging; dark blue is SFV4(3H)-eGFP and light blue is SFV4(3L)-eGFP. (b) RT-
PCR genotyping of virus RNA using nsP3 - nsP4 primers on RNA samples isolated
from BHK-21 monolayers at passages 2, 3, 4 and 5; the passage number is indicated
at the top left of each panel. In all panels, lanes l - 3 are the triplicate passages of
SFV4(3H)-eGFP and lanes 4-6 are the triplicate passages of SFV4(3L)-eGFP
(except in bottom right panel where there is no lane 6). The red arrow corresponds to
the l .5 kb band of the DNA ladder and the blue arrow corresponds to the 0.5 kb band
of the DNA ladder.
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Cell tropism of recombinant viruses in vitro
Experimental design
SFV is a neurotropic virus transmitted by mosquitoes, to determine if the insertion of
eGFP had any effect on the ability of the virus to infect mosquito cells and cells of
the vertebrate nervous system, cultures of C6/36 cells from Aedes albopictus and of
rat hippocampal neurons were infected with SFV4(3H)-eGFP. Only SFV4(3H)-eGFP
was used in these studies as the previous in vitro experiments had shown that it had
higher genetic stability compared to SFV4(3L)-eGFP. eGFP expression was
monitored using fluorescence microscopy. Infected C6/36 cells were immunostained
with anti-nsP3 antibody to determine if the distribution of eGFP and nsP3 were the
same as in BFIK-21 cells. C6/36 cells were infected at an M.O.I of 10. Rat
hippocampal neurons were plated at their optimal density (150 cells/mm*" on 22x22
mm coverslips) and infected at an M.O.I of 10.
In vitro cell tropism
SFV4(3H)-eGFP was able to infect C6/36 cells and express eGFP (Figure 3.7a &
3.7d). The distribution and the intensity of the eGFP signal were similar to those
observed in BHK-21 cells; eGFP stained both the cytoplasm and the nucleus of the
infected cells. When the infected cells were immunostained with anti-nsP3 antibody
the nsP3 staining was cytoplasmic and exhibited the characteristic punctate
distribution observed in BHK-21 cells (Figure 3.7b and 3.7e). Merging the green
(eGFP) and red channels (Alexa Fluor 594; anti-nsP3 immunostaining) it was
observed that some eGFP-positive cells (marked with an asterisk in Figure 3.7f) were
not positive for nsP3. The cells were fixed and stained 16 hours after addition of
virus (M.O.I of 10). It is possible that these eGFP-positive nsP3-negative cells were
recently infected and that nsP3 had not accumulated to adequate amounts to be
detected by immunostaining. Additional experiments would be required to
investigate this. C6/36 cultures infected with SFV4 and SFV4(3H)-eGFP were also
monitored for the presence of CPE; none was observed over 5 days of study.
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Given that eGFP expression was detectable in both BF1K-21 and C6/36 cells for at
least 20 hours, neuronal cultures were examined after overnight infection with
SFV4(3H)-eGFP (approximately 16 hours), at that time no eGFP was detectable.
Due to the shortage of neuronal cultures, the experiment was not repeated. The CPE
induced by both SFV4 and SFV4(3H)-eGFP was taken to indicate that both viruses
infected vertebrate neurons and that the recombinant virus had not lost this property.
Cells looked healthy for up to 48 hours post-infection, after which widespread cell
death was observed. All cells were dead by 4 days post-infection. Parallel cultures
infected with SFV4 showed the same pattern on the development of CPE whereas
mock-infected cultures remained viable throughout the study.
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eGFP a-nsP3 merged
Figure 3.7. Infection of C6/36 cells from Aedes albopictus with SFV4(3H)-eGFP.
Panels (a) and (d) show eGFP expression in C6/36 cells infected with SFV4(3H)-
eGFP at an M.O.I of 10 for 16 hours. Panels (b) and (e) show immunostaining of the
same monolayer with anti-nsP3 antibody. Inset of panel (e) demonstrates the
characteristic punctate cytoplasmic staining at high magnification. Merged images
shown on panels (c) and (f). The asterisk on (f) marks an area with cells which
expressed eGFP but were negative for nsP3. Non-infected control culture is shown in
panels (g), (h) and (i). Bars in all panels correspond to 100 pm. All images were
acquired with a Zeiss confocal microscope.
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Virus pathogenesis following intraperitoneal inoculation
To investigate the course of recombinant virus infection in vivo following




Groups (n=10) of adult (4-5 week old female) Balb/c mice were inoculated i.p. with
5 x 103 PFU of SFV4, SFV4(3H)-eGFP, SFV4(3L)-eGFP, SFV L10 (virulent strain
of SFV) or mock-infected with PBSA. Weight-loss is indicative of clinical disease
and mice were weighed daily for the first 4 days post-infection (PID). On PID 4, five
mice from each group (except the group infected with SFV L10) were euthanised and
their brains were sampled. Half of each brain was snap frozen and used for infectious
virus titration. The other half was processed for frozen sections to examine eGFP
expression. The remaining mice from each group were kept for 10 days and
monitored daily for symptoms of viral encephalitis. The data was used to construct
survival curves.
Results
Infected and mock-infected mice were weighed daily (Figure 3.8a). Mice infected
with SFV4, SFV4(3FI)-eGFP or SFV4(3L)-eGFP gained weight over the first four
days of the infection (average change of +2%). However, this increase was
approximately 5 times lower than the control group mock-infected with PBSA
(change of +9.7%). In contrast, mice infected with SFV L10 showed a weight-loss of
-13.3%. On PID 2 all mice in the L10 group had symptoms of severe encephalitis
(ataxia and paralysis) and, after measuring their weight, were euthanised. On PID 4,
five mice from each of the remaining groups were sampled; half brain for virus
titration and half for histological study, as described previously. None of these mice
exhibited symptoms of viral encephalitis. Mice were sampled at this time as previous
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studies have shown that the highest levels of infectious virus are detectable in the
brain 3-4 days after i.p. inoculation (Fazakerley et al., 1993). Flowever, previous
studies were performed with SFV A7(74) and the efficiency of SFV4 to cross the
blood-brain barrier and replicate in the brain has not previously been characterised.
All PID 4 brain samples titrated for infectious virus were below the limit of detection
of the assay (2.4 Logio PFU/g) suggesting that the virus did not cross the blood-brain
barrier or, at least that it had not done so by PID 4. Examination of frozen sections
(12 pm thick) of brain tissue (6 slides per brain sample, 3 sections per slide) of all the
mice infected with SFV4(3H)-eGFP or SFV4(3L)-eGFP and sampled on PID 4
showed no eGFP expression. This result is consistent with the absence of detectable
infectious virus.
Data on the survival of the infected mice was used to plot survival curves (Figure
3.8b). In contrast to the SFV L10 infected group in which 100% of the animals were
dead or had reached clinically defined terminal end-points by PID 3, 100% of the
animals infected with SFV4, SFV4(3H)-eGFP or SFV4(3L)-eGFP survived the
infection without any clinical signs. According to other researchers using SFV4
(personal communication), neuroinvasion of SFV4 appears to be dose dependent but
once the virus is in the brain it confers lethal neurovirulence. Therefore the
experiment was repeated using a higher dose of virus (5 x 105 PFU) and mice were
monitored for 10 days for signs of viral encephalitis. The results obtained were
identical to the results of the first experiment, with no clinical evidence of brain
infection by the SFV4 viruses (data not shown).
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Figure 3.8. Changes in body weight and survival rates of Balb/c mice following
i.p. inoculation with SFV. (a). Average body weight of i.p. infected mice (n=!0). At
the end of the experiment (PID4), SFV4-infected animals had a 2.7% weight increase.
For SFV4(3H)-eGFP and SFV4(3L)-eGFP-infected animals this increase was 2.2%
and 1.1%, respectively. Animals infected with SFV L10 had a 13.3% weight
decrease. In contrast the animals mock-infected with PBSA had a 9.7% weight
increase (b). Survival rates ofmice (n=5) following i.p. inoculation.
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Experiment II-Determination ofviraemia
Experimental design
To examine if the recombinant viruses were able to establish a peripheral infection
(viraemia), groups of 6 adult Balb/c mice were inoculated i.p. with 5 x 103 PFU of
SFV4, SFV4(3H)-eGFP, SFV A7(74), SFV L10 or mock-infected with PBSA. SFV
A7(74) is an avirulent strain, in adult mice, known to be neuroinvasive following
extraneural inoculation,(Bradish et a!., 1971; Pathak & Webb, 1978). Twenty-four
hours post-infection mice were euthanised and heparinised blood was collected and
titrated for infectious virus.
Results
It was hypothesised that SFV4 and SFV4-based constructs expressing eGFP failed to
infect the brain of Balb/c mice following i.p. inoculation because they did not
replicate to high enough titres in the periphery. To test this hypothesis groups ofmice
were infected, as described above, with SFV4, SFV4(3H)-eGFP, SFV L10 or mock-
infected with PBSA and virus titres in the blood were determined at 24 hours.
SFV4(3L)-eGFP was excluded since it appears to be no different to SFV4(3H)-eGFP
and the in vitro characterisation of the viruses showed that it loses its ability to
express eGFP fairly quickly.
Titration of blood samples at 24 hours post-infection showed that 5 out of 6 mice
infected with SFV4 and 4 out of 6 mice infected with SFV4(3H)-eGFP had
detectable levels of infectious virus. On the other hand, all mice infected with SFV
A7(74) or SFV L10 (6/6) were positive. SFV4 infected mice had an average titre of
3.7 Logio PFU/ml (SD: 1.4) and SFV4(3H)-eGFP an average titre of 3.3 Logio
PFU/ml (SD: 1.6). Statistical analysis using paired t-test showed no significant
difference between the two viruses (P>0.05). In contrast, SFV A7(74) infected mice
had an average titre of 7.2 Logio PFU/ml (SD: 0.4) and mice infected with SFV L10
had an average titre of 6.6 Logio PFU/ml (SD: 0.7). Using paired t-test the values of
the titres for SFV A7(74) and SFV L10 were not statistically different (P>0.05).
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However, the titres of both these viruses were significantly higher than those of
SFV4 and SFV4(3H)-eGFP (P<0.05) (Figure 3.9a). As expected, all mice mock-
infected with PBSA had no detectable infectious virus. Comparison of the plaque
sizes (on BHK.-21 cells) produced by these viruses showed that SFV4 and
SFV4(3H)-eGFP produced plaques with a very similar size (0.5-1 mm), Figure 3.9b,
which were smaller than the plaque size produced by SFV A7(74) (1.5-3 mm),
Figure 3.9c. These results suggest that insertion of eGFP in the non-structural ORF
did not attenuate SFV4 since SFV4(3H)-eGFP had the same phenotype as SFV4
following intraperitoneal inoculation. However, titres of SFV4 and SFV4(3H)-eGFP
were significantly lower than those of SFV A7(74) and SFV L10 (approximately 3
logs) and the plaque sizes were smaller, indicating that SFV4 virus and viruses
derived form it, replicate less efficiently in vitro and in vivo than SFV A7(74) or SFV
L10. This probably explains why SFV4 and SFV4-based recombinant viruses failed
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Figure 3.9. Comparison of levels of viraemia and of plaque size caused by
various SFV strains, (a) SFV4 (dark blue circle) and SFV4(3H)-eGFP (light blue
circle) had significantly lower titres than SFV A7(74) (inverted dark blue triangle) or
SFV L10 (green triangle) (P<0.05; paired t-test). SFV4 and SFV A7(74) were not
significantly different to SFV4(3H)-eGFP and SFV L10 respectively (P>0.05; paired
t-test). Mock-infected mice (PBSA, dark blue square) had no infectious virus in the
blood as expected. All samples were collected at 24 hours post-infection. Plaques
produced by SFV4 and SFV4(3H)-eGFP had a similar size; representative plaques
can be seen on (b. The plaques produced by SFV A7(74) (c) were larger. Monolayers
of BHK-21 cells shown on (b) and (c) were infected with heparinised blood; sampled
from mice infected with SFV4(3H)-eGFP and SFV A7(74), respectively. Cells were
fixed 2 days post-infection and stained with toluidine blue.
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Experiment Ill-Virus spread in wt mice and mice deficient in type-I interferon
responses
Since the SFV4 icDNA was originally derived from the SFV prototype strain which
is related to SFV L10, the difference between SFV4 and SFV L10 is surprising. Most
likely some changes were introduced into the SFV4 as a result of this cloning process.
These could have affected one of more aspects of the virus life-cycle, but changes in
receptor binding or interaction with host defences are two important factors of
infection which could be responsible for the difference between SFV4 and SFV L10.
To investigate the role of the IFN system the following experiment was performed.
Experimental design
Type-I interferon is an important factor affecting the outcome of viral infections
(Isaacs & Lindenmann, 1957). To study the spread of the infection in the absence of
type-I interferon, groups (n=3) of adult (4-5 week old, female) IFN a/(3 receptor
knock-out mice (A 129) (Muller et al., 1994) and wtl29 mice were infected with 5 x
10J PFU of SFV4 or SFV4(3H)-eGFP. One mouse from each group was sampled at
24 hours post-infection and the remaining mice were sampled on PID 2. Heparinised
blood was collected to determine the amount of infectious virus present. In
SFV4(3H)-eGFP infected mice; spleen, pancreas, heart, lung, kidney, and brain were
sampled and processed for frozen sections. Sections were examined for eGFP
expression.
Results
Blood samples from A129 (IFN a/(3 R°/0) and wtl29 mice infected (i.p.) with SFV4
or SFV4(3H)-eGFP were titrated and the results are summarised in Table 3.1. SFV4
and SFV4(3H)-eGFP infected wtl29 mice had similar titres on PID 1 (0.15 Logio
PFU/ml difference). All wtl29 mice sampled on PID 2 had no detectable virus in the
blood. As expected A129 mice, which lack type-I interferon responses, were not able
to control the infection and had much higher titres of virus in the blood. On PID 1
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SFV4 and SFV4(3H)-eGFP had a viral load of 8.5 and 7.9 Logio PFU/ml
respectively (0.6 Logio PFU/ml difference). On PID 2 both remaining mice infected
with SFV4 were found dead. SFV4(3H)-eGFP infected mice had an average titre of
8.3 Logio PFU/ml. It is not possible to draw any firm conclusions, due to the small
number of animals used per time-point, however the results suggest that in the
absence of active type-I interferon responses, insertion of eGFP had a slight
attenuating effect on SFV4. A129 mice infected with SFV4(3H)-eGFP had lower
titres of infectious virus in the blood at PID 1 and survived longer than A129 mice
infected with SFV4. A study with a larger number of animals is required to obtain
results with statistical significance. These results also illustrate that the type-I
interferon system very effectively limits SFV4 infection; blood virus titres at 24
hours were increased in the order of 10,000-fold in the absence of an intact type-I
interferon system. Other data from this laboratory indicates that titres of SFV A7(74)
also increased in the absence of type-I interferon response but not to the same extent
suggesting that SFV4 either generates more interferon or is more sensitive to it than
SFV A7(74).
Virus PID 1 wt!29 PID 2 wtl29 PID1 A129 PID2 A129
SFV4 4.4 (1/1) <1.4 (2/2) 8.5 (1/1) -
SFV4(3H)-eGFP 4.2 (1/1) <1.4 (2/2) 7.8 (1/1) 8.3 (2/2)
Table 3.1. Levels of viraemia in A129 and wtl29 mice. All values are expressed
as Logio PFU/ml of blood. On PID 2 both mice infected with SFV4 were found dead
(-)•
Frozen sections of several different tissues from wtl29 mice sampled on PID I were
examined for eGFP expression. For each tissue, six slides each with 3 sections of
spleen (12 pm thick), pancreas (14 pm thick), heart (12 pm thick), lung (12 pm
thick), kidney (12 pm thick), and brain (12 pm thick) were examined for eGFP
expression using a Zeiss Axioskop microscope. None of these tissues was eGFP-
positive.
Sections of the same tissues from A129 mice sampled on PID 1 or 2 were also
examined for eGFP expression. Heart, lung, kidney and brain tissues showed no sign
of eGFP expression at any time-point (6 slides per tissue with 3 sections per slide). In
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contrast, pancreas (Figure 3.10a - 3.1 Of) and spleen (Figure 3.10g-3.1 Oi) had eGFP
expression. Interestingly, in the pancreas only cells of the exocrine pancreas had
eGFP expression. The infected cells found in the spleen were predominantly cells at
the marginal zone between the red pulp and the white pulp; probably macrophages.
Haematoxylin and eosin staining masked the fluorescent signal, so it was not
possible to undertake a detailed analysis of the pathology in these tissues.
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Figure 3.10. Distribution of SFV4(3H)-eGFP in the absence of type-I
interferons, (a) low magnification image of eGFP expression in pancreatic tissue,
(b) bright field image of the same section, (c) merged image of (a) and (b) Bars
represent 100 pm in all panels, (d) high magnification image of a focus of infection
in pancreatic tissue, (e) bright field image of the same section, (f) merged image of
(d) and (e). Bars represent 20 pm in all panels (g) high magnification image of
infected splenic cells at the marginal zone, arrows point at representative cells, (h)
bright field image of the same section, (i) merged image of (g) and (h). Bars
represent 20 pm in all panels. All tissues are from a A129 mouse sampled on P1D 2.
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Virus pathogenesis following intracerebral inoculation
As SFV4 and the two recombinant viruses expressing eGFP as a cleavable
component of the replicase polyprotein did not efficiently spread to the brain of
Balb/c mice following intraperitoneal inoculation it was decided to administer these
viruses directly into the brain (intracerebral inoculation; i.e.) to investigate if the
recombinant virus was able to replicate efficiently in the brain.
Experiment I-Virulence following direct brain inoculation
Experimental design
To determine the efficiency of replication and virus virulence following i.e.
inoculation, groups (n=6) of adult (4-5 week old, female) Balb/c mice were infected
i.e. with 1,000 PFU of SFV4, SFV4(3H)-eGFP, SFV4(3L)-eGFP, or mock-infected
with PBSA. Mice were monitored at regular intervals for clinical end-points of viral
encephalitis. All animals exhibiting substantial clinical signs of disease were
euthanised and their brains were snap frozen for virus titration.
Results
Direct inoculation of SFV4, SFV4(3H)-eGFP and SFV4(3L)-eGFP in the CNS led to
the development of severe encephalitis in all animals. In particular, at approximately
24 hours post-infection, mice had reduced motility and piloerection. By 48 hours
100% (6/6) of the infected animals had reached clinically defined terminal end-points
indicative of substantial disease and were killed. In contrast, mock-infected animals
(PBSA) were healthy for the 10 days that the experiment lasted (Figure 3.1 la). All
mice infected with SFV4, SFV4(3H)-eGFP or SFV4(3L)-eGFP developed clinical
signs at the same time post-inoculation. The brains from SFV4, SFV4(3H)-eGFP and
mock-infected animals were titrated to determine infectious virus titres. As expected,
100% of virus inoculated animals had high levels of infectious virus in the brain.
SFV4 infected mice had an average infectious virus titre of 9.5 LogioPFU/g of brain
(SD: 0.11). SFV4(3Fl)-eGFP infected mice had an average titre of 9.7 LogioPFU/g
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of brain (SD: 0.15). Paired t-tests showed no significant difference between the brain
titres of SFV4 and SFV4(3H)-eGFP infected animals (P>0.05). Mock-infected mice
















Figure 3.11. Survival rates and brain virus titres in Balb/c mice following i.e.
inoculation, (a) Survival rates of Balb/c mice inoculated i.e. with SFV4, SFV4(3H)-
eGFP, SFV4(3L)-eGFP or mock-infected with PBSA. (b) Infectious virus titres of
SFV4 and SFV4(3H)-eGFP in the brains of Balb/c mice inoculated i.e. with 1,000
PFU. Each group had 6 mice. Mice were sampled on PID 2. Values are expressed as
Logio PFU/g of brain tissue. The two groups were compared using paired t-test and
were not statistically different (P>0.05).
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Experiment Il-eGFP expression and distribution
Experimental design
To determine whether eGFP was expressed in the brain following i.e. inoculation,
groups (n=6) of adult (4-5 week old, female) Balb/c mice were inoculated i.e. with
1,000 PFU of SFV4(3H)-eGFP. On PID 2 the mice were killed and their brains
sampled and processed for frozen sections (12 pm thick). In addition, to study the
expression of eGFP at different stages of infection, sections of brain tissue were
stained with anti-nsP3 and anti-structural protein antibodies. Also, to find out if the
insertion of eGFP altered the cell tropism of SFV4 in the CNS, antibodies against
cell-specific markers of neurons, astrocytes and oligodendrocytes were used.
Results
Six out of six mice inoculated (i.e.) with SFV4(3H)-eGFP developed signs of severe
encephalitis approximately 48 hours post-inoculation and the animals were sampled.
Frozen sections of brain tissue from all animals were examined using a Zeiss
Axioskop and a Zeiss confocal microscope. Expression of eGFP was evident in areas
of white and gray matter. Figure 3.12a. shows infected cells at the alveus
hippocampus (alv), a white matter tract below the corpus callosum (cc); the cc is the
major white mater tract of the brain. On the same panel a cell of the granular dentate
gyrus (GrDG) (gray matter) is expressing eGFP. Figure 3.12b and 3.12c show higher
magnification images of the same field acquired with a standard and a confocal
microscope respectively. Cells with low (asterisk) or high (arrow) intensity of eGFP
signal were detected. The morphology of these cells and their anatomical position
strongly suggests that these were oligodendrocytes. It is likely that the intensity of
the fluorescent signal is related to the stage of infection of the cell. A cell at the early
stages of infection, when expression of non-structural proteins is very active will, be
brighter than a cell at the late stages of infection, when the levels of expression of
non-structural proteins (and consequently of eGFP) are reduced. Multiple foci of
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infection were found scattered around the cortex of the brain in areas of gray matter
(Figure 3.12d & e) and in areas of white matter (Figure 3.12f).
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Figure 3.12. eGFP expression and distribution following i.e. inoculation of
Balb/c mice with SFV4(3H)-eGFP. (a & b) GrDG: granular dentate gyrus; cc:
corpus callosum; py: pyramidal cell layer of the hippocampus probably CA1-2 of
Ammon's horn; alv: alveus hippocampus white matter, bar represents 100 pm. (c)
Arrows and asterisk mark cells exhibiting high and low eGFP fluorescence,
respectively. The anatomic position of these cells and their morphology suggests that
they are oligodendrocytes, bar represents 20 pm. (d) A focus of infection in the brain
cortex is shown inside the dotted circle, bar represents 100 pm (e) Large focus of
infection found in the brain cortex. Different levels of eGFP fluorescence are
observed, bar represents 100 pm. (f) The lighter areas correspond to myelinated
tracts (white matter:wm), these tracts contain many eGFP-positive cells, these are
most likely oligodendrocytes. Bar represents 100 pm. All tissue sections shown here
were cut from brains sampled on PID 2. Images on panels (a), (b), (e) and (f) were
acquired using a Zeiss Axioskop. Images on panels (c) and (d) were acquired by
confocal microscopy.
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eGFP expression vs nsP3 non-structuralprotein expression
Although green fluorescence was readily detectable in the brains of all infected
animals, the number of positive (green) cells was smaller than expected. Since
SFV4(3H)-eGFP was as virulent as SFV4 (survival rates; Figure 3.1 la) and reached
titres similar to those of the wild-type SFV4 virus (Figure 3.11b) and because the
half-life of eGFP in BHK-21 cells was short (Figure 3.3b) frozen sections were
immunostained using an anti anti-nsP3 antibody to investigate the hypothesis that
infection was actually widespread, as was expected with SFV4, but that due to the
short half-life of eGFP this was not apparent from the number of green cells.
The results verified this hypothesis; nsP3-positive cells (red fluorescent signal,
Figure 3.13) outnumbered eGFP-positive cells. Counting nsP3 and eGFP-positive
cells, it was found that the ratio varied between 3:1 and 5:1 depending on the area of
the brain (at least 6 slides with 3 sections per slide were examined). As expected, the
vast majority (approximately 100%) of eGFP-positive cells also stained positive for
nsP3. Only rare were eGFP-positive, nsP3-negative cells observed. Representative
images of double-labelled cells are shown on Figure 3.13, panel (a)-(f). At the top
left of panel (c) marked with an asterisk, the CA3 zone of pyramidal neurons of
Ammon's horn is shown. Although, many cells presumably neurons, in this area
stained positive for nsP3 protein, none was eGFP-positive at the same time.
Interestingly, numerous small cells in close proximity to the nsP3-positive cells were
eGFP-positive (Figure 3.13c and inset). The position and morphology of these small
eGFP-positive cells is consistent with satellite oligodendrocytes. Perhaps, these cells
were infected later than the adjacent pyramidal neurons or these two cells differ in
their interaction with this virus. The characteristic punctate staining observed when
infected BHK-21 cells were immunostained with an anti-nsP3 antibody was also
apparent in the frozen brain tissue sections stained with this antibody (Figure 3.13e
inset & Figure 3.14c). On Figure 3.14, the hypothetical progress of infection in vivo
based on eGFP vs nsP3 expression is shown. Early in infection, eGFP is visible
throughout the cytoplasm and the nucleus of infected cells and nsP3 is located in the
outer areas of the cytoplasm (panel a). Later in infection (panel b) the intensity of
eGFP signal declines and punctate, cytoplasmic nsP3 is prominent. At the very late
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stage of infection (panel c) eGFP is not detectable and nsP3-specific staining is found
in abundance and is punctate and cytoplasmic. As discussed earlier, the distribution
of the punctate nsP3 staining is consistent with the known distribution of SFV
replication complexes.
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Figure 3.13. eGFP expression and nsP3 expression in the brains of SFV4(3H)-
eGFP infected mice, (a) low power magnification showing several scattered eGFP-
positive cells, (b) low power magnification of nsP3-specific staining on the same
section showing many more nsP3-positive cells, (c) merged image of (a) and (b),
GrDG: granular dendate gyrus, Th: thalamus, asterisk marks the CA3 zone of
pyramidal cell layer of the Ammon's horn. Arrow points at a focus of infection on
the GrDG. The area in the dotted circle is shown in high magnification in the inset.
The eGFP-positive cell proximal to the nsP3-positive cell is most probably a satellite
oligodendrocyte. Bar in panels a-c represents 100 pm. (d) eGFP expression in a
focus of infection in the brain cortex, (e) nsP3-specific staining on the same section;
the cell surrounded by the dotted circle is shown in high magnification in the inset,
the arrow points at the punctate distribution of nsP3 staining, (f) merged image of (d)
and (e), arrows mark examples of double-labelled cells. Bar in panels d - f represents
20 pm. Non-infected and no secondary antibody controls are shown on (g) and (h),
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respectively; bar in both represents 100 pm. All tissue sections shown here were cut







Figure 3.14. eGFP expression and nsP3 expression in vivo. Hypothetical
progress of infection, (a) double-labelled cells at the early stages of infection, (b)
double-labelled cells later in infection; note the reduction in eGFP signal, (c) nsP3
stained cells at the very late stage of infection. Arrow points at the punctate staining.
Bar in panels a - b represents 20 pm. All images were from the same section. All
tissue sections were from a brain sampled on PID 2. All images were acquired with a
Zeiss confocal microscope.
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eGFP expression vs SFVstructuralprotein expression
Frozen sections of infected brain tissue were also immunostained using an antibody
recognising the structural viral proteins. The results obtained verified the findings of
the nsP3-specific immunostaining; infection was widespread as determined by
immunostaining of virus structural proteins but only a small percentage of these cells
were eGFP-positive. However, in contrast to the nsP3 staining where approximately
100% of eGFP-positive cells were also nsP3-positive, only a small fraction (1-5%;
different areas of the brain examined, at least 6 slides with 3 sections per slide) of
eGFP-positive cells were positive for SFV structural proteins (Figure 3.150- In most
instances, SFV structural protein-positive cells were distinct from the eGFP-positive
cells. A representative example is shown on panels (a)-(c) of Figure 3.15; the vast
majority of the eGFP-positive cells (green) are on the right hand-side of the field of
vision whereas most of the SFV structural protein positive cells (red) are on the left
hand-side. This would be consistent with infection having started from the left hand-
side and spread towards the right hand-side. In foci of infection where eGFP-positive
cells and cells positive for SFV structural proteins were in close proximity, a few
double-labelled cells were found (Figure 3.15f)- On Figure 3.16, the hypothetical
progress of infection in vivo based on eGFP and structural protein expression is
shown. Early in infection, eGFP is expressed throughout the cytoplasm and the
nucleus of infected cells but SFV structural proteins are not detected (panel a). Later
in infection (panel b) and while eGFP is still present, viral structural proteins are
detected. Cells like the one shown here were very rare. At later stages of infection
(panel c) eGFP signal is no longer detectable whereas structural protein staining is
still present. The distribution of the structural proteins was as expected; proteins were
found on the outer area of the cytoplasm, most probably associated with the cell
membrane.
The percentage of double-labelled cells (eGFP/nsP3-positive vs eGFP/structural-
positive) is different but is as expected given that the two viral promoters (genomic
(42S and subgenomic 26S) are active at different stages post-infection and the half-
life of eGFP was short. The findings of the immunostainings using anti-nsP3 and
anti-structural antibodies suggest that SFV4(3H)-eGFP has potential application for
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in vivo pathogenesis studies. This virus may be useful to distinguish cells in which
the replicase polyprotein is being synthesised from those in which the synthesis of
this particular polyprotein has been terminated.
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eGFP a-structural merged
Figure 3.15. eGFP expression and viral structural protein expression in the
brain of SFV4(3H)-eGFP infected mice, (a) low power magnification showing
several scattered eGFP-positive cells, (b) low power magnification of structural
proteins specific staining on the same section showing many more virus positive
cells, (c) merged image of (a) and (b). Bar in panels a-c represents 100 pm. (d) eGFP
expression in a focus of infection on the brain cortex, (e) viral structural protein
specific staining on the same section (f) merged image of (d) and (e), arrows mark
double-labelled cells, most cells are not double labelled. Bar in panels d-f represents
20 pm. Non-infected and no secondary antibody controls are shown on (g) and (h).
Bar in both represents 100 pm. All tissue sections shown here were cut from brains
sampled on P1D 2. All images were acquired with a Zeiss confocal microscope.
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Figure 3.16. eGFP expression and viral structural protein expression in vivo.
Hypothetical progress of infection, (a) eGFP positive cells at the early stages of
infection, (b) double-labelled cells later in infection. The asterisk marks two adjacent
cells, one eGFP-positive but negative for virus structural proteins and one which
exhibits the opposite, (c) Cells at the later stages of infection stained positive for
virus structural proteins; eGFP was not detectable. Bar in panels a - c represents 20
pm. All images were from the same section. All tissue sections shown here were cut
from a brain sampled on P1D 2. All images were acquired with a Zeiss confocal
microscope.
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Cell tropism ofSFV4(3H)-eGFP in the CNS
One of the major advantages of a virus expressing a marker gene is the ability to
study its in vivo tropism, and the effect of tropism on virulence, without the
requirement for double-immunostaining. Traditionally, to study the tropism of a
virus in vivo, it has been necessary to immunostain for viral protein, or hybridise for
viral nucleic acid and also to immunostain for a cell-specific marker. Using a virus
like SFV4(3FI)-eGFP the need for the detection of viral protein or nucleic acid is
eliminated simplifying the whole procedure.
SFV has previously been described to infect neurons and oligodendrocytes but not
astrocytes (Fazakerley et al., 2006). To examine if the insertion of eGFP altered the
tropism of SFV in the CNS, sections of SFV4(3H)-eGFP infected brains were stained
with antibodies against neurons (NeuN). This antibody specifically recognizes the
DNA-binding, neuron-specific protein NeuN, which is present in the nuclei and
perikarya of most CNS neurons. An antibody against 2'3'-Cyclic nucleotide 3'-
phosphohydrolase (CNPase) was used as a specific marker for oligodendrocytes.
Finally, an antibody against glial fibrillary acidic protein (GFAP) a member of the
intermediate filament family, found exclusively in astroglial cells, was used as a
marker for astrocytes.
Surprisingly, although the NeuN immunostaining worked extremely well, it was not
possible to detect eGFP-positive NeuN-positive cells (Figure 3.17). This is consistent
with the observation (see also Figure 3.13) that SFV4(3H)-eGFP did not result in
eGFP-positive cells which were anatomically and morphologically clearly neurons
(Figure 3.13c). Whereas it is possible that neurons with eGFP fluorescence might not
be efficiently recognised by the anti-NeuN antibody, there were numerous neurons in
the cortical area of the brain which stained positive for NeuN but none of these was
eGFP-positive. When frozen sections were stained with anti-nsP3 antibody,
numerous cells in areas of the brain known to be rich in neurons stained positively
(Figure 3.13a - c). Yet, no eGFP-positive cells were detected in these areas. It can be
hypothesised that neurons have the ability to switch off the 42S genomic promoter
controlling the expression of non-structural proteins and eGFP and because eGFP has
short half-life it was not detected. However, a double immunostaining with anti-nsP3
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and anti-NeuN antibodies is required to determine with certainty if NeuN-positive
neurons can be infected with SFV4(3H)-eGFP; certainly cells that are
morphologically and anatomically neurons can be infected by this virus.
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Figure 3.17. Immunostaining using NeuN neuronal marker on brain sections
from Balb/c mice infected i.e. with SFV4(3H)-eGFP. (a) Positive nuclei stained by
To-Pro3 nuclear marker. (b) Positive nuclei stained by NeuN neuron-specific
antibody, (c) merged image of (a) and (b), signals from the nuclear marker and the
neuron-specific immunostaining co-localise. Bars represent 20 pm in all panels, (d)
eGFP positive cells on a 12 pm thick frozen brain tissue section, (e) NeuN specific
staining on the same section, (f) merged image of (d) and (e). No co-localisation was
observed; at least 6 slides with 3 sections per slide were examined. Bars represent 20
pm in all panels. Panels (g) (h) and (i) show the green channel, red channel, and
merged image of both channels respectively on a control non-infected brain section.
Sections were immunostained with NeuN antibody but secondary antibody was not
included. Bars represent 100 pm in all panels. All other tissue sections shown here
were cut from brains sampled on PID 2. All images were acquired with a Zeiss
confocal microscope.
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SFV4(3H)-eGFP has the ability to infect areas of white and gray matter.
Oligodendrocytes can be found in both areas but are far more abundant in white
matter tracts where they perform their main function, synthesis and maintenance of
the myelin sheaths around axons. Previous studies using SFV4 have shown that SFV
has the ability to infect oligodendrocytes (Atkins & Sheahan, 1982; Balluz et al.,
1993). Oligodendrocytes are the predominant cell type infected when the avirulent
A7(74) strain of SFV is inoculated intracerebrally (Fazakerley et al., 2006).
Figure 3.18a shows a focus of infection which spreads between the corpus callosum
(cc), the major white matter tract of the brain and the cingulum (eg) another white
matter tract located on the top of the corpus callosum. Oligodendrocyte-specific
staining (anti-CNPase; Figure 3.18b) showed numerous positive cells (red colour)
scattered in the gray matter area surrounding the area of pyramidal neurons of the
hippocampus. As expected, the number of oligodendrocytes detected was much
greater in the white matter area defined by the corpus callosum and the cingulum
(greater intensity of red signal). The area surrounded by the dotted circle in Figure
3.18c is shown in higher magnification in panels (d) to (f) of the same figure. Most
infected cells (indicated by the green colour) in this field of vision appeared to be
oligodendrocytes (CNPase positive; red colour). Representative double-labelled cells
are marked with white arrows on panel (d). This indicates that insertion of eGFP in
the replicase ORF did not interfere with the ability of SFV4 to infect
oligodendrocytes.
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Figure 3.18. Immunostaining using CNPase as oligodendrocyte marker on brain
sections from Balb/c mice infected i.e. with SFV4(3H)-eGFP. (a) Focus of
infection in by the major white matter tract of the brain, the corpus calossum (cc) and
another white matter tract, the cingulum (eg), (b) CNPase-positive cells
(oligodendrocytes) scattered on the same section; py corresponds to the layer of the
pyramidal neurons of the hippocampus, (c) merged image of (a) and (b). Bars
represent 100 pm in all panels, (d) The area of panel (c) surrounded by the dotted
circle is shown in higher magnification. Different levels of eGFP intensity can be
observed, (e) CNPase specific staining of the same section, (f) merged image of (d)
and (e). Representative double-labelled cells marked with white arrows. Bars
represent 20 pm in all panels. Same secondary antibody as the one used for anti-nsP3
and anti-structural immunostaining was used; therefore negative controls can be seen
in Figure 3.13 or 3.15. All sections shown here were cut from brains sampled on PID
2 and had a thickness of 12 pm. All images were acquired with a Zeiss confocal
microscope.
113
Chapter 3 Insertion of eGFP in the non-structural ORF
Astrocytes provide physical and biochemical support for neurons and are activated in
infected or damaged areas of the brain. Previous studies by this laboratory (on SFV
A7(74)) and others (on SFV4) have shown that SFV does not infect astrocytes. To
verify that this remained the case for SFV4(3H)-eGFP, sections of SFV4(3H)-eGFP
infected brain tissue were immunostained with an anti-GFAP antibody. On Figure
3.19a a focus of infection can be seen; note that the astrocyte-specific staining is
concentrated in and around the focus of infection (Figure 3.19b & 3.19c); this is as
expected since astrocytes get activated by the infection. Six slides with 3 sections per
slide were examined for co-localisation of eGFP and GFAP-specific staining. No
double-labelled cells were observed after thorough microscopic examination ofmany
different areas on each section. Astrocytes appeared to be around infected cells
(Figure 3.19f). The characteristic star-like shape of astrocytes can be seen in the inset
of panel f.
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Figure 3.19. Immunostaining using GFAP as astrocyte marker on brain sections
from Balb/c mice infected i.e. with SFV4(3H)-eGFP. (a) Focus of infection in the
brain cortex (b) GFAP-positive cells (astrocytes;red signal), (c) merged image of (a)
and (b). Astrocytes are around and within the focus of infection. Bars represent 100
pm in all panels, (d) Higher magnification of (a) Different levels of eGFP intensity
can be observed, (e) GFAP specific staining of the same section, (f) merged image of
(d) and (e). Bars represent 20 pm in all panels. Same secondary antibody as the one
used for anti-nsP3 and anti-structural immunostainings was used; therefore negative
controls can be seen in Figure 3.13 or 3.15. All sections shown here were cut from
brains sampled on PID 2 and had a thickness of 12 pm. All images were acquired
with a Zeiss confocal microscope.
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In vivo phenotypic and genotypic stability of SFV4(3H)-eGFP in Balb/c
mice
Experimental design
To determine the genetic stability of SFV4(3H)-eGFP after several passages in vivo
the virus was passaged 5 times in Balb/c mice and examined for phenotypic and
genotypic changes after each passage. Figure 3.20 outlines the experimental design
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Figure 3.20. Experimental design to investigate in vivo phenotypic and genotypic
stability. Two Balb/c mice were inoculated i.c with 20 p.l of 5 x 104 PFU/ml virus
stock. At PID 2 their brains were sampled, half of each brain was homogenised and
titrated and half was used for extraction of total RNA, which was analysed by RT-
PCR. One brain homogenate was passaged into the brains of another two Balb/c
mice and also used to infect (20 PFU) fresh BHK-21 cells. These monolayers were
overlayed with agar and 96 plaques were purified; individual plaques were
transferred to 24-well plates and each well was analysed for eGFP expression. The
passaging procedure was repeated four more times.
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Phenotypic stability ofSFV4(3H)-eGFP in vivo
In an identical manner to the one applied to assess the in vitro stability of
recombinant viruses, 96 plaques were purified from each of the 5 in vivo passages.
Each mouse was infected with 1,000 PFU and the brain was removed on PID 2; by
this time all infected mice had symptoms of severe encephalitis. SFV4(3H)-eGFP
exhibited remarkable phenotypic stability in vivo. All 96 isolated plaques were found
to produce eGFP-positive viruses for the first 4 passages through the mouse brain. Of
the 96 plaques isolated from the material obtained after the 5th passage, only one
plaque was found to be eGFP negative; 98.96% plaques were positive (Figure 3.21a).
Genotypic stability ofSFV4(3H)-eGFP in vivo
One half of the brain from each infected mouse at each passage was stored in
RNAlater, an RNA stabilising reagent, and total RNA was extracted and used for
RT-PCR to detect the absence or presence of the eGFP insert. If the eGFP insert was
absent a PCR product with a size of -670 bp was expected. If the eGFP insert was
present a PCR product with a size of -1,500 bp would be produced. Figure 3.21b
shows the results obtained from each of the 5 in vivo passages as well as the product
obtained when total RNA from brains of animals infected with SFV4 was amplified
using RT-PCR. Between passage 1 through 4 no eGFP-negative virus was detectable.
Minor amounts were detected after passage 5. These results are in agreement with
the phenotypic stability analysis by plaque purification of viral clones. Since no
intermediate bands were observed no sequence analysis was performed.
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Figure 3.21. In vivo phenotypic and genotypic stability of SFV4(3H)-eGFP. (a)
percentage of eGFP positive plaque purified viruses after serial passaging, (b) RT-
PCR genotyping of SFV4(3H)-eGFP using nsP3 - nsP4 primers on RNA samples
extracted from infected brain material. Passage number is indicated across the top of
each strip. The red arrow corresponds to the 1.5 kb band of the DNA ladder and the




Insertion of eGFP in the non-structural ORF
Summary of in vitro analysis ofSFV4(3H)-eGFP and SFV4(3L)eGFP
• Insertion of eGFP in the non-structural ORF of SFV4 resulted in the
production of viable viruses (SFV4(3H)-eGFP and SFV4(3L)-eGFP) which
were able to replicate in BHK-21 cells to levels similar to SFV4. Both
recombinant viruses were slightly slower in their replication compared to
SFV4. eGFP was expressed to adequate levels for detection using a standard
fluorescent microscope. However, the intensity of the eGFP signal quickly
decreased and late in infection cells had a dull green colour. In terms of
development of cytopathic effect (CPE) both recombinant viruses induced
CPE in an identical manner to SFV4.
• All viral non-structural proteins and eGFP were expressed and processed
properly. Minor amounts of an eGFP-nsP4 fusion protein were detected but
most protein was released free indicating that both H and L processing sites
were functional. A pulse-chase experiment suggested that eGFP is degraded
soon after infection. This resulted in low levels of eGFP fluorescence late in
infection.
• In infected BHK-21 cells, eGFP was present in both the cell cytoplasm and
the nucleus. In some instances the eGFP signal was stronger in the nucleus
than in the cytoplasm. The ability of eGFP to spread throughout the
cytoplasm and the nucleus again suggests that processing of the polyprotein
was efficient and eGFP was released free. The nsP3-specific staining was
punctate and strictly cytoplasmic. The staining probably corresponds to the
position of the virus replication complexes.
• After 5 passages in BHK-21 cells, 93.6% of plaque purified SFV4(3H)-eGFP
was able to express eGFP. In contrast only 50% of SFV4(3L)-eGFP plaque
purified viruses maintained that ability after 5 passages. RT-PCR showed the
presence of recombinant viruses with complete or partial deletions of eGFP.
Sequencing of some of these viruses showed large in-frame deletions of
eGFP.
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• SFV4(3H)-eGFP was able to infect C6/36 cells from Aedes albopictus and
eGFP was expressed in these cells. Virus was used to infect rat hippocampal
neurons but eGFP was not detected in these cells. However, CPE developed
in these cells at the same time as in cells infected with SFV4.
Summary of in vivo analysis ofSFV4-steGFP
• Following intraperitoneal inoculation of SFV4(3H)-eGFP or SFV4(3L)-eGFP
in Balb/c mice 100% of the mice remained asymptomatic and survived the
infection. In contrast to groups of control mice infected with SFV L10 or
mock-infected with PBSA, which lost and gained considerable amounts of
body weight respectively, mice infected with SFV4, SFV4(3H)-eGFP and
SFV4(3L)-eGFP did not lose or gain weight. SFV4(3H)-eGFP reached
similar levels of viraemia to SFV4 (no statistical difference) but considerably
lower levels (statistically significant) than SFV L10 and SFV A7(74).
• SFV4(3H)-eGFP virus was used to infect IFN a/p receptor knock-out mice.
This virus had slightly lower titres than SFV4 in the blood of infected mice
but all animals succumbed to infection at the same time (PID 2). In wtl29
mice (background strain of IFN a/p knock-out mice used as control)
SFV4(3H)-eGFP had similar titres to SFV4. eGFP-positive cells were
observed in the acinar cells of the exocrine pancreas and in cells in the
marginal zone of the spleen.
• Intracerebral inoculation of Balb/c mice with SFV4(3H)-eGFP and
SFV4(3L)-eGFP caused lethal encephalitis in 100% of the mice. Symptoms
and death occurred at the same time for all groups of mice infected with the
recombinant viruses and SFV4. Titres of SFV4(3H)-eGFP in the brain were
not different to those of SFV4.
• eGFP expression was evident in both white and gray matter in the brains of
mice infected with SFV4(3H)-eGFP. eGFP-positive cells were not as
widespread as expected and frozen sections of infected brain tissue were
immunostained using anti-nsP3 and anti-SFV antibodies. The infection was
much more widespread when immunostaining was used. The reason for this
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is probably rapid degradation of eGFP. All eGFP-positive cells stained
positive for nsP3 as expected. In contrast, very rarely, eGFP-positive cells
were also positive for viral structural proteins.
• In vivo SFV4(3H)-eGFP had impressive genetic stability. After 5 passages in
the brain of Balb/c mice approximately 99% of plaque purified viruses were
able to express eGFP. Minor amounts of recombinant viruses which managed
to completely eliminate the eGFP insert were detected by RT-PCR.
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Discussion
Alphaviruses have short genomes expressing large polyproteins which are then
processed into individual proteins by the activity of virus encoded proteinases (ten
Dam et al., 1999). Increasing the size of the genome of such a virus by insertion of a
heterologous gene affects the production of infectious particles (packaging
constraints due to the compact icosahedral nucleocapsid). In addition, the size of the
inserted sequence is an important factor for the genetic stability of recombinant
viruses; viruses with smaller inserts appear to be more stable than viruses with large
inserts (Hahn et al., 1992; Frolov et al., 1996). Recombinant alphaviruses carrying
foreign sequences under the control of a duplicated subgenomic promoter appear to
eliminate the inserted genes. This genome instability has been shown for SV
(Pugachev et al., 1995; Pugachev et al., 2000), SFV (Vaha-Koskela et al., 2003) and
VEEV (Caley et al., 1999). The mechanism of elimination has not been clarified but
it has been suggested that recombination occurs between the duplicated subgenomic
promoters (Thomas et al., 2003).
Initially, a virus expressing eGFP as a fusion protein inserted in-frame at the C-
terminus of nsP3 was constructed; SFV4(3F)-eGFP. Similar SV nsP3-fusion
constructs expressing luciferase in a temperature sensitive manner (Bick et al., 2003)
and eGFP (Zhimin Liang and Guangpu Li, 2005; Frolova et al., 2006) have been
previously described. Data on both SV and SFV has shown that large in-frame
deletions of the hypervariable C-terminus of nsP3 (12 - 159 amino acids for SV and
50 amino acids for SFV) can be tolerated and the resulting viruses are viable and able
to replicate (Lastarza et al., 1994; Vihinen et al., 2001). SFV4(3F)-eGFP was viable
and a nsP3-eGFP fusion protein was expressed. eGFP and nsP3 proteins co-localised
in cytoplasmic structures (punctate staining) and had the typical distribution of nsP3
protein observed in cells infected with SV or SFV (Froshauer et al., 1988; Kujala et
al., 2001). These structures are most probably the virus replication complexes
(Frolova et al., 2006; Tamberg et al., 2007). The major disadvantage of SFV4(3F)-
eGFP was its genetic instability, which can probably be attributed to problematic
formation and function of the virus replication complexes. The data obtained is in
agreement with that of Frolova et. al. (2006); the position of the eGFP insertion
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affects the genetic stability. SFV4(3F)-eGFP (like its SV analogues) is therefore
useful for in vitro studies on replication complex formation, replicase proteins
interaction with host cell proteins and host cell transcriptional/translational shut-off
but not for in vivo pathogenesis studies (Ryman et al., 2005; Ventoso et al., 2006;
Frolova et al., 2006; Cristea et al., 2006). Recently, similar fusion constructs in
which eGFP was inserted in the coding sequence of nsP2 have been described for SV
(Atasheva et al., 2007).
For SFV the nsP2 protease processing sequence between nsP3 and nsP4 has been
well characterised (Merits et al., 2001; Vasiljeva et al., 2001; Lulla et al., 2006). To
circumvent the problems caused by the fusion of eGFP to nsP3, the eGFP-insert was
flanked by two different nsP2-protease processing sites. The resulting recombinant
viruses (SFV4(3H)-eGFP and SFV4(3L)-eGFP) had a slight delay in their replication
compared to SFV4 in vitro. This data is not directly comparable to data on SV
expressing eGFP as a fusion to nsP3 since the eGFP gene is inserted as a cleavable
component of the non-structural ORF in the viruses used in the present study but
some interesting trends can be observed. SV recombinant constructs having eGFP
inserted at position 389 (amino acid) of nsP3 were engineered by two different
groups. According to the results of Liang & Li (2005), insertion of eGFP at this
particular position results in a delay in replication. However, this is in contrast to the
data published by Frolova et. al. (2006), which suggests that replication efficiency of
SV is not affected by insertion of eGFP after amino acid 389. A recombinant SV
which is very similar to SFV4(3H)-eGFP and SFV4(3L)-eGFP was described by
Frolova et. al. This virus had eGFP fused to amino acid position 549, the last amino
acid of SV nsP3. In the recombinant viruses used in the present study eGFP was
inserted after the last amino acid of SFV nsP3 (amino acid 482). As with SFV4(3H)-
eGFP and SFV4(3L)-eGFP, SIN/549 was slower in BHK-21 cells but later in
infection, 10-12 hours, it caught up with the wild-type Totol 101. SFV4(3H)-eGFP
and SFV4(3L)-eGFP were also slower to replicate in BHK-21 cells than SFV4 but
they caught up with the wt titres more rapidly. The delay in the replication of both
recombinant SV and SFV can be attributed to the larger size of the replicase ORF or
to delayed/defective formation of viral replication complexes. In alphaviruses, nsP3
is associated with viral RNA synthesis, of the minus-strand intermediate in particular,
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and viruses with deletions in nsP3 produce lower amounts of viral RNA in BHK-21
cells (LaStarza et al., 1994; Lemm et al., 1994; Wang et al., 1994; Galbraith et al.,
2006). Insertion of eGFP at the C-terminus of nsP3 might therefore slow down the
production of the minus-strand RNA and delay viral replication. Most recently, a SV
expressing eGFP as a fusion protein with nsP2 has been constructed. This virus has
even slower replication than the nsP3 fusion viruses. This is not surprising since
nsP2 is the protease responsible for processing of the replicase polyprotein and
alphaviruses with even single amino acid mutations in nsP2 replicate less efficiently
(Rikkonen, 1996; Dryga et al., 1997).
BF1K-21 cells infected with SFV4(3H)-eGFP and SFV4(3L)-eGFP showed only a
transient eGFP expression. eGFP has been used extensively as a marker protein
expressed by alphavirus vectors with expression detectable over long periods of time
(Kim et al., 2004; Graham et al., 2006). Transient expression of eGFP has never
been reported for alphavirus vectors expressing this protein. The pulse labelling
study showed that the eGFP was rapidly degraded. It can be hypothesised that the
instability of eGFP is due to the additional virus derived sequences at the N and C-
termini. Following processing of the replicase polyprotein and release of eGFP, its
N-terminus has a glycine residue, which according to the N-end rule is one of the
most stabilising amino acids (Varshavsky, 1996). It is therefore logical to assume
that the destabilising sequence is located at the C-terminus of eGFP, which is the C-
terminal sequence of nsP3 (amino acid residues 453 - 482). Further experiments
done by our Estonian colleagues using plasmids expressing eGFP fused to different
lengths of the C-terminal sequence of nsP3 have verified this assumption and suggest
that degradation is most efficient when the last 70 amino acids (residues 413 - 482)
are fused to the C-terminus of eGFP (unpublished data). These results suggest that
this nsP3 sequence contains a degron signal which in its native location has a
different function or its effect is inhibited by interactions with one or more of the
other non-structural proteins (Tamberg et al., 2007). Further experiments (currently
in progress) are required to clarify the role of this sequence, to see if its effect is
exclusive in fluorescent molecules like eGFP or more generic. Fluorescence was
more intense in the nucleus of infected BHK-21 cells; that could result from the more
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rapid proteasome-mediated degradation in the cytoplasmic compartment, a
phenomenon observed with cellular proteins (Doherty et al., 2002).
Genetic stability of replication-competent alphavirus vectors has been previously
investigated by assessing their ability to express marker genes in vitro (Thomas et al.,
2003) and in vivo (Cook & Griffin, 2003). The methods used in both these studies are
not very sensitive and detect only relatively large changes in the virus population. In
the present study, the method employed to assess the genetic stability of SFV4(3H)-
eGFP and SFV4(3L)-eGFP was also simple but was more sensitive allowing direct
assessment of the appearance and proportion of eGFP-negative genomes. For
unknown reasons SFV4(3L)-eGFP was less stable than SFV4(3H)-eGFP in vitro. In
the late in vitro passages some truncated genomes, possibly resulting from RNA
recombination between the duplicated sequences of nsP3, were detected by RT-PCR.
Sequencing of some of these genomes showed large in-frame deletions. This was
expected since if the deletion was not in-frame the translation of the replicase
polyprotein would be halted and therefore virus would not be viable. The very
similar SV (SIN/549) demonstrated low but detectable levels of genetic instability
(Frolova et al., 2006). Only the stability of SFV4(3H)-eGFP was assessed in vivo.
The results indicate that the virus is remarkably stable in vivo and thus suitable for
pathogenesis studies. SFV4(3H)-eGFP was apparently more stable in vivo. A
possible explanation for this is that fewer virus particles were used for each in vivo
passage compared to the amount of infectious virus passaged in each in vitro passage.
No animal experiments were performed using SIN/549 thus no data for comparison
is available. Alphaviruses have the ability to replicate in a variety of vertebrate and
insect cells (Kaariainen & Soderlund, 1978; Strauss & Strauss, 1994). In infected
cells, alphaviruses induce the formation of cytoplasmic membranous structures
known as cytoplasmic vacuoles (CPVs). Froshauer et. al. (1988) have shown that
CPVs are modified endosomes and lysosomes, which have non-structural proteins
(nsP3 and nsP4) on their surfaces (Peranen & Kaariainen, 1991). On the external
surface of CPVs numerous invaginations called spherules can be found. According to
several studies these spherules are the sites of RNA synthesis during viral replication
(Grimley et al., 1968; Kujala et al., 2001). Replication complexes consisting of the 4
mature non-structural proteins are targeted to the endosomal compartment. Two non-
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structural proteins, nsPl and nsP3, are known to facilitate the anchoring of the
replication complexes on the surface of cellular membranes (Salonen et al., 2003;
Galbraith et al., 2006). In numerous studies, antibodies against the non-structural
viral proteins have been employed to investigate the location of the viral replication
complexes. The results of the present study are coherent with those of previous
studies (Peranen & Kaariainen, 1991; Salonen et al., 2003; Frolova et al., 2006). The
punctate pattern observed in infected cells immunostained using anti-nsP3 antibody
marks the location of the replication complexes. In cells infected with fusion viruses
like SFV4(3F)-eGFP and the SV constructs described by Frolova et. al. (2006) and
Atasheva et. al. (2007) the staining for non-structural proteins co-localises with the
eGFP signal. In contrast, when SFV4(3H)-eGFP or SFV4(3L)-eGFP was used, eGFP
was released free from the replication complex (Tamberg et al., 2007). Similar
distributions of non-structural proteins have been reported for other viruses including
hepatitis C virus (HCV) and equine arteritis virus (EAV) (van der Meer et al., 1998;
Yamaga & Ou, 2002). The use of viruses expressing marker proteins like eGFP
facilitates studies on the replication mechanisms and on the interaction between viral
and cellular proteins.
The recombinant viruses were based on SFV4, a virus derived from the prototype
SFV strain. Although SFV4 has been used extensively for in vitro studies,
knowledge on its neuroinvasive efficiency and its in vivo pathogenesis is incomplete.
One of the important parameters that should be taken under consideration when
performing in vivo pathogenesis studies simulating a natural arboviral infection is the
amount of virus transmitted. Various studies have estimated the virus content of
mosquito saliva to be between 40 and 200,000 infectious units (reviewed in Weaver,
2006) but it has been shown that mosquitoes transmit much less virus (Collins, 1963;
Mellink, 1982). To mimic the natural infection a fairly low dose of virus was used in
the present study. It appears that SFV4 virulence is dose-dependent. In studies by
two different groups, 106 PFU of SFV4 were used to infect Balb/c mice
intraperitonially. Studies by the Atkins group showed that this dose of virus killed
approximately 60% of the animals (Glasgow et al., 1991; Tarbatt et al., 1997). A
more recent study showed that 90% of mice died after intraperitoneal inoculation of
the same amount of virus (Tuittila et al., 2000). In the present study, 200-fold less
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virus was used for in vivo pathogenesis studies (5 x 1(F PFU). This has been shown
to be enough to produce high levels of viraemia and encephalitis with SFV L10 (the
prototype strain from which SFV4 is derived) and SFV A7(74). When Balb/c mice
were given this dose intraperitoneally none of the animals succumbed to infection.
This was also observed by other studies in this laboratory (Breakwell, PhD thesis,
2006).
Brains of animals infected via the intraperitoneal route were sampled on PID 4 which
according to other studies is when the virus reaches its maximum titre in the brain.
No infectious virus was found in the brain of any of the animals sampled at this time-
point post-infection. Studies by other members of the laboratory using Balb/c and
wtl29 mice have also shown that SFV4 is poorly neuroinvasive; an average of 21%
of animals infected had detectable virus in the brain and the titres were very low
(Kim Roberts, BSc dissertation 2003 and Breakwell, PhD thesis 2006). It can be
concluded that neuroinvasiveness and subsequent neurovirulence of SFV4 is dose-
dependent.
The inability of SFV4 and the two eGFP-expressing recombinants (SFV4(3H)-eGFP
and SFV4(3L)-eGFP) to invade the brain was attributed to the low level plasma
viraemia. SFV4 and SFV4-based viruses had approximately 3.5 Logio PFU/ml lower
titres in the blood that the virulent L10 and the avirulent SFV A7(74) strains. Tuittila
et. al. (2000) showed that if a high dose of virus is given intraperitoneally both SFV4
and SFVA7(74) reach similar titres in the blood. Notably, the levels of SFV A7(74)
were very similar between our studies and the Tuittila study exhibiting the efficiency
of that particular virus to replicate in the periphery.
Type-I interferon has been shown to protect mice following infection by alphaviruses.
Infection of mice lacking an intact type-I interferon system by either virulent or
avirulent strains of alphavirus causes lethal disease. This has been shown for many
alphaviruses including SFV, SV and Venezuelan equine encephalitis virus (Grieder
& Vogel, 1999; Ryman et al., 2000; Fazakerley, 2004). There are two possibilities
related to interferon which could explain the inability of SFV4 and SFV4(3H)-eGFP
to produce a high titre plasma viraemia. Either SFV4 induces more type-I interferon
than SFV L10 and SFV A7(74) or SFV4 is more sensitive to interferon.
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The first hypothesis seems unlikely. Previous studies in our laboratory have shown
that in vitro (in L929 cells) SFV4 and SFV A7(74) induce very similar levels of
interferon as determined by bioassay (Breakwell, 2006). This was also shown for
SFV L10 and the avirulent strain SFV V42 (Deuber & Pavlovic, 2007). The situation
could be different in vivo but a recent study on a mouse model of Eastern equine
encephalitis, another alphavirus, has shown that strains of virus with different
virulence induce similar levels of IFN a/p suggesting that differences in virulence
are not due to differential induction of type-1 IFN (Aguilar et al., 2005). It has been
shown that many viruses are able to suppress the interferon response. In alphaviruses,
nsP2 may be involved in the suppression of type-I IFN production (Frolova et al.,
2002; Breakwell et al., 2007). The results of the present study suggest that during in
vivo infection by SFV4, antagonism of the IFN response is weak or non-existent.
Higher sensitivity of SFV4 to IFN would explain the lack of high levels of plasma
viraemia following intraperitoneal inoculation. Variation in the sensitivity of viruses
to IFN has been shown for alphaviruses as well as for other viruses. More
specifically SFV L10 is less sensitive to IFN than SFV V42 (Deuber & Pavlovic,
2007). Also the attenuated stain TC-83 of VEEV induces less IFN than the virulent
strains (Anishchenko et al., 2004). SFV4 is generally considered to be a virulent
strain, as it was derived from the virulent prototype strain and it is virulent when
inoculated i.e., may be more sensitive to IFN than the avirulent A7(74) strain. The
results from IFN a/p knockout mice indicate that IFN is responsible for the inability
of SFV4 to replicate efficiently in the periphery since in the absence of type-I IFN
responses virus rapidly replicates to high titres. However, there must be other factors
that control the ability of the virus to replicate more efficiently because SFV A7(74)
produces approximately 1 log more virus in the same strain of mice (Breakwell, PhD
2006). Perhaps when SFV4 was derived from L10 changes introduced by cloning
affected the ability of the virus to replicate in the periphery and thus invade the CNS.
Although the neuroinvasiveness of SFV4 and SFV4(3H)-eGFP is limited the virus is
highly neurovirulent when even small doses of virus are administered directly into
the brain via the intracerebral or the intranasal route. All animals given SFV4 and
SFV4-based viruses through these two routes succumbed to infection. In contrast
animals given SFV A7(74) directly into the CNS did not exhibit clinical signs of
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encephalitis and survive. Virulent strains of SFV cause lethal encephalitis because
they replicate very rapidly and efficiently in neurons before intervention of the
immune system (Atkins & Sheahan, 1982; Gates et al., 1985). The avirulent strains
either replicate less efficiently like the M9 strain or their replication is totally
restricted in neurons like the A7(74) strain (Smyth et al., 1990; Fazakerley et al.,
1993). Virulence of SV, EEE and VEE is associated with their ability to replicate in
neurons (Lustig et al., 1988; Griffin, 1995; Charles et al., 1995; Del Piero et al.,
2001).
Determinants of neurovirulence on SFV are located in both the structural and the
non-structural ORF as well as on the 5' and 3' non-translated regions. Comparison of
the sequence of SFV4 with SFV A7(74) showed numerous amino acid differences in
the non-structural proteins (Tuittila et al., 2000). The structural proteins, especially
E2 also appear to play important role in SFV neurovirulence (Glasgow et al., 1991;
Santagati et al., 1995). Nevertheless, multiple studies suggest that the most important
determinants of neurovirulence lie on the non-structural region and possibly in the 5'
non-translated region (NTR). When the 5' NTR and the non-structural ORF of
A7(74) were replaced by those of SFV4 the resulting virus was highly virulent, a
reciprocal virus (SFV4 with A7(74) structural ORF) was avirulent (Tuittila et al.,
2000). Also it has been reported that deletions in nsP3 affect the neurovirulence of
SFV (Galbraith et al., 2006). Most studies on the identification of SV neurovirulence
determinants suggest that those are found in the El and E2 structural proteins (Lustig
et al., 1988; Tucker et al., 1997). Neurovirulence of SV is also affected by mutations
in nsPl, nsP3 and the 5' and 3' NTR (Kuhn et al., 1992).
The cell tropism of SFV4(3H)-eGFP in the mouse CNS is not altered relative to that
of the parental SFV4. The virus infects neurons, and oligodendrocytes but not
astrocytes. This is coherent with other studies that have shown that the tropism of
both virulent and avirulent strains of SFV is very similar (Balluz et al., 1993;
Fazakerley et al., 2006). As already mentioned SV is able to infect neurons in vivo
but no reports for infection of other cell types can be found in the literature. EEEV
and VEEV can also infect neurons and it has been reported that they also infect
oligodendrocytes and astrocytes (Schoneboom et al., 1999; Del Piero et al., 2001).
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Surprisingly, although cells morphologically and anatomically known to be neurons
were infected by SFV4(3H)-eGFP (as assessed by immunostaining for nsP3) no
double-labelled neurons were observed when the NeuN specific neuronal marker was
used for immunostaining. Neurons may switch off the 42S genomic promoter more
rapidly that other cell types, for example oligodendrocytes. Possibly something
similar happens in peripheral tissues as well since in IFN a/p receptor knockout mice,
green cells were observed only in certain organs (spleen and pancreas) and only in
certain cell types (for example pancreatic acinar cells), although it is known from
other studies that both SFV4 and SFV A7(74) can infect most of the peripheral
tissues in these mice (see Chapter 4).
Overall, SFV4(3H)-eGFP does not differ much to SFV4 and can be useful for in vivo
pathogenesis studies as eGFP is only expressed in cells in which the genomic
promoter is active. Therefore the rapid eGFP degradation observed is a useful
property and this virus can be used to distinguish between cells infected at the early
and the late stages of infection.
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Introduction
Alphavirus replication is rapid and very efficient leading to the production of high
numbers of infectious virus particles. In addition, alphaviruses have a broad range of
susceptible host cells and organisms including vertebrates (mammals and birds) and
invertebrates (insects) (Strauss & Strauss, 1994). These properties together with the
ability to produce high levels of foreign proteins have made alphaviruses very
appealing vector systems for protein expression (Frolov et al., 1996; Lundstrom,
1997; DiCiommo & Bremner, 1998).
The 26S subgenomic promoter which drives the expression of the viral structural
proteins in alphaviruses is very potent (Tubulekas et al., 1997). In all alphavirus-
based vector systems, this property has been exploited and the viral structural
proteins have been replaced by foreign genes of interest including various marker
genes like eGFP. Expression of foreign genes is rapid, high level and prolonged
(Jeromin et al., 2003; Graham et al., 2006). These vectors, also known as replicons,
cannot be packaged unless the viral structural proteins are provided in trans either as
a separate RNA or in packaging cell lines (Polo et al., 1999; Karlsson & Liljestrom,
2003). As already mentioned, these vectors can only undergo a single cycle of
infection and this limits their applications especially for in vivo studies.
To take advantage of the strong, prolonged expression properties of the subgenomic
promoter without sacrificing the ability of the virus to replicate productively,
constructs expressing the foreign gene of interest under the control of a duplicated
subgenomic promoter have been constructed and utilised in various studies. Such
replication-competent vectors have been described for several alphaviruses including
SFV, SV and Chikugunya viruses (Raju & Huang, 1991; Hahn et al., 1992; Vaha-
Koskela et al., 2003; Vanlandingham et al., 2005).
The genetic instability of viruses with double-subgenomic promoter and the inability
of replicon vectors to undergo multiple rounds of replication are the major limiting
factors for the use of both these expression systems for in vivo pathogenesis or for
virus persistence studies. Replication-competent vectors with increased genetic
stability have been constructed by insertion of foreign genetic material in the non¬
structural ORF of alphaviruses as detailed in Chapter 3 (Bick et al., 2003; Frolova et
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al., 2006; Tamberg et al., 2007; Atasheva et al., 2007). Although insertion into the
non-structural ORF has enhanced the genetic stability of replicating vectors,
expression of the foreign gene is not as strong and prolonged as it would be if the
insertion was under the control of the 26S subgenomic promoter. Late in alphavirus
replication the fully processed replicase enzyme complex exclusively synthesises the
subgenomic message and stops transcribing the full-length genomic message (Strauss
& Strauss, 1994; Kao et al., 2001).
As an alternative to a duplicated subgenomic promoter or insertion into the non-
strtuctural ORF, Thomas et. al. (2003) constructed SV vectors expressing foreign
proteins (GFP and VP7 protein of bluetongue virus) as a cleavable component of the
structural ORF. In the present study, a similar SFV vector carrying eGFP was
constructed, fully characterised in vitro and in vivo and its suitability for in vivo
pathogenesis study was evaluated.
Objectives
The objectives of this study were:
• To examine whether the insertion of eGFP as a cleavable component of the
structural ORF of Semliki Forest virus (SFV) has an effect on the replication
efficiency of the virus.
• To investigate if insertion of eGFP in the structural ORF has an impact on the
in vitro and in vivo virulence of SFV4.
• To assess the in vitro and in vivo phenotypic and genotypic stability of the
recombinant virus expressing eGFP as a component of the structural ORF.
• To test if the insertion of eGFP at this position affected the cell type tropism
of SFV4 both in vitro and in vivo.
• To use the recombinant marker virus in a pathogenesis study in order to
determine its usefulness.
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Construction of a recombinant virus expressing eGFP as a cleavable
component of the structural ORF
A novel replicating vector, annotated pSFV4-st, was designed to express a foreign
gene as a cleavable component of the structural ORF. The construction of this vector
was based on a similar sindbis virus (SV) vector designed by Thomas et. al. (2003).
pSFV4-st was constructed by Professor Andres Merits at the Estonian Biocentre. As
with the recombinant viruses described in Chapter 3, pSFV4 (Liljestrom & Garoff,
1991) was used as the backbone of this virus. For the insertion of foreign sequences
in this vector, a polylinker containing Apal and BumHI restriction sites followed by
the sequence for the foot-and-mouth disease virus (FMDV) 2A peptide were inserted
between the regions encoding the capsid and the p62 protein. The efficiency of the
2A peptide is affected by the presence of the amino acids at its N-terminal and C-
terminal regions (Ryan et al., 1991). The 16 amino acids comprising the 2A peptide
were therefore flanked by three amino acids from the C-terminus of the FMDV ID
protein and the proline from the N-terminus of the FMDV 2B protein. Previous
studies indicate that the proteolytic activity of capsid protein is independent of
downstream sequences (Sjoberg et al., 1994; Frolov et al., 1996). Flowever, to ensure
proper processing of the capsid protein from the rest of the structural polyprotein, the
first three amino acids of the p62 protein (serine, alanine, proline) were duplicated
between the capsid and the polylinker sequence. As described previously, enhanced
green fluorescent protein (eGFP) was amplified with primers incorporating Apa\ and
BamH\ restriction sites (shown in the materials and methods chapter). Both the
pSFV4-st vector and the eGFP insert were digested with these two restriction
endonucleases and ligated using T4 DNA ligase. This construct was designated
pSFV4-steGFP and was used to produce infectious virus (SFV4-steGFP) according
to the method described by Liljestrom et al. (1991) (Fig 4.1).
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Capsid + eGFP | 2A + p62
Figure 4.1. Schematic representation of the construction of SFV4-steGFP virus.
SFV4-steGFP construction and predicted processing of the structural polyprotein; the
three N-terminal amino acids (SAP) of p62 protein (E2 & E3) were duplicated
upstream of the eGFP gene. The 2A peptide from FMDV flanked by three amino
acids (red) from the C-terminus of FMDV ID protein and the N-terminal proline
(blue) from FMDV 2B protein was inserted after eGFP. Following expression of the
structural ORF, all structural proteins and eGFP with 2A fused to its C-terminus
were expected to be released free.
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Assessment of the expression levels of eGFP as part of the structural
ORF and the effect of this insertion on virus viability and replication.
Experimental design
To assess the impact that eGFP insertion in the structural ORF had on virus viability
and replication efficiency, monolayers of BHK.-21 cells were infected with SFV4 and
SFV4-steGFP at a multiplicity of infection (M.O.I) of 10 in triplicate. Two hundred
pi of virus containing supernatant were collected and replaced with an equal amount
of fresh medium every 2 hours for 12 hours. All samples were titrated using standard
plaque assay as previously described. To investigate the dynamics of eGFP
expression in vitro, cultures of BHK-21 cells were infected with SFV4-steGFP at an
M.O.I of 10 and were monitored for expression of eGFP every hour for the first 12
hours post-infection and every 4-6 hours thereafter until 48 hours post infection.
Simultaneously, cultures were monitored for the development of cytopathic effect
(CPE). For comparison, parallel cultures of BHK-21 cells were infected with SFV4.
One-step growth curves
The results obtained from the one-step growth curves (Figure 4.2a) suggest that
insertion of eGFP into the structural ORF did not have any major effect on virus
viability and replication since SFV4-steGFP was able to infect BHK-21 cells and
replicated to similar levels to SFV4. However, the insertion reduced the replication
rate of the virus relative to wild-type SFV4. Statistical analysis using a paired t-test
showed that at 4 and 6 hours post-infection SFV4-steGFP had significantly lower
titres than SFV4 (P<0.05). From 8 hours onwards, SFV4-steGFP had similar titres to
SFV4 (no significant difference, P>0.05). SFV4-steGFP produced plaques with a
similar size to SFV4 (data not shown).
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eGFP expression and development ofCPE in BHK-21 cells
Following infection of BHK-21 cells with SFV4-steGFP, cells were observed at
regular intervals to determine when eGFP fluorescence and CPE were evident. eGFP
fluorescence was first visible 5-6 hours post-infection. The eGFP signal reached its
peak between 10 and 12 hours post-infection and remained high throughout the rest
of the experiment (48 hours). Figure 4.2b shows eGFP expression in BHK-21 cells
20 hours post-infection with SFV4-steGFP. In contrast to SFV4, where CPE was
initially observed between 16-20 hours after infection, cells infected with SFV4-
steGFP exhibited the first signs of CPE at approximately 36 hours post-infection.
Until that time-point cells appeared to be healthy (no CPE observed) and maintained
the characteristic morphology of BHK-21 cells (Figure 4.2b and 4.2b inset). Typical
morphology of cells undergoing cell death was observed at approximately 36 hours
post-infection. Cells were rounded and the eGFP signal that until that point was
mainly cytoplasmic was able to diffuse to the nucleus. This could have resulted from
a loss of integrity of the nuclear membrane. By 48 hours all cells had this
morphology (Figure 4.2c and 4.2c inset). Shortly after, the cell monolayer
completely detached. The delay on the development of CPE, as well as the delay
between first signs of CPE and cell death (compared to SFV4) suggests that the
insertion of eGFP in the structural ORF of SFV does have an attenuating effect on
the virus in vitro.
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Figure 4.2. Growth curves and expression of eGFP in BHK-21 cells, (a)
Monolayers of BHK-21 cells were infected in triplicate with SFV4 (dark blue
circles) or SFV4-steGFP (light blue circles) at an M.O.I of 10. Each point represents
the mean of 3 samples; the bar represents the standard deviation (SD). The values at
each time-point were compared using paired t-test, asterisk (*) indicates statistically
significant difference. All growth curves shown in this thesis were performed in
parallel. The data for SFV4 presented in this figure is identical to that shown in
Figures 3.2a and 5.3a allowing comparison of the growth of all recombinant viruses.
(b) and (c) Images of BHK-21 cells infected, with SFV4-steGFP virus at an M.O.I of
10 taken 24 and 48 hours post-infection, respectively. Levels of eGFP expression
were consistently high even at late time-points. The inset in panel (b) shows the
morphology of BHK-21 cells prior to the development of CPE. On the inset in panel
(c) cells with a morphology indicative of CPE can be seen. Note that at this stage
eGFP expression is strong in the nucleus. Pictures were acquired with a Zeiss
Axioskop microscope.
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Expression of the replicase complex, capsid and eGFP proteins in
SFV4-steGFP virus
Comparison of the expression of capsid, eGFP & of the replicase proteins ofSFV4,
SFV4(3H)-eGFP and SFV4-steGFP in BHK-21 cells
To determine whether eGFP insertion in the structural ORF of SFV had any effect on
the correct processing of the non-structural or the structural proteins of the virus,
BHK-21 cells were infected with SFV4, SFV4(3H)-eGFP or SFV4-steGFP at an
M.O.I of 20 for 6 hours. PBSA was used as a negative control to mock-infect cells.
The samples were analysed by western blotting. Briefly, 6 hours post-infection, cells
were lysed and samples corresponding to 100,000 cells were separated on a 10%
SDS polyacrylamide gel. Proteins were transferred to a nitrocellulose membrane.
Antibodies recognising specific epitopes on nsPl, nsP2, nsP3, nsP4, capsid and
eGFP were then used to detect the respective proteins.
SFV4-steGFP expressed all the non-structural proteins and capsid protein as
expected with no size differences between SFV4 and SFV4(3H)-eGFP (Figure 4.3).
Note that western blotting for nsPl (black arrowhead) and capsid (blue arrowhead)
was performed on a single membrane since the two proteins have different molecular
weights allowing easy differentiation. As expected, no eGFP protein was detectable
in the lysate of cells infected with SFV4. In contrast, eGFP was detectable in the
lysates of cells infected with SFV4(3H)-eGFP or SFV4-steGFP. The eGFP protein
expressed from SFV4(3H)-eGFP (black arrow) had a slight size difference to the
eGFP expressed from SFV4-steGFP. This is as expected since for SFV4(3H)-eGFP
30 amino acids from the C-terminal area of nsP3 had been fused to the C-terminus of
eGFP to re-create the natural nsP3/4 nsP2 protease processing site between eGFP
and nsP4. In SFV4(3H)-eGFP infected cells an eGFP containing band with a higher
molecular weight than eGFP can also be seen. The origin of this band remains
unclear, it was not previously observed when this antibody was used for western
blotting (Chapter 3). That a second band is seen in Figure 4.3 is inconsistent and the
explanation is not clear. However, both experiments (described in Chapter 3 and
Chapter 4) are correct. Since these experiments were not performed on the same day,
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possible explanations for the presence of the additional band include differences in
BHK-21 cells confluence and differences in processing of the samples, for example
the activity of protease inhibitors in lysis buffer. In the previous western blot of
SFV4(3H)-eGFP infected cells, Chapter 3, Figure 3.3a, a band corresponding to an
eGFP-nsP4 fusion protein was detected with both the anti-nsP4 and anti-eGFP
antibodies. In the present blot (Figure 4.3) an eGFP-nsP4 fusion protein was detected
only with the anti-nsP4 antibody (blue arrow). In Figure 3.3a, the amount of eGFP-
nsP4 fusion protein is much lower than the amounts of processed eGFP and nsP4
proteins. Perhaps in Figure 4.3 the amount of the eGFP-nsP4 fusion protein, was
below the limit of detection of the eGFP antibody. An eGFP-2A-p62 fusion protein
was detectable when the same (anti-eGFP) antibody was used with the lysate of
SFV4-steGFP infected BHK-21 cells (red arrow). The band above this is most
probably another fusion protein of eGFP and p62. These bands suggest that the 2A
sequence was not 100% efficient. Due to time constraints, the western blots were not
repeated. Further studies are required to fully characterise the processing of the
structural proteins. These would require antibodies recognising epitopes on the p62
and El proteins; at the time of completion of this project these antibodies were not
available.
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Figure 4.3. Expression of the replicase complex, capsid and eGFP proteins in
SFV4, SFV4(3H)-eGFP and SFV4-steGFP infected BHK-21 cells. Western
blotting of cell lysates of BHK-21 cells infected with SFV4(3H)-eGFP (1), SFV4-
steGFP (2) or SFV4(3) (M.O.I 20) and PBSA (mock-infection M). Specific bands of
the appropriate molecular weight for nsPl, nsP2, nsP3, nsP4 non-structural proteins
and eGFP are shown with black arrowheads. Bands corresponding to the capsid
protein are highlighted with a blue arrowhead. The blue arrowhead on the panel
corresponding to the western blot for nsP4 protein points at an eGFP-nsP4 fusion
protein (only for SFV4(3H)-eGFP, lane 1). The red arrowhead on the panel
corresponding to the western blotting for eGFP highlights an eGFP-2A-p62 fusion
protein. It appears that nsPl of SFV4(3H)-eGFP has slightly smaller size. This
difference is not real and it can most probably be attributed to the loading of the
sample and the way the gel was ran.
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Distribution of eGFP and nsP3 non-structural protein in BHK-21 cells
infected with SFV4-steGFP
Experimental design
To investigate the distribution of eGFP and nsP3 proteins in BFIK-21 cells following
infection with SFV4-steGFP, cells were grown on glass slides with culture chambers
until approximately 80% confluent and then infected with SFV4-steGFP (M.O.I of
10). As a control, virus-like particles (VLPs) expressing eGFP, previously described
in Graham et. al. (2006) were used to infect parallel cultures. Sixteen hours post¬
infection, cells were fixed and immunostained with anti-nsP3 antibody. This time-
point was chosen to give plenty of time for eGFP to be expressed to high levels; as
shown previously nsP3 is detectable for at least 24 hours (Figure 3.3b).
Distribution ofeGFP vs distribution ofnsP3 in BHK-21 cells
The distribution of eGFP in BHK-21 cells infected with SFV4-steGFP was different
to the distribution observed when these cells were infected with either viruses
expressing eGFP as part of their non-structural ORF (SFV4(3H)-eGFP & SFV4(3L)-
eGFP) (Figure 3.4) or SFV virus-like particles (VLPs) expressing eGFP from the
subgenomic promoter. In BHK-21 cells infected with SFV-eGFP VLPs, eGFP
expression was distributed throughout the cytoplasm and the nucleus of the infected
cells (Figure 4.4a). Punctate nsP3 staining, probably corresponding to the position of
the virus replication complexes, was visible in the cytoplasm of the infected cells











Figure 4.4. Distribution of eGFP and nsP3 in BHK-21 cells infected with SFV-
eGFP VLPs. (a) Distribution of eGFP 16 hours post-infection with VLPs at an
M.O.I of 10. Fluorescence is visible in the cytoplasm and in the nucleus of infected
cells. Notably, the fluorescent signal is stronger in the nucleus. Arrows point at cells
with characteristic distribution of eGFP. Cells were Fixed and stained with a anti-
nsP3 antibody, (b) nsP3-specific staining was as expected, cytoplasmic and punctate.
This can be best seen in panel (c) where arrows point at cells with a typical
distribution of nsP3-specific staining. A non-infected control was performed and
very low levels of background fluorescence were observed (as was observed
previously, Figure 3.4). All images were acquired with a Zeiss microscope.
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In BHK-21 cells infected with SFV4-steGFP, the vast majority of the eGFP
fluorescence was localised in the cytoplasm particularly around the nuclei of the
infected cells (Figure 4.5a, 4.5d and 4.5g). This distribution was unexpected and the
experiment was repeated 3 more times and gave the same result. This finding was
also verified by our Estonian collaborators (A. Merits, personal communication).
Punctate, cytoplasmic, nsP3-specific staining was visible in approximately 100% of
cells. The distribution of nsP3-specific staining was identical for all viruses and
virus-like particles irrespective ofwhether eGFP was expressed as a cleavable part of
the non-structural or the structural ORF. Typical nsP3-specific staining is shown in
Figures 4.5b, 4.5e and 4.5h. A small percentage of cells were positive for nsP3 but
eGFP-negative. These were probably the cells most recently infected with virus.
Examples of such cells are shown in Figure 4.5d - f and g - i (white arrows). Cells
with characteristic distribution of both eGFP and nsP3-specific staining are
highlighted by an asterisk in all panels of Figure 4.5. In the inset of panels a - c of
the same figure, a cell with punctate nsP3-specific staining, which has a large
number of very bright eGFP-containing vacuoles can be seen. These vacuoles may
be the remains of an adjacent cell that died and was phagocytosed. The eGFP
distribution, although different to the one observed in cells infected with viruses
expressing eGFP as part of their non-structural ORF or in cells infected with VLPs
expressing eGFP alone from the subgenomic promoter, is not totally unexpected and
will be further discussed later in this chapter. It is important to note that although
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Figure 4.5. Distribution of eGFP and nsP3 in BHK-21 cells infected with SFV4-
steGFP. At 16 hours post-infection cultures were fixed and stained with anti-nsP3
antibody, (a) eGFP fluorescence had high levels of intensity and was mostly
localised in the cytoplasm especially around the nucleus. The white arrow points to a
cell with multiple eGFP-containing vacuoles, (b) nsP3-specific staining of the same
field of vision. Typical punctate staining can be seen, (c) merged image of (a) and
(b), the asterisk indicates a cell with characteristic eGFP and nsP3-specific
staining.(d) Infected cells exhibiting cytoplasmic and perinuclear eGFP expression,
(e) Typical distribution of nsP3-specific staining in the same cells, (f) merged image
of (d) and (e), the asterisk indicates a cell with characteristic eGFP and nsP3-specific
staining. The white arrow points at a cell which is stained positive for nsP3 but does
not express eGFP. (g), (h) and (i). High power images of a different field of vision.
Again the white arrow points at a cell which stained positive for virus (nsP3) but was
eGFP-negative. The asterisk highlights a cell with typical eGFP and nsP3
distributions. Controls for immunostaining were included; results were identical to
those previously observed (Figure 3.4). All images were acquired with a Zeiss
confocal microscope.
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Distribution of eGFP and SFV structural proteins in BHK-21 cells
infected with SFV4-steGFP
Distribution ofeGFP vs distribution ofSFV structuralproteins in BHK-21 cells
Since SFV4-steGFP expresses eGFP as a cleavable part of the structural ORF an
experiment comparing the distribution of eGFP to that of the virus structural proteins
was performed. The experiment was identical to the one described above, which was
used to investigate the distribution of eGFP and nsP3 non-structural protein. The
only difference was that after fixation cells were immunostained using a a-SFV
polyclonal antibody. VLPs expressing eGFP were not included in this experiment
since they lack the viral structural proteins.
The eGFP distribution was as described previously (Figure 4.6a and 4.6d). The
intensity of the green fluorescent signal was variable. Most probably this resulted
from cells at different stages of infection (with dull green indicating early stages of
infection and bright green late stages of infection respectively). Viral structural
proteins were found exclusively in the cytoplasm (Figure 4.6b & 4.6e). This was as
expected as the location of the viral structural proteins is known from previous
studies and this particular antibody has been used by other members of the laboratory
with identical results. In panel f of figure 4.6 it can be seen that the structural protein
specific staining co-localises with the eGFP staining (indicated by the orange colour).
Rare cells stained positive for viral structural proteins but were eGFP-negative (white
arrows in the same panel). These cells are probably, like cells that stained positive
for nsP3 but were eGFP-negative, the most recently infected cells of the culture.
Alternatively, both eGFP-negative/nsP3-positive and the eGFP-negative/structural-
positive could result from infection with virus that has eliminated (even partially) the
eGFP insert. Interestingly, although approximately 100% of the monolayer was
infected (as determined by the eGFP signal) only 15-20% of these eGFP-positive
cells were positive for viral structural proteins (Figure 4.6c). This was unexpected;
the experiment was repeated two more times with very similar results. The possible
explanations for this finding will be discussed later in this chapter.
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a-structural merged
Figure 4.6. Distribution of eGFP and SFV structural proteins in BHK-21 cells
infected with SFV4-steGFP. At 16 hours post-infection cultures were fixed and
stained with anti-SFV antibody, (a) and (d) eGFP expression; cells with variable
levels of fluorescent signal can be observed. Differences in eGFP signal intensity are
possibly because cells were at different stages of the infection (early/late), (b) and (e)
SFV-specific staining (for structural proteins). The staining had the expected
distribution; exclusively cytoplasmic. This can be seen more clearly on panel
(e).From panels a - c it is clear that there are many double-labelled cells. However, it
appears that there are also bright green cells which are not red and some red cells that
are not green. The area denoted by the dotted box is shown in the lower right with
increased brightness; again there are cells that are only red and cells that are only
green. This is confirmed by the high power images (d - f). In the high power image
(f) double-labelled cells, indicated by orange colour can be seen. White arrows
indicate cells that have stained positive for SFV structural proteins (red colour) but
were eGFP-negative. Asterisk indicates a cell that is clearly eGFP-positive but
apparently structural-protein-negative. All images were acquired with a Zeiss
confocal microscope.
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In vitro phenotypic and genotypic stability of SFV4-steGFP in BHK-21
cells
Experimental design
In an identical manner to that described in Chapter 3 (Figure 3.5), the ability of
SFV4-steGFP to maintain eGFP expression and an intact eGFP gene after several
passages in vitro was assessed. Six-well plates were seeded with BHK-21 cells.
SFV4-steGFP was passaged 5 times in BHK-21 cells (M.O.I 0.01). Between each
passage the virus was titrated using a standard plaque assay. The passage sample was
then diluted to give approximately 20 plaques per well and ninety-six plaques were
picked from each of the 5 in vitro passages and were used to infect BHK-21 cells in
24-well plates. eGFP expression in each well was determined by fluorescent
microscopy.
Phenotypic stability ofSFV4-steGFP
The results show that 100% of plaque purified viruses were eGFP positive after the
first passage. This percentage went down to 96.9% after the 2nd passage and 78.6%
after the 3rd passage. During the last two passages SFV4-steGFP lost its ability to
express eGFP. More specifically, only 2% of the plaque purified viruses were eGFP-
positive after the 4th passage. No positive clones were detected after the last (5th)
passage (Figure 4.7a).
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Genotypic stability ofSFV4-steGFP
Following removal of the virus-containing supernatant, after each passage RNA was
extracted from the infected cells. As previously, 2 pg of RNA were reverse-
transcribed to cDNA. Primers flanking the area of the eGFP insertion in the
structural ORF were designed and used for amplification. If the insert was present a
product with a size of approximately 1,650 bp was expected. If the insert was
eliminated the expected product would have a size of approximately 826 bp. Figure
4.7b shows the results of the amplification for passages 2-5. The red and blue
arrows in each panel correspond to the 1,500 bp and 1,000 bp bands of the DNA
marker respectively. The experiment was done in triplicate for each passage.
After the 2nd passage, when the majority of plaque purified viruses were still eGFP-
positive, most of the amplified product had a size of ~ 1,650 bp. A faint band with a
size of ~ 850 bp was visible. This band had a slightly bigger size to the band
corresponding to the product of PCR amplification of material originating from cells
infected with SFV4, which was expected to be 826 bp in size (lane 4). After the 3rd
passage, the amount of PCR product corresponding to viruses with the eGFP coding
sequence in their genome was reduced and the amount of PCR product
corresponding to viruses which had eliminated the eGFP insert was increased. The
amplicon band produced from viruses which maintained the eGFP sequence was
barely visible after the 4th passage and was totally absent after the 5th passage. In all
panels of figure 4.7b it can be seen that as the passage number increased bands with
sizes smaller than the ~ 1,650 bp expected appeared (especially after 2nd, 3rd & 4th
passage). These bands probably correspond to viruses with large in frame deletions
of eGFP (as shown previously by sequencing of passaged SFV4(3H)-eGFP and
SFV4(3L)-eGFP viruses). The predominant deletion product however had a size of ~
850 bp and was slightly bigger than the amplicon produced when SFV4-infected
material was used. This finding suggests that the deletion of the inserted sequences
was not complete and some sequences remained in the viral genome.
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Figure 4.7. In vitro phenotypic and genotypic stability of SFV4-steGFP. (a)
Percentage of eGFP positive plaque purified viruses after serial passaging, (b) RT-
PCR genotyping of SFV4-steGFP using capsid - E3 primers on RNA samples
isolated from BHK-21 monolayers at passages 2, 3, 4 and 5; the passage number is
indicated at the top left of each panel. In the panels corresponding to 2nd and 4th
passage lanes 1 - 3 are the triplicate passages of SFV4-steGFP. Lane 4 in the same
panels shows the PCR product obtained from the amplification of SFV4-infected
material (positive control). In the panels corresponding to the 3rd and 5lh passage
lanes 2 - 4 are the triplicate passages of SFV4-steGFP. Lane 1 in the same panels
shows the PCR product obtained from the amplification of SFV4-infected material
(positive control). Note that the viruses carrying eGFP deletions have a slightly
larger amplicon size indicating incomplete deletion. Passage number is indicated at
the left top side of each panel. The red and blue arrows correspond to the 1.5 kb and
the 1 kb band of the DNA marker, respectively.
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Cell tropism of SFV4-steGFP in vitro
SFV4-steGFP was able to infect BHK-21 cells and express eGFP in these cells. To
determine whether the insertion of eGFP into the structural ORF of the virus altered
the tropism of SFV4 in vitro; its ability to infect mosquito cells (natural virus vector)
and neurons (important target of alphaviruses in vivo) was investigated. SFV4-
steGFP was used to infect cultures of C6/36 cells from Aedes albopictus and of rat
hippocampal neurons. The cultures were infected at an M.O.I of 10, as previously
described. Cells were then monitored for eGFP expression using a fluorescent
microscope. To assess the efficiency of the infection on C6/36 cells, infected
monolayers were fixed at 16 hours post-infection and stained using anti-nsP3
antibody. Parallel cultures were infected with SFV4 or SFV4-steGFP and monitored
at regular intervals for presence of CPE for up to 5 days. In rat hippocampal neurons
the infection was allowed to progress until the death of the cells, no immunostaining
was performed.
C6/36 cells infected with SFV4-steGFP expressed eGFP to high levels (Figure 4.8a,
4.8d & 4.8g). In contrast to BHK-21 cell infection, eGFP was distributed throughout
the cell cytoplasm and nucleus. Notably some of the nuclei were brighter than the
cytoplasm surrounding them. The range of intensity of the eGFP fluorescence was
variable as observed in BHK-21 cells. The intensity of the signal probably reflects
the stage of the infection; bright cells are at the late stages of infection whereas less
bright cells are the most recently infected ones. Cells having numerous vacuoles
containing large amounts of eGFP, like the one indicated by the white arrow in panel
(d) of figure 4.8, and in higher magnification in the inset of the same panel, were
found scattered throughout the SFV4-steGFP infected cultures.
When C6/36 cells infected with SFV4-steGFP were immunostained for nsP3 non¬
structural protein, approximately 100% of the cells stained positive (Figure 4.8b, 48e
& 4.8h). The distribution of the nsP3-specific staining was cytoplasmic and in many
instances showed the characteristic punctate pattern observed previously. Typical
nsP3 staining is shown in the inset of Figure 4.8i (high magnification of the cell
marked with an asterisk). Occasional nsP3-positive/eGFP-negative cells were
observed, there cells were probably at the early stages of infection and eGFP had not
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reached detectable levels, or were infected by a virus which had eliminated the eGFP
insert, an example is highlighted with a white arrow in panels g - i. C6/36 cells
infected with SFV4 or SFV4-steGFP were monitored frequently using microscopy to
investigate if cytopathic effect (CPE) would develop. No signs of CPE were
observed over the 5 days of this study.
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Figure 4.8. Infection of C6/36 cells from Aedes albopictus with SFV4-steGFP. (a)
(d) & (g) Cells were infected with SFV4-steGFP (M.O.I of 10) and fixed at 16 hours
post-infection. Cells with different levels of eGFP expression, probably indicative of
different stages in infection can be seen. In some cells, fluorescence was more
intense in the nucleus, (d) The white arrow indicates a cell with numerous vacuoles
containing large amounts of eGFP, a high magnification image of this cell is shown
in the inset. Immunostaining with anti-nsP3 antibody can be seen in (b) (e) and (h).
Merged images are shown in panels (c) (f) & (i); the vast majority of eGFP-positive
cells were also nsP3-positive. A cell with typical nsP3 staining is marked with an
asterisk in panels (g) - (i). In the same panels the white arrow indicates a cell stained
positive for nsP3 which was eGFP-negative. Negative controls were performed and
were identical to the ones shown in Figure 3.7. All images were acquired with a
Zeiss confocal microscope.
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Rat hippocampal neurons infected with SFV4-steGFP exhibited high levels of eGFP
fluorescence (Figure 4.9). eGFP was distributed evenly throughout the cytoplasm
and the nucleus of the infected cells. In addition. eGFP was able to spread to the
axonal processes of the neurons (seen in panels a, g, h & i). These primary cultures
contain many cell types, but principally neurons and oligodendrocytes.
Oligodendrocytes are a known target of SFV (Fazakerley et al., 2006). In these rat
hippocampal neuron cultures, cells with oligodendrocyte morphology were infected
by SFV4-steGFP. Some of these cells (pointed by white arrows or found inside the
encircled area in figure 4.9a - 4.9c) appear to be in close proximity to axonal
processes. Studies have shown that oligodendrocyte precursors or mature
oligodendrocytes have the ability to myelinate rat hippocampal neurons in vitro
(Rubio et al., 2004; Kang et al., 2007). These putative oligodendrocytes may be
myelinating the adjacent axons.
Infection of rat hippocampal neurons with SFV4-steGFP resulted in death of the
cultures by 4 days. After 24 hours, the cells looked perfectly healthy (Figure 4.9a,
49b & 4.9c). Forty eight hours after infection most cells looked normal but some
started developing CPE and some cells had the characteristic morphology of cells
undergoing apoptosis; condensed nuclei and blebbing (Figure 4.9d, 4.9e &4.9f).
Widespread cell death was evident from 72 hours onwards; however, some cells
were still surviving at this point (Figure 4.9g, 4.9h & 4.9i). All cells were detached 4
days after infection. The infection progressed in an identical way in cells infected
with SFV4.
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merged
Figure 4.9. Infection of rat hippocampal neurons with SFV4-steGFP. (a), (b) and
(c) In the middle of the field of vision an infected neuron with multiple long
processes can be seen. White arrows indicate cells with oligodendrocyte morphology
that are in close proximity to the axons of this infected neuron. The dotted circle
marks an area rich in processes (best seen in the bright field image), which also
contains multiple infected cells with oligodendrocyte morphology. All images
acquired 24 hours after infection; no signs of CPE were obvious at this time, (d), (e)
and (f) Images taken 48 hours after infection; most cells looked normal but some
showed evidence of CPE and death by apoptosis. In panel (d) two cells which show
condensed nuclei (bottom inset) and blebbing (dotted circle and top inset) can be
seen. Later in infection (72 hours) widespread death was observed in the infected
cultures, a few cells were still surviving and had normal morphology. Examples can
be seen in panels (g), (h) and (i). All images were acquired with a Nikon inverted
microscope.
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In vivo pathogenesis following intraperitoneal inoculation
Assessement ofvirulence and determination ofviraemia
To assess the virulence of SFV4-steGFP, groups (n=10) of adult (4-5 week old,
female) Balb/c mice were infected i.p. with 5 x 103 PFU of SFV4-steGFP or mock-
infected with PBSA. To minimise the number of animals used no animals were
infected with SFV4 or SFV L10 since these experiments had been done previously
(Figure 3.8b). Infected animals were maintained for 10 days and monitored daily for
symptoms of viral encephalitis. In addition, to determine the plasma viraemia
following extraneural inoculation six adult (4-5 week old) Balb/c mice were
inoculated i.p. with 5 x 103 PFU of SFV4-steGFP. Twenty-four hours later the
animals were euthanised and heparinised blood was collected and titrated using a
standard plaque assay.
Results
In the previous experiments using SFV4 (Figure 3.8b) mice did not succumb to the
infection, it was expected therefore that the same would happen following infection
with SFV4-steGFP. None of the SFV4-steGFP inoculated mice showed any clinical
signs of disease throughout the 10 day period that the experiment lasted. The
heparinised blood collected from the SFV4-steGFP infected animals was titrated and
100% (6/6) of the samples were below the limit of detection of the assay. Insertion of
eGFP in the structural ORF therefore had an attenuating effect on the in vivo
replication efficiency of SFV4 following inoculation via the intraperitoneal route
since SFV4 was able to establish a viraemia at 24 hours post-infection (Figure 3.9a).
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Virus spread in wt mice and mice deficient in type-I interferon responses
Type-I interferon (IFN) appears to play a very crucial role in limiting virus
replication and determining the outcome of infection (Isaacs & Lindenmann, 1957).
To determine whether SFV4-steGFP was being suppressed by the IFN system, the
course of infection in the absence of an intact type-I IFN response was investigated.
Groups (n=3) of adult (4-5 week old, female) IFN a/p receptor knock-out mice
(A 129) (Muller et al., 1994) and wtl29 mice were infected i.p. (at the same time
using the same vial of virus) with 5 x 103 PFU of SFV4-steGFP. One mouse from
each group was sampled 24 hours post-infection. The remaining mice from the
control group (wtl29) were sampled on PID 2, whereas a mouse from the A129
group was sampled on PID 2 and the last mouse from this group was sampled when
symptoms of viral encephalitis developed on PID 4. To titrate the infectious virus in
the peripheral blood, heparinised blood was collected. Numerous tissues from SFV4-
steGFP infected mice including: spleen, pancreas, heart, lung, kidney, and brain were
also sampled. The removed tissues were directly observed for fluorescence using a
Zeiss stereomicroscope and were then processed into frozen sections. To facilitate
visualisation of the tissue structure, tissue sections were incubated with
diaminobenzidine (DAB) to obtain a light background staining. Sections were then
examined microscopically for eGFP expression.
Results
The results obtained from the titration of the heparinised blood samples are shown in
Table 4.1. For comparison the results previously obtained (Table 3.1) from SFV4
infected animals are also shown. In contrast to the SFV4-infected wtl29 mouse
which had detectable levels of infectious virus on PID 1, the mouse infected with
SFV4-steGFP had no detectable infectious virus at this time. On PID 2 none of the
wtl29 mice infected with either SFV4 or SFV4-steGFP had infectious virus in the
blood. In contrast, in A129 mice, infected with SFV4-steGFP, a viraemia was
established. However, on PID 1, the titre of SFV4-steGFP was 6.3 Logio PFU/ml, 2.2
Logio PFU/ml lower than that of SFV4. On PID 2 the titre of SFV4-steGFP had
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increased slightly (6.7 Logio PFU/ml). Since the A129 mice were not exhibiting
signs of encephalitis it was decided to keep the third mouse until signs of
encephalitis (including limb paralysis and ataxia) developed. On PID 4 this mouse
was moribund and was euthanised. Infectious virus in the blood had a titre of 6 Logio
PFU/ml. Given that on PID 1 and PID 2, 3/3 wtl29 infected mice had no detectable
viraemia and 2/2 A129 mice had high titre viraemia, it can be concluded that as with
SFV4, the IFN system very efficiently controls SFV4-steGFP replication, at least in
extraneural tissues. Based on the virus titres and the delay in the development of
clinical symptoms it can be suggested that insertion of eGFP in the structural ORF of
SFV attenuated the virus in mice lacking an intact type-I IFN system following i.p.
inoculation. Only a small number of mice were used for these experiments; a
breeding colony of A129 mice was not available at the departmental animal unit.
Due to the small number of animals it is not possible to perform any statistical











SFV4 4.3 (1/1) <1.4 (2/2) 8.5 (1/1) - N/A
SFV4-steGFP <1.4 (1/1) <1.4 (2/2) 6.3 (1/1) 6.7(1/1) 6.0(1/1)
Table 4.1. Infectious virus titres in the blood of A129 and wtl29 mice infected
with SFV4-steGFP. All values are expressed as Logio PFU/ml of whole blood. On
PID 2 both A129 mice infected with SFV4 were found dead (-).
Although no infectious virus was detected on PID 1 in the blood samples of the
wtl29 mice infected with SFV4-steGFP it was decided to examine the tissue sections
for eGFP expression. Slides with tissue sections of brain, heart, lung, liver, pancreas,
kidney and spleen tissue were prepared; the thickness of the tissue sections was the
same for all tissues (12 pm) except for pancreatic tissue (14 pm). Six slides with 3
sections on each slide were examined microscopically for eGFP expression. No
eGFP fluorescence was observed in any of these tissues.
For A129 mice, all removed tissues were fixed and examined using a stereoscopic
fluorescent Zeiss microscope. Only the brain of the A129 mouse sampled on PID 4
showed evidence of high levels of eGFP expression (Figure 4.10a). The infected
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areas of this brain included the inferior colliculus (ic), a midbrain nucleus of the
auditory system with high metabolic activity (Gross et al., 1987), the main olfactory
bulb (mob), an area of the brain associated with the perception of odours (Davison &
Katz, 2007) and the frontal cortex (fctx). Foci of infection in close proximity to
blood vessels were apparent, however, it is not possible to determine if these were
definitely associated with the blood vessels because the depth of the eGFP signal
could not be determined.
Following gross examination, frozen sections were cut from all tissues (same
thickness as for the wtl29 mice). Again, multiple slides were examined using a Zeiss
Axioskop confocal microscope. Infected (eGFP-positive) cells were apparent in
several tissues. Throughout the brain, SFV4-steGFP infected meningeal cells (Figure
4.10b) and neurons. In Figure 4.10c several infected neuronal populations including
pyramidal neurons of the hippocampus (CA3 field ofAmnion's horn), neurons of the
granular dentate gyrus (GrDG), of the polymorph layer of the dentate gyrus (PoDG)
and of the thalamus can be seen. In heart tissue many cells were infected in the
valves (Figure 4.1 Od &4.IOe) whereas, very few infected cells were seen in the
myocardium (heart muscle; Figure 4.1 Of). In the spleen (Figure 4.10g & 4.1 Oh), the
majority of the infected cells were located in the marginal zone (mz) between the red
pulp (rp) and the white pulp (wp). This area of the spleen is known to be rich in
macrophages so there is a high probability that the infected cells were macrophages.
In the pancreas (Figure 4.1 Oi) many eGFP expressing cells, were observed.
Interestingly, the infected cells were acinar cells of the exocrine pancreas; no
infected cells were observed in the endocrine pancreas despite examination of many
sections (at least 6 slides with 3 sections per slide). Cells in the kidney glomeruli
were infected as were smooth muscle cells surrounding the ureter (ur) (Figure 4.1 Oj).
Adipose tissue was heavily infected (Figure 4.10k). Foci of infection were also
observed in cells lining the alveoli in the lungs (Figure 4.101). It is important to
point-out that SFV4-steGFP showed a preferential cellular tropism in most tissues
examined; for example cells of the heart valves in the heart, acinar cells of the
exocrine pancreas in the pancreas and cells of the marginal zone of the spleen (most
probably macrophages).Using SFV4-steGFP it was possible to show the spread of
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the infection in the absence of a functional type-I IFN response system without the
need for immunostaining.
161
Chapter 4 Insertion of eGFP in the structural ORF
Figure 4.10. Distribution of SFV4-steGFP in the absence of type-I interferons.
(a) Picture of the dorsal surface of the brain taken with a Zeiss stereomicroscope.
Foci of infection were observed in the inferior colliculus (ic), the frontal cortex (fctx)
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and the main olfactory bulb (mob). Arrows point to two foci of infection that appear
to be associated with blood vessels. The depth of the image shown is unknown so it
is not possible to definitely determine the association of these foci of infection with
their adjacent blood vessels, (b) Section of the same brain exhibiting infection of
meningeal cells (white arrow), (c) Infected neuronal populations in: the CA3 field of
Ammon's horn of the pyramidal layer of neurons in the hippocampus (py). The
granular dentate gyrus (GrDG) and the polymorph layer of the dentate gyrus (PoDG).
A focus of infection can also be observed below the line that separates the dentate
gyrus from the thalamus (bottom left-hand side of the panel). To make observation
easier nuclei were stained with PI (red), (d) and (e) Sections of heart tissue showing
infection of the heart valves in low and high magnification respectively (f) High
magnification image of myocardial tissue showing SFV4-steGFP infected cells, (g)
Section of spleen tissue, infection had a circular distribution in the marginal zone
(mz) between the red pulp (rp) and the white pulp (wp). This area of the spleen is
known to be rich in machrophages. (h) High magnification image of infected cells at
the same area, (i) Section of pancreas with numerous infected cells. Interestingly
only acinar cells of the exocrine pancreas (example shown with white arrow) were
infected, (j) Kidney cells including cells in the glomeruli were infected (kd). The
smooth muscle surrounding the ureter (ur) was found to be heavily infected, (k)
Adipose tissue exhibiting high levels of eGFP fluorescence. Adipose tissue was one
of the most heavily infected. (1) Focus of infection in the lung. Bars represent 100
pm in all panels. All tissues are from a mouse sampled on PID 4. Tissues shown in
panel D - L were incubated shortly with DAB to give a light staining allowing better
visualisation of the tissue structure. As mentioned earlier haematoxylin staining
quenches the eGFP signal and for that reason it was not used. All images except (a)
were acquired using a Zeiss confocal microscope.
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Virus pathogenesis following intracerebral inoculation
Except in mice with a deficient type-I IFN system, \n vivo replication of SFV4 and
SFV4-based recombinant viruses was limited following extraneural administration of
the virus and caused no clinical signs in mice. To observe events in the brain of wt
mice, SFV4-steGFP was inoculated intracerebraly (i.e.). Two experiments were
performed.
Assessment ofvirus virulence
To assess virus virulence and titres of virus in the brain following direct inoculation
in the brain; groups (n=6) of adult (4-5 week old, female) Balb/c mice were infected
i.e. with 1,000 PFU of SFV4-steGFP or mock-infected with PBSA. Data for i.e.
infection of this dose of SFV4 was already available (Figure 3.1 lb) and was not
repeated. Mice were monitored at regular intervals for clinical signs of viral
encephalitis. All animals exhibiting substantial clinical signs were euthanised and
their brains removed and snap frozen for virus titration.
Results
Initial signs of viral encephalitis, including pilar erection and reduced motility,
appeared approximately 24 hours post-infection in the group of mice infected with
SFV4. The mice infected with SFV4-steGFP reached the same end-point
approximately 24 hours later (48 hours post-infection). All (6/6) SFV4 infected
animals were sick on P1D 2 with signs of fulminant encephalitis. SFV4-steGFP
infected mice developed indistinguishable symptoms 24 hours later, on P1D 3. The
mock-infected animals (PBSA) remained asymptomatic until PID 10 when the
experiment was terminated (Figure 4.11 a).
All animals infected with SFV4 or SFV4-steGFP had high levels of infectious virus
in their brains. More specifically, SFV4 infected mice had an average infectious
virus titre of 9.5 Logio PFU/g of brain (SD: 0.11) on PID 2. The brains of SFV4-
steGFP infected mice had an average titre of 8.4 Logio PFU/g of brain (SD: 0.34) on
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PID 3. The time-points at which the two groups of mice were sampled were different
because it was decided to sample the mice when they exhibited signs of terminal
disease. Statistical analysis using paired t-test showed that for mice with clinical
encephalitis, SFV4 reached statistically significant higher brain virus titres than
SFV4-steGFP (P<0.05). As expected, all mock-infected (PBSA) animals were
negative for infectious virus (Figure 4.1 lb). These results indicate that neither SFV4
nor SFV4-steGFP were attenuated in their ability to replicate and spread in the brain.
This is in stark contrast to their poor replication outside the CNS. Insertion of eGFP
into the structural ORF did have an attenuating effect on the in vivo pathogenesis of
SFV4 following i.e. infection; signs of encephalitis developed with a 24 hour delay
and SFV4-steGFP reached significantly lower titres in the brain.
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Figure 4.11. Survival rates and brain virus titres in Balb/c mice following i.e.
inoculation with SFV4, SFV4-steGFP or PBSA. (a) Survival rates in Balb/c mice.
Groups (n=6) of adult female Balb/c mice were inoculated i.e. with 1,000 PFU of
virus or PBSA (mock), (b) Infectious virus titres in the brains of Balb/c mice
inoculated i.e. with 1,000 PFU. Mice were sampled on PID 2 and PID 3 for SFV4
and SFV4-steGFP, respectively. The two groups were compared using paired t-test
and found to be statistically different (P<0.05).
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eGFP expression and distribution
To examine eGFP expression and distribution in the brain, groups of (n=6) adult (4-5
week old, female) Balb/c mice were inoculated i.e. with 1,000 PFU of SFV4-steGFP.
On PI D 3 the mice were euthanized and their brains removed, fixed and processed
for frozen sections (12 pm thick). These were used to assess eGFP expression. To
compare the expression of eGFP to that of viral non-structural proteins and viral
structural proteins, brain sections were immunostained with antibodies targeting
epitopes on nsP3 and viral structural proteins. The cell tropism of SFV4-steGFP in
the CNS, was studied using antibodies recognising cell-specific markers of neurons,
astrocytes and oligodendrocytes.
Results
Brains of all mice infected with SFV4-steGFP sampled on PID 3 were processed and
frozen sections cut. Multiple sections from each brain were microscopically
examined for eGFP expression using a Zeiss Axioskop confocal microscope. In total,
6 slides with 3 sections each were examined from each brain. Infection with SFV4-
steGFP was widespread and large foci of infection were scattered throughout the
brain. A representative image showing the spread of the infection and the intensity of
the eGFP signal can be seen in Figure 4.12a. SFV4-steGFP was present in areas of
white matter including the corpus callosum (cc) and in areas of gray matter including
for example, the layer of pyramidal neurons of the hippocampus (py) and the
cerebral cortex (asterisk). The area enclosed by the dotted circle is shown in higher
magnification in Figure 4.12b. In the inset of that panel, a chain of cells with typical
oligodendrocyte morphology was observed in the corpus callosum, an area known to
be rich in oligodendrocytes. In putative oligodendrocytes most of the eGFP
fluorescence was concentrated in the cytoplasm. This was similar to the eGFP
distribution observed in BHK.-21 cells in vitro but in contrast to that in rat
hippocampal neurons. In the latter eGFP was evenly distributed in the cytoplasm and
nucleus (Figure 4.9). A large focus of infected cells located in the cortex of the brain
is shown in Figure 4.12d. In SFV infection, foci of infection in the CNS are usually
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perivascular. eGFP was present throughout the neuronal cell body and the axons of
infected neurons (Figure 4.12e & 4.12g). Different levels of eGFP expression were
observed. The brighter cells are probably the ones infected for longest and the less
bright cells the ones most recently infected. Axons of infected cells can be seen in
detail in panel f of the same figure. The encircled area is magnified in the inset
image; multiple neurite varicosities, most probably caused by the infection were
observed. To verify that eGFP was distributed in both the cytoplasm and the nucleus
of infected cells, sections were incubated with To-Pro3 nuclear marker. In panel i,
the merged image of eGFP (4.12g) and To-Pro3 (4.12h) is shown. In the cells in
which this confocal optical section cuts through the nucleus, the blue signal from the
nuclear marker overlaps with the green signal produced by eGFP verifying the
presence of eGFP in the nucleus of infected cells as well as in the cytoplasm.
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Figure 4.12. eGFP expression and distribution in the brain following i.e.
inoculation of Balb/c mice with SFV4-steGFP. (a) Low magnification image
showing infection of the corpus callosum (cc), the pyramidal neurons of the
hippocampus (py) and the cerebral cortex (crtx); a large focus of infection in the
cortex is marked with an asterisk. Bar represents 50 pm. The area in the dotted circle
is shown in higher magnification in panel (b). Infection of the cc and of the py was
extensive. The area surrounded by the dotted circle is magnified in the inset; these
cells have the characteristic morphology of oligodendrocytes and were in an area of
the brain rich in oligodendrocytes. Bar represents 100 pm. (c) Oligodendrocytes (by
morphology and anatomic position) infected with SFV4-steGFP. Note that most of
the eGFP signal is in the cytoplasm of these cells. Bar represents 20 pm. (d) A focus
of infection in the brain cortex, bar represents 100 pm. (e) Higher magnification
image of infected cortical neurons. eGFP was present in the cell body and the axonal
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processes. Levels of eGFP fluorescence varied; signal intensity probably corresponds
to the stage of infection, the brighter cells being the ones infected first. Bar
represents 20 pm. (f). In this field eGFP expressing axons can be seen. The area
inside the dotted circle is magnified in the inset. White arrows point to varicosities on
a neurite if an infected neuron. Bar represents 20 pm. (g), (h), and (i) SFV4-steGFP
infected cortical neurons. The section was treated with To-Pro3 nuclear marker
(blue). Merged image of the two channels verified that eGFP was present in the
nucleus of infected neurons. Typical cells are pointed by white arrows. Bars in these
panels represent 20 pm. All sections are from SFV4-steGFP infected animals
sampled on PID3. Images acquired using a Zeiss Axioskop confocal microscope.
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eGFP expression v.v nsP3 non-structural protein expression
Intracerebral inoculation of SFV4-steGFP resulted in a large number of infected cells
expressing variable levels of fluorescence in the brain. During in vitro studies, it was
observed that in SFV4-steGFP infected cultures, a small percentage of cells stained
positive for nsP3 protein but were eGFP-negative. To investigate if the situation was
the same in vivo, frozen sections from the brains of animals sampled on PID 3 were
immunostained with anti-nsP3 antibody.
Microscopic examination of multiple brain sections (at least 6 slides with 3 sections
each) immunostained with an antibody recognising the nsP3 non-structural protein
showed that there was almost complete correspondence between nsP3 and eGFP
staining. In Figure 4.13 three different sections of SFV4-steGFP infected brain tissue
stained with anti-nsP3 antibody are shown. It can be observed, especially in panels a
- c which show a large area of infection, that all eGFP-positive cells (green) are also
nsP3-positive (red). Rarely, cells which were nsP3-positive but eGFP-negative were
observed. These cells could either have been infected with a virus which had
eliminated the eGFP insert or could have been just recently infected (eGFP had not
accumulated enough to be clearly visible). An example of a putative recently infected
cell is shown in panels g - i.(marked with an asterisk); this cell has strong positive
nsP3 staining, which would be expected since levels of non-structural proteins are
very high at the early stages of viral replication, but the eGFP signal is low.
The distribution of nsP3-specific staining was identical to that previously observed,
cytoplasmic and punctate (insets in Figure 4.13f &4.13i). Each one of these spots
probably corresponds to virus replication complexes on the surface of modified
endosomes and lysosomes (Froshauer et al., 1988). It is worth mentioning that the
intensity of the nsP3-specific signal was linked to the intensity of the eGFP
fluorescence. Dull green cells stained very strongly for nsP3 (cells marked with
asterisk in 4.13d - f) whereas bright green cells had dull red signal (dotted circle in
the same panels). The variety in the intensity of the eGFP/nsP3 signals may provide a
way to distinguish between cells that have been infected for different lengths of time.
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eGFP a-nsP3 merged

































Figure 4.13. eGFP expression and nsP3 expression in the brains of SFV4-
steGFP infected mice, (a) low magnification of eGFP expression. Variable levels of
eGFP fluorescence can be seen, (b) low magnification of nsP3-specific staining on
the same section, (c) merged image of (a) and (b). Note that all eGFP-positive cells
(green) are also nsP3-positive (red). Bar in panels a - c represents 100 pm. (d) eGFP
expression in a focus of infection in the brain cortex, (e) nsP3-specific staining on the
same section, (f) merged image of (d) and (e). In the insets of this panel two cells
with cytoplasmic, punctate nsP3-specific signal are shown; these cells are marked
with arrows. The area surrounded by the dotted circle in all panels contains bright
green cells with low intensity red signal for nsP3. An area exhibiting the opposite
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pattern is marked with an asterisk. Bar in panels d - f represents 20 pm. (g) SFV4-
steGFP infected cells in the midbrain, (h) nsP3-specific staining of the same area (i)
merged image of (g) and (h). The arrow points to a cell with characteristic nsP3
staining shown in large magnification in the inset. The asterisk in all panels marks a
cell with dull green signal but very strong nsP3-specific signal. Bar 20 pm in all
panels. All tissue sections shown here were cut from brains sampled on P1D 3.
Appropriate controls were included. Results of the controls were identical to those
previously observed (Figure 3.13). All images were acquired with a Zeiss confocal
microscope.
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eGFP expression vs SFV structuralproteins expression
When BHK-21 cells were infected with SFV4-steGFP at high multiplicity of
infection (M.O.I) it was observed that although approximately 100% cells were
infected (as shown by the presence of eGFP fluorescence) only a fraction (15 - 20%)
of these stained positive for the viral structural proteins when a polyclonal antibody
against SFV structural proteins was used (Figure 4.6). To study if the situation was
similar in vivo, frozen sections of brain tissue from Balb/c mice infected with SFV4-
steGFP were stained and examined using fluorescent microscopy.
Microscopic examination of multiple sections (at least 6 slides with 3 sections per
slide) showed that almost every eGFP-positive cell stained positive for viral
structural proteins (Figure 4.14a - 4.14c & .4.14d - 4.14f). eGFP was distributed
evenly throughout the cell cytoplasm and nucleus whereas, SFV immunostaining was
exclusively cytoplasmic. Rarely, there were eGFP-positive cells that were negative
for viral structural proteins (Figure 4.14g - 4.14i). These eGFP-positive cells were
most often found at the edges of foci of infection and were dull green. As mentioned
earlier, SFV forms foci of infection around blood vessels in the brain (Fazakerley et
al., 1993). The cells in the middle of the focus of infection are therefore the first to
be infected while those at the outer edges are the ones most recently infected. It is
most likely therefore that the dull green cells negative for viral proteins are the most
recently infected cells in which structural proteins have not yet accumulated to
adequate levels to be detected by immunostaining. Furthermore, cells that had the
highest expression levels of eGFP also had the strongest signal when stained for
virus structural proteins. Similarly, cells with lower levels of eGFP fluorescence had
less structural protein immunostaining. Taken together, these observations suggest
that detection of eGFP was more sensitive than detection by immunostaining of the
virus structural proteins but that eGFP and viral proteins were always expressed in a
similar ratio, as would be expected since they are derived from the same ORF.
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Figure 4.14. eGFP expression and viral structural protein expression in the
brain of SFV4-steGFP infected mice, (a) Foci of infection in the cortex of the brain
showing high levels of eGFP expression (b) anti-SFV staining on the same area, (c)
merged image of (a) and (b). Note that brightest cells are in the centre of the focus of
infection and that the SFV immunostaining follows a very similar pattern. Bar in
panels a - c represents 100 pm. (d) High magnification image of a focus of infection.
eGFP levels were very variable with the brightest cells being in the centre of the area
and the cells with less bright signal at the edges, (e) anti-SFVstaining of the same
area, (f) merged image of (d) and (e). Cells with very high levels of eGFP also have
high levels of SFV-specific staining and vice versa. Bar in panels d - f represents 20
pm. (g) Another area with infected cells which have variable levels of eGFP
expression, (h) SFV-specific immunostaining of that area, (i) merged image of g - h
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eGFP was distributed evenly in the cytoplasm and the nucleus of most infected cells.
In contrast SFV structural proteins were found exclusively in the cytoplasm. Arrows
point to dull green cells which did not stain positive for SFV proteins. These are
probably cells at the early stages of infection. Bar in panels g - i represents 20 pm.
Appropriate controls were included and were identical to the ones shown in Figure
3.15. All tissue sections shown here were cut from brains sampled on PID 3. All
images were acquired with a Zeiss microscope.
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Cell tropism ofSFV4-steGFP in the CNS
Amongst other potential applications, marker viruses, like SFV4-steGFP could be
used for in vivo pathogenesis studies to investigate the tropism of the virus in various
animal models (for example in mice with deficient type I interferon responses). SFV
in particular has been used extensively in studies on viral encephalitis (Fazakerley,
2002) and on the tropism of neurotropic positive-strand RNA viruses in murine
models (Balluz et al., 1993). These studies can be greatly simplified by the use of a
virus expressing a marker protein like eGFP. The ability of SFV4-steGFP to infect
three different cell types in the mouse brain was investigated by immunostaining.
The cell types chosen for this study were neurons, oligodendrocytes and astrocytes.
The antibodies used were anti-NeuN, anti-CNPase and anti-GFAP.
Immunostaining for the neuronal marker NeuN showed that many of the SFV4-
steGFP infected cells were neurons. It was previously assumed that a large
percentage of the cells infected by this virus were neurons based on their morphology
and their anatomic position in the brain; the immunostaining result verified this
assumption. Infected neurons were found scattered throughout the brains of the
infected animals. In Figure 4.15 examples from two different areas of the brain, the
cerebral cortex (panels a - c) and the hippocampal region are shown (panels d - i).
Most of the infected cells in the cortex were neurons as demonstrated by positive
staining with the anti-NeuN antibody. In the inset of 4.15c some double-labelled
cells can be seen in high magnification. Infection was widespread in the pyramidal
layer of neurons in the hippocampus (py); cells expressing eGFP were visible in all
the fields (CA1-3) of Ammon's horn. This structure, together with the granular
dentate gyrus (GrDG) consists of neuronal cell bodies, which stained positive
allowing their direct visualisation just by looking at the channel corresponding to the
NeuN immunostaining (Figure 4.15e). That compensated for the absence of the
standard histopathology stains (eosin and haematoxylin) which cannot be used in
conjunction with fluorescence because the fluorescent signal is quenched. A high
magnification of infected neurons in the hippocampus can be seen in panel g. All the
infected cells in this section also stained positive for NeuN (panels h & i). Some cells
with typical pyramidal neuron morphology are marked with an asterisk.
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Figure 4.15. Immunostaining using NeuN neuronal marker on brain sections
from Balb/c mice infected i.e. with SFV4-steGFP. (a) Focus of infection in the
brain cortex. (b). Positive NeuN immunostaining of the same area, (c) merged image
of (a) and (b). The orange colour is indicative of co-localisation of eGFP (virus) and
NeuN signals indicating that the infected cells are neurons. Typical double-labelled
cells (inside the dotted circle) are shown in high magnification in the inset of this
panel. Bars represent 100 pm in all panels, (d) Low magnification image of eGFP
expressing cells in the pyramidal layer of neurons in the hippocampus (py). Infection
has spread in all fields (CA1-3) of Amnion's horn, (e) NeuN specific staining on the
same area. The granular dentate gyrus (GrDG) is also visible, (f) merged image of
(d) and (e). At low power it is difficult to determine co-localisation of the two signals.
However, double-labelled cells (dotted circle) are shown in high magnification in the
inset. Bars represent 20 pm in all panels, (g) Z-stack of an infected region in py.
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Cells with characteristic morphology of pyramidal neurons are marked with an
asterisk, (h) NeuN-specific staining of the same region, (i) merged image of (g) and
(h). All eGFP-positive cells appear to be NeuN-positive. Bars represent 20 pm in all
panels. Negative control (no secondary antibody on brain sections from a non-
infected animal) was included and found to be identical to the one shown in Figure
3.17. All other tissue sections shown here were cut from brains sampled on PID 3.
All images were acquired with a Zeiss confocal microscope.
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Oligodendrocytes are a known target of various strains of SFV including SFV4 (the
backbone virus of SFV4-steGFP) and the avirulent strain A7(74) (Balluz et al., 1993;
Fazakerley et al., 2006). To examine if the insertion of eGFP in the structural ORF
altered the ability of the virus to infect oligodendrocytes, brain tissue sections were
immunostained with anti-CNPase antibody.
Infected CNPase-positive oligodendrocytes were found in both the cortex (Figure
4.16a - c) and in white matter tracts (Figure 4.16d - f) indicating that the
recombinant virus was still able to infect these cells.
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Figure 4.16. Immunostaining using CNPase as oligodendrocyte marker on brain
sections from Balb/c mice infected i.e. with SFV4-steGFP. (a) Infected cells
expressing eGFP in the brain cortex, (b) CNPase-specific staining in the same
section, (c) merged image of (a) and (b). Three different kinds of cells can be seen:
cells that are non-infected but CNPase-positive (red), infected cells which are
CNPase-negative (green) and double-labelled cells (green & red). Bars represent 20
pm in all panels, (d) Focus of infection in a white matter tract, (e) CNPase-specific
staining of the same section, (f) merged image of (d) and (e). White arrows point to
infected cells which stained positive for CNPase. Bars represent 20 pm in all panels.
Appropriate negative control was included. The secondary antibody was the same as
the one used for anti-nsP3 and anti-structural immunostainings was used; therefore
negative controls can be seen in Figure 3.13 or 3.15. All sections shown here were
cut from brains sampled on PID 3. All images were acquired with a Zeiss confocal
microscope.
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Although astrocytes can be infected by SFV in vitro (McKimmie & Fazakerley,
2005) there are no reports supporting the ability of SFV to infect this cell type in vivo.
The ability of SFV4-steGFP to infect astrocytes was investigated by immunostaining
sections of infected brain with anti-GFAP antibody. In response to infection or
trauma, astrocytes around the area of infection/trauma get activated. This was
observed in SFV infected brains. Multiple tissue sections (at least 6 slides with 3
sections on each slide) were immunostained and thoroughly examined using
fluorescent microscopy. No infected GFAP-positive cells were found in areas of



















Figure 4.17. Immunostaining using GFAP as astrocyte marker on brain sections
from Balb/c mice infected i.e. with SFV4-steGFP. (a) Widespread infection in the
corpus callosum (cc) and the pyramidal layer of neurons in the hippocampus, (b)
Cells with GFAP-specific staining in the same section (c). merged image of (a) and
(b) GFAP-positive cells appear to be around the infected cells but it was not possible
to determine at this magnification if any of the infected cells had positive
immunostaining for GFAP. In the inset typical astrocytes with star-like shape are
shown. Bars in all panels represent 100 pm. (d) Infected hippocampal neurons, (e)
GFAP-specific staining of the same section, (f) merged image of (d) and (e)
Astrocytes are found around the infected cells but no green cells stained positively
for GFAP. Bars represent 20 pm in all panels. Appropriate negative control was
included. Same secondary antibody as the one used for anti-nsP3 and anti-structural
immunostainings was used; therefore negative controls can be seen in Figure 3.13 or
3.15. Sections were cut from brains sampled on PID 3. All images were acquired
with a Zeiss confocal microscope.
183
Chapter 4 Insertion of eGFP in the structural ORF
In vivo phenotypic and genotypic stability of SFV4-steGFP in Balb/c
mice
Experimental design
In vitro, almost all SFV4-steGFP plaque purified viruses eliminated the eGFP insert
after the 4th passage. To determine genetic stability in vivo, SFV4-steGFP was
passaged 5 times in the brain of Balb/c mice as previously described.
Phenotypic stability ofSFV4-steGFP in vivo
Balb/c mice were infected with 1,000 PFU of SFV4-steGFP intracerebrally. On PID
3 the brain was removed and homogenised. Homogenate was used to infect a new
mouse. This process was repeated 5 times. At the end of the procedure 96 viruses
from each passage were plaque purified and used to infect monolayers of BHK-21
cells. Presence of eGFP was monitored using fluorescent microscopy. All (100%) of
plaque purified viruses from passage 1 to passage 4 were able to express eGFP.
Approximately 95% (94.8%) of the viruses purified after the 5th passage were still
expressing eGFP (Figure 4.18a).
Genotypic stability ofSFV4-steGFP in vivo
RT-PCR with primers flanking the eGFP insertion in the structural ORF was
performed using total RNA extracted from the brain of infected mice. SFV4 plasmid
DNA was used as a positive control for the amplification. The expected amplicon
had a size of 826 bp if eGFP insert was absent and a size of-1,650 bp if the eGFP
insert was intact. The results obtained confirmed the phenotypic stability results.
Between passage 1 and 4 no band corresponding to complete or partial deletion of
the eGFP insert was detectable. All PCR products detected had a size of-1,650 bp.
After the 5th passage, the passage that eGFP-negative viruses were first observed
during the phenotypic stability passage, few bands indicating partial deletion of the
eGFP insert were detected. However, the amplification product corresponding to
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eGFP-positive virus was present in greater abundance than these partial deletion
products. The PCR results of passage 2 to passage 5 are shown in Figure 4.18b.
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Figure 4.18. In vivo phenotypic and genotypic stability of SFV4-steGFP. (a)
Percentage of eGFP-positive plaque purified viruses after 5 passages in the brain of
Balb/c mice, (b) RT-PCR genotyping of SFV4-steGFP using capsid - E3 primers on
RNA samples isolated from infected brain material at passages 2, 3, 4 and 5; The
passage number is shown in top left of each panel. In all panels, lanes 1 and 2 are the
duplicate passages of SFV4-steGFP and lane three is the SFV4-specific PCR product
(positive control). The red arrow corresponds to the 1.5 kb band of the DNA ladder
and the blue arrow corresponds to the 0.5 kb band of the DNA ladder.
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Summary of Findings
Summary of in vitro analysis ofSFV4-steGFP
• Insertion of eGFP into the structural ORF resulted in the production of viable
virus able to replicate in BHK-21 cells to levels similar to parental SFV4.
However, SFV4-steGFP replication was slower. The virus was able to
express high levels of eGFP. Insertion of eGFP slightly attenuated the virus;
in SFV4-steGFP infected BHK-21 cells, cytopathic effect (CPE) developed
16 - 20 hours later than in cells infected with SFV4.
• In BHK-21 cells all viral non-structural proteins, structural proteins and eGFP
were processed to give free proteins. However, the presence of eGFP-2A-p62
fusion protein indicates that the "cleavage" efficiency of the 2A sequence was
not 100%.
• In infected BHK-21 cells, eGFP was exclusively cytoplasmic. The majority
of the fluorescent protein was concentrated around the nucleus. The
distribution of nsP3-positive virus replication complexes and of viral
structural proteins was as expected. Virtually, all eGFP-positive cells stained
positive for nsP3 protein. In contrast, only 15-20% of the eGFP-positive cells
stained positive for viral structural proteins.
• After 3 in vitro passages SFV4-steGFP lost its ability to express eGFP. RT-
PCR showed that the eGFP insert was rapidly eliminated upon passage in
BHK-21 cells.
• SFV4-steGFP infected C6/36 cells (Aedes albopictus) and rat hippocampal
neurons and produced eGFP in both. Notably eGFP was present in both the
cytoplasm and the nucleus of both cell types.
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Summary of in vivo analysis ofSFV4-steGFP
• Following intraperitoneal inoculation of SFV4-steGFP, 100% of Balb/c mice
survived the infection without any clinical signs. Titration of whole blood
showed that the virus did not readily establish a peripheral viraemia.
• A129 mice infected i.p. with SFV4 succumbed to infection more rapidly than
mice infected with SFV4-steGFP indicating that insertion of eGFP in the
structural ORF slightly attenuated the virus. Cells expressing eGFP were
found in brain, heart valves, the myocardium, spleen (especially in the
marginal zone), pancreas (acinar cells of the exocrine pancreas), kidneys,
lungs and adipose tissue.
• Intracerebral inoculation of Balb/c mice with SFV4 or SFV4-steGFP resulted
in fulminant encephalitis in all animals. Nevertheless, SFV4-steGFP infected
mice survived longer than SFV4 infected mice and had slightly but
significantly lower virus titres in their brains.
• Following intracerebral inoculation infection was widespread and eGFP
expression reached very high levels. Virtually all eGFP-positive cells stained
positive for nsP3 and virus structural proteins. Punctate cytoplasmic staining
for nsP3 and cytoplasmic staining for viral structural proteins.
• The tropism of SFV4-steGFP was not altered by insertion of eGFP. The virus
infected neurons and oligodendrocytes but not astrocytes.
• In vivo SFV4-steGFP was much more stable than in vitro. After 5 passages in
the brain of Balb/c mice 94.8% of plaque purified viruses were able to
express eGFP. RT-PCR verified the findings of the phenotypic stability; only
partial deletions were observed after the 5th passage.
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Discussion
One of the important factors that should be considered when replication-competent
alphavirus vectors are constructed is that insertion of foreign genes in the native
transcriptional units can have an impact on virus viability and replication efficiency.
It appears that the position of insertion, the size of the insert and its nature play a key
role in the genetic stability of recombinant alphaviruses (Hahn et al., 1992; Thomas
et al., 2003; Atasheva et al., 2007).
SFV4-steGFP construction was based on a design described for SV which takes
advantage of the properties of the 2A sequence of foot-and-mouth disease virus
(FMDV), an apthovirus of the picornaviridae. As for most RNA viruses with a
positive strand genome, FMDV encodes its proteins in the form of large polyproteins
which after processing release the functional proteins (Donnelly et al., 2001a;
Donnelly et al., 2001b). FMDV 2A appears to function in a novel, unique manner
self-cleaving at its C-terminus. Unlike most viral polypeptides involved in
polyprotein processing 2A does not act proteolytically. The mechanism of action is
not completely elucidated but the predominant theory is that 2A cleavage occurs co-
translationally and intraribosomally; the ribosome skips the formation of a glycyl-
propyl peptide bond at the C-terminus of the 2A sequence (Donnelly et al., 2001b; de
Felipe et al., 2003). The complete sequence of 2A is 18 amino acid residues long.
However, previous studies have shown that the minimum length required for 2A to
be functional is 13 residues. 2A is active in all eukaryotic organisms tested to date,
these include insect, plant, mammalian, fungal and yeast cells (Ryan & Drew, 1994;
de Felipe et al., 1999; El Amrani et al., 2004; de Felipe & Ryan, 2004). In applied
virology, the 2A sequence has been used widely; some examples include
multicistronic lentiviral and retroviral vectors, adeno-associated viruses and
recombinant poliovirus vectors (Mattion et al., 1996; Furler et al., 2001; Chinnasamy
et al., 2006).
In the present study, the 2A sequence was added to the C-terminus of eGFP and this
was placed between the capsid and the p62 protein of SFV4. During replication of
this virus and following protein synthesis the eGFP protein should be released free
by the activities of the flanking capsid protease and the 2A sequence. SFV4-steGFP
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had a slight delay in its replication in BHK-21 cells compared to the parental SFV4.
In a similar way to the viruses described in Chapter 3 virus replication caught up
with the wild-type virus titres. The delay in replication is probably due to the
increased size of the genome, which needs longer time to be replicated and
transcribed and delayed production of properly processed viral structural proteins.
Western blotting on cell lysates from SFV4-steGFP infected BHK-21 cells (Figure
4.3) showed that the 2A mediated cleavage was not 100% efficient and that an eGFP-
2A-p62 fusion protein was present. Given the presence of this fusion protein, which
most probably cannot be packaged into new infectious viral particles, SFV4-steGFP
may produce correctly processed glycoproteins more slowly than SFV4; this could
explain the delay in early replication as assessed by infectious virus production of
SFV4-steGFP in the one-step growth curve. Another factor that could contribute to
the delayed replication of SFV4-steGFP is reduced production of viral glycoproteins
due to termination of translation after 2A. It has been shown in experiments using in
vitro polyprotein expression systems that proteins at the N-terminus of 2A are found
in greater abundance than proteins at its C-terminus (Donnelly et al., 2001b). In
FMDV the replicase proteins are downstream of the 2A sequence and the structural
proteins upstream. The current hypothesis is that late in infection structural protein
synthesis is favoured over replicase protein synthesis and that 2A regulates this
process (personal communication with Dr Martin Ryan). This hypothesis is logical
since late in infection virus does not need non-structural proteins but it does need
large amounts of structural proteins to form new virions. If 2A carried over this
property when placed between eGFP and p62 expression of the viral glycoproteins
would be reduced and fewer infectious viral particles would be released from each
cell giving rise to the observed slower replication rate. In contrast to SFV4-steGFP
which caught up with the SFV4 titres, the very similar SV denoted GFP/2A had
approximately 100-fold lower yields in BHK-21 cells compared to its parental virus
SV TR339 (Thomas et al., 2003). Although insertion of genes in the structural ORF
of alphaviruses has an effect on their replication efficiency, studies suggest that this
is milder compared to the effect observed in the replication of recombinant viruses
with duplicated subgenomic promoter because in these constructs the two promoters
compete for viral replication complexes (Raju & Huang, 1991).
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Cytopathic effect (CPE) in BHK-21 cells infected with SFV4 is usually observed
around 24 hours post-infection and cell lysis is complete at approximately 48 hours
(Vaha-Koskela et al., 2003). BHK-21 cultures infected with SFV4(3H)-eGFP or
SFV4(3L)-eGFP developed CPE in an identical way. In contrast, CPE was delayed
in BHK-21 cultures infected with SFV4-steGFP. The delay in the appearance of CPE
could be linked to reduced production of viral glycoproteins by this recombinant
virus. Studies with SV have shown that strains of SV that synthesise high levels of
structural proteins cause CPE more rapidly than strains which synthesise lower levels
of these proteins (Frolov & Schlesinger, 1994a). In C6/36 cells from Aedes
albopictus no CPE was observed after infection with SFV4, SFV4(3H)-eGFP or
SFV4-steGFP. This was expected since many alphaviruses including SFV and SV
have previously been reported to persistently infect these cells (Davey & Dalgarno,
1974; Karpf et al., 1997b). Rat hippocampal neurons infected with the same viruses
developed CPE at the same time post-infection. This might suggest that high levels
of eGFP expression were possibly toxic for these neuronal cultures; eGFP has been
previously reported to trigger apoptosis in cultured mouse cortical neurons (Detrait et
al., 2002). Like SFV, SV is also able to infect neurons in vitro and cause CPE
(Glasgow et al., 1997; Vernon & Griffin, 2005). Recently many vectors with reduced
cytotoxicity in neurons have been constructed (Ehrengruber et al., 1999; Kim et al.,
2004). Thomas et al. (2003) report that SV GFP/2A induces CPE in BHK-21 cells
but do not provide any further information.
In terms of eGFP expression, in all cell types tested (BHK, C6/36 & rat hippocampal
neurons), SFV4-steGFP was superior to both the recombinant viruses expressing
eGFP as a cleavable component of their replicase polyprotein. In vitro, expression
was long lasting and the fluorescent signal was very strong. In vivo, eGFP expression
was much more widespread with SFV4-steGFP compared to SFV4(3H)-eGFP and
almost all infected cells (assessed by immunostaining for nsP3 and viral structural
proteins) were eGFP-positive whereas for SFV4(3H)-eGFP the rapid degradation of
eGFP resulted in expression only in recently infected cells. In neurons, the higher
levels of expression from the SFV4-steGFP virus allowed visualisation of neuronal
processes. Strong expression of eGFP was not surprising. Multiple in vitro and in
vivo studies using alphaviruses or alphavirus-based vectors expressing eGFP under
191
Chapter 4 Insertion of eGFP in the structural ORF
the control of the subgenomic promoter have shown very high levels of prolonged
expression of this particular marker protein both in vitro and in vivo. Examples
include SFV, SV, VEE and chikungunya viruses (Thomas et al., 2003; Vaha-Koskela
et al., 2003; Sato et al., 2004; Kim et al., 2004; Gehrke et al., 2005; Vanlandingham
et al., 2005).
An interesting observation was that in BHK-21 cells infected with SFV4-steGFP, the
eGFP signal was cytoplasmic and large amounts were perinuclear, possibly at the
endoplasmic reticulum. This is in contrast to what was observed in BHK-21 cells
infected with SFV and SV viruses expressing eGFP either as a part of the non¬
structural ORF or under the direct control of a duplicated subgenomic promoter
(Lundstrom et al., 2003; Frolova et al., 2006; Tamberg et al., 2007; Atasheva et al.,
2007). In these studies eGFP is distributed evenly throughout the cytoplasm and the
nucleus of the infected cells. Possible explanations for this interesting observation
are given below.
During the normal course of infection by an alphavirus, the capsid protein is self-
cleaved (co-translationally at its C-terminus like the 2A sequence) from the
following polyprotein which is subsequently translocated to the endoplasmic
reticulum by the emerging signal sequence in p62 (Bonatti & Blobel, 1979;
Melancon & Garoff, 1986; Garoff et al., 1990; Strauss & Strauss, 1994). Many
polyproteins of RNA viruses have internal signal sequences that facilitate their
translocation to the ER and processing of the polyprotein (Melancon & Garoff, 1986;
Fazakerley & Ross, 1989; Wu, 2001). As shown by western blotting, the 2A-
mediated cleavage is not 100% efficient and an eGFP-2A-p62 fusion protein is also
synthesised. If the signal sequence (ss) of p62 is active internally it would transfer
and anchor the eGFP-2A-ss-p62 fusion polypeptide to the ER (eGFP being on the
cytosolic side), signalise processing would release p62 but the eGFP-2A-ss would
remain anchored in the ER membrane. This would explain the high concentration of
the eGFP signal around the nucleus. Nuclear exclusion of eGFP could also be
attributed to its increased size (by the addition of the 2A and p62 sequences at the C-
terminus); eGFP does not have a nuclear localisation signal, it diffuses passively to
the nuclei of cells in which it is expressed due to its small size (Miron et al., 2004).
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Functionality of the 2A sequence may be cell type specific because in C6/36 cells
and in rat hippocampal neurons eGFP was present in both the cytoplasm and the
nucleus of the infected cells. The difference between these cells and BHK-21 cells
could be explained as follows. If protein synthesis of the structural polyprotein stops
after the 2A sequence and not even the p62 signal sequence is synthesised, eGFP
would be released from the ribosomes into the cytoplasm and it would be free to
diffuse into the nucleus. Functionality of the 2A sequence may also depend on the
presence or absence of host defence responses; BHK-21 cells do not have a type-1
IFN system whereas neurons do, or even on differentiation states or cell cycle of
individual cell types.
The data of the present study is consistent with that of Thomas et al. (2003). Cells
infected with SV GFP/2A exhibited cytoplasmic fluorescence in BHK-21 cells. Also
eGFP-positive cells were observed in the brains of CD-I mice infected
subcutaneously with this virus. However, no pictures showing eGFP expression in
cells or tissues were shown in the Thomas study so the precise localisation of the
eGFP signal is not clear.
The genetic stability of SFV4-steGFP was assessed both in vitro in BHK-21 cells and
in vivo after serial passaging in the brain of adult Balb/c mice. In vitro, SFV4-steGFP
showed low genetic stability. No eGFP-positive viruses were detected after five
passages in BHK-21 cells whereas more than 90% of SFV4(3H)-eGFP viruses and
50% of SFV4(3L)-eGFP viruses were able to express eGFP after five passages in the
same cell line. Possibly, insertion of a foreign gene in the structural ORF imposes
greater stress on virus replication (deficient particle formation) and thus it is
eliminated more quickly. Like SFV4(3H)-eGFP, SFV4-steGFP was very stable in
vivo and therefore suitable for pathogenesis studies. The difference between the in
vitro and in vivo genetic stability of SFV4-steGFP can probably be attributed to the
amount of virus passaged, which in the case of the brain serial passaging is much
lower than for BHK-21 cells. In addition, BHK-21 cells do not have an active
interferon system and therefore more viruses are produced in each passage whereas
the functional IFN system of the mouse suppresses the uncontrolled production of
new viral particles and therefore delays the growth of eGFP-negative viruses, which
upon their appearance quickly outnumber the eGFP carrying viruses due to their
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replication advantage (smaller genome and thus faster replication). In the study of
Thomas et al. (2003) eGFP expression was maintained for at least 10 passages in
BHK-21 cells. However, the M.O.I used in that study was higher and the method
employed to assess expression stability not as sensitive as the method used here. It
seems that eGFP is better tolerated between capsid and p62 protein in the SV than in
the SFV genome.
Alphavirus replication is cytoplasmic and occurs on the surface of membranous
structures of endosomic and lysosomic origin called cytoplasmic vacuoles (CPVs)
(Froshauer et al., 1988). On the surface of CPVs invaginations called spherules are
located. In these spherules the viral replication complexes are anchored and RNA
synthesis takes place (Grimley et al., 1968; Kujala et al., 2001; Salonen et al., 2003).
As with SFV4(3H)-eGFP and SFV4(3L)-eGFP, when anti-nsP3 antibody was used to
immunostain BHK-21 cells infected with SFV4-steGFP typical punctate staining
corresponding to the position of the replication complexes was observed.
Surprisingly, when SFV4-steGFP infected cells were immunostained with an
antibody targeting the viral structural proteins only a fraction of the infected cells
stained positive for these proteins although 100% of the cells in culture were eGFP-
positive indicating that the structural ORF was translated at least as far as eGFP. In
addition, the observation appears to be specific for BHK-21 cells because in infected
brain sections stained with the same antibody virtually all eGFP-positive cells were
also positive by immunostaining. The 2A sequence has previously been shown to be
functional in BHK-21 cells (de Felipe et al., 1999). Possibly the 2A sequence used in
SFV4-steGFP has reduced efficiency in BHK-21 cells. That some SFV4-steGFP
infected, eGFP-positive cells stained positive for virus structural proteins and some
did not is intriguing and could also be attributed to differential functionality of the
2A sequence at different times of the cell cycle.
SFV4-steGFP was used to infect immunocompetent mice intraperitoneally. Previous
studies (Chapter 3) have shown that SFV4 and SFV4-based recombinant viruses are
poorly neuroinvasive and SFV4-steGFP was not different. The poor
neuroinvasiveness of SFV4 was attributed to the low level plasma viraemia. In
contrast to mice infected with SFV4 and SFV4(3H)-eGFP that had low but
detectable titres of virus in their blood, mice infected with SFV4-steGFP had no
194
Chapter 4 Insertion of eGFP in the structural ORF
detectable virus in their blood. This finding suggests that insertion of eGFP-2A
further attenuated SFV4. Perhaps problematic packaging delayed virus production
sufficiently for host defences to then prevent a productive infection.
The protective effect of type-I interferon (IFN) against the spread of viral infection in
the murine CNS has been shown for many viruses including Dugbe, Sindbis, and
Venezuelan equine encephalitis virus (Grieder & Vogel, 1999; Ryman et al., 2000;
Boyd et al., 2006). The importance of the type-I IFN system is further shown by the
fact that avirulent strains of viruses establish widespread infections in mice lacking
an intact IFN system (Mrkic et al., 1998; Ryman et al., 2000; Bray, 2001). When
SFV4(3H)-eGFP was used to infect IFN a/p knockout mice, eGFP was visible only
in the pancreas and the spleen of these mice. In contrast, when the same strain of
mice was infected with SFV4-steGFP, fluorescent signal was visible in most
peripheral tissues (heart, spleen, pancreas, kidney, adipose tissue and lung) and in the
brain. This result could be explained by the 42S genomic promoter being less active
in some cell types than in others. Further studies are however required to verify this
hypothesis. Interestingly, SFV4-steGFP exhibited a selective cellular tropism. For
example, cells of the exocrine but not the endocrine pancreas were heavily infected.
Similarly, in the heart many cells of the heart valves were infected compared to few
cells of the myocardium. SFV and SV are known to infect cells of the heart in vitro
and in vivo (Datwyler et al., 1999; Loot et al., 2004). Other viruses are also known to
infect the heart and especially the valves, examples include enteroviruses in mice and
patients with chronic rheumatic heart disease (Burch et al., 1966; Li et al., 2002). In
the spleen most infected cells were found at the marginal zone between the red pulp
and the white pulp (most likely macrophages). In a study by Ryman et al. (2000) IFN
a/p knockout mice infected with SV showed similar distribution of virus in the
spleen and these cells were shown to be cells of the macrophage/dendritic lineage.
The magnitude of the effect that the IFN system exerts on viral replication was seen
when immunocompetent mice infected with SFV4-steGFP were examined. No sign
of eGFP expression was evident despite examination of many sections. The IFN
system appears to be capable of powerfully suppressing alphavirus replication and in
the absence of a functional IFN system the true tropism and the potential of SFV4-
steGFP was revealed.
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The attenuating effect that insertion of eGFP at this position of the genome has in the
virus was further proven following i.p. inoculation of IFN a/p knockout mice. The
virus reached approximately 100-fold (2 Logio PFU/ml) lower titres in the blood of
these mice compared to SFV4 and SFV4(3H)-eGFP. This result suggests that factors
other than type-I IFN may contribute to the control of the peripheral replication of
SFV.
As with SFV4 and recombinant viruses which express eGFP as part of their replicase
ORF, SFV4-steGFP was virulent when administered directly into the brain of mice.
However, these mice survived one day longer than mice inoculated i.e. with SFV4;
suggesting that neurovirulence of SFV4-steGFP was affected by the insertion of
eGFP. As mentioned before, determinants of neurovirulence for alphaviruses lie in
both the non-structural and the structural ORFs as well as on the 5' and 3' NTR
(Kuhn et al., 1992; Tuittila et al., 2000; Galbraith et al., 2006). In the structural
region of the genome determinants of neurovirulence are located in the El and E2
proteins (Lustig et al., 1988; Glasgow et al., 1991; Santagati et al., 1995; Tucker et
al., 1997). It is reminded that eGFP-2A is inserted directly upstream the E2 protein
(p62) and it appears that 2A cleavage is not 100% efficient as eGFP-2A-p62 fusion
protein is detected by western blotting. Slower processing of the structural
polyprotein probably delays the formation and budding of viral particles and
therefore attenuates the neurovirulence of SFV4-steGFP.
Cell tropism of SFV4-steGFP was not altered compared to SFV4. Infection of
neurons and oligodendrocytes but not of astrocytes was evident. The cell tropism
observed has been previously reported for SFV4 and SFV A7(74) (Balluz et al.,
1993; Fazakerley et al., 2006). When SFV4(3H)-eGFP was used to infect mice i.e.
no double-labelled neurons were found (eGFP and NeuN neuronal marker). The
situation was totally different when mice were inoculated with SFV4-steGFP and a
large percentage of the infected cells was found to be neurons (were both eGFP and
NeuN-positive). The hypothesis that the 42S genomic is switched off more rapidly in
some cell types is reinforced by this result.
Although slightly attenuated, SFV4-steGFP is suitable for in vivo pathogenesis
studies. Expression of eGFP is strong and long lasting and the virus infected all
tissues and cell types previously known to be infected by SFV4. The use of SFV4-
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steGFP will simplify pathogenesis studies since it abolishes the requirement for
double immunostaining. Furthermore, the virus can be used together with SFV4(3H)-
eGFP to examine events at early and late stages of infection. Possibly a virus
expressing a different marker (DSRed for example) or a virus expressing two
different fluorescent proteins, one from the replicase and one from the structural
ORF, can be engineered to facilitate such studies.
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Introduction
In order to avoid recognition and elimination by the immune system and establish a
persistent infection, viruses have evolved numerous evasive mechanisms. Among the
most successful strategies for immune evasion is the infection of areas with limited
surveillance by the immune system, so-called immunoprivileged sites. One such site,
which is the target for many viral infections, is the central nervous system (CNS)
(Cserr & Knopf, 1992; McGavern et al., 2002). The factors that contribute to make
the CNS an immunoprivileged site are the low levels of MHC expression, and the
presence of the blood brain barrier (BBB), which excludes serum antibodies,
complement proteins and lymphocytes (Cserr & Knopf, 1992; Fabry et al., 1994).
However, upon infection activated B and T cells and large amounts of intrathecal
antibody are present in the CNS (Morris et al., 1997; Pachner et al., 2007). The
unique immune responses of the CNS allow the persistence of many RNA viruses
including Borna, Theiler's murine encephalomyelitis, mouse hepatitis, lymphocytic
choriomeningitis and measles viruses (Schneider-Schaulies et al., 1993; Rodriguez et
al., 1996; Matthews et al., 2001; de la Torre, 2002).
In rodents with deficiencies in immune responses, alphaviruses are able to establish
persistent infections. Examples include Ross river virus (RRV), Venezuelan equine
encephalitis virus (VEEV), Sindbis virus (SV) and Semliki Forest virus (SFV)
(Levine et al., 1991; Linn et al., 1996; Fazakerley, 2002; Navarro et al., 2005).
Persistence of SFV and SV in the CNS has been studied extensively. In the brain of
immunocompetent mice, infectious SFV and SV are cleared within 7-8 days post-
inoculation (Johnson et al., 1972; Amor et al., 1996). In mice with severe combined
immunodeficiency (SCID) both SFV and SV can persist for long periods of time in
the CNS (Levine et al., 1991; Ubol et al., 1995; Fazakerley, 2002). Passive transfer
of hyperimmune serum (HI) has been shown to clear infectivity but when
administration of HI serum is withdrawn infectivity returns suggesting that antibody
responses are important to control virus persistence (Levine et al., 1991; Levine &
Griffin, 1992; Dixon, 2007, PhD thesis). SFV infection of athymic nu/nu mice results
in a lifelong persistent infection of the CNS (Fazakerley & Webb, 1987; Atkins et al.,
1999). SFV and SV are also known to persist in vitro in mammalian and insect cells
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(Meinkoth & Kennedy, 1980; Dryga et al., 1997; Karpf et al., 1997a). In terms of
RNA persistence, numerous studies have shown that the RNA of both SFV and SV
can persist in the CNS of immunocompetent and immunocompromised mice for long
periods of time (Levine & Griffin, 1992; Donnelly et al., 1997).
Regulation of alphavirus persistence appears to be multi-factorial but the nature of
this persistent infection is not clear. The virus may persist in the same cell for many
months or virus infection in any individual cell could be cleared after time and other
cells infected. Clearance of the virus could be cytotoxic or non-cytotoxic. Depending
on the mechanism of clearance the fate of infected cells, especially of long-living
cells like neurons would be determined.
In the present study, a system with the potential to clarify the fate of neurons
following infection by an RNA virus was utilised; the Cre-LoxP system. Cre-LoxP is
a widely used method of conditional mutagenesis (Nagy, 2000; Morozov et al.,
2003), which utilises the properties of Cre recombinase, a 38 kDa protein of the
integrase family naturally found in bacteriophage PI. Cre recombinase has the ability
to recognise a 34 bp long consensus sequence (LoxP) and facilitates the
recombination between two LoxP sites. Depending on the orientation of the LoxP
system the outcome of recombination is different; the possibilities are excision and
inversion (Voziyanov et al., 1999; Aranda et al., 2001; Ghosh & Van Duyne, 2002;
Lee & Sadowski, 2003). Early studies have shown that Cre recombinase is also
functional in mammalian cells (Sauer & Henderson, 1988; Sauer & Henderson,
1989). The system has been extensively used for developmental studies in mice using
conditional transgene activation or inactivation including studies on neuronal
development in the brain (Hirasawa et al., 2001; Adams et al., 2003; Morozov et al.,
2003). In most studies, two mouse strains, one with the gene of interest flanked by
two LoxP sites and another which expresses Cre recombinase only in the cells of
interest under the control of a specific promoter (for example a brain region-selective
promoter), are bred and the outcome of Cre-mediated recombination is visible in the
offspring (Kilby et al., 1993; Tsien et al., 1996). An alternative approach for the
delivery of Cre recombinase in the CNS is the use of viral vectors. To date Cre
delivery vectors have been constructed based on adenovirus, adeno-associated virus,
retroviruses, feline immunodeficiency virus (FIV) and herpes virus (Brooks et al.,
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2000; Kaspar et al., 2002; Ahmed et al., 2004; Sinnayah et al., 2004; Tashiro et al.,
2007).
The hypothesis to be tested was that infection of SFV carrying Cre recombinase in
Cre-reporter mice would result upon infection in permanent marking of infected cells
and that the nature of the CNS infection could be determined by observing whether
all marked cells contained virus (proteins or RNA). Marked cells containing no trace
of virus would indicate that cells, perhaps neurons which are relatively resistant to
apoptosis can eliminate the infection and survive (Fazakerley & Allsopp, 2001). All
marked cells containing virus would indicate that cells either cannot eliminate the
infection on that they cannot do so without dying. It is a fundamental unanswered
question in virology; can infected cells in vivo eliminate a virus infection and
survive?
In the present study, novel SFV-based viruses and virus-like particles (VLPs)
carrying Cre recombinase were constructed. The Cre gene was inserted, as a
cleavable component, in two different positions in the SFV4 genome; the non¬
structural or the structural ORF. The viruses were characterised in vitro and in vivo
and used to infect Cre-reporter mice.
Objectives
The objectives of this study were:
• To construct viruses expressing Cre as a cleavable component of the non¬
structural or the structural ORF of SFV and investigate if the insertion of
euCre has an effect on the replication efficiency of the virus.
• To examine the effect of the Cre insertion on the in vitro and in vivo virulence
of SFV4.
• To assess the phenotypic and genotypic stability of recombinant viruses in
vitro and in vivo.
• To evaluate the suitability of the recombinant viruses for in vivo pathogenesis
studies using Cre-reporter mice.
• To assess the status of the CNS infection by determining whether marked
cells always contain viral material.
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Construction of recombinant viruses and VLPs expressing Cre
recombinase
Recombinant viruses used for this project were constructed by Professor Andres
Merits at the Estonian Biocentre. The three novel replicating vectors expressing
foreign proteins as a cleavable component of the non-structural (pSFV4(3L) and
pSFV4(3H)) and the structural (pSFV4-st) ORF described in Chapter 3 and Chapter
4 of this thesis respectively were used to express Cre recombinase. A plasmid
expressing Cre recombinase with a nuclear localisation signal and modified for
optimal expression in eukaryotic cells (denoted euCre in this chapter) was kindly
donated by Dr Andras Nagy (Mount Sinai Hospital, Toronto). The fragment of the
plasmid corresponding to euCre was amplified using primers incorporating Apal and
BglII adapter sites (shown in the materials and methods chapter). The three vectors,
pSFV4(3L), pSFV4(3H) and pSFV4-st were digested with Apa\ and BamW\ whereas
the euCre insert was digested with Apa\ and BglU (producing compatible ends with
BamHl). The insert was then ligated into position using T4 DNA ligase. The
resulting constructs were designated pSFV4(3H)-euCre, pSFV4(3L)-euCre and
pSFV4-steuCre. Using the method described by Liljestrom et al. (1991) infectious
viruses were produced from the icDNA clones. These newly made viruses were
annotated SFV4(3H)-euCre, SFV4(3L)-euCre (Figure 5.1a) and SFV4-steuCre
(Figure 5.1b). Another infectious virus expressing euCre as a cleavable component of
the structural ORF was constructed. The only difference in this virus compared to
SFV4-steuCre was a single amino acid change at the nuclear localisation signal of
nsP2 which consists of three consecutive arginine residues (RRR). During infection
50% of nsP2 protein localises in the nucleus of infected cells. Mutation of the nuclear
localisation signal of nsP2 from RRR to RDR leads to the production of an avirulent
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Figure 5.1. Schematic representation of euCre expressing replicating vectors, (a).
SFV4(3L)-euCre and SFV4(3H)-euCre, construction and predicted processing of the
non-structural polyprotein. The amino acid sequence, the position of both the
artificial and the native nsP2 protease recognition sites and the 30 amino acids (453-
482) from the C-terminus of nsP3 which were fused at the C-terminus of euCre are
shown. Tyrosine residue in the native cleavage site and glycine residue in the
artificial sites are shown in red. In the predicted processing of SFV4(3Fl)-euCre, (6)
corresponds to the 1FSSDT sequence. The proline (P) residue at the end of both L
and 11 constructs is the result of the insertion of Apa\ restriction site. (b).
Construction and predicted processing of the structural polyprotein in SFV4-steuCre.
The first three N-terminal amino acids of p62 protein (E2) were duplicated upstream
of the euCre gene. A 16 amino acid long FMDV 2A protease flanked by three amino
acids (red) from the C-terminus of FMDV ID protein and the N-terminal proline,
which is essential for efficient cleavage, (blue) from FMDV 2B protein, was fused to
the C-terminus of euCre. Following expression of the structural ORF, all structural
proteins and euCre with the 2A sequence fused to its C-terminus were expected to be
released free.
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To construct virus like particles (VLPs) expressing euCre, the coding sequence of
euCre was amplified using primers incorporating a BglU restriction site at the 5' end
of the gene and a Smal restriction site at its 3' end. The amplified product was blunt-
ended and inserted into a commercial vector in order to be sequenced. Sequencing
showed that the product had no incorporated errors and that it was suitable for further
experiments. The SFV replicon plasmid (pSFVl, Figure 5.2a) was digested with
BamHl and Smal restriction endonucleases and the euCre insert was digested with
BglU and Smal. The two fragments were ligated using T4 DNA ligase and the
resulting construct was annotated pSFVl-euCre (Figure5.2b). Correct insertion of the
euCre gene was verified by restriction analysis. To generate VLPs, pSFVl-euCre and
pHelper plasmid were linearised, in vitro transcribed and the two RNAs co-
electroporated in BHK-21 cells. Expression of euCre was verified by western
blotting (Figure 5.4).
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Figure 5.2. Schematic representation of pSFVl and pSFVl-euCre. (a), plasmid
map of pSFVl vector, (b). plasmid map of pSFVl-euCre.
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Virus viability and replication efficiency following insertion of Cre
recombinase gene into the non-structural and the structural ORFs of
SFV4.
Experimental design
To assess the effect of euCre insertion on virus viability and replication efficiency,
BHK-21 cells were infected with SFV4, SFV4(3H)-euCre, SFV4-steuCre or SFV4-
RDR-steuCre at a multiplicity of infection (M.O.I) of 10 in triplicate and virus
replication was compared in a one-step growth curve. Parallel cultures of BHK-21
cells were infected to investigate the effect of euCre insertion on the in vitro
virulence of SFV4 and the induction of cytopathic effect (CPE).
One-step growth curves
All viruses with euCre inserted in their genome were viable and able to replicate in
vitro. However, one-step growth curves (Figure 5.3a) suggested that insertion of the
euCre gene into either the non-structural or the structural ORF of SFV4 had a
significant effect on replication efficiency. All viruses tested were able to infect
BHK-21 cells but production of new infectious virus particles was significantly
reduced compared to the parental virus (P<0.05). SFV4(3H)-euCre and SFV4-
steuCre replicated in a very similar way and reached peak titres which were not
significantly different (P>0.05). Both these viruses had significantly lower titres
(P<0.05) compared to SFV4 throughout the 12 hours of the experiment.
Insertion of the coding sequence of euCre into the structural ORF of SFV4-RDR,
which is a well characterised attenuated SFV strain, severely affected its growth
efficiency. According to Rikkonen et al. (1992), SFV4-RDR replicates slower but
reaches catches up with SFV4. SFV4-RDR-steuCre had significantly lower titres
compared to SFV4 (P<0.05) throughout the experiment. In addition, its peak titres
were also significantly lower compared to these of both SFV4(3H)-euCre and SFV4-
steuCre (P<0.05). Titres at each time-point were compared using a paired t-test.
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In vitro virulence and development ofCPE in BHK-21 cells
Although all euCre expressing viruses had reduced growth rates compared to SFV4
no difference was observed in their in vitro virulence. Cultures of BHK-21 cells
infected with SFV4, SFV4(3H)-euCre, SFV4-steuCre or SFV4-RDR-steuCre were
dead by 48 hours post-infection (Figure 5.3c). At early time-points cells looked
healthy and had the typical elongated morphology of BHK-21 cells with no signs of
CPE (Figure 5.3b). Evidence of CPE was initially observed between 16-20 hours
post-infection for SFV4 and SFV4(3H)-euCre. CPE induction was delayed when
monolayers of BHK-21 cells were infected with SFV4-steuCre or SFV4-RDR-
steuCre and it was first apparent approximately 36 hours post-infection for both
viruses. To investigate if euCre was expressed, infected cells were fixed and
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Figure 5.3. Growth curves and CPE following infection of BHK-21 cells with
euCre expressing viruses, (a) Monolayers of BHK-21 cells were infected in
triplicate with SFV4 (dark blue circles), SFV4(3H)-euCre (light blue circles), SFV4-
steuCre (inverted dark blue triangles) or SFV4-RDR-steuCre (green triangle) at an
M.O.I of 10. Supernatant samples were collected every 2 hours for 12 hours and
titrated for infectious virus. Each point represents the mean of 3 samples. The bar
represents the standard deviation (SD). All growth curves shown in this thesis were
performed in parallel. The data for SFV4 presented in this figure is identical to that
shown in Figures 3.2a and 4.2a allowing comparison of the growth of all
recombinant viruses, (b) and (c) Images of BHK-21 cells infected with SFV4-
steuCre virus at an M.O.I of 10 taken 8 and 36 hours post-infection, respectively.
Early after infection (b) typical morphology of BHK-21 cells can be observed. All
viruses used in this study caused cell death (c). CPE was evident approximately 16-
20 hours earlier for the viruses expressing euCre as part of their replicase ORF but in
all cases most cells were dead by 48 hours post infection.
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Expression of euCre protein from euCre expressing viruses and virus¬
like particles (VLPs)
Experimental design
To determine if recombinant viruses and virus-like particles (VLPs) were able to
properly express euCre as a cleavable component of their replicase or structural
ORFs, BHK-21 cells were infected with SFV4(3H)-euCre, SFV4(3L)-euCre, SFV-
steuCre, SFV-RDR-steuCre or SFV 1-euCre VLPs at an M.O.I of 20. PBSA was used
as a negative control to mock-infect cells. After 6 hours, cells were lysed and
samples corresponding to 100,000 cells were separated on an SDS-PAGE gel and
proteins were transferred to a nitrocellulose membrane. An a-Cre antibody was used
to detect Cre recombinase protein. Since SFV4(3H) and SFV4(3L) vectors were
previously shown to express the viral non-structural proteins properly these western
blottings were not repeated.
Expression ofeuCre in BEIK-21 cells
All recombinant viruses and virus-like particles (VLPs) expressed euCre as can be
seen in Figure 5.4. Processing of viruses expressing euCre as a cleavable component
of the non-structural ORF appears to be very efficient and no bands corresponding to
euCre-nsP4 fusion protein can be seen (Figure 5.4a). As expected expression under
the control of the subgenomic promoter was very strong; the density of the bands
corresponding to euCre is indicative of the amount of protein produced (Figure 5.4b
& 5.4c). However, when cells were infected with SFV4-steuCre or SFV4-RDR-
steuCre a strong band with higher molecular weight was observed. This band
probably corresponds to an euCre-2A-p62 fusion protein suggesting that the
efficiency of the 2A sequence is not optimal. This was also observed with SFV4-
steGFP virus (Chapter 4; Figure 4.3).
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Figure 5.4. Expression of euCre by recombinant viruses and virus-like particles.
(a) Western blotting of cell lysates of BHK-21 cells infected with SFV4. SFV4(3H)-
euCre (3H) or SFV4(3L)-euCre (3L) (M.O.I 20). Specific bands of the appropriate
molecular weight for euCre are shown with a black arrowhead, (b) Western blotting
of cell lysates infected with euCre expressing VLPs or mock-infected with PBSA
(M). Black arrowhead marks specific bands corresponding to euCre protein, (c)
Western blotting of cell lysates of BHK-21 cells infected with SFV4-steuCre (st),
SFV4-RDR-steuCre (RDR-st) or mock-infected with PBSA (M). euCre specific
bands are shown with a black arrowhead. euCre-2A-p62 fusion protein is marked
with a red arrowhead.
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In vitro phenotypic and genotypic stability of SFV4(3H)-euCre,
SFV4(3L)-euCre and SFV4-steuCre in BHK-21 cells
Experimental design
To examine whether the recombinant viruses maintained their ability to express
euCre or if the inserted gene was eliminated after several passages in vitro,
SFV4(3H)-euCre, SFV4(3L)-euCre or SFV4-steuCre were passaged 5 times in
BHK.-21 cells at an M.O.I of 0.01. Since euCre cannot be visualised a Cre reporter
cell line was required to assess the phenotypic stability of the euCre expressing
viruses. A mouse embryonic fimbrobiast (MEF) cell line was made from ROSA26
Cre reporter mice. An additional Cre reporter cell line named K562-DSRed[eGFP]
was kindly donated by Dr Peter Ponsaerts (Van den Plas et al., 2003). This cell line
constitutively expresses DSRed and upon Cre-mediated recombination expresses
eGFP. More specifically, the coding sequence of DSRed is flanked by LoxP sites and
is under the control of the CMV promoter. The stop codon at the end of DSRed gene
prohibits expression of eGFP. Following Cre-mediated recombination, the DSRed
coding sequence is removed and eGFP expression occurs. Both these cell lines were
used to determine if euCre expressed by SFV recombinant viruses was functional.
Genotypic stability of the euCre expressing viruses was performed using RT-PCR as
previously described on the respective sections of Chapters 3 & 4 of this thesis.
Phenotypic stability ofeuCre expressing viruses
Initially, in order to establish if the Cre reporter ROSA26 MEFs and K562-
DSRedjeGFP] cells were functional, cells were electroporated with a euCre
expressing plasmid, in which the expression of euCre is driven by a cytomegalovirus
(CMV) promoter. ROSA26 MEFs were expected to express eGFP following Cre-
mediated recombination but no sign of eGFP expression was observed in two
consecutive experiments. In contrast, K562-DSRed[eGFP] cells expressed eGFP
following electroporation of the euCre plasmid. Expression was first evident four
days post electroporation of euCre expressing plasmid (Figure 5.5). Other groups in
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the department have also tried to use MEFs obtained from ROSA26 mice
unsuccessfully. For that reason it was decided to use K562-DSRed[eGFP] to
investigate the functionality of euCre following expression by recombinant SFV
viruses. However, infected cells died before reporting Cre-mediated recombination
and it was not possible to assess phenotypic stability of euCre viruses using this cell
line. The designers of this cell line have shown that optimal Cre-mediated DSRed
excision occurs 5 days after electroporation with Cre recombinase mRNA (Van den
Plas et al., 2003), cells infected with euCre expressing viruses or VLPs were dead by
48 hours post-infection.
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Figure 5.5. eGFP expression in K562-DSRed[eGFP] cells following Cre-
mcdiated recombination, (a) K562-DSRed[eGFP] cells constitutively express
DSRed, following Cre-mediated recombination DSRed gene is excised and eGFP is
expressed (b) eGFP expressing K562-DSRed[eGFP] cells 4 days post electroporation
with euCre expressing plasmid. (c) Merged image of (a) and (b) the area in the
dotted square is shown in higher magnification in panels d - f. Note that eGFP
expressing cells are not DSRed-positive. All images acquired using a Zeiss
AxioSkop confocal microscope.
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Genotypic stability ofSFV4(3H)-euCre, SFV4(3L)-euCre and SFV4-steuCre
As previously described, RNA was extracted from virus infected BHK-21 cells and
used for RT-PCR in order to determine how quickly the euCre expressing
recombinant viruses were eliminating the euCre gene inserted in either the non¬
structural or the structural ORF of SFV. For the amplification, primers flanking the
areas of the euCre insertion were used. The viruses expressing euCre as part of their
replicase ORF would produce an amplicon with a size of approximately 1800 bp if
the insert was intact. For the viruses expressing euCre as a cleavable component of
the structural region the product corresponding to a virus with a complete euCre gene
would have a size of approximately 1950 bp. If the insert was eliminated, the
expected products would have sizes of approximately 670 bp and 826 bp,
respectively.
When SFV4(3H)-euCre and SFV4(3L)-euCre were passaged in BHK-21 cells, the
intensity of the band, and therefore the amount of PCR product corresponding to a
virus with complete elimination of the euCre insert (-670 bp) increased gradually
between the 2nd and the 5th passage. After the last passage, the amount of product
corresponding to euCre-negative viruses exceeded that of euCre positive (-1800 bp).
Although the density of the bands was not analysed it can be seen that elimination of
the inserted sequence in both SFV4(3H)-euCre and SFV4(3L)-euCre progressed in a
very similar way. In addition, it should be pointed out that after the 5th passage a
percentage of the passaged viruses were still euCre positive and viruses with
incomplete deletions had appeared (Figure 5.6a).
In contrast, elimination of euCre insert was more rapid when SFV4-steuCre was
passaged in BHK-21 cells and euCre-positive viruses disappeared after the 4th
passage. Bands corresponding to euCre-negative viruses were detected already after
the 2nd passage. After the 3rd passage the amount of euCre-positive viruses (product
of-1950 bp) dramatically decreased and was much lower compared to the amount of
euCre viruses. The multiple bands corresponding to viruses which have eliminated
the euCre sequences suggest deletions of fragments with different sizes. All these
deletions must have been in frame otherwise they would have been deleterious for
the viruses. Notably, the elimination of euCre insert was not complete and some
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small fragments of the inserted sequences remained intact even after the 5th passage
(Figure 5.6b).
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a b
Figure 5.6. In vitro genotypic stability of euCre expressing viruses, (a) RT-PCR
genotyping of virus RNA using nsP3 - nsP4 primers on RNA samples isolated from
BHK-21 monolayers at passages 2, 3, 4 and 5; the passage number is indicated at the
top left of each panel. In all panels, lanes 1 - 3 are the triplicate passages of
SFV4(3H)-euCre and lanes 4-6 are the triplicate passages of SFV4(3L)-euCre. The
red arrow corresponds to the 1.5 kb band of the DNA ladder and the blue arrow
corresponds to the 1 kb band of the DNA ladder, (b) RT-PCR genotyping of SFV4-
steuCre using capsid - E3 primers on RNA samples isolated fom BF1K-21
monolayers at passages 2, 3, 4 and 5; the passage number is indicated at the top left
of each panel. In the panels corresponding to 2nd and 3rd passage, lanes 1 - 3 are the
triplicate passages of SFV4-steuCre and lane 4 is the SFV4-specific PCR product
(positive control). In the panels corresponding to 4th and 5th passage, lanes 2-4 are
the triplicate passages of SFV4-steuCre and lane 1 is the SFV4-specific PCR product
(positive control). The red arrow corresponds to the 1.5 kb band of the DNA ladder
and the blue arrow corresponds to the 1 kb band of the DNA ladder.
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In vivo pathogenesis of euCre expressing viruses
To study the course of recombinant virus infection in vivo following intraperitoneal
(i.p.) and intracerebral (i.e.) infection and compare it with that of wild type SFV4
infection two experiments were performed.
Experiment I-Assessment of in vivo virulencefollowing i.p. and i.e. inoculation
Experimental design
To assess the virulence of euCre expressing viruses following i.p. inoculation, groups
(n=10) of adult (4-5 week old female) Balb/c mice were inoculated i.p. with 5 x 10J
PFU of SFV4, SFV4(3H)-euCre, SFV4(3L)-euCre, SFV4-steuCre, SFV L10
(virulent strain of SFV) or mock-infected with PBSA. Mice were kept for 10 days or
until signs indicative of terminal disease were obvious.
To assess the virulence of euCre expressing viruses following i.e. inoculation, groups
(n=10) of adult (4-5 week old female) Balb/c mice were inoculated i.e. with 1,000
PFU of SFV4, SFV4(3H)-euCre, SFV4-steuCre, SFV4-RDR-steuCre or mock-
infected with PBSA. Mice were kept for 10 days or until signs indicative of terminal
disease were obvious.
Results
Data on the survival of mice after inoculation via the i.p. or the i.e. route was used to
plot survival curves (Figure 5.7). In Figure 5.7a the data obtained following i.p.
inoculation is shown. All mice of the SFV L10 infected group were either dead or
moribund on PID 3 and they were euthanised. None of the animals infected with
SFV4, SFV4(3Fl)-euCre, SFV4(3L)-euCre or SFV4-steuCre exhibited signs of viral
encephalitis and 100% of these animals survived throughout the 10 days of that
experiment. Previous experiments described on Chapters 3 and 4 have shown similar
results so this finding was expected. SFV4-RDR-steuCre was not included in this
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study because it is known that the virus is avirulent following i.p. inoculation in adult
mice (Rikkonen et al., 1992).
In Figure 5.7b the data obtained following i.e. inoculation is plotted. Since
SFV4(3H)-euCre and SFV4(3L)-euCre viruses appear to be very similar only the
first one was used in this study. All animals infected with SFV4 or SFV4(3FI)-euCre
succumbed to infection on PID 2 having reached clinically defined terminal end-
points indicative of substantial disease (limb paralysis and ataxia). Mice infected
with SFV4-steuCre also died (100%) but one day later on PID 3. In contrast, all mice
(10/10) infected with SFV4-RDR-steuCre survived the infection without any clinical
symptoms. None of the PBSA mock-infected animals had any symptoms. At PID 10
this experiment was also terminated.
These results further illustrate the poor neuroinvasiveness of SFV4 and SFV4-based
recombinant viruses and suggest that insertion of a foreign gene in the structural
ORF has a more severe effect on the in vivo virulence of the virus than insertion of





























Figure 5.7. Survival rates of Balb/c mice following i.p. and i.e. inoculation with
SFV. (a). Survival rates of mice (n=10) following i.p. inoculation, (b). Survival rates
of mice (n=10) following i.e. inoculation.
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Experiment II-Blood and brain virus litres following i.p. and i.e. inoculation
Experimental design
To examine if the recombinant viruses were able to establish a plasma viraemia,
groups (n=6) of adult Balb/c mice (4-5 weeks old) were inoculated i.p. with 5 x 103
PFU of SFV4, SFV4(3H)-euCre, SFV4-steuCre, SFV A7(74), SFV L10 or mock-
infected with PBSA. Twenty-four hours post-infection mice were euthanised and
heparinised blood was collected and titrated for infectious virus.
Additionally, to compare the peak titres of the euCre expressing recombinant viruses
in the brain of infected mice and to compare them with SFV4 groups (n=6) of adult
Balb/c mice (4-5 weeks old) were inoculated i.e. with 1,000 PFU of SFV4,
SFV4(3H)-euCre, SFV4-steuCre or mock-infected with PBSA. When the mice
reached clinically defined terminal end-points indicative of substantial disease they
were euthanised and their brains snap frozen for virus titration.
Results
Both SFV4 and SFV4(3H)-euCre were able to establish a low level plasma viraemia
24 hours post-inoculation. In both groups, 5 out of 6 mice (83.3%) had detectable
levels of infectious virus. The average titre in SFV4 infected mice was 3.3 Logio
PFU/ml (SD: 1.4). The average titre for SFV4(3H)-euCre was 4.0 Logio PFU/ml
(SD: 1.0). In contrast, none of the animals infected with SFV4-steuCre had
detectable levels of infectious virus at this time-point. When compared using paired
t-test the titres of SFV4 and SFV4(3H)-euCre showed no significant statistical
difference (P>0.05). Titration of blood samples from mice infected with avirulent
SFV A7(74) or virulent SFV L10 showed that 100% ofmice infected with these two
viruses (6 in each group) had high levels of plasma viraemia. The average titres and
the standard deviations were 7.2 Logio PFU/ml (SD: 0.4) for SFV A7(74) infected
mice and 6.6 Logio PFU/ml (SD: 0.7) for SFV L10 infected mice. Statistical analysis
using paired t-test showed no significant difference between the titres of SFV A7(74)
and SFV L10 (P>0.05). Both these viruses had significantly higher titres to SFV4
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and SFV4(3H)-euCre (P<0.05) (Figure 5.8a). The findings of this experiment
suggest that insertion of euCre into the structural ORF had greater impact on the
ability of the virus to replicate following extraneural infection than did insertion of
euCre into the replicase ORF. This is probably due to delayed virus replication and
problematic morphogenesis of virus infectious particles.
Following intracerebral inoculation of SFV4, SFV4(3H)-euCre and SFV4-steuCre all
infected mice succumbed to infection exhibiting signs of viral encephalitis. However,
SFV4-steuCre mice died a day later (PID 3) compared to the mice infected with
SFV4 or SFV4(3H)-euCre. The infectious virus in the brains of the infected animals
was titrated as close to the time of death of the animals to estimate the peak virus
titres. SFV4 infected mice had an average infectious virus titre of 9.5 Logio PFU/g of
brain tissue (SD: 0.1). The average infectious virus titre in the brains of SFV4(3H)-
euCre was 8.8 Logio PFU/g of brain (SD: 0.4). Comparison by paired t-test showed
that the peak titres of SFV4(3H)-euCre were significantly lower to the respective
titres of SFV4 (P<0.05). SFV4-steuCre produced even lower peak titres compared to
the other two viruses mentioned above. The average titre was 8.0 Logio PFU/g; SD:
0.4. Paired t-tests showed that the peak titres of SFV4-steuCre infected brains were
significantly lower compared to both SFV4 and SFV4(3H)-euCre (P<0.05), Figure
5.8b. These results indicate that insertion of euCre had a slight attenuating effect
when inserted in the non-structural ORF. This effect was more severe when the gene
































Figure 5.8. Comparison of plasma viraemia and brain virus titres caused by
various SFV strains, (a) SFV4 (dark blue circle) and SFV4(3H)-euCre (light blue
circle) had significantly lower titres than SFV A7(74) (green triangle) or SFV LIO
(dark blue square) (P<0.05; paired t-test). SFV4 and SFV A7(74) were not
significantly different to SFV4(3H)-euCre and SFV LIO respectively (P>0.05; paired
t-test). All samples were collected at 24 hours after i.p. inoculation, (b) Following i.e.
inoculation SFV4 (dark blue circle) had significantly higher peak-titres compared to
both SFV4(3H)-euCre (light blue circle) and SFV4-steuCre (dark blue inverted
triangle) (P<0.05; paired t-test). SFV4-steuCre titres were significantly lower
compared to these of SFV4(3H)-euCre (P<0.05; paired t-test)
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In vivo genotypic stability of Cre expressing viruses in Balb/c mice
Experimental design
To determine the genetic stability of SFV4(3H)-euCre and SFV4-steuCre after
several passages in vivo. The viruses were passaged 5 times through the brain of
Balb/c mice and examined for genotypic changes after each passage using RT-PCR.
Phenotypic stability was not examined due to the absence of a valid system for that
kind of experiment.
Genotypic stability ofSFV4(3H)-euCre and SFV4-steuCre in vivo
Total RNA was extracted from the brains of the infected animals and used for RT-
PCR to examine the genetic stability of SFV4(3H)-euCre and SFV4-steuCre after
serial passaging. SFV4(3H)-euCre showed remarkable stability and only minor
amounts of euCre-negative virus (indicated by a -670 bp band) were present after the
5th passage (Figure 5.9a). In contrast, SFV4-steuCre exhibited high instability. After
the 3rd passage no recombinant virus with a euCre insert was detectable by RT-PCR.
The detectable product had a slightly larger molecular mass compared to the product
obtained by amplification of the same region of the SFV4 genome (-826 bp band)
suggesting incomplete removal of inserted sequence.
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Figure 5.9. In vivo genotypic stability of SFV4(3H)-euCre and SFV4-steuCre. (a)
RT-PCR genotyping of SFV4(3H)-euCre using nsP3 - nsP4 primers on RNA
samples isolated from infected brain material after passages 1, 2, 3, 4 and 5. The
passage number is indicated at the top of each strip. The strip labelled SFV4 is the
SFV4-specific PCR product (positive control), (b) RT-PCR genotyping of SFV4-
steuCre. Passage number is indicated at the top of each panel. In all panels, lanes I
and 2 are the duplicate passages of SFV4-steuCre and lane 3 is the SFV4-specific
PCR product (positive control). The red arrow corresponds to the 1.5 kb band of the
DNA ladder and the blue arrow corresponds to the 0.5 kb band of the DNA ladder.
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In vivo Cre-mediated recombination following infection with euCre
expressing viruses
To investigate if euCre expressing viruses were able to induce Cre-mediated
recombination in vivo, four different Cre-reporter mouse strains were used. ROSA26
(Mao et al., 2001), ROSA26-EYFP (Srinivas et al., 2001), sGFP7 (Gilchrist et al.,
2003) and sGFP97, kindly donated by the Medvinsky Group, Kings Buildings,
Edinburgh. Initially, groups of mice (n=3) were inoculated intracerebrally with 1,000
PFEI of SFV4(3Fl)-euCre or SFV4-steuCre. When the mice exhibited symptoms of
viral encephalitis, generally between 2 and 3 days, they were euthanised and various
tissues including brain, heart, lung, liver, spleen, pancreas and kidney were collected
and processed for frozen sections.
Multiple sections from various tissues (at least 6 slides with 3 sections per slide)
from the infected Cre-reporter mice were examined for the presence of fluorescence.
No positive cells/tissues were observed.
Viruses expressing euCre were constructed to study the nature of the SFV CNS
infection. This required survival of the infected animals for long enough to express
their Cre recombination marker. Previous studies using viral vectors for the delivery
of Cre recombinase in the brain have shown that the first evidence of Cre-mediated
recombination appears between 3 and 7 days (Ahmed et al., 2004; Sinnayah et al.,
2004). Given that the mice were generally sampled at 2 - 3 days post-infection,
insufficient time may have resulted in the negative result.
In a second experiment, avirulent SFV4-RDR-steuCre and euCre expressing VLPs
were used in groups of sGFP7 mice (n=3; 1,000 PFU of virus per animal). Also
groups of sGFP7 mice (n=3) inoculated with SFV4(3H)-euCre or SFV4-steuCre
(1,000 PFU per animal) were rescued using hyper-immune (HI) serum against SFV
on PID 2, 5, 8 and 11 (raised by Dr C. Dixon). All animals except the mice
inoculated with VLPs, which surprisingly succumbed to infection on PID 3, were
sampled on PID 14 and same tissues as mentioned above were collected. In the
second experiment only sGFP7 mice were used because experiments by other groups
in the department had shown these mice to successfully report Cre-mediated
recombination, at least in the spleen. The mice survived for 14 days. Examination of
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many tissue sections again resulted in no cells expressing marker of recombination.
This result will be discussed later in this chapter.
Brain sections from both experiments were immunostained for Cre-recombinase but
multiple attempts were unsuccessful. A new Cre antibody is currently in production
but it was not available in time for this project. Also tissue sections were stained for
SFV structural proteins but none was detected. This was expected since the virus is
cleared from the CNS 7-8 days after infection (Amor et al., 1996). An additional
problem was that the supply of mice was not constant and only small numbers of
animals was used for each experiment. For that reason it was impossible to repeat the
experiment in the timeframe of this project.
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Summary of Findings
Summary of in vitro analysis ofeuCre expressing viruses
• Insertion of euCre in the non-structural or the structural ORF of SFV4
resulted in the production of viable viruses which were able to replicate in
BHK-21 cells. All recombinant viruses were considerably slower in their
replication and their peak titres were significantly lowered compared to SFV4.
In cells infected with viruses with euCre insertion in the non-structural ORF
cytopathic effect developed at the same time as in cells infected with SFV4.
Development of CPE was delayed when viruses with euCre insertion in the
structural ORF were used.
• All viruses and VLPs were able to express the euCre recombinase protein as
shown by western blotting. Only a percentage of SFV4(3H)-euCre and
SFV4(3L)-euCre maintained the euCre insert after the 5th passage in BHK-21
cells. SFV4-steuCre had almost completely eliminated the insert after the 4th
in vitro passage.
Summary of in vivo analysis ofeuCre expressing viruses
• As with SFV4, none of the euCre expressing viruses was able to cause fatal
disease in any animal infected intraperitoneally. SFV4(3H)-euCre was able to
establish a low level plasma viraemia which was not different compared to
the levels of viraemia established by SFV4. SFV4-steuCre however, was not
detectable by plaque assay at the same time. This result is indicative of the
more severe effect that insertion of euCre in the structural ORF has on the in
vivo ability of the virus to replicate efficiently.
• Intracerebral inoculation of Balb/c mice with SFV4(3H)-euCre and SFV4-
steuCre resulted in death in 100% of the inoculated mice. Mice inoculated
with SFV4(3H)-euCre succumbed to infection 48 hours post-inoculation
concurrently with SFV4 infected animals. Development of symptoms and
death was delayed in mice inoculated with SFV4-steuCre. These animals died
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24 hours later (PID 3). As expected SFV4-RDR-steuCre was avirulent.
Surprisingly VLPs which are supposed to be avirulent because they can only
undergo a single round of replication killed the animals for unknown reasons.
SFV4(3Fl)-euCre and SFV4-steuCre had significantly lower peak titres
compared to SFV4. Insertion of euCre in the structural ORF appears to affect
in vivo pathogenesis of SFV4 more drastically that the same insertion in the
replicase ORF. No Cre-mediated recombination was observed when Cre-
reporter mice were inoculated with Cre expressing viruses and VLPs.
• In vivo, SFV4(3FI)-euCre was very stable. RT-PCR analysis of material
passaged 5 times in Balb/c mice brain showed minor amounts of recombinant
viruses with complete elimination of the euCre insert. In contrast, SFV4-
steuCre was genetically unstable. After the 3rd passage no recombinant virus




SFV vectors expressing Cre recombinase
Insertion of eGFP in the non-structural and the structural ORFs of SFV4 resulted in
the production of viable, replicating recombinant viruses with properties suitable for
in vivo pathogenesis studies. Alphavirus replicating and non-replicating vectors
based on SV and SFV have been used extensively in neurobiology. Levels and length
of gene expression and gene transfer efficiency in neurons have been shown to be
superior in alphavirus vector systems compared to other widely used viral vectors
(Levine et al., 1996; Gwag et al., 1998; Ehrengruber et al., 2001; Ehrengruber, 2002;
Vaha-Koskela et al., 2003; Sato et al., 2004). To address fundamental questions on
the nature of SFV infection of the CNS, the gene encoding Cre recombinase was
inserted into the SFV4 genome.
It was previously mentioned that the size and the nature of the inserted sequence as
well as its position in the viral genome is critical for the virus viability, replication
efficiency and genetic stability. Insertion of euCre in either the replicase or the
structural ORF of SFV4 affected the virus more severely than did eGFP insertion at
exactly the same positions. All euCre expressing viruses replicated slower than SFV4
and eGFP expressing viruses and in contrast to the eGFP recombinants they did not
reach similar titres to the parental virus. This can perhaps be attributed to the
increased size of the genome (euCre is -300 bp larger than the eGFP insert).
Insertion of the larger euCre gene in the non-structural ORF may have further
delayed the formation of viral replication complexes and slowed down the
production of virus progeny. It can also be hypothesised that insertion of a foreign
gene at the C-terminus of nsP3 might have an effect on minus-strand RNA synthesis
and thus delay replication. The same insertion in the structural ORF, may affect the
packaging of the genome and formation of new virus particles perhaps due to the
larger genome size and to the non-efficient processing of the structural polyprotein.
The western blotting for SFV4-steuCre and SFV4-RDR-steuCre showed high levels
of euCre-2A-p62 fusion protein. This suggests that the 2A sequence was not as
efficient in the context of these viruses; this could have affected the processing of the
structural polyprotein as discussed in Chapter 4 resulting in reduced numbers of
budding viruses. The size of the genome appears to be very important. Thomas et al.
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(2003) showed that viruses expressing longer transgenes as a cleavable component of
their structural ORF replicate less efficiently compared to viruses with shorter
foreign sequences. In their studies a virus expressing eGFP replicated more
efficiently compared to the same virus expressing VP7, a structural protein of
bluetongue virus involved in virus attachment and penetration which has
approximately twice the size of eGFP (Xu et al., 1997). The impact of euCre
insertion on virus growth could have been more severe if insertion had been under
the control of a duplicated subgenomic promoter because as well as the longer size of
genome the virus would have to overcome the competition between the two 26S
promoters for replication complexes (Raju & Huang, 1991). Notably, both viruses
expressing euCre as part of the replicase or the structural ORF replicated in a very
similar way. In contrast, replication of SFV4-RDR-steuCre was less efficient. This
was expected since this virus, as well as the euCre insert, has a point mutation in the
nuclear localisation signal of nsP2 and alphaviruses with mutations in that protein are
known to have slower replication and lower virulence (Rikkonen et al., 1992; Dryga
etal., 1997).
In vitro, SFV4(3H)-euCre and SFV4(3L)-euCre have similar genotypic stability with
the respective viruses expressing eGFP as part of the replicase ORF. SFV4-steuCre
was less stable following five serial passages in BHK-21 cells compared to SFV4-
steGFP and truncated genomes indicating deletions of the euCre gene were observed
more rapidly. This difference can be attributed to the longer genome size of SFV4-
steuCre. Similar instabilities were observed in the very similar recombinant SV
described by Thomas et al. (2003). More specifically, expression of VP7 protein
from that virus declined after the 6th passage in BHK-21 cells whereas eGFP
expression was unchanged for at least 10 passages. It is hypothesised that the
secondary structure that might be introduced in the genome of an RNA virus by two
different transgenes has a possible impact on genome stability. Secondary structure
of RNA has been previously shown to be important for genome stability of viruses
like HCV (Smith et al., 2002; Thomas et al., 2003).
In vivo, SFV4(3H)-euCre had high genotypic stability and after 5 passages minor
amounts of euCre-negative viruses were detected by RT-PCR. Insertion in that
position of the genome appears to be well tolerated in both SFV and SV constructs
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(Frolova et al., 2006; Tamberg et al., 2007). In contrast, no euCre-positive genomes
were detected after 3 passages of SFV4-steuCre in Balb/c mice. Elimination of the
euCre insert was very fast. This is not surprising because insertion of a foreign gene
does not offer any selective advantage to the virus. In addition, viruses with shorter
genomes replicate more efficiently and therefore swiftly outnumber the ones
replicating slower (Caley et al., 1999; Thomas et al., 2003; Tamberg et al., 2007).
A major problem during this project was the absence of a suitable cell line to assess
the functionality of euCre following serial passaging of viruses in vitro and in vivo.
Cre-mediated recombination is a slow process; SFV infection killed the reporter cells
by 48 hours most probably before recombination took place (Van den Plas et al.,
2003). This problem could be possibly solved by using a cell line resistant to SFV
induced cell death such as a mosquito cell line. Cell lines derived from mosquitoes
do not die, they become persistently infected by SFV and SV (Davey & Dalgarno,
1974; Karpf et al., 1997b). However a mosquito Cre reporter cell line was not
available. Possibly in the future the construct used in K562-DSRed[eGFP] cells
could be used to produce a stable mosquito cell line. The advantage of a cell line like
that will be double; it will help assess the functionality of euCre expressed by the
viruses described in this chapter and additionally has potential uses for in vitro virus
persistence studies.
The in vivo virulence of SFV4 does not appear to be impaired following insertion of
euCre in the non-structural ORF. All mice inoculated i.e. succumbed to infection at
the same time post-inoculation. As previously discussed, SFV4 and viruses based on
that backbone are poorly neuroinvasive; consequently mice inoculated i.p. showed
no signs of viral encephalitis. Poor neuroinvasiveness is attributed to deficient
peripheral replication of these viruses. However, SFV4(3H)-euCre reached very
similar levels of plasma viraemia compared to SFV4. Insertion of euCre in the
structural ORF has a more substantial effect on SFV4. Although direct inoculation
of SFV4-steuCre in the CNS resulted in fulminant encephalitis and death, the course
of infection was delayed for 24 hours. In addition, the peak-titres that SFV4-steuCre
reached in the brain were significantly lower compared to SFV4 and SFV4-steGFP.
These differences possibly arise from the delayed replication of SFV4-steuCre.
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The main objective of this project was to study alphavirus persistence in the CNS
using the conditional marker gene activation offered by the Cre-LoxP system. This
objective was not accomplished. The possible reasons for this one discussed below.
Cre-mediated recombination has been used extensively to study development and
functions of different areas and genes of the brain, in murine models. Examples
include studies on the function of dopamine and serotonin neurons and on the
function of genes specifically found on the cardiovascular circuits of the mouse brain
(Hirasawa et al., 2001; Thevenot et al., 2003; Zhuang et al., 2005; Sinnayah et al.,
2006). Cre recombinase is delivered to the area of interest either by breeding of a
mouse expressing Cre recombinase under the control of a cell/tissue specific
promoter (for example murine neurofilament-H promoter) with a Cre-reporter mouse
or by inoculation of viral vectors expressing the Cre gene.
Various viruses have been used for that purpose. Among the most common viral
vectors used for Cre recombinase delivery are adenoviral, lentiviral, retroviral, and
adeno-associated vectors (Pfeifer et al., 2001; Kaspar et al., 2002; Thevenot et al.,
2003; Ahmed et al., 2004). Usually, Cre-mediated recombination in the brain is
assessed 7-9 days after inoculation suggesting that it is a fairly slow procedure.
This has also been shown in vitro in the K562-DSRed[eGFP] cell line (Kaspar et al.,
2002; Thevenot et al., 2003; Van den Plas et al., 2003).
In the present study, an alphavirus expressing Cre recombinase was described for the
first time. However, no Cre-mediated recombination was observed in vitro or in vivo
using euCre expressing SFV viruses and VLPs. The most obvious reason for that
would be expression of non-functional Cre recombinase. However, this seems highly
unlikely because SFV replicating and non replicating vectors have been used
successfully for the expression of many different genes and the plasmid from which
the euCre gene was extracted has been previously used for various studies (Hardouin
& Nagy, 2000; Liang et al., 2004). Assuming that the euCre protein produced by the
recombinant viruses was functional, the absence of Cre-mediated recombination can
be explained fairly easily in vitro; reporter cell lines did not survive long enough for
recombination to occur. To circumvent the problem of cell death a cell line surviving
for longer should be used. No such cell line was available during this project.
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Possible solutions include the use of mosquito cell lines for the construction of Cre-
reporter cell lines or cultures of neurons from Cre-reporter mice.
In vivo, the explanation is more complicated; lack of Cre-mediated recombination
could be due to either the Cre-reporter mice or the recombinant viruses expressing
euCre. Since all mouse strains used in this project have shown extensive
recombination following viral delivery of Cre recombinase it can be hypothesised
that recombination did not occur for reasons entirely attributed to the viruses used.
A possibility is that the virus did not express Cre recombinase long enough for
recombination to occur. This is a likely explanation for SFV4(3H)-euCre. Any
foreign gene inserted in the pSFV4(3H) vector has the last 30 amino acid residues of
nsP3 fused to its C-terminus and it is believed that this sequence contains a degron
signal. If euCre was degraded as quickly as eGFP (Figure 3.3), and taking into
account that Cre-mediated recombination is a slow procedure, it is not surprising that
recombination did not take place. However, this should not be the case for SFV4-
steuCre, SFV4-RDR-steuCre and Cre-expressing VLPs. An alternative explanation is
that the fusion of 2A to the C-terminus of euCre affected the euCre functionality, to
investigate this possibility; a construct expressing euCre-2A fusion protein under the
control of a eukaryotic promoter (CMV for example) could be used.
It has been previously shown that SFV recombinant viruses and vectors expressing
foreign genes under the control of the 26S subgenomic promoter offer long-term
strong expression (Vaha-Koskela et al., 2003). Two experiments were performed
using SFV4-steuCre. In the first one infection was allowed to progress and mice died
on PI D 3 before being able to report Cre-mediated recombination. In the second
experiment mice were rescued by passive transfer or HI serum. The first dose of HI
serum was given on PID 2; probably administration of HI serum cleared the virus
from the brain too early and did not give enough time for recombination to occur.
SFV4-RDR-steuCre was avirulent following i.e. inoculation and mice survived for
the 14 days of this study but examination of multiple brain and peripheral tissue
sections did not show any evidence of recombination. Most probably the virus was
cleared by the immune response quickly and thus it was not possible to induce
recombination. The absence of a working immunostaining for Cre recombinase did
not allow us to assess for how long after inoculation Cre was expressed. A possible
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solution to these problems would be to use the replicating SFV A7(74) vector
described by Vaha-Koskela et al. (2003) for expression of Cre recombinase. This
virus is able to persist in the brain of infected animals for at least 7 days therefore it
would give enough time for the recombination to occur (Amor et al., 1996).
However, such a system would be limited due to the reduced efficiency of SFV
A7(74) to replicate in neurons of adult mice (Fazakerley et al., 1993). Another
explanation for the absence of cells that recombination had happened is that all the
infected cells died. Neurovirulence of virulent strains of SFV is due to its ability to
replicate in neurons and kill them before the intervention of the immune response
(Gates et al., 1985; Smyth et al., 1990).
Studies on the cytotoxicity of SFV-based vectors showed that following stereotaxic
inoculation vectors persist at the site of inoculation and express the foreign gene for
up to 21 days in neuronal cell bodies this time should have been enough for
recombination to take place (Graham et al., 2006). Surprisingly, mice inoculated
with Cre recombinase expressing VLPs were found dead on P1D 3. A possible
explanation is that the high levels of Cre recombinase expressed by the VLPs were
cytotoxic and caused the death of the animals. Studies have shown that high levels of
Cre recombinase are toxic in vitro and in vivo (Loonstra et al., 2001; Forni et al.,
2006). This problem has been addressed by the use of vectors in which the Cre gene
is flanked by LoxP sites and therefore it is self-excised (Pfeifer et al., 2001; Silver &
Livingston, 2001). This approach is not applicable in SFV-based systems because the
Cre-LoxP system is only active on DNA genomes.
In conclusion, the Cre-LoxP system is a powerful system which has potential
applications in studies of virus persistence. However, during the time available in




During this project, replication competent vectors expressing eGFP and euCre
recombinase as a cleavable component of the non-structural or of the structural ORF
of SFV4 were constructed.
Viruses expressing eGFP as a cleavable component of the non-structural ORF were
viable, genetically stable and able to replicate to high titres similar to the parental
SFV4. Although rapid degradation of eGFP was an unexpected finding, this feature
might prove advantageous for in vivo pathogenesis studies because it offers a means
to distinguish cells recently infected from cells infected for some time. Furthermore,
these viruses allow us to identify cells and tissues in which the genomic promoter is
switched off. Atasheva et al. (2007) showed that the genome of SV can tolerate
insertions of multiple reporter genes (eGFP and cherry red) in the replicase ORF. A
recombinant SFV expressing two different reporters from the genomic and
subgenomic promoter respectively might provide the ability to distinguish cells in
which the genomic or the subgenomic promoter is active indicating the stage of
infection of individual cells without any requirement for immunostaining. The
putative degron signal at the C-terminus of nsP3 discovered during these studies
might be very useful in biotechnological applications in which rapid degradation of
proteins is required.
The virus incorporating eGFP as a cleavable component of the structural ORF gave
prolonged, high level expression and its usefulness for in vivo pathogenesis studies
was exhibited in both immunocompetent and immunodeficient animals. This virus,
although slightly attenuated, highlighted in a very obvious way the major impact of
type-I interferon response on virus replication following extraneural inoculation. The
FMDV 2A sequence used to facilitate release of eGFP from the rest of the structural
polyprotein was not 100% efficient and may be responsible for the different
distributions of eGFP in certain cell types; in which case efficiency of the 2A-
mediated cleavage is dependent on the cell type. Sub-optimal efficiency of the 2A
sequence has been previously demonstrated in a recombinant equine arteritis virus
(van den Born et al., 2007).
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Concluding remarks
Insertion of the euCre recombinase gene into the replicase or the structural ORF of
SFV4 produced viable viruses capable of expressing the gene. However, the
replication of these viruses and their genetic stability was reduced compared to the
eGFP expressing viruses. These results point out the impact that the size and the
nature of the inserted sequence might have on virus fitness. In the three years of this
PhD project, unfortunately was not possible to get the CrdLoxP system working but
this technology has the potential to answer a fundamental virological question and
further studies using various strains of virus or replicons with insertions of euCre
recombinase in different positions of the genome may be required to determine if
Cre-mediated recombination can occur following expression by SFV.
Overall, the work undertaken during this project has shown that SFV can tolerate and
express multiple genes as part of its natural transcription units. In addition, the
application of these novel reporter viruses was established. Following on from the
studies of this thesis, additional marker genes including DSRed and Renilla
luciferase have been inserted in the same positions into the genome of SFV4
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Appendix I: Common Solutions and Reagents
Common solutions and reagents used in this thesis are appended here:
Virus-Like Particles and Viruses
TNE buffer:
To make 10X TNE buffer for long-term storage of viruses and virus-like particles the
following recipe was followed:
In 800 ml of dHhO 12.1 g of Trizma Base (Sigma, UK), 3.7 g of disodium EDTA
(Sigma, UK) and 116.8 g NaCl (Sigma, UK) were added. The pH was adjusted to 7.4
and the solution was made up to a final volume of 1 L. Following autoclaving 10X
TNE buffer was diluted with nuclease-free water (Sigma, UK) to give IX TNE and
used.
Centrifuges and Centrifuge Rotors
For clarification of supernatants a Beckman J2-21 centrifuge and the JA-20 rotor was
used. For ultracentrifugation of VLP and virus stocks through sucrose cushions a
Beckman L8-70M ultracentrifuge and the SW-28 swing-out rotor was used.
In vitro transcription
Reagents used in the in vitro transcription reaction were
10X SP6 buffer. This was custom made and it contained the following:
400 mM HEPES potassium salt (Sigma, UK) pH adjusted to 7.4.
60 mM magnesium acetate tetrahydrate (Sigma, UK).
20 mM Spermidine trihydrochoride (Sigma, UK).
The buffer was filter sterilised using a 0.22 pm filter (Sartorius, bought through SLS,
UK).
M7GpppG (cap analog) was purchased from Amersham Biosciences, UK.
DTT was purchased from Sigma, UK.
rNTPs used were purchased from Amersham Biosciences, UK in the form of stock
solutions (40 mM) ATP, CTP, UTP and GTP.
fUO (DNase, RNase-free water) was purchased from Sigma, UK.
RNAsin inhibitor was purchased from Promega, UK.
SP6 RNA polymerase was purchased from Amersham Biosciences, UK.
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Animal work
PBSA was made by adding 3.75 g of Bovine Serum Albumin (Sigma, UK) in 500 ml
of dH20. The solution was filter sterilised through a 0.22 pm Sartorius filter (SLS,
UK).
KNAlater for the storage of animal tissues for RNA extraction was purchased either
from Sigma, UK or Ambion, UK.
OCT medium was purchased from the European branch of Sakura, Japan.
Immunostaining
Triton X-100 was purchased from BDH, UK.
Proteinase K was purchased from Sigma, UK.
To-Pro nuclear marker was a Molecular Probes product (Invitrogen, UK).
Propidium iodide containing mounting medium was purchased from VectorLabs,
USA.
PBS was purchased in the form of tablets from VWR international (UK branch).
CAS block is a Zymed, US product. The company is now part of Invitrogen, UK.
Cell Lines
All media used in this thesis were purchased from Gibco, UK. The company is now
part of Invitrogen, UK.
Western Blotting




Tris-base was purchased from Sigma, UK.
1.5M Tris-base pH8.8
98.6 g Tris-base
500 ml dl I20
pH to 8.8
10% APS (ammonium persulphate)
1 g APS (Sigma, UK)
10 ml dH20
Preferably, use fresh, alternatively store at -20°C in 100 pi aliquots
Resolving Gel (12% Acrylamide)
30 ml 40% Acrylamide (Sigma, UK)
43 ml dH20
25 ml 1.5M Tris-base pH8.8
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1 ml 10% SDS
Store at 4°C in dark, max 1 month
Stacking Gel (4% Acrylamide)
10 ml 40% Acrylamide (Sigma, UK.)
64 ml dH20
25 ml 0.5M Tris-base pH6.8
1 ml 10% SDS
Store at 4°C in dark, max 1 month
Running Buffer
BioRad lOx Tris/Glycine/SDS Buffer
(BioRad, UK)
Dilute to lx with dH20
Transfer Buffer
3.03 g Tris-base
14.4 g Glycine (Sigma, UK)
200 ml Methanol (Sigma, UK)
800 ml dH20
PBST
999 ml lx PBS (VWR International, UK Branch)
1 ml Triton X-100 (BDH, UK)
Blocking Solution
10 g Dried Milk
200 ml PBST (Tween-20 was purchased from BDH, UK).
Spin -1500 rpm, 5min to remove any lumps
Laemmli Sample Buffer, 2x
(Sigma, UK. Store at -20°C)
Mix 1:1 with sample
ECL Kit was purchased from Amersham Biosciences, UK.
Hybond ECL Nitrocellulose was purchased from Amersham, Biosciences, UK.
RNA extraction
RNeasy Lipid tissue kit is a product of Qiagen, UK.
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Reverse transcription and Polymerase Chain Reaction (PCR)
For RT-PCR the Superscript II RNase H+ reverse transcriptase enzyme kit
(Invitrogen, UK) was used. OligodT primer, dNTPs and RNasin inhibitor were
purchased from Promega, UK. Nuclease-free water was purchased from Sigma, UK.
For PCR, Pfx DNA polymerase was purchased from Invitrogen, UK. Taq polymerase
was purchased from Promega.
Agarose Gel Electrophoresis
Agarose gels were made using 0.5M TBE buffer and agarose powder purchased from
Promega, UK. The synthesis of the TBE buffer was:
1 litre 5X TBE buffer stock
54 g Tris Base
27.5 g boric acid
20 ml 0.5M EDTA (pH 8)
All reagents were from Sigma, UK.
DNA ladders used for size comparisons were purchased from New England Biolabs,
UK.
Molecular Cloning
Two different commercially available cloning kits were used for the purposes of this
project; Zero-Blunt TOPO obtained from Invitrogen, UK. And pGEM-T Easy kit
obtained from Promega, UK.
For dephosphorylation of linearised vectors calf intestinal alkaline phosphatase
(C1AP) was used. This was purchased from Roche, UK.
To purify digested plasmids the Jetquick PCR purification kit (Genomed, Germany)
was used.
Bacterial Techniques
Two different strains of recombinant E. coli bacteria were used during this project.
DE15a (Invitrogen, UK) and XL-10 gold (Stratagene, UK). To grow liquid cultures
LB (Luria-Bertani) medium was used. The composition of LB medium was 10 grams
tryptone, 5 grams of yeast extract, 10 grams of NaCl. This was purchased as
premixed powder from Fischer, UK and 15 grams of the powder mix were added to
500 ml of dEUO. The medium was then autoclaved and used.
Following transformation a rich medium was used to help recovery of bacteria. The
medium of choice was SOC (Invitrogen, UK). The composition of SOC medium is
as that of LB with the addition of KC1, MgCE, MgSCU and glucose
Sequencing




Sequencing of recombination products of SFV4(3H)-eGFP.
The beginning of PCR primers is marked with red for the forward primer (in nsP3)
and brown for the reverse primer in nsP4.
30 aa from end of nsP3 are highlighted with yellow.
nsP2 protease recognition sites are highlighted with blue.
The start codon of eGFP is highlighted with red.



























5 15 25 35 45 55
ATACCATGTA GATGGGGTGC AGAAGGTAAA GTGCGAGAAG GTTCTCCTGT TCGACCCGAC
ATACCATGTA GATGGGGTGC AGAAGGTAAA GTGCGAGAAG GTTCTCCTGT TCGACCCGAC
65 75 85 95 105 115
GGTACCTTCA GTGGTTAGTC CGCGGAAGTA TGCCGCATCT ACGACGGACC ACTCAGATCG
GGTACCTTCA GTGGTTAGTC CGCGGAAGTA TGCCGCATCT ACGACGGACC ACTCAGATCG
125 135 145 155 165 175
GTCGTTACGA GGGTTTGACT TGGACTGGAC CACCGACTCG TCTTCCACTG CCAGCGATAC
GTCGTTACGA GGGTTTGACT TGGACTGGAC CACCGACTCG TCTTCCACTG CCAGCGATAC
185 195 205 215 225 235
CATGTCGCTA CCCAGTTTGC AGTCGTGTGA CATCGACTCG ATCTACGAGC CAATGGCTCC
CATGTCGCTA CCCAGTTTGC AGTCGTGTGA CATCGACTCG ATCTACGAGC CAATGGCTCC
245 255 265 275 285 295
CATAGTAGTG ACGGCTGACG TACACCCTGA ACCCGCAGGC ATCGCGGACC TGGCGGCAGA
CATAGTAGTG ACGGCTGACG TACACCCTGA ACCCGCAGGC ATCGCGGACC TGGCGGCAGA
305 315 325 335 345 355
TGTGCACCCT GAACCCGCAG ACCATGTGGA CCTCGAGAAC CCGATTCCTC CACCGCGCCC
TGTGCACCCT GAACCCGCAG ACCATGTGGA CCTCGAGAAC CCGATTCCTC CACCGCGCCC
365 375 385 395 405 415
GAAGAGAGCT GCATACCTTG CCTCCCGCGC GGCGGAGCGA CCGGTGCCGG CGCCGAGAAA
GAAGAGAGCT GCATACCTTG CCTCCCGCGC GGCGGAGCGA CCGGTGCCGG CGCCGAGAAA
425 435 445 455 465 475
GCCGACGCCT GCCCCAAGGA CTGCGTTTAG GAACAAGCTG CCTTTGACGT TCGGCGACTT
GCCGACGCCT GCCCCAAGGA CTGCGTTTAG GAACAAGCTG CCTTTGACGT TCGGCGACTT
485 495 505 515 525 535
TGACGAGCAC GAGGTCGATG CGTTGGCCTC CGGGATTACT TTCGGAGACT TCGACGACGT
TGACGAGCAC GAGGTCGATG CGTTGGCCTC CGGGATTACT TTCGGAGACT TCGACGACGT
545 555 565 575 585 595
CCTGCGACTA GGCCGCGCGG GTGCAGGGAT TTTCTCCTCG GACACTGGGC CCGGG((§GT
CCTGCGACTA GGCCGCGCGG GTGCAGGGAT TTTCTCCTCG GACACTG
605 615 625 635 645 655























665 675 685 695 705 715
CGTAAACGGC CACAAGTTCA GCGTGTCCGG CGAGGGCGAG GGCGATGCCA CCTACGGCAA
725 735 745 755 765 775
GCTGACCCTG AAGTTCATCT GCACCACCGG CAAGCTGCCC GTGCCCTGGC CCACCCTCGT
785 795 805 815 825 835
GACCACCCTG ACCTACGGCG TGCAGTGCTT CAGCCGCTAC CCCGACCACA TGAAGCAGCA
845 855 865 875 885 895
OSACTTCTTC AAGTCCGCCA TGCCCGAAGG CTACGTCCAG GAGCGCACCA TCTTCTTCAA
905 915 925 935 945 955
GGACGACGGC AACTACAAGA CCCGCGCCGA GGTGAAGTTC GAGGGCGACA CCCTGGTGAA
965 975 985 995 1005 1015
CCGCATCGAG CTGAAGGGCA TCGACTTCAA GGAGGACGGC AACATCCTGG GGCACAAGCT
1025 1035 1045 1055 1065 1075
GGAGTACAAC TACAACAGCC ACAACGTCTA TATCATGGCC GACAAGCAGA AGAACGGCAT
1085 1095 1105 1115 1125 1135
CAAGGTGAAC TTCAAGATCC GCCACAACAT CGAGGACGGC AGCGTGCAGC TCGCCGACCA
1145 1155 1165 1175 1185 1195
CTACCAGCAG AACACCCCCA TCGGCGACGG CCCCGTGCTG CTGCCCGACA ACCACTACCT
1205 1215 1225 1235 1245 1255
GAGCACCCAG TCCGCCCTGA GCAAAGACCC CAACGAGAAG CGCGATCACA TGGTCCTGCT
1265 1275 1285 1295 1305 1315
(3H)-eGFP GGAGTTCGTG ACCGCCGCCG GGATCACTCT CGGCATGGAC GAGCTGTACA AGGGATCCGA
de!843
1325 1335 1345 1355 1365 1375




1385 1395 1405 1415 1425 1435
(3H)-eGFP CGTCCTGCGA CTAGGCCGCG CGGGTGCATA TATTTTCTCC TCGGACACTG GCAGCGGACA
del843 GCAGCGGACA
1445 1455 1465 1475 1485 1495
(3H) -eGFP TTTACAACAA AAATCCGTTA GGCAGCACAA TCTCCAGTGC GCACAACTGG ATGCGGTCCA
del843 TTTACAACAA AAATCCGTTA GGCAGCACAA TCTCCAGTGC GCACAACTGG ATGCGGTCCA
1505 1515
(3H)-eGFP GGAGGAGAAA ATGTACCCGC C




























5 15 25 35 45 55
ATACCATGTA GATGGGGTGC AGAAGGTAAA GTGCGAGAAG GTTCTCCTGT TCGACCCGAC
ATACCATGTA GATGGGGTGC AGAAGGTAAA GTGCGAGAAG GTTCTCCTGT TCGACCCGAC
65 75 85 95 105 115
GGTACCTTCA GTGGTTAGTC CGCGGAAGTA TGCCGCATCT ACGACGGACC ACTCAGATCG
GGTACCTTCA GTGGTTAGTC CGCGGAAGTA TGCCGCATCT ACGACGGACC ACTCAGATCG
125 135 145 155 165 175
GTCGTTACGA GGGTTTGACT TGGACTGGAC CACCGACTCG TCTTCCACTG CCAGCGATAC
GTCGTTACGA GGGTTTGACT TGGACTGGAC CACCGACTCG TCTTCCACTG CCAGCGATAC
185 195 205 215 225 235
CATGTCGCTA CCCAGTTTGC AGTCGTGTGA CATCGACTCG ATCTACGAGC CAATGGCTCC
CATGTCGCTA CCCAGTTTGC AGTCGTGTGA CATCGACTCG ATCTACGAGC CAATGGCTCC
245 255 265 275 285 295
CATAGTAGTG ACGGCTGACG TACACCCTGA ACCCGCAGGC ATCGCGGACC TGGCGGCAGA
CATAGTAGTG ACGGCTGACG TACACCCTGA ACCCGCAGGC ATCGCGGACC TGGCGGCAGA
305 315 325 335 345 355
TGTGCACCCT GAACCCGCAG ACCATGTGGA CCTCGAGAAC CCGATTCCTC CACCGCGCCC
TGTGCACCCT GAACCCGCAG ACCATGTGGA CCTCGAGAAC CCGATTCCTC CACCGCGCCC
365 375 385 395 405 415
GAAGAGAGCT GCATACCTTG CCTCCCGCGC GGCGGAGCGA CCGGTGCCGG CGCCGAGAAA
GAAGAGAGCT GCATACCTTG CCTCCCGCGC GGCGGAGCGA CCGGTGCCGG CGCCGAGAAA
425 435 445 455 465 475
GCCGACGCCT GCCCCAAGGA CTGCGTTTAG GAACAAGCTG CCTTTGACGT TCGGCGACTT
GCCGACGCCT GCCCCAAGGA CTGCGTTTAG GAACAAGCTG CCTTTGACGT TCGGCGACTT
485 495 505 515 525 535
TGACGAGCAC GAGGTCGATG CGTTGGCCTC CGGGATTACT TTCGGAGACT TCGACGACGT
TGACGAGCAC GAGGTCGATG CGTTGGCCTC CGGGATTACT TTCGGAGACT TCGACGACGT
545 555 565 575 585 595
CCTGCGACTA GGCCGCGCGG GTGCAGGGjfcT TTTCTCCTCG GACACTGGGC CCGGGI^GT
CCTGCGACTA GGCCGCGCGG GTGCAGGGAT TTT
605 615 625 635 645 655
GAGCAAGGGC GAGGAGCTGT TCACCGGGGT GGTGCCCATC CTGGTCGAGC TGGACGGCGA
665 675 685 695 705 715



























725 735 745 755 755 775
GCTGACCCTG AAGTTCATCT GCACCACCGG CAAGCTGCCC GTGCCCTGGC CCACCCTCGT
785 795 805 815 825 835
GACCACCCTG ACCTACGGCG TGCAGTGCTT CAGCCGCTAC CCCGACCACA TGAAGCAGCA
845 855 865 875 885 895
CGACTTCTTC AAGTCCGCCA TGCCCGAAGG CTACGTCCAG GAGCGCACCA TCTTCTTCAA
905 915 925 935 945 955
GGACGACGGC AACTACAAGA CCCGCGCCGA GGTGAAGTTC GAGGGCGACA CCCTGGTGAA
965 975 985 995 1005 1015
CCGCATCGAG CTGAAGGGCA TCGACTTCAA GGAGGACGGC AACATCCTGG GGCACAAGCT
1025 1035 1045 1055 1065 1075
GGAGTACAAC TACAACAGCC ACAACGTCTA TATCATGGCC GACAAGCAGA AGAACGGCAT
1085 1095 1105 1115 1125 1135
CAAGGTGAAC TTCAAGATCC GCCACAACAT CGAGGACGGC AGCGTGCAGC TCGCCGACCA
1145 1155 1165 1175 1185 1195
CTACCAGCAG AACACCCCCA TCGGCGACGG CCCCGTGCTG CTGCCCGACA ACCACTACCT
1205 1215 1225 1235 1245 1255
GAGCACCCAG TCCGCCCTGA GCAAAGACCC CAACGAGAAG CGCGATCACA TGGTCCTGCT
A GCAAAGACCC CAACGAGAAG CGCGATCACA TGGTCCTGCT
1265 1275 1285 1295 1305 1315
GGAGTTCGTG ACCGCCGCCG GGATCACTCT CGGCATGGAC GAGCTGTACA AGGGATCCGA
GGAGTTCGTG ACCGCCGCCG GGATCACTCT CGGCATGGAC GAGCTGTACA AGGGATCCGA
1325 1335 1345 1355 1365 1375
CTTTGACGAG CACGAGGTCG ATGCGTTGGC CTCCGGGATT ACTTTCGGAG ACTTCGACGA
CTTTGACGAG CACGAGGTCG ATGCGTTGGC CTCCGGGATT ACTTTCGGAG ACTTCGACGA
1385 1395 1405 1415 1425 1435
CGTCCTGCGA CTAGGCCGCG CGGGTGCATA TATTTTCTCC TCGGACACTG GCAGCGGACA






1445 1455 1465 1475 1485 1495
TTTACAACAA AAATCCGTTA GGCAGCACAA TCTCCAGTGC GCACAACTGG ATGCGGTCCA
TTTACAACAA AAATCCGTTA GGCAGCACAA TCTCCAGTGC GCACAACTGG ATGCGGTCCA
{3H)-eGFP
del645







5 15 25 35 45 55
(3H) -eGFP ATACCATGTA GATGGGGTGC AGAAGGTAAA GTGCGAGAAG GTTCTCCTGT TCGACCCGAC
del603 ATACCATGTA GATGGGGTGC AGAAGGTAAA GTGCGAGAAG GTTCTCCTGT TCGACCCGAC
(3H)-eGFP
del603
65 75 85 95 105 115
GGTACCTTCA GTGGTTAGTC CGCGGAAGTA TGCCGCATCT ACGACGGACC ACTCAGATCG
GGTACCTTCA GTGGTTAGTC CGCGGAAGTA TGCCGCATCT ACGACGGACC ACTCAGATCG
(3H) -eGFP
del603
125 135 145 155 165 175
GTCGTTACGA GGGTTTGACT TGGACTGGAC CACCGACTCG TCTTCCACTG CCAGCGATAC
GTCGTTACGA GGGTTTGACT TGGACTGGAC CACCGACTCG TCTTCCACTG CCAGCGATAC
(3H)-eGFP
del603
185 195 205 215 225 235
CATGTCGCTA CCCAGTTTGC AGTCGTGTGA CATCGACTCG ATCTACGAGC CAATGGCTCC
CATGTCGCTA CCCAGTTTGC AGTCGTGTGA CATCGACTCG ATCTACGAGC CAATGGCTCC
{3H)-eGFP
del603
245 255 265 275 285 295
CATAGTAGTG ACGGCTGACG TACACCCTGA ACCCGCAGGC. ATCGCGGACC TGGCGGCAGA
CATAGTAGTG ACGGCTGACG TACACCCTGA ACCCGCAGGC ATCGCGGACC TGGCGGCAGA
(3H) -eGFP
del603
305 315 325 335 345 355
TGTGCACCCT GAACCCGCAG ACCATGTGGA CCTCGAGAAC CCGATTCCTC CACCGCGCCC
TGTGCACCCT GAACCCGCAG ACCATGTGGA CCTCGAGAAC CCGATTCCTC CACCGCGCCC
(3H)-eGFP
del603
365 375 385 395 405 415
GAAGAGAGCT GCATACCTTG CCTCCCGCGC GGCGGAGCGA CCGGTGCCGG CGCCGAGAAA
GAAGAGAGCT GCATACCTTG CCTCCCGCGC GGCGGAGCGA CCGGTGCCGG CGCCGAGAAA
(3H)-eGFP
del603
425 435 445 455 465 475
GCCGACGCCT GCCCCAAGGA CTGCGTTTAG GAACAAGCTG CCTTTGACGT TCGGCGACTT
GCCGACGCCT GCCCCAAGGA CTGCGTTTAG GAACAAGCTG CCTTTGACGT TCGGCGACTT
(3H) -eGFP
del603
485 495 505 515 525 535
TGACGAGCAC GAGGTCGATG CGTTGGCCTC CGGGATTACT TTCGGAGACT TCGACGACGT
TGACGAGCAC GAGGTCGATG CGTTGGCCTC CGGGATTACT TTCGGAGACT TCGACGACGT
545 555 565
(3H) -eGFP CCTGCGACTA GGCCGCGCGG GTGCAGGGAT





605 615 625 635 645 655
GAGCAAGGGC GAGGAGCTGT TCACCGGGGT GGTGCCCATC CTGGTCGAGC TGGACGGCGA
665 675 685 695 705 715




























725 735 745 755 765 775
GCTGACCCTG AAGTTCATCT GCACCACCGG CAAGCTGCCC GTGCCCTGGC CCACCCTCGT
785 795 805 815 825 835
GACCACCCTG ACCTACGGCG TGCAGTGCTT CAGCCGCTAC CCCGACCACA TGAAGCAGCA
845 855 865 875 885 895
CGACTTCTTC AAGTCCGCCA TGCCCGAAGG CTACGTCCAG GAGCGCACCA TCTTCTTCAA
905 915 925 935 945 955
GGACGACGGC AACTACAAGA CCCGCGCCGA GGTGAAGTTC GAGGGCGACA CCCTGGTGAA
965 975 985 995 1005 1015
CCGCATCGAG CTGAAGGGCA TCGACTTCAA GGAGGACGGC AACATCCTGG GGCACAAGCT
1025 1035 1045 1055 1065 1075
GGAGTACAAC TACAACAGCC ACAACGTCTA TATCATGGCC GACAAGCAGA AGAACGGCAT
1085 1095 1105 1115 1125 1135
CAAGGTGAAC TTCAAGATCC GCCACAACAT CGAGGACGGC AGCGTGCAGC TCGCCGACCA
1145 1155 1165 1175 1185 1195
CTACCAGCAG AACACCCCCA TCGGCGACGG CCCCGTGCTG CTGCCCGACA ACCACTACCT
A ACCACTACCT
1205 1215 1225 1235 1245 1255
GAGCACCCAG TCCGCCCTGA GCAAAGACCC CAACGAGAAG CGCGATCACA TGGTCCTGCT
GAGCACCCAG TCCGCCCTGA GCAAAGACCC CAACGAGAAG CGCGATCACA TGGTCCTGCT
1265 1275 1285 1295 1305 1315
GGAGTTCGTG ACCGCCGCCG GGATCACTCT CGGCATGGAC GAGCTGTACA AGGGATCCGA
GGAGTTCGTG ACCGCCGCCG GGATCACTCT CGGCATGGAC GAGCTGTACA AGGGATCCGA
1325 1335 1345 1355 1365 1375
CTTTGACGAG CACGAGGTCG ATGCGTTGGC CTCCGGGATT ACTTTCGGAG ACTTCGACGA
CTTTGACGAG CACGAGGTCG ATGCGTTGGC CTCCGGGATT ACTTTCGGAG ACTTCGACGA
1385 1395 1405 1415 1425 1435
CGTCCTGCGA CTAGGCCGCG CGGGTGCATA TATTTTCTCC TCGGACACTG GCAGCGGACA
CGTCCTGCGA CTAGGCCGCG CGGGTGCATA TATTTTCTCC TCGGACACTG GCAGCGGACA
276
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1445 1455 1465 1475 1485 1495
(3H) -eGFP TTTACAACAA AAATCCGTTA GGCAGCACAA TCTCCAGTGC GCACAACTGG ATGCGGTCCA
del603 TTTACAACAA AAATCCGTTA GGCAGCACAA TCTCCAGTGC GCACAACTGG ATGCGGTCCA
1505 1515
(3H) -eGFP GGAGGAGAAA ATGTACCCGC C


























5 15 25 35 45 55
ATACCATGTA GATGGGGTGC AGAAGGTAAA GTGCGAGAAG GTTCTCCTGT TCGACCCGAC
ATACCATGTA GATGGGGTGC AGAAGGTAAA GTGCGAGAAG GTTCTCCTGT TCGACCCGAC
55 75 85 95 105 115
GGTACCTTCA GTGGTTAGTC CGCGGAAGTA TGCCGCATCT ACGACGGACC ACTCAGATCG
GGTACCTTCA GTGGTTAGTC CGCGGAAGTA TGCCGCATCT ACGACGGACC ACTCAGATCG
125 135 145 155 165 175
GTCGTTACGA GGGTTTGACT TGGACTGGAC CACCGACTCG TCTTCCACTG CCAGCGATAC
GTCGTTACGA GGGTTTGACT TGGACTGGAC CACCGACTCG TCTTCCACTG CCAGCGATAC
185 195 205 215 225 235
CATGTCGCTA CCCAGTTTGC AGTCGTGTGA CATCGACTCG ATCTACGAGC CAATGGCTCC
CATGTCGCTA CCCAGTTTGC AGTCGTGTGA CATCGACTCG ATCTACGAGC CAATGGCTCC
245 255 265 275 285 295
CATAGTAGTG ACGGCTGACG TACACCCTGA ACCCGCAGGC ATCGCGGACC TGGCGGCAGA
CATAGTAGTG ACGGCTGACG TACACCCTGA ACCCGCAGGC ATCGCGGACC TGGCGGCAGA
305 315 325 335 345 355
TGTGCACCCT GAACCCGCAG ACCATGTGGA CCTCGAGAAC CCGATTCCTC CACCGCGCCC
TGTGCACCCT GAACCCGCAG ACCATGTGGA CCTCGAGAAC CCGATTCCTC CACCGCGCCC
365 375 385 395 405 415
GAAGAGAGCT GCATACCTTG CCTCCCGCGC GGCGGAGCGA CCGGTGCCGG CGCCGAGAAA
GAAGAGAGCT GCATACCTTG CCTCCCGCGC GGCGGAGCGA CCGGTGCCGG CGCCGAGAAA
425 435 445 455 465 475
GCCGACGCCT GCCCCAAGGA CTGCGTTTAG GAACAAGCTG CCTTTGACGT TCGGCGACTT
GCCGACGCCT GCCCCAAGGA CTGCGTTTAG GAACAAGCTG CCTTTGACGT TCGGCGACTT
485 495 505 515 525 535
TGACGAGCAC GAGGTCGATG CGTTGGCCTC CGGGATTACT TTCGGAGACT TCGACCACGT
TGACGAGCAC GAGGTCGATG CGTTGGCCTC CGGGAT
545 555 565 575 585 595
CCTGCGACTA GGCCGCGCGG GTGCAGGGAT TTTCTCCTCG GACACTGGGC CCGGG^^GT
605 615 625 635 645 655
GAGCAAGGGC GAGGAGCTGT TCACCGGGGT GGTGCCCATC CTGGTCGAGC TGGACGGCGA
278
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665 675 685 695 705 715
(3H) -eGFP5 CGTAAACGGC CACAAGTTCA GCGTGTCCGG CGAGGGCGAG GGCGATGCCA CCTACGGCAA
del537del75 - -
725 735 745 755 765 775
(3H) -eGFP GCTGACCCTG AAGTTCATCT GCACCACCGG CAAGCTGCCC GTGCCCTGGC CCACCCTCGT
del537del75
785 795 805 815 825 835
<3H) -eGFP GACCACCCTG ACCTACGGCG TGCAGTGCTT CAGCCGCTAC CCCGACCACA TGAAGCAGCA
de!537del75
845 855 865 875 885 895
(3H) -eGFP CGACTTCTTC AAGTCCGCCA TGCCCGAAGG CTACGTCCAG GAGCGCACCA TCTTCTTCAA
del537del75 -
905 915 925 935 945 955
(3H) -eGFP GGACGACGGC AACTACAAGA CCCGCGCCGA GGTGAAGTTC GAGGGCGACA CCCTGGTGAA
del537del75
965 975 985 995 1005 1015
(3H) -eGFP CCGCATCGAG CTGAAGGGCA TCGACTTCAA GGAGGACGGC AACATCCTGG GGCACAAGCT
del537del75 -
1025 1035 1045 1055 1065 1075
(3H) -eGFP GGAGTACAAC TACAACAGCC ACAACGTCTA TATCATGGCC GACAAGCAGA AGAACGGCAT
del537del75 CATGGCC GACAAGCAGA AGAACGGCAT
1085 1095 1105 1115 1125 1135
(3H) -eGFP CAAGGTGAAC TTCAAGATCC GCCACAACAT CGAGGACGGC AGCGTGCAGC TCGCCGACCA
del537del75 CAAGGTGAAC TTCAAGATCC GCCACAACAT CGAGGACGGC AGCGTGCAGC TCGCCGACC-
1145 1155 1165 1175 1185 1195
(3H)-eGFP CTACCAGCAG AACACCCCCA TCGGCGACGG CCCCGTGCTG CTGCCCGACA ACCACTACCT
del537del75
1205 1215 1225 1235 1245 1255
(3H) -eGFP GAGCACCCAG TCCGCCCTGA GCAAAGACCC CAACGAGAAG CGCGATCACA TGGTCCTGCT
del537del75 CCCTGA GCAAAGACCC CAACGAGAAG CGCGATCACA TGGTCCTGCT
1265 1275 1285 1295 1305 1315
(3H) -eGFP GGAGTTCGTG ACCGCCGCCG GGATCACTCT CGGCATGGAC GAGCTGTACA AGGGATCCGA
del537del75 GGAGTTCGTG ACCGCCGCCG GGATCACTCT CGGCATGGAC GAGCTGTACA AGGGATCCGA
1325 1335 1345 1355 1365 1375
(3H) -eGFP CTTTGACGAG CACGAGGTCG ATGCGTTGGC CTCCGGGATT ACTTTCGGAG ACTTCGACGA
del537del75 CTTTGACGAG CACGAGGTCG ATGCGTTGGC CTCCGGGATT ACTTTCGGAG ACTTCGACGA
279
Appendix II Sequencing
1385 1395 1405 1415 1425 1435
(3H) -eGFP CGTCCTGCGA CTAGGCCGCG CGGGTGCATA GCAGCGGACA
del537del75 CGTCCTGCGA CTAGGCCGCG CGGGTGCATA TATTTTCTCC TCGGACACTG GCAGCGGACA
! |
1445 1455 1465 1475 1485 1495
(3H) -eGFP TTTACAACAA AAATCCGTTA GGCAGCACAA TCTCCAGTGC GCACAACTGG ATGCGGTCCA
del537del75 TTTACAACAA AAATCCGTTA GGCAGCACAA TCTCCAGTGC GCACAACTGG ATGCGGTCCA
| | •
1505 1515
(3H)-eGFP GGAGGAGAAA ATGTACCCGC C
del537del75 GGAGGAGAAA ATGTACCCGC C
280
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Insertion of EGFP into the replicase gene of
Semliki Forest virus results in a novel, genetically
stable marker virus
Nele Tamberg,1t Valeria Lulla,11 Rennos Fragkoudis,2 Aleksei Lulla,3
John K. Fazakerley2 and Andres Merits1,3
1 Estonian Biocentre, Tartu, Estonia
2Centre for Infectious Diseases, College of Medicine and Veterinary Medicine, University of
Edinburgh, Edinburgh, UK
institute of Molecular and Cell Biology, University of Tartu, Tartu, Estonia
Alphavirus-based vector and replicon systems have been extensively used experimentally and
are likely to be used in human and animal medicine. Whilst marker genes can be inserted easily
under the control of a duplicated subgenomic promoter, these constructs are often genetically
unstable. Here, a novel alphavirus construct is described in which an enhanced green fluorescent
protein (EGFP) marker gene is inserted into the virus replicase open reading frame between nsP3
and nsP4, flanked by nsP2 protease-recognition sites. This construct has correct processing of
the replicase polyprotein, produces viable virus and expresses detectable EGFP fluorescence
upon infection of cultured cells and cells of the mouse brain. In comparison to parental virus,
the marker virus has an approximately 1 h delay in virus RNA and infectious virus production.
Passage of the marker virus in vitro and in vivo demonstrates good genetic stability. Insertion
of different markers into this novel construct has potential for various applications.
Infectious cDNA (icDNA) clones and corresponding
expression vectors have been developed for several alpha-
viruses (Liljestrom & Garoff, 1991; Strauss & Strauss, 1994;
Simpson et al., 1996). In most alphavirus-based expression
vectors, the viral structural genes are replaced by foreign
genes. These vectors are capable of only one round of
infection and are thus non-mobilizable, a property that
has severely hampered their use in studies that require a
spreading, propagating infectious process. Marker and
other recombinant alphaviruses have been produced by
expressing the foreign gene from an internal ribosomal
entry site element or from a duplicated 26S promoter (Raju
& Huang, 1991; Hahn et al., 1992; Pugachev et al., 2000;
Vaha-Koskela et al., 2003). Double-subgenomic vectors
containing marker genes allow direct observation of infec¬
tion and have been used successfully in animal experiments
(Levine et al., 1996; Cook & Griffin, 2003). Unfortunately,
these vectors tend to suffer from genome instability, pro¬
bably because the inserted genes are introduced as separate
transcription units and have no selective value (Pugachev
et al., 1995, 2000).
An alternative strategy is to insert genes into natural gene
expression units. A marker gene has been inserted success¬
fully into the Sindbis virus (SIN) structural gene (Thomas
tThese authors contributed equally to this work.
et al., 2003). SIN genomes with markers inserted into the
non-structural replicase to produce nsP3-fusion proteins
have also been produced (Bick et al., 2003; Frolova et al.,
2006). Production of non-structural-marker fusion pro¬
teins has also been successful in other viruses, including
Poliovirus, Hepatitis C virus, Equine arteritis virus and
several filamentous plant viruses (Mueller & Wimmer,
1998; Moradpour et al., 2004; Rajamaki et al., 2005; van
den Born et al., 2005). Here, we report that Semliki Forest
virus (SFV) nsP3-enhanced green fluorescent protein
(EGFP) fusion protein marker virus is viable, but geneti¬
cally unstable; however, by the novel strategy of placing the
EGFP insert between nsP3 and nsP4 flanked by duplica¬
tions of the nsP3/4 nsP2 protease-recognition site, we have
generated a viable, genetically stable virus with only minor
changes in phenotype.
An SFV nsP3-EGFP fusion protein virus was engineered
by subcloning and PCR-based mutagenesis. The C residue
at position 5447 of pSFV4 (Liljestrom et al., 1991) was
changed to G and a 12 bp long sequence, GGGCCCAT-
AGGATCC, was inserted after the modified codon. The
resulting construct was designated pSFV(3F)4. The sequ¬
ence encoding EGFP was PCR-amplified, cloned into
pSFV(3F)4 and the resulting icDNA clone was designated
pSFV(3F)4-EGFP (Fig. la). Infectious virus, SFV(3F)4-
EGFP, was obtained by electroporation of capped in vitro
0008-2436 © 2007 SGM Printed in Great Britain 1225
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Fig. 1. (a) Schematic representation of recombinant SFV genomes. The sequences of the inserted High (H) site and the native
nsP3/4 nsP2 cleavage sites are shown. The 30 aa sequence from the C terminus of the nsP3 (aa 453-482), which was fused
to the C terminus of EGFP, is indicated. The nsP2 protease-cleavage sites are indicated by i . Numbers indicate positions of
amino acid residues in nsP3; (6) indicates the sequence IFSSDT (from nsP4). (b) Growth of SFV4 and SFV(3H)4-EGFP in
BHK-21 cells infected with P2 viruses, (c) Localization of EGFP and nsP3 in BHK-21 cells infected with SFV(3F)4-EGFP. (d)
Localization of EGFP and nsP3 in BHK-21 cells infected with SFV(3H)4-EGFP. In both (c) and (d), cells infected at an m.o.i. of
1 were fixed at 5 h post-infection. EGFP was detected by its fluorescence, and nsP3 with a polyclonal antibody and a
secondary antibody conjugated to Texas red. (e) Virus-infected EGFP-positive cells (green) in mouse brain 2 days post-
inoculation, detected by confocal microscopy; p denotes the hippocampal pyramidal cell layer and c the cortex. Bar, 100 pm.
transcripts as described by Liljestrom et al. (1991). The
primary virus stocks (PI) were collected after 24 h, titrated
and used to infect fresh BHK-21 cells (m.o.i., 0.1). The
second-passage stocks (P2) were also harvested at 24 h.
SFV(3F)4-EGFP virus was viable and expressed the
expected nsP3-EGFP fusion protein (Fig. 2a). However,
plaque purification followed by analysis of the fluorescence
produced by individual plaques and Western blotting
demonstrated that this virus was genetically unstable; a
truncated form of the nsP3-EGFP fusion protein was
present even in cells transfected directly with in vitro-
synthesized RNA. The genetic instability of this virus is
most probably due to defect(s) in the formation or func¬
tioning of replication complexes. As with SIN nsP3-fusion
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Fig. 2. (a) Expression of EGFP and viral ns proteins by
recombinant viruses. BHK-21 cells were infected (m.o.i., 20) with
SFV4 (wt), P2 stock of SFV(3H)4-EGFP (H) or P1 stock of
SFV(3F)4-EGFP (F), or were mock-infected (M), and cell lysates
were analysed by Western blotting. The antibody used for
detection is indicated at the top of each panel. Specific signals
for nsP1, nsP2, nsP3, nsP4 or EGFP are indicated with a solid
arrow; bands corresponding to nsP3-EGFP and EGFP-nsP4
fusion proteins are marked with an open arrow, (b) Proteins
synthesized in infected cells were labelled metabolically at 3 h
post-infection and chased for 1, 3, 8 or 24 h. Cell lysates were
immunoprecipitated with anti-nsP1, anti-nsP3 or anti-EGFP
antibodies and analysed by SDS-PAGE.
constructs (Ryman et al., 2005; Frolova et al., 2006;
Ventoso et al., 2006), SFV(3F)4-EGFP and its analogues
may have uses to study replicase gene expression, replicase
protein localization and interactions, but its instability
precludes application in in vivo pathogenesis studies.
In a novel strategy, a second virus was engineered in which
EGFP was placed between nsP3 and nsP4 flanked by nsP2
cleavage sites. Starting with pSFV(3F)4-EGFP, the C
terminus of nsP3 was restored and an nsP2 protease-
recognition site was added between nsP3 and EGFP
(Fig. la). The inserted protease-recognition sequence was
based on the nsP3/4 junctional sequence, which is cleaved
with high efficiency (Merits et al., 2001; Vasiljeva et al.,
2001). The first amino acid residue after the inserted
cleavage point was also changed from Tyr to Gly; nsP2
prefers Gly in the PI' position and Gly represents a
stabilizing amino acid (Lulla et al., 2006; Varshavsky,
1996). The PI' Gly was followed by aa 2-7 from the N
terminus of nsP4 (Fig. la). The region encoding the C
terminus of nsP3 with indicated downstream sequence
was created by PCR amplification and cloned into
pSFV(3F)4-EGFP. The resulting clone and virus were
designated pSFV(3H)4-EGFP and SFV(3H)4-EGFP,
respectively (Fig. la).
Infectious-centre assays (Gorchakov et al., 2004) demon¬
strated that 3.1 x 105 to 4.4 x 103 plaques (pg transfected
RNA)-1 were obtained for both pSFV(3H)4-EGFP and
pSFV4 transcripts, with no statistically significant differ¬
ence between them. In one-step growth studies (m.o.i., 20),
relative to SFV4, production of infectious SFV(3H)4-EGFP
was delayed by approximately 1 h (Fig. lb). However, as
SFV(3H)4-EGFP was able to replicate to 109 p.f.u. ml-1
within 10 h, it can be concluded that insertion of EGFP
between nsP3 and nsP4 did not affect virus replication
substantially.
To determine whether the EGFP insertion in SFV(3H)4-
EGFP was inherited stably, 96 virus plaques were purified
from each of five in vitro passages (P1-P5) in BHK-21 cells
(m.o.i., 0.1) and each of five in vivo passages (M1-M5) in
mouse brains. After each passage, the percentage of viruses
expressing EGFP was assessed by random selection of 96
plaques followed by determination of EGFP expression. All
plaques from the P2 stock of SFV(3H)4-EGFP were EGFP-
positive and >90 % were EGFP-positive after the fifth
passage. Even greater stability was observed for in vivo-
propagated stocks; after the fifth passage, only one plaque
(1/96) was EGFP-negative. As an EGFP-negative phenotype
could result from EGFP inactivation by point mutation or by
deletion, we RT-PCR-amplified and sequenced the corre¬
sponding regions for several of the EGFP-negative (in vitro-
passaged) plaque-purified viruses. In all cases, these genomes
contained large in-frame deletions, indicating that deletions
in the marker gene do occur upon passage of SFV(3H)4-
EGEP. Whilst the frequency of this process may be low, given
their growth advantage, deleted genomes are likely to
increase in the viral population following multiple passages.
In SFV-infected cells, nsP3 is known to associate with
modified endosomes and lysosomes (Froshauer et al.,
1988). In contrast, free EGFP is typically localized diffusely
in the cytoplasm and more abundantly in the nucleus. In
SFV(3F)4-EGFP-infected BHK-21 cells, EGFP co-localized
with nsP3 to punctate cytoplasmic structures, presumably
virus replicase complexes (Fig. lc). In contrast, SFV(3H)4-
EGFP-infected cells showed granular cytoplasmic staining
for nsP3 and diffuse, predominantly nuclear staining for
EGFP (Fig. Id). The independent localization of nsP3 and
EGFP in the SFV(3H)4-EGFP-infected cells indicates that
EGFP was released from the replication complexes.
To determine the phenotype of SFV(3H)4-EGFP in vivo,
groups of six 5-6-week-old female BALB/c mice were
inoculated (20 pi) intracerebrally with SFV4(3H)-EGFP or
SFV4. All animal experiments were carried out under the
authority of a UK Home Office licence and were approved
by the University of Edinburgh ethical-review process.
Mice in both groups had clinical signs of encephalitis at day
2 and were sampled. Half brains were fixed in 4 % neutral-
buffered formalin for 16 h, processed through graded
sucrose solutions, frozen in OCT and cut into sections
(12 pm). EGFP-positive cells were observed readily in all
(n=6) brains infected with SFV(3H)4-EGFP (Fig. le).
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Titration of the other half brain, as described previously
(Fazakerley et al., 1993), demonstrated titres of infectious
virus ranging from 1 x 109 to 3 x 109p.f.u. g~\ with no
difference between mice infected with SFV(3H)4-EGFP
and those infected with parental SFV4. We conclude that,
as with SFV4, SFV(3H)4-EGFP is neurovirulent and can
replicate and spread efficiently in the mouse brain and that
SFV(3H)4-EGFP-infected brain cells express sufficient
EGFP to be observed readily by fluorescence microscopy.
Expression of the ns proteins in SFV(3H)4-EGFP- and
SFV(3F)4-EGFP-infected BHK-21 cells was examined by
Western blotting (Fig. 2a). At 6 h post-infection, cells were
lysed in Laemmli buffer and samples corresponding to
100 000 cells were separated by SDS-PAGE. Monospecific
rabbit polyclonal antibodies were used to detect nsPl, nsP3
and nsP4, and a mouse monoclonal antibody was used to
detect nsP2 (Peranen et al., 1988; Laakkonen et al., 1994;
Rikkonen et al., 1994; Kujala et al., 1997). Individual nsPl,
nsP2, nsP3, nsP4 and EGFP were observed readily in
SFV(3H)4-EGFP-infected cells. No nsP3-EGFP fusion pro¬
tein was detected, but a small amount of unprocessed EGFP-
nsP4 was detected by antibodies to both nsP4 and EGFP. In
SFV(3F)4-EGFP-infected cells, nsP3 was, as expected, present
predominantly as an nsP3-EGFP fusion protein. A small
amount of free nsP3 was also present; this may have resulted
from the rapid generation of EGFP-negative genomes.
To study the dynamics of cleavage of the SFV(3H)4-
EGFP polyprotein, infected cells (m.o.i., 100) were pulse
labelled metabolically for 15min with 50 piCi (1.85 MBq)
[35S]methionine and [35S]cysteine, and nsP3 and its
precursors were immunoprecipitated with antiserum
against nsP3 and Protein A-Sepharose. Immunocomplexes
were separated by SDS-PAGE and radiolabelled proteins
were visualized by autoradiography. In pulse-labelled cells,
the P123-EGFP, P3-EGFP-4 and P3-EGFP processing
intermediates were all detected, whereas in chased
samples, processing intermediates were not detected or
were present in lower quantities, and the amount of fully
processed nsP3 was increased (data not shown). Thus, all
expected processing products, except the very rapidly
processed P123-EGFP-4, were detected and no apparent
disturbance of processing was observed.
In BHK-21 cells, EGFP is generally quite stable, with an
estimated half-life of 24 h. However, in BHK-21 cells
infected with SFV(3H)4-EGFP, the EGFP signal detected
late in infection by fluorescence microscopy had decreased
considerably, suggesting low EGFP stability. To assess the
stability of the EGFP and ns proteins, BHK-21 cells infected
with SFV(3H)4-EGFP or SFV4 were labelled metabolically,
chased and EGFP, nsPl and nsP3 were immunoprecipi¬
tated. For both viruses, only a small decrease in nsPl and
nsP3 was detected over 24 h (Fig. 2b). In contrast, by 24 h,
the amount of EGFP was below the detection limit of this
analysis (Fig. 2b). Thus, the low amounts of EGFP
observed by microscopy indeed represent rapid degrada¬
tion of EGFP. The processed EGFP has a Gly residue at its
N terminus that, according the N-end rule, is stabilizing.
Most likely, EGFP instability results from the duplicated
C-terminal sequence of nsP3 (Fig. la), which, as a result
of the construction strategy, remains attached to the C
terminus of EGFP. If this is the case, then the effect of this
same sequence in its native location (C terminus of nsP3)
is either different or is suppressed by interaction(s) with
other components of the replicase complex.
Virus RNA synthesis by SFV4 and SFV(3H)4-EGFP was
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Fig. 3. (a) Synthesis of virus RNA. BHK-21 cells were infected with SFV4 or SFV(3H)4-EGFP; at 1 h post-infection,
actinomycin D (2 pg ml-1) and, at 2 h, 25 pCi (0.925 MBq) [3H]uridine, were added. Cells were collected at 3, 4, 5, 6, 7 and 8 h
post-infection. Total RNA was precipitated by trichloroacetic acid. Incorporated radioactivity was measured by liquid
scintillation. Each bar represents the mean of six replicates; error bars indicate SD. (b) Shutdown of cellular translation in BHK-
21 cells infected with SFV4 or SFV(3H)4-EGFP. Proteins synthesized in infected cells were labelled metabolically at 1 h
intervals and cell lysates were analysed by SDS-PAGE. M, Mock-infected cells.
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cells, SFV(3H)4-EGFP-infected cells had a delay in virus
RNA synthesis (Fig. 3a); this was most obvious at 3-5 h
post-infection and less so at later time points. To analyse
whether insertion of the marker gene altered the temporal
expression of SFV structural proteins or the shutdown of
host-cell translation, protein synthesis in infected BF1K-21
cells was studied by metabolic labelling. As observed with
virus growth (Fig. lb) and RNA synthesis (Fig. 3a), pro¬
duction of viral proteins C, El and p62 in SFV(3H)4-
EGFP-infected cells started approximately 1 h later than
in SFV4-infected cells. A longer, approximately 2 h, delay
was observed for host-cell translational shutdown (Fig. 3b).
In all measurements of virus replication and growth,
SFV(3H)4-EGFP was slightly slower than SFV4. The possi¬
ble reasons for this include effects resulting from larger ns
polyprotein sizes and delays or defects in replicase-complex
formation. However, these changes are unlikely to preclude
use of this virus, as it replicates to high titres and remains
neurovirulent. Despite the small duplication of viral sequ¬
ence necessitated by the addition of the nsP2 processing
site upstream of EGFP, SFV(3H)4-EGFP demonstrated
remarkably improved genetic stability relative to SFV(3F)4-
EGFP. However, it should be noted that, at late passages
in vitro, some genomes with a deletion in the marker gene
were present. Attempts to reduce this by removing the
duplicated 6 aa from the N terminus of EGFP, or by
decreasing the length of the nsP3 C-terminal fragment
fused to the C terminus of EGFP, resulted in viable
viruses, but did not increase their genetic stability (data
not shown). Importantly, following replication and spread
of SFV(3H)4-EGFP in the mouse brain, no deletion
variants were observed until passage M5, demonstrating
the utility of this virus for in vivo pathogenesis studies.
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La Crosse virus (LACV) is a mosquito-transmitted member of the Bunyaviridae family that causes severe
encephalitis in children. For the LACV nonstructural protein NSs, previous overexpression studies with
mammalian cells had suggested two different functions, namely induction of apoptosis and inhibition of RNA
interference (RNAi). Here, we demonstrate that mosquito cells persistently infected with LACV do not undergo
apoptosis and mount a specific RNAi response. Recombinant viruses that either express (rLACV) or lack
(rLACVdelNSs) the NSs gene similarly persisted and were prone to the RNAi-mediated resistance to super¬
infection. Furthermore, in mosquito cells overexpressed LACV NSs was unable to inhibit RNAi against Semliki
Forest virus. In mammalian cells, however, the rLACVdelNSs mutant virus strongly activated the antiviral type
I interferon (IFN) system, whereas rLACV as well as overexpressed NSs suppressed IFN induction. Conse¬
quently, rLACVdelNSs was attenuated in IFN-competent mouse embryo fibroblasts and animals but not in
systems lacking the type I IFN receptor. In situ analyses of mouse brains demonstrated that wild-type and
mutant LACV mainly infect neuronal cells and that NSs is able to suppress IFN induction in the central
nervous system. Thus, our data suggest little relevance of the NSs-induced apoptosis or RNAi inhibition for
growth or pathogenesis of LACV in the mammalian host and indicate that NSs has no function in the insect
vector. Since deletion of the viral NSs gene can be fully complemented by inactivation of the host's IFN system,
we propose that the major biological function of NSs is suppression of the mammalian innate immune
response.
La Crosse virus (LACV) is an important mosquito-borne
pathogen in North America, causing severe encephalitis and
aseptic meningitis in children and young adults (37, 42, 57).
Around 75 to 100 cases of La Crosse encephalitis requiring
hospitalization are reported annually (12), and up to 57%
percent of these patients need to be admitted to the intensive
care unit (37). More than 10% of the hospitalized patients will
have long-lasting neurological deficits (37, 38), with severe
economic and social consequences (52). As less than 1.5% of
LACV infections are clinically apparent, it is estimated that
more than 300,000 infections occur annually in the Midwestern
United States alone (11, 38).
Like other arboviruses, LACV cycles between vertebrate
and invertebrate hosts, able to replicate both in mammals and
in insects. Depending on the host, however, the outcome of
infection is different (7). In mammalian cells, infection is lytic
and causes host cell shutoff and cell death. In insect cells,
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infection is noncytolytic and leads to long-term viral persis¬
tence.
LACV belongs to the California serogroup of the genus
Orthobunyavirus, family Bunyaviridae (7). Bunyaviruses are a
large group of mainly arthropod-transmitted viruses. They are
classified into five genera: Orthobunyavirus, Phlebovirus, Hanta¬
virus, Nairovirus, and Tospovirus. Some members are human
pathogens and can cause encephalitis, febrile illness, or hem¬
orrhagic fever; among them are LACV, Oropouche virus, Han¬
taan virus, Rift Valley fever virus (RVFV), and Crimean-
Congo hemorrhagic fever virus (19, 56). Bunyaviruses are
enveloped and have a trisegmented single-stranded RNA ge¬
nome of negative or ambisense polarity, replicate in the cyto¬
plasm, and bud into the Golgi apparatus. They encode four
common structural proteins: the viral polymerase (L) on the
large (L) segment, two glycoproteins (Gn and Gc) on the
medium (M) segment, and the viral nucleocapsid protein (N)
on the smallest (S) segment.
Some bunyaviruses encode on their S segment a nonstruc¬
tural protein which is termed NSs. For LACV, two different
functions for viral pathogenicity have been assigned to this
accessory protein. Firstly, NSs has similarity to the Drosophila
protein reaper and is an efficient inducer of apoptosis if over-
expressed in mammalian cells (14). Our own studies using
recombinant LACV expressing or lacking NSs supported this
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notion (6). Secondly, overexpressed NSs was shown to effi¬
ciently suppress RNA interference (RNAi) in mammalian cells
(49), suggesting that LACV NSs is important for evasion of this
antiviral system. By contrast, in vivo studies with the orthobu-
nyavirus Bunyamwera virus (BUNV) or the phlebovirus
RVFV provided evidence that their NSs proteins arc efficient
inhibitors of type I interferon (IFN-u/p) synthesis and that this
activity is relevant for infection ofmammalian hosts (8, 25, 55).
IFNs are cytokines which establish a first line of defense
against viral pathogens by stimulating the synthesis of antiviral
proteins and activating the adaptive immune system (43). In
most cell types, virus infection activates a signaling pathway
that results in the immediate synthesis of IFN-(3 and IFN-a4,
which is followed by a second burst of IFN which comprises a
large number (at least 14 in mice) of different a subtypes (36,
53). In plasmacytoid dendritic cells, which are the professional
IFN producers of the immune system, IFN-t* is directly syn¬
thesized after stimulation (13).
The biological function of LACV NSs in the mammalian
host has to date not been clarified, and the role of NSs in
infection of the insect vector has not been resolved for any of
the bunyaviruses. Here, we used our recently generated recom¬
binant LACV mutant lacking NSs (rLACVdelNSs) (6) to in¬
vestigate these issues. Our results strongly suggest that LACV
NSs evolved mainly to counteract the antiviral IFN system of
the mammalian host.
MATERIALS AND METHODS
Chemicals, cells, and viruses. Poly(l • C) (Sigma) was dissolved and used as
indicated by the manufacturer. Mouse embryo fibroblasts (MEFs) were prepared
by trypsin digestion of 14-day-old embryos. The cultures were used between
passages 3 to 8. MEFs and human 293 cells were cultivated in Dulbecco's
modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum
(FCS). BSR-T7/5 cells (10), which constitutively express the bacteriophage T7
RNA polymerase, were additionally provided with 1 mg/ml geneticin (G418).
Aedes albopictus C6/36 and U4.4 cells (a kind gift of D. T. Brown, North Carolina
State University, Raleigh, NC) and Aedes triseriatus MAT cells were grown at
30°C (C6/36 and MAT cells) or 28°C (U4.4 cells) without C02 in Leibowitz L-15
medium (Gibco-BRL) supplemented with 10% FCS, antibiotics, and 4% tryp-
tose phosphate broth (Difco). The recombinant virus strains rLACV and
rLACVdelNSs were grown and maintained as described previously (6).
RNAi detection. Insect cells were infected with LACV at a multiplicity of
infection of 10, and maintained in Leibovitz L-15 maintenance medium (1% fetal
bovine serum). At predetermined times postinfection, the cells were harvested,
RNA was extracted, and small RNAs were enriched by precipitation of high-
molecular-weight species with 5% polyethylene glycol 8000-0.5 M NaCl (26).
Low-molecular-weight RNAs were fractionated by 16% polyacrylamide-7 M
urea gel electrophoresis, transferred to nylon filters, and hybridized at 42°C with
a 32P-labeled viral RNA sense probe. The S segment mRNA from the same
extracts was separated by 1.2% agarose gel electrophoresis, blotted, and hybrid¬
ized with the same probe.
Plaque assay. Vero cells grown on six-well plates to 90% confluence were
inoculated with 10-fold serial dilutions of supernatants from infected cells, di¬
luted in DMEM with 2% FCS. After a 1-h incubation at 37°C, the inoculum was
removed, and the cells were overlaid with 3 ml of DMEM with 2% FCS, 0.02%
DEAE dextran, and 0.3% agar noble (Difco); cells were incubated for another
72 h at 37°C. Cells were fixed and stained with 1% crystal violet. 3.6% formal¬
dehyde, 1% methanol, and 20% ethanol, and titers were calculated from the
plaque numbers according to the dilution.
Plasmid constructs and PCR. DNA plasmids were constructed and propa¬
gated using standard techniques. PCR was carried out with AccuPrime Pfx DNA
polymerase (for cloning purposes; Invitrogen) or Taq DNA polymerase (for
diagnostic purposes and addition of single adenosines for TA cloning; Eppen-
dorf). TA cloning was done using a pcDNA3.1/V5-His TOPO TA Expression
kit (Invitrogen) according to the manufacturer's instructions. A recombinant
Semliki Forest virus (SFV) replicon encoding LACV NSs (SFV-LACV NSs)
equipped with an N-terminal FLAG epitope was generated by PCR amplifica¬
tion and cloning into pSFV-1 (35) using the BamHl restriction site. SFV repli-
cons SFV-Luc (expressing firefly luciferase), SFV-TSWV NSs (expressing the
NSs of tomato spotted wilt virus), and SFV-NS1 (expressing the influenza A virus
NS1 protein) were kindly provided by Michele Bouloy (Institute Pasteur, Paris,
France) and Marcel Prins (Wageningen University, Wageningen, The Nether¬
lands) (22). The minireplicon plasmid pT7ribo-LACV-cM-GFP encoding the
enhanced green fluorescent protein (EGFP) gene flanked by the antigenomic
LACV M segment promoter sequences under control of the bacteriophage T7
promoter was constructed by inserting the EGFP coding sequence into the
LACV M provector pT7ribo-LACV-cMPro (6), using engineered Bpil restric¬
tion enzyme sites. The eukaryotic expression plasmid pI.18-HA-LACV-NSs was
constructed by ligating a PCR fragment encompassing the LACV NSs sequence
with a 5'terminal hemagglutinin (HA) tag into the cloning vector pi.18 (kindly
provided by Jim Robertson, National Institute for Biological Standards and
Control, Hertfordshire, United Kingdom). The T7 promoter-driven expression
constructs pTM-LACV-L and pTM-LACV-N were described previously (5). The
firefly lucifcrasc (FF-Luc) reporter plasmid for monitoring TFN-0 promoter
activation (p-125Luc) was kindly provided by Takashi Fujita, Institute for Virus
Research, Kyoto University, Japan (58). The control plasmid pRL-SV40 (Pro-
mega) contains the Renilla luciferase (REN-Luc) gene under control of the
constitutive simian virus 40 (SV40) promoter.
RNAi reporter assay. RNAi against an SFV replicon expressing FF-Luc in
insect cells was established as described by Garcia et al. (22). pSFV-l-derived
plasmids were linearized with Spel (SFV-Luc and SFV-NS1) or Sapl (SFV-
TSWV NSs and SFV-LACV NSs) and in vitro transcribed and capped using SP6
RNA polymerase. Replicon RNA was purified using an RNeasy Mini Kit and
resuspended in nuclease-free H20. For cotransfection experiments with replicon
RNA, 2 X 10"* U4.4 cells grown in 24-well dishes were transfected using 125 ng
of each RNA (as indicated) and 0.75 pi of Lipofectamine 2000 (Invitrogen).
Transfection mixes were not removed from the supernatant over the course of
the experiment, and no cytopathic effect or difference in cell numbers was
observed. At 3 days posttransfection, cells were lysed in 50 pi of passive lysis
buffer per well, and luciferase activities were determined as described by the
manufacturer (Promega).
In vivo reconstitution and passaging of LACV nucleocapsids. Subconfluent
monolayers of BSR-T7/5 cells in six-well dishes were transfected with 0.5 pg each
of plasmid pT7ribo-LAC-cM-GFP, pTM-LACV-L, and pTM-LACV-N using the
Fugene 6 transfection reagent (Roche) in 200 pi of serum free-medium (Opti-
MEM; Gibco-BRL). At 24 h posttransfection, cells were infected with viruses at
a multiplicity of infection of 5, incubated for 1 h, and washed two times with
phosphate-buffered saline (PBS). After an incubation period of 24 h, cells and
supernatants containing newly generated viruses were harvested by three freeze-
thaw cycles, and centrifuged for 1 min at 14,000 X g to pellet residual cell debris,
and 500 pi was used to infect C6/36 mosquito cells for 1 h. These C6/36 cells had
been mock infected or persistently infected with recombinant viruses, as indi¬
cated in the text. The superinfected C6/36 cells were washed with medium and
then incubated for 24 h. Expression of EGFP and LACV N was assayed by
immunofluorescence microscopy as described previously (6).
RT-PCR analyses. Total RNA was extracted from infected cells using the
TriFast reagent (Peqlab). For reverse transcription (RT), 1 pg of total RNA was
incubated with 200 U of Superscript II reverse transcriptase (Gibco-BRL) and
100 ng of random hexanucleotides in 20 pi of IX RT buffer (Gibco-BRL)
supplied with a 1 mM concentration of each deoxynucleotide triphosphate, 20 U
of RNasin, and 10 mM dithiothreitol. The resulting cDNA was amplified by 30
cycles of PCR, with each cycle consisting of 30 s at 94°C, 1 min at 58°C, and
1 min at 72°C, with a final 10-min step at 72°C. Primer sequences for ampli¬
fying mouse (i-actin were from Shaw-Jackson and Michiels (46), those for
IFN-fJ were from Marie et al. (36), and those for the LACV N gene were as
published previously (6).
Transient transfections and reporter gene assays. Subconfluent cell monolay¬
ers grown in six-well dishes were transfected with 0.5 pg of pl25-luc reporter
plasmid (FF-Luc gene under control of the IFN-|3 promoter), 0.05 pg of control
plasmid pRL-SV40 (REN-Luc gene under control of the SV40 promoter), and 1
pg of expression plasmid in 400 pi of OptiMEM (Gibco-BRL) containing 5 pi of
DAC-30 (Eurogentec). At 8 h posttransfection, cells were transfected with 10 pg
of poly(I • C) as described previously (55). After overnight incubation, cells were
harvested and lysed in 200 pi of reporter lysis buffer (Promega). An aliquot of 20
pi of lysate was used to measure FF-Luc and REN-Luc activity as described by
the manufacturer of the dual luciferase assay kit (Promega).
Virus growth in tissue culture. MEF cells were grown in six-well dishes to 80%
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mock ♦ ♦ ♦ ♦ ♦
LACV ♦ ♦ ♦ ♦ ♦
days p.i. 1 3 5 7 9
days p.i. 1 3 5 7 9
FIG. I. Formation of LACV-specific small RNAs during persistent
infection of C6/36 mosquito cells. Cells were infected with 10 PFU per
cell of LACV and passaged twice weekly, and total RNAs were ex¬
tracted at given time points. (A) To monitor infection, RNAs were
separated by 1.2% agarose gel electrophoresis and hybridized to a
negative sense S segment RNA probe. (B) Small RNAs were detected
after precipitation of the RNA samples with 5% polyethylene glycol,
separation on 16% polyacrylamide gels, and hybridization using the
same RNA probe as used in panel A. Arrows show the positions of
20-nucleotide markers which were run on the same gel. p.i., postin¬
fection.
supplied with DMEM containing 10% FCS. Supernatants were taken at various
times postinfection and assayed in plaque assays on Vero cells.
Pathogenicity studies. Wild-type (wt) C57BL/6 mice and congenic mutant
mice with targeted disruptions of the u-subunit of the IFN-a/p receptor (40) or
the IFN-p gene (20) were bred locally. Groups of 6 mice at an age of 16 to 18
days were inoculated intraperitoneally with 10,000 PFU of virus in 0.1 ml of PBS.
The animals were monitored twice daily over a 9-day period. Mice that were
moribund or severely paralyzed were killed.
ISH studies. For in situ detection of IFN mRNAs, RNA probes described in
Delhaye et al. (17) were used. The probe used for IFN-a detection was comple¬
mentary to IFN-o5 (the predominant IFN subtype in the central nervous system)
but can recognize other IFN-a subtypes as well. Brain preparation and in situ
hybridizations (ISH) were performed as described previously (17). Sections were
cut at 8 or 12 p.m. Control hybridizations performed with positive-sense probes
instead of antisense probes failed to yield any signal.
For ISH in combination with immunohistochemistry of neurons, sections were
treated for immunohistochemistry immediately after the last washes of the hy¬
bridization. Sections were blocked in TNB (0.1 M Tris-HCl [pH 7.50] 0.15 M
NaCl, 0.5% blocking reagent; Perkin-Elmer) and then incubated with the rabbit
anti-LACV N antibody for 2 to 12 h at room temperature. The Dako CSA system
(K1500) or Envision kit (K4006/K4010) were used for detection and diamino-
benzidine staining.
Immunohistofluorescence analysis. Freshly collected brains were immersed in
Tissue-Tek optimal cutting temperature compound (Sakura) and frozen at
—80°C. Tissue sections 7 |xm thick were cut in a cryostat, placed on SuperFrost
Plus slides, and dried at 37°C overnight. Sectionswere fixed with ice-cold acetone
for 10 min and washed before processing for immunohistofluorescence. Anti¬
bodies used for double labeling were a polyclonal antibody directed against the
N protein of LACV and monoclonal antibodies directed against either the
ncuron-specific nuclear protein ([NcuN] MAB377; Chcmicon), the astroeytc-
specific glial fibrillary acidic protein ([GFAP] 13-0300; Zymed), the oligodendro-
cyte-specific myelin basic protein (MAB386; Chemicon), or the microglia/macro-
phage-specific markers GDI lb (553308; Pharmingen) and F4/80 (MCA497R;
Serotec). Secondary antibodies were either labeled with Alexa 488 orwith Alexa 594
(Molecular probes).
RESULTS
Formation of short LACV-specific RNAs in persistently in¬
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FIG. 2. Time course of persistent LACV infection of mosquito
cells. C6/36 cells were infected with 10 PFU per cell of either rLACV
or rLACVdelNSs and passaged twice weekly. Viral titers in the super¬
natants were determined by plaque assay.
immune responses (31). For the defense of viral pathogens,
they deploy instead mechanisms like the ubiquitous RNAi
system, which is based on the sequence-specific recognition
and destruction of viral RNA (44, 54). We wondered whether
insect cells are capable of mounting an RNAi response against
LACV. To investigate this, we established persistent infection
of A. albopictus C6/36 cells with LACV and monitored the
formation of virus-specific small RNAs, the hallmark of RNAi.
Conventional Northern blot analysis of RNAs which were ex¬
tracted from mock-infected or LACV-infected C6/36 cells at
predetermined time points postinfection confirmed that infec¬
tion with LACV was stable and persistent (Fig. 1A; see also
Fig. 2). Fractionation and detection of low-molecular-weight
RNAs derived from LACV demonstrated that C6/36 cells in¬
deed produce small RNAs in response to infection (Fig. IB).
We have cloned and sequenced the small RNAs from LACV-
infected C6/36 cells and confirmed them to be derived from the
LACV S segment (data not shown). Similar observations were
obtained in/I. triseriatus MAT cells (data not shown), indicat¬
ing a general phenomenon. Of note, microscopic examinations
of infected cell cultures did not reveal any signs of cell death
(data not shown), as observed previously (7).
NSs does not influence virus growth in insect cells. LACV
NSs expressed from a transfected cDNA plasmid was previ¬
ously shown to inhibit the RNAi pathway in mammalian cells
(49). Our newly generated recombinant viruses expressing
(rLACV) or lacking (rLACVdelNSs) NSs offer the possibility
to evaluate the influence of NSs in the viral context. To deter¬
mine if the anti-RNAi activity of NSs is important to establish
or maintain infection in arthropods, we compared the persis¬
tence of rLACV and rLACVdelNSs in insect cells. C6/36 cells
were infected with recombinant viruses, cells were passaged
over several weeks, and titers in the supernatants were deter¬
mined at every passage. As shown in Fig. 2, both viruses ex¬
hibited the wave-like titer pattern which is typical for growth of
bunyaviruses in insect cells (45). No difference was observed
between rLACV and rLACVdelNSs, indicating that NSs is not
required for infection and persistence of LACV in insect cells.
Protection from superinfection. Insects infected with LACV
are resistant to superinfection with California serogroup or-
thobunyaviruses but remain permissive for Bunyamwera sero¬
group orthobunyaviruses (1). This pathogen-derived resistance
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FIG. 3. Protection of C6/36 mosquito cells from superinfection.
(A) Experimental outline. C6/36 mosquito cells were infected with
LACV and maintained for several passages to establish persistent
infection (first infection). The persistently infected cells were then
superinfected with GFP-expressing reporter viruses (second infection).
The reporter viruses were generated by incorporating GFP-RNPs (re¬
constituted by transfecting BSR-T7/5 cells with expression constructs
for N, L, and a GFP minireplicon) into LACV particles as a fourth
segment. Both first and second infections involved either wl viruses or
delNSs mutants. (B) Results. C6/36 mosquito cells persistently infected
with either rLACV or rLACVdelNSs or left uninfected (mock) were
superinfected with GFP reporter viruses. At 24 h postinfection, cells
were fixed and stained with antibodies against GFP and LACV N
protein.
(PDR) is most likely based on RNAi (4, 21, 44), since expres¬
sion of the LACV S sequences by recombinant Sindbis virus is
sufficient to protect insect cells from infection with LACV (41).
Given that LACV provokes an RNAi response in mosquito
cells and that transfection of LACV NSs blocks RNAi in mam¬
malian cells, we wondered about the influence of NSs on the
PDR phenomenon in insect cells. To investigate this, we su¬





SFV-Luc SFV-Luc SFVJ-uc SFV-Luc
• SFVNS1 ♦SFV-TSWV •SFV-LACV
NSs NSs
FIG. 4. Effect of LACV NSs on RNAi in insect cells. U4.4 cells
were transfected with SFV-Luc SFV-NS1, SFV-TSWV NSs„ or SFV-
LACV NSs as indicated. At 3 days posttransfection, cells were lysed,
and luciferase activities were determined. Mean values and standard
deviations from three independent experiments are shown.
viruses expressing a reporter gene. The role of NSs was ad¬
dressed by using viruses expressing or lacking NSs in the first,
persistent infection, as well as in the second, the superinfec¬
tion. The outline of the experiment is depicted in Fig. 3A.
Insect cells infected with recombinant viruses and passaged to
establish persistency were .superinfected with GFP-expressing
reporter viruses. For the generation of the reporter viruses, we
took advantage of an improved version of our LACV RNP
reconstitution system which allows efficient incorporation of
GFP-expressing reporter gene segments into LACV particles
(5). Detection of GFP in superinfected insect cells indicates
that the second virus infection was successful, whereas absence
of GFP indicates that PDR took place. As expected, mock-
infected insect cells were readily infected with GFP-expressing
rLACV or rLACVdelNSs (Fig. 3B). However, in persistently
infected cells, no GFP expression was observed, indicating
establishment of PDR. Importantly, all combinations of
rLACV and rLACVdelNSs used for the first infection and/or
the superinfection led to the same resistance to superinfection,
strongly suggesting that neither the ability of the first viruses to
establish PDR nor the inability of the second viruses to over¬
come it was dependent on NSs.
NSs does not inhibit RNAi in insect cells. We employed an
SFV-based reporter assay (22) to test whether NSs would be
capable of suppressing RNAi in insect cells. A. albopictus U4.4
cells were chosen because C6/36 cells show cytopathic effects
after infection with SFV (15). Garcia et al. have demonstrated
that FF-Luc expression by an SFV replicon (SFV-Luc) in in¬
sect cells is reduced due to RNAi over time but that expression
can be rescued by coexpressed RNAi inhibitors (22). U4.4 cells
were transfected with SFV-Luc and cultivated for 3 days to
establish an RNAi response. Figure 4 shows that cotransfec-
tion with SFV-NS1 enhanced luciferase expression by SFV-
Luc, as expected (22), since the double-stranded RNA (dsRNA)-
binding NS1 can neutralize interference by small RNAs (34).
Similarly, the NSs protein of TSWV, a known RNAi inhibitor
(9), rescued SFV expression to some extent. By contrast, SFV-
LACV NSs had no such enhancing effect, indicating the ab¬
sence of anti-RNAi activity. Identical results were obtained
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mock rLACV delNSs mock rLACV delNSs
P-actin
B l IFN-beta promoter □ SV40 promoter
empty vector LACV NSs
FIG. 5. Effect of LACV NSs on IFN induction. (A) Detection of
IFN-p mRNA in infected mammalian cells. MEFs isolated from wt or
IFNAR""1 mice were either mock infected or infected with rLACV or
rLACVdelNSs. At 18 h postinfection, RNA was extracted and inves¬
tigated by RT-PCR for the presence of mRNAs for IFN-fi. LACV N
protein, or p-actin. (B) Suppression of the IFN-p promoter by NSs.
Human 293 cells were transfected with luciferase-expressing plasmids
under control of either the IFN-p promoter (FF-Luc) or the constitu-
tively active SV40 promoter (REN-Luc), along with the NSs expres¬
sion plasmid pI.18-HA-LACV-NSs or the empty vector. At 8 h post-
transfection, cells were either mock treated or transfected with dsRNA
and lysed 18 h later to measure luciferase activity. Mean values and
standard deviations from four independent experiments are shown.
with recombinant SFV suicide particles infecting Aedes pseiido-
scutillaris Ap61 cells (data not shown).
Together, our results shown so far imply that the LACV-
specific RNAi response mounted in insect cells (Fig. 1) is not
countered by NSs, since NSs neither confers a growth advan¬
tage (Fig. 2) nor influences PDR (Fig. 3) nor inhibits RNAi
against a heterologous virus (Fig. 4). It therefore appears that
the anti-RNAi activity of NSs observed in mammalian cells
plays no decisive role for LACV in the mosquito vector.
Inhibition of IFN induction in fibroblasts. Previous work
demonstrated that NSs proteins of BUNV as well as RVFV
efficiently block the antiviral type I IFN response of mamma¬
lian hosts (3, 8, 55). To measure this activity for LACV, we
infected IFN-competent wt MEFs with recombinant viruses
and measured IFN induction by RT-PCR. Figure 5A shows
that rLACVdelNSs strongly activated transcription of the
I FN-(3 gene. NSs-expressing rLACV, by contrast, did not in¬
duce significant amounts of IFN. Similarly, MEFs derived from
mice lacking the type 1 IFN receptor (IFNARn/0 MEFs) pro¬










































FIG. 6. Growth of viruses in IFN-competent and IFN-deficient
cells. Primary MEFs derived from wt mice (A), IFNAR0'0 mice (B), or
IFN-p'"0 mice (C) were infected with rLACV or rLACVdelNSs at
0.0001 PFU per cell, and virus titers in the supernatants were deter¬
mined at 24, 48, and 72 h postinfection. Mean values and standard
deviations from three independent experiments are shown.
that IFN induction occurred in a direct manner and was inde¬
pendent of secreted IFN. Control RT-PCRs for the LACV N
gene showed that viruses replicated to comparable levels, and
RT-PCRs for the cellular p-actin mRNA demonstrated that all
preparations contained similar amounts of RNA, Of note, RT-
PCR analysis for some RNA polymerase II-dependent, consti-
tutively expressed cellular genes shows a strong reduction in
wt-infected cells (6), supporting the view that LACV NSs may
influence cellular transcription in a manner similar to BUNV
NSs and RVFV (32, 33, 51).
To confirm that the block in IFN induction is solely medi¬
ated by NSs, we measured its effect on IFN-p promoter activity
independent of the viral context. Human 293 cells were trans¬
fected with an NSs-expressing plasmid and an IFN-p promoter
reporter plasmid, and promoter activity was measured after
stimulation of cells with synthetic dsRNA. As shown in Fig. 5B,
expression of LACV NSs efficiently inhibits induction of the
IFN-p promoter by dsRNA, confirming that NSs is sufficient to
suppress IFN production.
Effect of NSs on viral growth in IFN-competent and -defi¬
cient systems. Given the strong effects of LACV NSs in mam¬
malian cells on apoptosis (6, 14), RNAi (49), and IFN induc¬
tion (Fig. 5), it was of interest for us to clarify which one of
these activities is relevant to the virus multiplication in the
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7. IFN-dependent virulence of viruses in vivo. Survival of wt
(A), IFNAR0'0 (B), or IFN-00'0 mice (C) infected with 10,000 PFU of
rLACV or rLACVdelNSs was monitored. Mice that were moribund or
severely paralyzed were killed and scored dead on that day.
mammalian host. Cells lacking an IFN system are still able to
undergo apoptosis induced by NSs (6), and in mammalian cells
the antiviral IFN system dominates the RNAi system (18, 47).
We therefore expected that an IFN-independent influence of
NSs on virus replication would show up in IFN-deficient cells
or animals. First, we compared the multistep growth of rLACV
and rLACVdelNSs in primary MEFs derived from wt and
IFNAR1"" mice. Since the delNSs mutant strongly activates
IFN-p transcription (Fig. 5A), we also investigated the role
of IFN-p by using cells from mice with a deleted IFN-p gene
(IFN-p""' MEFs). Figure 6A shows that in IFN-competent wt
MEFs, the NSs-expressing rLACV had a clear growth advan¬
tage over the delNSs mutant. A difference of 4 log steps was
observed at 24 h postinfection. Although this gap was reduced
to a difference of about 1 log step at 72 h postinfection, rLACV
was always superior to rLACVdelNSs. By contrast, in IFNAR0'"
MEFs which are unable to respond to IFN, no apparent dif¬
ference was observed at 24 h postinfection, and at 72 h postin¬
fection the titers of rLACVdelNSs were even higher than those
of rLACV (Fig. 6B). In IFN-p'"" MEFs, the delNSs mutant
multiplied at a slightly lower rate than rLACV, but the differ¬
ence between the two viruses was much less pronounced than
in wt MEFs. This indicates that IFN-P contributes to the
growth restriction of rLACVdelNSs in cell culture.
We also investigated the interaction of LACV NSs and the
IFN system in vivo, wt and mutant mice were inoculated with
" Brain weight was 0.4 g on average.
the recombinant viruses by the intraperitoneal route to mimic
natural infection by mosquitoes (48). The NSs-expressing
rLACV killed IFN-competent wt mice more rapidly and more
efficiently than the delNSs mutant (Fig. 7A). IFNAR"'" mice,
by contrast, were killed by both viruses with the same efficiency
(Fig. 7B), and both viruses reached comparable titers in the
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FIG. 8. Infection of neurons in vivo. (A) Brain sections of wt mice
infected with rLACV (frame 1) or rLACVdelNSs (frames 2 to 4) were
stained for viral antigen (green) and the neuron marker NeuN (red).
Frames 1 to 3 show sections of the cortex, and frame 3 is a magnifi¬
cation of the section shown in frame 2. Frame 4 shows a section of the
thalamus. (B) Brain sections from mice infected with rLACVdelNSs
were double stained for viral antigen and markers for astrocytes
(GFAP) or macrophages (CDllb).
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FIG. 9. Induction of IFN in the mouse brain. ISH with IFN-J3 or IFN-a probes (see Materials and Methods) was performed on brain sections
of mice infected with rLACV or rLACVdelNSs. Macroscopic analysis (A) and microscopic analysis (B) using a combination of ISH to detect IFN-p
or IFN-a mRNA (black silver grains) and immunohistochemical analysis for LACV N (brown stain).
an intermediate type of survival kinetics (Fig. 7C), as these
animals succumbed more rapidly to infection than their wt
counterparts but more slowly than the IFNAR"/0 mice. This
suggests that IFN-@ plays a minor, but not a decisive, role in
the protection from LACV infection in vivo.
Infection of neuronal cells. In the mammalian host, in¬
cluding humans, LACV is known to disseminate into the
central nervous system and infect neuronal cells (28), caus¬
ing severe aseptic encephalitis (23). To investigate whether
rLACVdelNSs preferentially infects neuronal cells in a manner
similar to rLACV, we analyzed the brains of wt mice with
severe disease. In situ double immunolluorescence was per¬
formed using a rabbit polyclonal antibody directed against the
LACV N protein together with various mouse monoclonal
antibodies for markers of major "brain cell types. NeuN-positive
cells were heavily infected by both rLACV and rLACVdelNSs
(Fig. 8A, frames 1 to 3), indicating that both viruses preferen¬
tially infected neurons. In some areas of the thalamus, almost
100% of the neurons were infected (Fig. 8A, frame 4). By
contrast, in cells positive for the astrocyte marker GFAP, the
oligodendrocyte marker myelin basic protein, or the macro¬
phage markers CD lib and F4/80, no viral antigen was clearly
detected (Fig. 8B and data not shown). Thus, rLACVdelNSs
has the ability to disseminate in the brain and to preferentially
infect neurons.
Induction of IFN by neurons. Given the similar ability of
LACV possessing or lacking NSs to infect neurons, we won¬
dered whether LACV would also block IFN induction in the
central nervous system. To address this question, we compared
IFN synthesis in brains from mice infected with either rLACV
or rLACVdelNSs. ISH analysis of whole-brain slices demon¬
strated that rLACVdelNSs induced significantly higher IFN-p
and IFN-a transcript levels than rLACV (Fig. 9A). To corre¬
late in vivo IFN mRNA synthesis with virus infection, we com¬
bined the analysis of IFN mRNA with immunostaining against
the LACV N protein. Examination of highly infected brain
areas showed that brain cells infected with the delNSs mutant
were more frequently positive for IFN mRNAs than those
infected with rLACV (Fig. 9B). We therefore concluded that
the IFN antagonist NSs of LACV is also functional in neurons.
DISCUSSION
In this study, we provided in vivo evidence that the IFN
antagonism of LACV NSs constitutes its major biological func¬
tion. In cells as well as in animals infected with wt rLACV,
synthesis of antiviral type I IFN mRNAs was strongly impaired,
demonstrating that LACV NSs abrogates IFN induction. Con¬
sequently, wt rLACV had a growth advantage over the delNSs
mutant in IFN-competent cells and mice. By contrast, in all
IFN-deficient systems including insect cells, no apparent dif¬
ference was observed between the two viruses. Thus, NSs is
only important in IFN-competent mammalian hosts and the
deletion of the viral NSs gene can be fully complemented by
inactivation of the host's IFN system. This strongly implies that
bunyaviruses, which as arboviruses need to rapidly establish
viremia in order to be transferred to new insect vectors,
evolved the accessory NSs gene to overcome the fast-respond¬
ing innate immune defense of the mammalian host.
Despite the strong effects of NSs on apoptosis (6, 14), no
detectable differences in growth and virulence of our virus pair
exist in IFN-deficient mammalian host systems (Fig. 6 and 7).
This suggests that the proapoptotic function of LACV NSs has
no apparent consequences for virus growth or virulence in vivo.
The ability to promote (as well as to prevent) apoptosis was
demonstrated for many different viruses (2), and it is thought
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that the correct timing of cell death is important to optimize
virus yields. However, reports have been contradictory with
respect to the biological significance of virus-induced apopto-
sis. For influenza A virus, which strongly promotes apoptosis
(27), reverse genetics experiments revealed no correlation be¬
tween the levels of apoptosis in infected cells and the extent of
virus replication (39). In line with this notion, it was found that
BUNV NSs has the opposite activity of LACV NSs. It inhibits
rather than promotes apoptosis (29), which raises a question
about the role of programmed cell death in the bunyavirus
infection cycle. The proapoptotic function of LACV NSs was
shown in mammalian cells, and its importance for virus repli¬
cation was inferred from its similarity with a C-terminal part of
the proapoptotic Drosophila protein reaper (14). However,
given the fact that reaper is an insect protein, it is curious that
NSs-expressing LACV as well as other bunyaviruses do not
induce cell death in insect cells (7). Thus, despite the sequence
similarity to the proapoptotic Drosophila reaper, NSs has no
apparent proapoptotic activity in insects, suggesting that NSs is
not simply a reaper protein that was snatched by the bunyavi¬
ruses to promote cell death of infected cells. Rather, we favor
the assumption that the proapoptotic function of LACV NSs is
a side effect of its molecular mechanism to block IFN induc¬
tion.
Expression of NSs from a cDNA construct was shown to
counteract the RNAi effect of transfected RNA oligonucleo¬
tides (49). RNAi is regarded as an antiviral mechanism of
insects (44), and we show that LACV infection provokes a
strong RNAi response in insect cells (Fig. 1). In mammalian
cells RNAi effects can be observed if the IFN system is deleted
(47) or circumvented by using short dsRNAs to induce RNAi
(18). Using recombinant viruses, we addressed the supposed
role of NSs in RNAi inhibition both in the mosquito system
and the mammalian host. Surprisingly, we could not detect any
advantage conferred by NSs expression in insect cells (Fig. 2)
or in IFN-deficient mammalian cells and animals (Fig. 6 and
7). Also, in insect cells the NSs-expressing rLACV virus estab¬
lished PDR to the same extent as the NSs-deleted mutant did,
and both viruses were equally subject to PDR (Fig. 3). Fur¬
thermore, LACV NSs was unable to counteract RNAi in insect
cells (Fig. 4), just as was shown for RVFV NSs (22). Similarly,
the NSs of BUNV has no effect on viral transcription in insect
cells (A., Kohl and R. M. Elliott, presented at the 12th Inter¬
national Conference on Negative-Strand Viruses, Pisa, Italy,
14 to 19 June 2003). These data do not support the view that
bunyavirus NSs plays a role as an anti-RNAi factor in the
context of infection. A similar negative conclusion was recently
drawn for other viral proteins with a proposed anti-RNAi
function (16, 30).
Our in vivo analyses not only established NSs as the IFN
antagonist of LACV but also demonstrated that both IFN-p
and IFN-a contribute to protection from LACV infection (Fig.
6 to 9). Nevertheless, a high percentage of wt mice eventually
succumbed to infection with LACV, even when the strong
IFN-inducer rLACVdelNSs was used (Fig. 7). It should be
noted that the most effective IFN-induced protein with antivi¬
ral activity against LACV is the human MxA protein (24) and
that the gene for the murine homologue Mx2 is defective in
most inbred mouse strains including the C57BL/6 mice used in
our experiments (50). We therefore assumed that our mice
could not launch a pronounced antiviral response against
rLACVdelNSs because they lack an Mx protein with anti-
bunyaviral activity. To follow this up, we compared the antivi¬
ral effect of type I IFN against wt and delNSs virus in the
MxA-expressing human Huh7 cells and the Mx-negative mouse
3T3 cells. IFN inhibited both viruses much more strongly (2 log
steps) in the human cell line than in the mouse cell line (data not
shown). Thus, the weak attenuation of the delNSs virus in wt mice
is, indeed, most probably due to the lack of the suitable IFN
effector protein.
In summary, we present evidence that the major biological
function of LACV NSs is to inhibit the antiviral type I IFN
system in the mammalian host. Further investigations of the
molecular mechanism of NSs action might reveal an interesting
link between apoptosis induction, the RNAi system, and the
IFN system.
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INTRODUCTION
The type I interferon system protects mice from
Semliki Forest virus by preventing widespread virus
dissemination in extraneural tissues, but does not
mediate the restricted replication of avirulent virus
in central nervous system neurons
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Amanda Boyd,1 Gerald Barry,1 Alain Kohl,1 Andres Merits2
and John K. Fazakerley1
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Semliki Forest virus (SFV) infection of the mouse provides a powerful model to study the
pathogenesis of virus encephalitis. SFV and other alphavirus-based vector systems are
increasingly used in biotechnology and medicine. This study analysed the strong susceptibility of
this virus to type I interferon (IFN) responses. Following intraperitoneal infection of adult mice, SFV
strain A7(74) was efficiently (100%) neuroinvasive. In contrast, SFV4 was poorly (21 %)
neuroinvasive. Upon entry into the brain, both viruses activated type I IFN responses. As
determined by quantitative RT-PCR, activation of the IFN-a gene was proportional to virus RNA
load. An intact type I IFN system was required for protection against both strains of SFV. IFN
strongly curtailed virus spread in many cell types and in many tissues. In mice with an intact type I
IFN system, infected cells were rarely observed and tissue tropism was difficult to determine. In
the absence of a functional type I IFN system, the tropism and the potential for rapid and
widespread infection of this virus was revealed. Virus infection was readily observed in the
myocardium, endocardium, exocrine pancreas, adipose tissue, smooth muscle cells and in the
brain in meningeal cells, ependymal cells and oligodendrocytes. In the brains of mice with and
without type I IFN responses, virus infection of neurons remained rare and focal, indicating that the
previously described restricted replication of SFV A7(74) in neurons is not mediated by type I IFN
responses.
Semliki Forest virus (SFV) is a mosquito-borne virus that
naturally circulates in sub-Saharan Africa. The virus is an
alphavirus of the family Togaviridae. Natural human and
equine infections have been described (Mathiot et al,
1990). The virus is closely related to Chikungunya virus,
responsible recently for an outbreak of severe arthralgia in
the islands of the Indian Ocean (Schuffenecker et al., 2006).
Other alphaviruses include Sindbis virus in North Africa
and Europe; Eastern, Western and Venezuelan equine
encephalitis viruses in the Americas and Ross River virus in
Australia. SFV infection of laboratory mice provides a
tractable model system for the study of virus pathogenesis
and in particular virus encephalitis (Fazakerley, 2004).
Virulence in mice has been characterized for several natural
isolates and their laboratory-passaged strains (Bradish et al.,
1971). The most commonly studied strains include A7 and
A7(74), which are avirulent in adult mice, and L10 and the
prototype, which are virulent in adult mice. All strains of
SFV are virulent in neonatal or young suckling mice
(Bradish et al., 1971; Pusztai et al., 1971; Seamer et al.,
1967).
tThese authors contributed equally to this work.
The most characterized avirulent strain of SFV, A7(74), is
virulent in mice infected at the age of 11 days or less, but is
avirulent in older mice; virus dissemination in the central
nervous system (CNS) is increasingly restricted with age
(Oliver et al., 1997). In 4-5-week-old mice, intraperitoneal
inoculation of SFV A7(74) results in a high-titre plasma
viraemia from which virus is seeded into perivascular foci
in the brain and spinal cord; there is little spread of virus
from cell to cell, foci do not enlarge with time and the
infection is restricted in mature neurons (Fazakerley et al.,
0008-3191 © 2007 SGM Printed in Great Britain 1
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1993). SFV A7(74) remains avirulent following direct
intracerebral inoculation, but inoculation by this route
results in a widespread infection of oligodendrocytes in the
major white matter tracts (Fazakerley et al., 2006). The
underlying events resulting in restriction of this strain of
the virus in mature neurons remain undetermined.
Intraperitoneal infection with the virulent L10 strain also
results in a high-titre plasma viraentia, but in this case
neuronal infection is not restricted and perivascular foci of
CNS infection rapidly enlarge to give rise to a fatal
panencephalitis (Fazakerley et al., 1993).
The prototype (SFV4) and A7(74) strains are available as
molecular cDNA clones (Liljestrdm & Garoff, 1991; Vaha-
Koskela et al., 2003). Infectious RNA can be derived by
in vitro transcription and infectious virus by electropora-
tion of this RNA into eukaryotic cells. In mice, SFV4 virus
is virulent by intranasal or intracerebral inoculation
(Fazakerley et al., 2002; Glasgow et al., 1991). There are
numerous genetic changes between the cDNA clones of
SFV4 and SFV A7(74), but changes in non-structural
protein 3 and the 5'-untranslated sequences appear to be
the most important in determining the ability of the virus
to replicate in the adult mouse brain (Tuittila et al., 2000).
Molecular engineering of the SFV cDNA has led to the
generation of a series of replicon vectors that are
increasingly used for protein expression, transient gene
transfer and increasingly importantly vaccination (Karlsson
& Liljestrom, 2004). The vector replicon can be packaged
into virus-like particles (VLPs), which have the ability to
infect cells in the same way as virus (Smerdou & Liljestrom,
1999). Following infection with virus or VLPs, or following
transfection of replicon RNA, cells in continuous culture
rapidly undergo apoptosis (Allsopp & Fazakerley, 2000;
Glasgow et al., 1997; Scallan et al., 1997).
Not long after the discovery of the interferon (IFN) system,
it was shown that a crude preparation of IFN derived from
West Nile virus-infected mice could protect mice against
the virulent MB strain of SFV (Finter, 1966). In this and
subsequent studies, the extent of protection was clearly
dependent on virus strain, dose and time of administration
(Bradish & Titmuss, 1981; Smillie et al., 1973). Conversely,
administration of anti-IFN antibodies exacerbated SFV
infection (Fauconnier, 1971). The kinetics of the type I IFN
response in SFV A7(74)-infected mice parallels the plasma
viraemia (Bradish et al., 1975). In the original studies on
mice with disruption of the type I IFN receptor a-chain
(IFNAR-l^/_), it was demonstrated that both adult and
neonatal mice without a functional type I IFN system
succumbed to infection with SFV much more rapidly than
did wild-type (wt) mice (Hwang et al., 1995; Muller et al.,
1994). The type I IFN system has also been demonstrated
to be crucial for the protection of mice from nominally
avirulent strains of the related alphaviruses Venezuelan
equine encephalitis virus and Sindbis virus (Grieder &
Vogel, 1999; Ryman et al., 2000). Strains of SFV and
eastern equine encephalitis virus vary in their sensitivity to
IFN (Aguilar et al., 2005; Deuber & Pavlovic, 2007). What
remains to be determined for SFV is the role of the type I
IFN system following infection with the most commonly
used A7(74) and SFV4 strains. Furthermore, not only for
alphaviruses but for many neurotropic viruses, the course
and role of IFN responses in the brain during virus
encephalitis remain to be fully characterized. In the case of
SFV encephalitis, it remains to be determined whether the
type I IFN system is involved in the restricted replication of
A7(74) in neurons and in the age-related virulence
(Fazakerley et al., 1993). Here, we have shown that: (i)
both A7(74) and SFV4 activate CNS type I IFN gene
expression in the mature mouse brain; (ii) IFN gene
expression is proportional to virus load; (iii) the type I IFN
response is crucial for protection against SFV A7(74); and
(iv) this protection works by strongly curtailing virus
spread in many cell types in many tissues including some
CNS cell types but is not responsible for the restricted
dissemination of SFV A7(74) in mature CNS neurones.
METHODS
Viruses. The A7(74) strain of SFV was derived from the AR2066
strain by seven passages through neonatal mouse brain and colony
selection on chick embryo fibroblasts; AR2066 was isolated from
Aedes argenteopunctatus mosquitoes in Namancurra, Mozambique
(Mcintosh et al., 1961). The 1.10 strain was derived from the original
isolate of SFV (Smithburn & Haddow, 1944) by eight intracerebral
passages through adult and two through baby mouse brains (Bradish
et al., 1971). Infectious SFV4 virus was generated from a cDNA
plasmid derived from the prototype strain of SFV (Liljestrom &
Garoff, 1991). The full-length pSP6-SFV4 cDNA was a kind gift from
Professor Peter Liljestrom, (Karolinska Institute, Stockholm,
Sweden).
SFV4 marker virus containing the gene for enhanced green
fluorescent protein (eGFP) was constructed by inserting the coding
sequence for eGFP followed by the foot-and-mouth disease virus 2A
cleavage sequence between that for the capsid protein and p62 in the
virus structural protein open reading frame. This strategy has been
used previously to construct an eGFP-labelled Sindbis virus (Thomas
et al., 2003). The resulting SFV4 marker virus, designated SFV4-
steGFP, replicated well in vitro and in vivo and infected cells showed
strong green fluorescence (R. Fragkoudis and others, unpublished).
SFV4 and SFV4-steGFP were generated from infectious cDNAs as
described previously (Liljestrom & Garoff, 1991). Briefly, the plasmid
was linearized with SpeI and capped transcripts were produced by
in vitro transcription with SP6 polymerase in the presence of
m7GpppG cap analogue (Amersham). RNA was electroporated into
BHK-21 cells using two consecutive 140 V square-wave pulses with a
pulse length of 25 ms on a Bio-Rad Gene Pulser X cell electroporator.
Virus stocks were collected after 24 h at 37 °C, titrated on monolayers
of BHK-21 cells and used to infect mice.
Virus infectivity assay. Virus titres were determined by plaque assay
on BHK-21 cells as described previously (Fazakerley et al., 1993).
Briefly, BHK cells (4 x 10s) were seeded into six-well plates in 2 ml
Glasgow minimum essential medium with 10% fetal calf serum and
incubated at 5% CO, and 37 °C until 80% confluent. The growth
medium was then removed, cells washed with PBS and 10-fold
dilutions of test samples were titrated in duplicate. Infected cells were
incubated for 1 h at room temperature in a humid atmosphere. After
the addition of agar, the plates were incubated for a further 48 h and
fixed with 10% neutral buffered formaldehyde for 3 h before staining
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with 0.1 % toluidine blue for at least 1 h. Plaques were counted after
washing.
Mouse strains. Strain 129/Sv(ev) and 129/Sv(ev) mice with a
disruption of the a-chain of the IFN-a//i receptor (IFNAR-l_/_)
(Muller et al., 1994) were purchased from B&K Universal Ltd. BAI.B/c
and CB17 nu/nu mice were purchased from Flarlan Olac. Mice were
bred and maintained in the Centre for Infectious Diseases Animal
Unit, College of Medicine & Veterinary Medicine, University of
Edinburgh, UK, in specific-pathogen-free and environmentally
enriched conditions with food and water supplied ad libitum. All
breeding and experimental studies were agreed by the University of
Edinburgh Ethical Review Committee and were carried out under the
authority of a UK Home Office licence.
Infection of mice. Experimental infection of mice was carried out at
4-6 weeks of age. Mice were inoculated intraperitoneally with 0.1 ml
PBS with 0.75% BSA (PBSA) containing 5 x 103 p.f.u. SFV or
intracranially with 20 pi PBSA containing 103 p.f.u. virus or with
PBSA alone. Mice were checked twice daily and euthanized on
reaching previously defined clinical end points considered to be
indicative of fatal disease; these included: paralysis in two or more
limbs; inability to move, feed or drink; incontinence; breathing
difficulties; and seizures. Mice to be sampled were deeply anaes¬
thetised with halothane and perfused with PBS through the left
cardiac ventricle; brains were removed, divided bilaterally down the
midline and either placed in RNA/nrer for RNA analysis, snap frozen
on dry ice for virus titration or immersion fixed in 10% phosphate-
buffered formal saline for histopathological study.
RNA extraction and quantitative PCR. RNA was extracted from
frozen cell-culture pellets or tissue samples stored in RNA/nfer using
Qiagen kits according to the manufacturer's instructions; the RNeasy
Lipid kit was used for brain samples. Extracted RNA was stored at
— 80 °C. The quality of the extracted RNA was determined using an
Agilent 2100 Bioanalyser and the RNA 6000 Nano assay. High-quality
RNA samples were reverse transcribed using Superscript II RNase H
reverse transcriptase. Samples to be directly compared were reverse
transcribed at the same time using the same master mix (all reagents
were from Invitrogen). The reaction mixture had a final volume of
20 pi and contained 1 pi oligo(dT)l2_i8 primer, 5 pg RNA template,
1 pi 10 mM dNTPs and DNase/RNase-free water to a volume of
12 pi. The mixture was heated for 5 min at 65 'C. Next, 4 pi 5 x
First-strand buffer, 2 pi 0.1 M DTT and 1 pi RNasin recombinant
RNase inhibitor were added. Reactions were incubated at 42 C for
2 min and 1 pi reverse transcriptase was added. The reactions were
incubated at 42 C for 1 h. The enzyme was inactivated by incubation
for 15 min at 70 °C. The cDNA was stored at —20 aC.
Levels of viral RNA and IFN transcripts were determined by real-time
quantitative (Q)PCR. Test samples and standards were assayed in
triplicate. QPCR was performed using a FastStart DNA Master SYBR
Green I kit (Roche). Briefly, in a total volume of 20 pi (made up in
RNase-free water), reaction mixes contained: 50 pM primers, 40 mM
dNTPs, 10 x buffer plus 2 mM MgCl2, SYBR Green (diluted
1:20 000; Biogene), 5 U FastStart Taq (Roche Applied Science) and
2 pi cDNA. Tubes were heated to 94 JC for 5 min and 40 cycles of
94 °C for 20 s, 62 °C for 20 s and 72 DC for 20 s were carried out on a
RotorGene 3000 (Corbett Research). As a positive control for SFV, an
in vitro transcript from the pGEMl-SFV cDNA plasmid containing
the structural genes of SFV was transcribed using a Promega RiboMax
kit. Serial dilutions of this plasmid were used to produce a standard
curve for quantification of the PCR amplicons and thus the virus
RNA. Brain samples were normalized to levels of /f-actin transcripts
(Brown et al., 2003). Sequences of the primers used in the assay were
as follows: IFN-a: 5'-AGGACAGGAAGGATTTTGGA-3' and 5'-
GCTGCTGATGGAGGTCATT-3' (degenerate primers based on
IFN-a4; McKimmie & Fazakerley, 2005); SFV El: 5'-CGCATCAC-
CttctttTGTG-3' and 5'-CCAGACCACCCGAGATTTT-3'; IFN-0:
5'-CACAGCCCTCTCCAT CAACT-3' and 5'-GCATCTTCTCCGTC-
ATCTCC-3'; /j-actin: 5'-CGTTGACATCCGTAAAGACC-3' and 5'-
CTGGAAGGTGGACAGTGAG-3'.
In situ hybridization. To observe virus distribution in the brain,
after immersion fixation in 10% phosphate-buffered formal saline,
half brains were embedded in paraffin and 5 pm sections cut onto
poly-L-lysine-coated (Sigma) or Biobond-coated (British BioCell
International) glass slides. Riboprobes were transcribed in vitro with
T7 polymerase (using a Riboprobe Gemini kit; Promega) from
HiucII-linearized pGEMl-SFV. As a control, some sections were
hybridized with a riboprobe to the PI region of the unrelated
Theiler's virus. Probes were hydrolysed in 0.04 M NaHC03 for
30 min at 60 C prior to use. In situ hybridization with 35S-labelled
riboprobes was carried out as described previously (Fazakerley et al.,
1993). Autoradiographic images of sections hybridized with 35S-
labelled riboprobes were produced by exposure of air-dried sections
to Hyperfilm /irnax (Amersham). Sections were subsequently dipped
in photographic emulsion (LM-1, diluted with 0.66 M ammonium
acetate; Amersham) and exposed, usually for 7 days, at 4 'C.
Histopathology. Immunostaining to detect SFV-infected cells in
paraffin-embedded tissues sections was performed as described
previously (Fazakerley et al., 2006). Tissues to be studied for the
distribution of eGFP-positive cells were fixed in 10% phosphate-
buffered formal saline overnight and examined on a Zeiss fluorescent
stereomicroscope with a GFP filter before cryopreserving by
sequential passage through 5, 10 and 25 % sucrose in PBS. After
freezing in OCT, 12—14 pm sections were cut onto poly-L-lysine-
coated glass slides using a cryomicrotome. Sections were stained with
propidium iodide to visualize cell nuclei or were lightly stained with
diaminobenzidine to allow visualization of the tissue structure (this
preserved the eGFP signal better than conventional stains such as
haematoxylin).
RESULTS
SFV A7(74) but not SFV4 is efficiently
neuroinvasive in adult mice, and brain infection
induces type I IFN gene expression
Following intraperitoneal inoculation, SFV A7(74) has
previously been demonstrated to be efficiently and
consistently neuroinvasive (Fazakerley et al., 1993; Pusztai
et al., 1971). SFV4 is neuroinvasive if given intranasally
(Glasgow et al., 1991). The neuroinvasive efficiency of
SFV4 following intraperitoneal infection has not been
studied in detail. To determine whether SFV4 is naturally
neuroinvasive following intraperitoneal inoculation and to
determine whether SFV neuroinvasion activates the type I
IFN system, 4—5-week-old BALB/c mice were inoculated
intraperitoneally with 5000 p.f.u. SFV A7(74) or SFV4. At
days 3 and 7 post-inoculation (p.i.), five mice from each
group were exsanguinated under terminal anaesthesia,
perfused through the left cardiac ventricle with PBS to
remove any remaining blood in the circulatory system, and
the brains removed and assayed for infectious virus and
IFN gene transcripts. Levels of infectious virus were assayed
by standard plaque assay. Levels of IFN transcripts were
assayed by QPCR. QPCR was used in preference to
http://vir.sgmjournals.org 3
« paper no. vir83191 charlesworth ref: vir83191»
R. Fragkoudis and others
assaying functional IFN as RNA levels are less likely to be
affected by levels of blood-derived material, particularly as
SFV A7(74) is known to disrupt the integrity of the blood-
brain barrier (Parsons & Webb, 1982).
At 3 and 7 days p.i., all (10/10) mice infected with SFV
A7(74) had infectious virus and IFN-a gene transcripts
detectable in the brain (Table 1), demonstrating that the
type I IFN system was activated in response to neuroinva-
sion by this strain of the virus. The levels of infectious virus
and the induced levels of IFN-a transcripts showed
considerable variation between individual mice. For the
virus titres, this was consistent with previous studies
(Fazakerley et al., 1993). Presumably, variation resulted
from temporal and spatial differences in virus neuroinva-
sion among individual mice. Interestingly, for individual
mice there was a very strong correlation (r=0.98) between
levels of virus RNA and levels of IFN transcripts (Fig. la);
the higher the brain virus titre, the higher the level of IFN
transcripts. Presumably, the greater the number of virus-
infected cells, the greater the number of cells producing
IFN.
In contrast to SFV A7(74) infection, intraperitoneal
infection with SFV4 resulted in only one of the five mice
at day 3 and none of the five mice at day 7 p.i. having
detectable infectious brain virus. Intraperitoneal infection
with SFV4 was repeated with nine mice per group with
similar results; only two had infectious virus in the brain at
day 3 and only one had infectious virus at day 7 p.i. In this
second experiment, the mean titre of the three virus-
positive brains was 2.3 logm p.f.u. g~'. It was concluded
that SFV4 is poorly neuroinvasive, with only 21 % of mice
(3/14) demonstrating neuroinvasion at day 3 p.i.
Direct intracerebral inoculation of SFV4 results in
widespread brain infection and activation of IFN
gene expression
Following intracerebral inoculation, SFV4 replicates effi¬
ciently in the CNS and produces a widespread infection
(Fazakerley et al., 2002). To determine whether this
infection activates IFN gene transcription, SFV4 was
Table 1. Levels of infectious virus and IFN-x transcripts in the brains of BALB/c and BALB/c nu/nu mice at 3, 7 and 140 days p.i.
following intraperitoneal inoculation with 5000 p.f.u. SFV A7(74)
Results are the mean values from at least four individual mouse brains. Virus titres were determined by standard plaque assay on BHK-21 cells and
are given as logm p.f.u. (g brain)-1. IFN-a gene transcripts were measured by QPCR and are given as the mean fold increase (MFI) relative to
uninfected brain tissue (which was given a value of 1 and was effectively zero, the limit of detection of the assay).
Days p.i. BALB/c mice CB-17 nu/nu mice
No. of mice Brain virus logio Brain IFN No. of mice positive Brain virus log10 Brain IFN
positive for virus p.f.u. g-1 transcripts MFI (sem) for virus p.f.u. g"' transcripts MFI (sem)
3 5/5 2.8 7 (6.5) 5/5 3.1 12 (4)
7 5/5 3.9 19 (6) 5/5 4.6 255 (140)
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Fig. 1. Correlation between the levels of SFV RNA and IFN-a
transcripts in adult (4-5-week-old BALB/c) mouse brains, (a)
Intraperitoneal inoculation with SFV A7(74), sampled at 3 and
7 days p.i. ^= 0.98. (b) Intracerebral inoculation with SFV4,
sampled between 12 and 40 h p.i. r2=0.64. Points indicate the
levels of transcripts determined by QPCR in individual mice; all
values are normalized to those of /f-actin and are given as copy
number per 10 copies of [S-actin.
inoculated intracerebrally into six 4-5-week-old BALB/c
mice. Two mice were each sampled at 12, 24 and 40 h p.i.
Infectious brain virus titres were detectable in all mice at all
time points. IFN-a gene transcripts were detectable in three
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out of six mice, with a mean titre of 102'9 copies per 1CP
copies of /J-actin (Fig. lb). SFV4 thus had no deficit in its
ability to replicate in the brain and this replication
activated IFN-a gene expression.
IFN gene transcription in the brain continues
during persistent infection
In mice with severe combined immunodeficiency (SCID)
or athymic nn/nu mice, SFV A7(74) establishes a persistent
infection of the brain; athymic nu/nu mice survive this
infection longer than SCID mice (Amor & Webb, 1986;
Fazakerley & Webb, 1987). To determine whether the brain
IFN response remained activated during persistent infec¬
tion, CB17 nu/nu mice were inoculated intraperitoneal^
with 5000 p.f.u. SFV A7(74), exsanguinated, perfused and
the brains assayed at 3, 7 and 140 days p.i. Infectious virus
and IFN transcripts were detectable in all mice at all three
time points (Table 1).
Type I IFN is required for protection against SFV
A7(74)
To determine whether the type I IFN system is required to
protect adult mice against intraperitoneal infection with
SFV, groups of ten 129/Sv(ev) mice lacking the x-chain of
the IFN-x//i receptor (IFNAR-1 ~/_) (Muller et al, 1994)
and IFN-competent 129/Sv(ev) mice were inoculated
intraperitoneally with 5000 p.f.u. SFV A7(74) or SFV4
and monitored for clinical disease. All 129/Sv(ev) mice
inoculated with SFV4 or A7(74) survived without clinical
signs for the 10 days studied. SFV4 virus is transcribed
from a molecular clone derived from the SFV prototype
virus, a virus closely related to SFV L10. Both prototype
and L10 are virulent, even at low doses, in adult mice
(Bradish et al., 1971). It was surprising, therefore, that
inoculation of 5000 p.f.u. SFV4 intraperitoneally was
avirulent in 129/Sv(ev) mice. For comparison, a group of
ten 129/Sv(ev) mice were inoculated intraperitoneally with
5000 p.f.u. SFV L10 virus. These mice aii died or reached
clinically defined terminal end points on day 3. It was
concluded that, relative to virulent L10 virus, SFV4 has an
attenuated phenotype when given intraperitoneally. In
contrast to the survival of 129/Sv(ev) mice, all IFNAR-1 _/~
mice inoculated with SFV A7(74) or SFV4 died or reached
clinically defined terminal end points within 3 days. The
fact that SFV4 and SFV A7(74) are rapidly virulent in
IFNAR-1 ~/_ mice but not in IFN-competent mice
demonstrated that type I IFN strongly and successfully
suppresses these strains of this virus.
Type I IFN in the brain controls viral infection of
meningeal and ependymal cells but is not
responsible for the restricted infection of neurons
Given that SFV A7(74) is efficiently neuroinvasive and
neurotropic and that infection with this strain of virus is
restricted in mature neurons of the adult mouse brain
SFV and type I IFN
(Fazakerley et al., 1993) and that brain infection is
associated with an IFN response (Fig. la), it was postulated
that mortality in the IFNAR-1mice was due to
widespread encephalitis. To determine the role of the type
I IFN response during brain infection, IFNAR-1and
129/Sv(ev) mice were inoculated intraperitoneally with
5000 p.f.u. SFV A7(74) and the distribution of virus-
infected cells in the brain was visualized by in situ
hybridization at 16 and 40 h p.i. (Fig. 2). The IFNAR-1-'-
mice had moderate or substantial clinical signs, but no or
only small foci of virus-infected cells in the brains (Fig.
2). This low level of infection was inconsistent with the
clinical signs, indicating that the mice were unlikely to
succumb to this infection due to events in the brain. To
observe the tropism and spread of A7(74) virus in the
brain and to determine whether the type I IFN response
was required for the restriction of SFV A7(74) replication
in neurons, mice were inoculated directly intracerebrally.
In both 129/Sv(ev) and IFNAR-1 _/~ mice, virus-positive
cells were observed predominantly in the major white
matter tracts such as the corpus callosum and the internal
capsule (Fig. 2); this confirmed the distribution observed
previously with direct intracerebral inoculation of A7(74)
virus in wt mice (Fazakerley et al., 2006). In the IFNAR-
1 but not the 129/Sv(ev) mice, many virus-positive
cells were observed in the meninges and in ependymal
cells lining the ventricles, demonstrating that IFN
normally protects these cells (Fig. 3). However, the extent
of neuronal infection was no different between the two
mouse strains. In both mouse strains, infection of
neurons was confined to a few cells around the white
matter tracts or to small foci scattered around the brain.
In the IFNAR-l_/~ mice, infection did not spread from
the cells in the extensively infected white matter tracts,
meninges and ependyma to adjacent neuronal popula¬
tions (Figs 2 and 3). It was concluded that the restricted
replication of A7(74) virus in the neurons of the adult
mouse brain does not require an intact type I IFN system.
Absence of a type I IFN response demonstrates
the tissues and cell types permissive for SFV
infection
Given that mortality in the IFNAR-1 _/_ mice was not
related to widespread CNS infection, the course of
extraneural infection was determined. Groups of 129/
Sv(ev) and IFNAR-1 ~/_ mice were inoculated intraper¬
itoneally with 5000 p.f.u. SFV A7(74) or SFV4 with an
eGFP marker gene inserted into the structural protein open
reading frame (SFV4-steGFP). Three mice were sampled
from each group ofmice at days 1 and 2 p.i. Blood samples
were taken for virus titration and samples of tissues from
several different organ systems were studied by microscopy.
Tissues from the SFV A7(74)-infected mice were processed
for paraffin histology, cut into 5 pm sections and
immunostained to visualize virus-infected cells (Fig. 3).
Tissues from SFV4-steGFP-infected mice were fixed, cut
into 12-14 pm sections on a cryomicrotome and studied
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Fig. 2. Representative autoradiographic images illustrating the distribution of virus RNA-positive cells (black) in parasagittal
sections of the brains of wt 129/Sv(ev) or IFNAR-1mice 16 or 40 h after intraperitoneal or intracerebral inoculation of SFV
A7(74). In situ hybridization using a negative-sense 35S-labelled riboprobe complementary to the viral genomic RNA. For each
of three mice sampled at each time point, three sections from each of three areas of the brain were studied; the images shown
are representative of each group of mice. All brains are in the same orientation; the main olfactory bulb (mob) and the cerebellum
(cb) demonstrate the rostro-caudal orientation. Following intraperitoneal inoculation, no virus-positive cells were observed at
16 h and only rare virus-positive cells were observed at 40 h (arrows); the mice sampled at 40 h had clear signs of infection
including a hunched posture, piloerection, weight loss, inactivity and tremor. Following intracerebral inoculation in both 129/
Sv(ev) and IFNAR-1 mice, virus-infected cells were present in the major white matter tracts of the corpus callosum and the
internal capsule (arrows). In addition in IFNAR-1"'" mice, ependymal cells surrounding the third and fourth ventricles (3V and
4V, respectively) and meningeal cells (m) were also positive for virus (see also Fig. 3a-c).
on a Zeiss confocal microscope (Fig. 4). At 1 day p.i., the
mean (n=3) blood virus titres were 109'2 and lO8"1 logm
p.f.u. ml-1 in IFNAR-l_/~ mice and 107'8 and 104'4 log]0
p.f.u. ml-1 in 129/Sv(ev) mice for SFV A7(74) and SFV4,
respectively. In SFV-infected 129/Sv(ev) mice, despite
examination ofmany sections from many tissues including
brain, lung, liver, kidney, heart, spleen, small intestine,
pancreas, skeletal and smooth muscle, virus-infected cells
were observed only rarely, most frequently in the exocrine
pancreas. In stark contrast, infected cells were readily
observed in all of these tissues in IFNAR-1 _/~ mice,
demonstrating the power of the type IIFN system to curtail
virus infection. No differences in tropism were observed
between the two viruses in IFNAR-1 mice. Most tissues
studied showed a selective cellular tropism (Figs 3 and 4
and Table 2). For example, cells of the exocrine but not the
endocrine pancreas were heavily infected; many cells in the
heart valves but only relatively few cells in the myocardium
were infected; many cells of the marginal zone of the
spleen, most probably macrophages were infected, as were
lymphocytes in the white pulp; adipose tissue showed the
most extensive infection; other infected cells included
hepatocytes, smooth muscle cells, cells of the kidney
glomeruli and cells in the lung. The difference in the
extent of infection between mice with and without a type I
IFN system dramatically illustrated the power of this
system to limit the spread of this virus. In the absence of
an intact IFN system, the true tropism and the potential
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Fig. 3. Immunostaining (brown) for virus structural proteins in SFV A7(74)-infected IFNAR-1~'~ mice, (a) Infection of the
meninges (arrow), (b) Infection of the ependymal cells of the fourth ventricle is apparent as a continuous line of immunostained
cells lining the ventricle, (c) High-power view of infected ependymal cells lining the lateral ventricle. Note that in (b) and (c) (see
also Fig. 2) there has been very little spread of the infection to the cells of the underlying brain parenchyma, (d) Virus infection
(arrow) of scattered acinar cells of the exocrine pancreas, (e) Virus-infected hepatocytes (arrow) in the liver, (f) Infected cells
(example indicated by arrow) in a glomerulus in the kidney, (g) Low-power image of the spleen; the circular distribution of
infected cells in the marginal zone between the white pulp (inner) and the red pulp (outer) is apparent, (h) High-power image of
the spleen; it is evident that many cells in the white pulp are also infected (example indicated by arrow) and that many cells in
this area have pycnotic nuclei indicative of cell death, (j) Widespread infection of cell bodies in adipocyte tissue (unstained
white areas are the fat vacuoles).
of this virus for rapid and widespread infection were
revealed.
DISCUSSION
Previous studies in the early days of IFN research showed
that intraperitoneal inoculation of adult mice with SFV
A7(74) induced IFN activity in the blood and that crude
preparations of IFN protected mice against virulent strains
of SFV (Bradish et al., 1975; Bradish & Titmuss, 1981;
Finter, 1966; Smillie et al., 1973). The first description of
IFNAR-l~/_ mice noted that SFV was rapidly fatal in these
mice but the strain of SFV used was not stated (Muller
et al., 1994). Here, we have shown that both the nominally
avirulent SFV A7(74) and the increasingly used SFV4 are
both virulent in IFNAR-l-/~ mice and that, in mice with
an intact type I IFN system, both viruses induce IFN gene
expression in the brain with levels of IFN-a gene transcripts
directly proportional to those of viral RNA; the more viral
http://vir.sgmjournals.org 7
■(b)
« paper no. vir83191 charlesworth ref: vir83191 »
R. Fragkoudis and others
RNA, the more IFN transcripts. Other studies have shown
that the type I IFN system is activated in the brain in
response to inoculation of poly I: C and to infection with
viruses including rabies virus, Theiler's virus, La Crosse
virus, simian immunodeficiency virus and lymphocytic
8
choriomeningitis virus (Barber et al., 2004; Delhaye et al.,
2006; Johnson et al., 2006; Prehaud et al., 2005; Roberts
et al., 2004). In the present study, our novel QPCR
approach demonstrated for the first time that the IFN gene
expression response is proportional to the viral RNA load.
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Fig. 4. Distribution of SFV4 in selected tissues of IFNAR-1_/ mice as visualized by expression (green) of an eGFP marker
gene expressed as part of the virus structural polyprotein. For tissue sections (b)-(l), the images are representative of at least
nine sections from at least three different areas of each tissue type from at least two mice. In many tissues, areas of infection
were apparent, even upon gross examination, as shown for the brain in (a) where areas of infection are present in the inferior
colliculi (ic), the frontal cortex (fctx) and the main olfactory bulb (mob); the cerebellum (cb) is marked to facilitate orientation.
Some foci of infection appeared to be associated with blood vessels (examples indicated by arrows); however, this was difficult
to determine without knowing the depth of tissue imaged). Sections from this brain demonstrated infection of meningeal cells
(b; cf. Fig. 2) and several neuronal populations as shown, for example in (c) for pyramidal neurons in the hippocampus (p) and
cells in the hilus of the dentate gyrus (dg); red propidium iodide staining of cell nuclei allowed visualization of the neuroanatomy.
The sections shown in (d)-(k) were lightly stained with diaminobenzidine to allow visualization of the tissue structure; red blood
cells appeared black. In the heart (d-f), strikingly there was consistent infection of cells in the heart valves (d, e) but only small
foci of infected cells in the myocardium (f). In the spleen (g, h), infected cells were principally in the marginal zones (mz) between
the red pulp (rp) and white pulp (wp), areas know to contain many macrophages and dendritic cells. In the pancreas (i), many
isolated scattered acinar cells were infected (example indicated by arrow) in the exocrine pancreas; infection of cells of the
endocrine pancreas was never observed. In the kidney (kd) (j), many cell types including cells in the glomeruli and tubule cells
were infected; the smooth muscle cell layers surrounding the ureter (ur) were heavily infected. One of the most widely infected
cell types was adipose tissue (k). Foci of infection were apparent in the lung (I). Bars, 100 pm.
In culture, CNS cells including neurons and glial cells have
been observed to activate the type I IFN system (McKimmie
& Fazakerley, 2005; Prehaud et al., 2005). Intrathecal
synthesis of IFNs and IFN-activated protein expression have
also been demonstrated in patients with CNS virus
infections (Dussaix et al., 1985; Ogata et al., 2004).
The type I IFN system has been shown to protect mice
against the spread of other viruses in the CNS including
Theiler's virus, Bunyamwera virus, Dugbe virus, Hantaan
virus, influenza A virus, vesicular stomatitis virus, lym¬
phocytic choriomeningitis virus, Sindbis virus and
Venezuelan equine encephalitis virus (Boyd et al., 2006;
Bridgen et al., 2001; Fiette et al., 1995; Garcia-Sastre et al.,
1998; Grieder & Vogel, 1999; Koerner et al., 2007; Muller
et al., 1994; Ryman et al., 2000; Wichmann et al., 2002).
Few studies have detailed the CNS cell types protected by
this IFN response. As documented previously, SFV A7(74)
is efficiently neuroinvasive, but in the adult mouse brain it
is restricted in its ability to replicate in and spread between
mature neurons (Fazakerley et al., 1993, 2006; Oliver &
Fazakerley, 1998; Pusztai et al., 1971). Mouse neurons,
both in culture and in the adult mouse brain, can respond
to IFNs (Ousman et al., 2005; Wang & Campbell, 2005;
Wang et al., 2002; Ward & Massa, 1995). This response
could underlie the restricted replication of SFV A7(74) in
neurons. Here, however, we showed that this restricted
replication is not mediated by type I IFN responses; A7(74)
replication in mature neurons remained restricted, even in
the absence of type I IFN responses. Type I IFN responses
did however control replication of SFV A7(74) in
meningeal and ependymal cells, as these cells were infected
only rarely in wt mice. Type I IFN responses have also been
shown to protect ependymal cells from measles virus,
meningeal cells from Sindbis virus and oligodendrocyte,
ependymal and choroid plexus cells from Theiler's virus
infections (Fiette et al., 1995; Mrkic et al., 1998; Ryman
et al., 2000). Given that, in the absence of type 1 IFN
responses, SFV A7(74) does not establish a widespread
infection of the brain parenchyma, other factors must be
operating to restrict replication of this virus in mature
neurons. We have previously suggested that the restricted
Organ Cell types infected
Brain Neurons, oligodendrocytes, ependymal cells, meningeal cells but not astrocytes
Heart Cells in the valves and occasional cells in the myocardium
Lung Alveolar lining cells
Liver Hepatocytes and occasional kupffer cells
Pancreas Acinar cells in the exocrine pancreas but not cells in the endocrine pancreas
Kidney Cells in the glomeruli and tubule cells
Adipose Widespread infection
Muscle Occasional skeletal muscle fibres and particularly smooth muscle
Spleen Cells in the marginal zone (macrophages?)
Table 2. Cell types infected by SFV A7(74) and SFV4 in IFNAR-1 1 mice
SFV A7(74)-infected cells were determined by immunostaining and SFV4-steGFP-infected cells were detected
by fluorescence. Cell types were determined by morphology and location within tissues. The same cell types
were found to be infected by SFV A7(74) and SFV4.
http://vir.sgmjournals.org 9
«paper no. vir83191 charlesworth ref: vir83191»
R. Fragkoudis and others
replication of A7(74) in the mature neurons of the adult
mouse brain is linked to neuronal differentiation and,
in particular, to the availability of freshly synthesized
intracellular membranes and their constituent lipids
(Oliver & Fazakerley, 1998; Oliver et al., 1997; Scallan &
Fazakerley, 1999).
We have shown that, although type I IFN does not
contribute to the restricted phenotype of SFV A7(74) in
adult brain neurons, it is essential to prevent virus spread
in extraneural tissues. Several other viruses, including
avirulent strains of the related alphavirus Sindbis virus,
which, like SFV A7(74), produces subclinical or even
unapparent infection, also establish widespread infections
in IFNAR-l-'- mice (Bray, 2001; Mrkic et al., 1998; Muller
et al., 1994; Ryman et al., 2000). In the case of SFV4 and
SFV A7(74), infection was observed in multiple tissues with
a similar extent of infection and tropism for both viruses.
Whether SFV tropism is determined by entry or post-entry
events is unclear. The receptor for this virus and its cellular
distribution remain unknown. In the absence of an IFN
response, the cell types with the greatest degree of infection
were the acinar cells of the exocrine pancreas and
adipocytes. To enable their secretion of large amounts of
digestive enzymes, pancreatic acinar cells contain large
amounts of rough endoplasmic reticulum and have a
highly vesiculated cytoplasm. Similarly, adipocytes contain
many vacuoles and have a highly developed lipid
metabolism. Extensive replication of SFV A7(74) in these
cell types would be consistent with a requirement for
lipids and freshly synthesized membranes, as suggested for
neurons. In the absence of the IFN response, infection of
heart valves was consistently observed and was more
extensive than infection of other parts of the heart. This
could have resulted from a greater exposure of the valves to
the high titres of virus in the blood or alternatively from an
increased susceptibility of this tissue to infection. In mice,
enteroviruses have been shown to preferentially infect valve
tissues and some patients with chronic rheumatic heart
disease have evidence of enterovirus replication in valve
tissue (Burch et al., 1966; Li et al., 2002). In the spleens of
IFNAR-1- mice, SFV was predominantly observed in
cells of the marginal zone, most likely macrophages or
dendritic cells. A similar distribution was observed in
IFNAR-1-'- mice infected with Sindbis virus where these
cells were shown to be cells of the macrophage/dendritic
cell lineage (Ryman et al., 2000).
Many RNA viruses antagonize IFN responses (Haller et al.,
2006). Viruses, even strains of the same virus, also differ in
their susceptibility to the actions of IFN. The virulent L10
strain of SFV is less sensitive to IFN than the avirulent V42
strain (Deuber & Pavlovic, 2007). That SFV A7(74) and SFV4
infections are much more widespread in IFNAR-1- mice
demonstrates the power of the type I IFN system to control
these strains; however it does not preclude the possibility that
SFV and other alphaviruses also antagonize IFN responses
(Breakwell et al., 2007; Fazakerley et al., 2002; Frolov, 2004;
Garmashova et al., 2007). Antagonism of the IFN response is
unlikely to be absolute; the timing and the magnitude of IFN
induction, action and suppression relative to the rate ofvirus
replication are likely to determine the extent of virus spread.
What is clear is that, in the mouse, the IFN response to SFV
A7(74) and SFV4 is sufficient to severely curtail the spread of
these viruses in many tissue systems.
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